Document And Entity Information	12 Months Ended
Document And Entity Information	Dec. 31, 2017
Document And Entity Information [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Entity Registrant Name	Endo International plc
Entity Central Index Key	0001593034

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
CURRENT ASSETS:
Cash and cash equivalents	$ 986,605	$ 517,250
Restricted cash and cash equivalents	320,453	282,074
Accounts receivable, net of allowance of $392 and $6,956 at December 31, 2017 and 2016, respectively	517,436	992,153
Inventories, net	391,437	555,671
Prepaid expenses and other current assets	43,098	77,523
Income taxes receivable	12,048	47,803
Assets held for sale	0	116,985
Total current assets	2,271,077	2,589,459
MARKETABLE SECURITIES	1,456	2,267
PROPERTY, PLANT AND EQUIPMENT, NET	523,971	669,596
GOODWILL	4,450,082	4,729,395
OTHER INTANGIBLES, NET	4,317,684	5,859,297
DEFERRED INCOME TAXES	11,582	7,817
OTHER ASSETS	59,728	417,278
TOTAL ASSETS	11,635,580	14,275,109
CURRENT LIABILITIES:
Accounts payable and accrued expenses	1,096,825	1,454,084
Current portion of legal settlement accrual	1,087,793	1,015,932
Current portion of long-term debt	34,205	131,125
Income taxes payable	2,086	9,266
Liabilities held for sale	0	24,338
Total current liabilities	2,220,909	2,634,745
DEFERRED INCOME TAXES	43,131	192,297
LONG-TERM DEBT, LESS CURRENT PORTION, NET	8,242,032	8,141,378
LONG-TERM LEGAL SETTLEMENT ACCRUAL, LESS CURRENT PORTION	210,450	0
OTHER LIABILITIES	434,178	605,100
COMMITMENTS AND CONTINGENCIES (NOTE 14)
SHAREHOLDERS’ EQUITY:
Euro deferred shares, $0.01 par value; 4,000,000 shares authorized and issued at both December 31, 2017 and December 31, 2016	48	42
Ordinary shares, $0.0001 par value; 1,000,000,000 shares authorized; 223,331,706 and 222,954,175 shares issued and outstanding at December 31, 2017 and December 31, 2016, respectively	22	22
Additional paid-in capital	8,791,170	8,743,240
Accumulated deficit	(8,096,539)	(5,688,281)
Accumulated other comprehensive loss	(209,821)	(353,434)
Total shareholders’ equity	484,880	2,701,589
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 11,635,580	$ 14,275,109

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 392	$ 6,956
Euro deferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Euro deferred shares, shares authorized	4,000,000	4,000,000
Euro deferred shares, shares issued	4,000,000	4,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	223,331,706	222,954,175
Common stock, shares outstanding	223,331,706	222,954,175

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
TOTAL REVENUES	$ 3,468,858	$ 4,010,274	$ 3,268,718
COSTS AND EXPENSES:
Cost of revenues	2,228,530	2,634,973	2,075,651
Selling, general and administrative	629,874	770,728	741,304
Research and development	172,067	183,372	102,197
Litigation-related and other contingencies, net	185,990	23,950	37,082
Asset impairment charges	1,154,376	3,781,165	1,140,709
Acquisition-related and integration items	58,086	87,601	105,250
OPERATING LOSS	(960,065)	(3,471,515)	(933,475)
INTEREST EXPENSE, NET	488,228	452,679	373,214
LOSS ON EXTINGUISHMENT OF DEBT	51,734	0	67,484
OTHER (INCOME) EXPENSE, NET	(17,023)	(338)	63,691
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAX	(1,483,004)	(3,923,856)	(1,437,864)
INCOME TAX BENEFIT	(250,293)	(700,084)	(1,137,465)
LOSS FROM CONTINUING OPERATIONS	(1,232,711)	(3,223,772)	(300,399)
DISCONTINUED OPERATIONS, NET OF TAX (NOTE 3)	(802,722)	(123,278)	(1,194,926)
CONSOLIDATED NET LOSS	(2,035,433)	(3,347,050)	(1,495,325)
Less: Net income (loss) attributable to noncontrolling interests	0	16	(283)
NET LOSS ATTRIBUTABLE TO ENDO INTERNATIONAL PLC	$ (2,035,433)	$ (3,347,066)	$ (1,495,042)
NET LOSS PER SHARE ATTRIBUTABLE TO ENDO INTERNATIONAL PLC ORDINARY SHAREHOLDERS—BASIC:
Continuing operations (in dollars per share)	$ (5.52)	$ (14.48)	$ (1.52)
Discontinued operations (in dollars per share)	(3.60)	(0.55)	(6.07)
Basic (in dollars per share)	(9.12)	(15.03)	(7.59)
NET LOSS PER SHARE ATTRIBUTABLE TO ENDO INTERNATIONAL PLC ORDINARY SHAREHOLDERS—DILUTED:
Continuing operations (in dollars per share)	(5.52)	(14.48)	(1.52)
Discontinued operations (in dollars per share)	(3.60)	(0.55)	(6.07)
Diluted (in dollars per share)	$ (9.12)	$ (15.03)	$ (7.59)
WEIGHTED AVERAGE SHARES:
Basic (shares)	223,198	222,651	197,100
Diluted (shares)	223,198	222,651	197,100

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statement of Comprehensive Income [Abstract]
CONSOLIDATED NET LOSS	$ (2,035,433)	$ (3,347,050)	$ (1,495,325)
Net unrealized (loss) gain on securities:
Unrealized (loss) gain arising during the period	(515)	(914)	2,299
Less: reclassification adjustments for gain realized in net loss	0	(6)	0
Net unrealized gain (loss) on securities	(515)	(920)	2,299
Net unrealized gain (loss) on foreign currency:
Foreign currency translation gain (loss) arising during the period	31,202	31,729	(284,722)
Less: reclassification adjustments for loss realized in net loss	112,926	0	25,715
Foreign currency translation gain (loss)	144,128	31,729	(259,007)
OTHER COMPREHENSIVE INCOME (LOSS)	143,613	30,809	(256,708)
CONSOLIDATED COMPREHENSIVE LOSS	(1,891,820)	(3,316,241)	(1,752,033)
Less: Net income (loss) attributable to noncontrolling interests	0	16	(283)
Less: Other comprehensive income (loss) attributable to noncontrolling interests	0	38	(495)
COMPREHENSIVE LOSS ATTRIBUTABLE TO ENDO INTERNATIONAL PLC	$ (1,891,820)	$ (3,316,295)	$ (1,751,255)

Consolidated Statements Of Shareholders' Equity - USD ($) $ in Thousands	Total	Auxilium Pharmaceuticals, Inc.	Par Pharmaceutical Holdings, Inc.	Total Endo International plc Shareholders’ Equity	Total Endo International plc Shareholders’ Equity Auxilium Pharmaceuticals, Inc.	Total Endo International plc Shareholders’ Equity Par Pharmaceutical Holdings, Inc.	Ordinary Shares	Ordinary Shares Auxilium Pharmaceuticals, Inc.	Ordinary Shares Par Pharmaceutical Holdings, Inc.	Euro Deferred Shares	Additional Paid-in Capital	Additional Paid-in Capital Auxilium Pharmaceuticals, Inc.	Additional Paid-in Capital Par Pharmaceutical Holdings, Inc.	Accumulated Deficit	Accumulated other comprehensive loss	Noncontrolling Interests
Shareholders' equity, beginning balance (in shares) at Dec. 31, 2014							153,912,985			4,000,000
Shareholders' equity, beginning balance at Dec. 31, 2014	$ 2,408,213			$ 2,374,757			$ 15			$ 48	$ 3,093,867			$ (595,085)	$ (124,088)	$ 33,456
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Net (loss) income	(1,495,325)			(1,495,042)										(1,495,042)		(283)
Other comprehensive income (loss)	(256,708)			(256,213)											(256,213)	(495)
Compensation related to share-based awards	61,185			61,185							61,185
Exercise of options (in shares)							880,885
Exercise of options	27,217			27,217							27,217
Tax benefits of share awards, net	20,051			20,051							20,051
Issuance of ordinary shares related to the employee stock purchase plan (in shares)							67,867
Issuance of ordinary shares related to the employee stock purchase plan	4,299			4,299							4,299
Ordinary shares issued (in shares)							27,982,302
Ordinary shares issued	2,300,000			2,300,000			$ 3				2,299,997
Equity issuance fees	(66,956)			(66,956)							(66,956)
Ordinary shares issued in connection with acquisitions (in shares)								18,609,835	18,069,899
Ordinary shares issued in connection with acquisition		$ 1,519,320	$ 1,325,248		$ 1,519,320	$ 1,325,248		$ 2	$ 2			$ 1,519,318	$ 1,325,246
Tax withholding for restricted shares	(15,398)			(15,398)							(15,398)
Share repurchases (in shares)							(4,361,957)
Share repurchases	(251,088)			(251,088)										(251,088)
Buy-out of noncontrolling interests, net	(39,608)			(6,876)							(2,972)				(3,904)	(32,732)
Fair value of equity component of acquired Auxilium Notes	266,649			266,649							266,649
Conversion of convertible debt (in shares)							5,170,239
Conversion of Auxilium Notes	160,892			160,892							160,892
Settlement of common stock warrants							1,792,379
Other (in shares)							(152)
Other	(15)			(15)						$ (5)	(10)
Shareholders' equity, ending balance (in shares) at Dec. 31, 2015							222,124,282			4,000,000
Shareholders' equity, ending balance at Dec. 31, 2015	5,967,976			5,968,030			$ 22			$ 43	8,693,385			(2,341,215)	(384,205)	(54)
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Net (loss) income	(3,347,050)			(3,347,066)										(3,347,066)		16
Other comprehensive income (loss)	30,809			30,771											30,771	38
Compensation related to share-based awards	59,769			59,769							59,769
Exercise of options (in shares)							62,589
Exercise of options	1,952			1,952							1,952
Tax benefits of share awards, net	(5,449)			(5,449)							(5,449)
Issuance of ordinary shares related to the employee stock purchase plan (in shares)							306,918
Issuance of ordinary shares related to the employee stock purchase plan	5,119			5,119							5,119
Ordinary shares issued (in shares)							460,386
Ordinary shares issued	0			0							0
Tax withholding for restricted shares	(11,500)			(11,500)							(11,500)
Other	(37)			(37)						$ (1)	(36)
Shareholders' equity, ending balance (in shares) at Dec. 31, 2016							222,954,175			4,000,000
Shareholders' equity, ending balance at Dec. 31, 2016	2,701,589			2,701,589			$ 22			$ 42	8,743,240			(5,688,281)	(353,434)	0
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Shareholders' equity, adjusted beginning balance	2,328,764			2,328,764						42	8,743,240			(6,061,106)	(353,434)	0
Effect of adopting ASU 2016-16 (NOTE 2) \| Accounting Standards Update 2016-16	(372,825)			(372,825)										(372,825)
Net (loss) income	(2,035,433)			(2,035,433)										(2,035,433)
Other comprehensive income (loss)	143,613			143,613											143,613
Compensation related to share-based awards	50,149			50,149							50,149
Ordinary shares issued (in shares)							377,531
Tax withholding for restricted shares	(2,078)			(2,078)							(2,078)
Other	(135)			(135)						$ 6	(141)
Shareholders' equity, ending balance (in shares) at Dec. 31, 2017							223,331,706			4,000,000
Shareholders' equity, ending balance at Dec. 31, 2017	$ 484,880			$ 484,880			$ 22			$ 48	$ 8,791,170			$ (8,096,539)	$ (209,821)	$ 0

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
OPERATING ACTIVITIES:
Consolidated net loss	$ (2,035,433)	$ (3,347,050)	$ (1,495,325)
Adjustments to reconcile consolidated net loss to Net cash provided by operating activities:
Depreciation and amortization	983,765	983,309	632,756
Inventory step-up	390	108,768	232,461
Share-based compensation	50,149	59,769	61,185
Amortization of debt issuance costs and discount	22,694	28,514	23,604
(Benefit) provision for bad debts	(1,649)	6,885	5,073
Deferred income taxes	(156,129)	(745,341)	(447,168)
Change in fair value of contingent consideration	49,949	23,823	(65,640)
Loss on extinguishment of debt	51,734	0	67,484
Asset impairment charges	1,154,376	3,802,493	1,390,281
(Gain) loss on sale of business and other assets	(13,809)	3,192	(10,294)
Changes in assets and liabilities which (used) provided cash:
Accounts receivable	486,359	(7,387)	(274,994)
Inventories	147,189	66,876	29,130
Prepaid and other assets	5,345	69,273	21,283
Accounts payable and accrued expenses	(69,608)	(682,515)	443,398
Other liabilities	(18,336)	(524,532)	69,926
Income taxes payable/receivable	(103,001)	682,066	(564,659)
Net cash provided by operating activities	553,985	528,143	118,501
INVESTING ACTIVITIES:
Purchases of property, plant and equipment	(125,654)	(138,856)	(81,774)
Acquisitions, net of cash and restricted cash acquired	0	(30,394)	(7,648,048)
Proceeds from sale of marketable securities and investments	0	34	1,230
Decrease in notes receivable	7,000	0	17
Patent acquisition costs and license fees	0	(19,206)	(43,968)
Proceeds from sale of business and other assets, net	223,237	10,870	1,588,779
Net cash provided by (used in) investing activities	104,583	(177,552)	(6,183,764)
FINANCING ACTIVITIES:
Proceeds from issuance of notes	300,000	0	2,835,000
Proceeds from issuance of term loans	3,415,000	0	2,800,000
Principal payments on notes	0	0	(899,875)
Principal payments on term loans	(3,730,951)	(103,625)	(473,376)
Proceeds from draw of revolving debt	0	380,000	525,000
Repayments of revolving debt	0	(605,000)	(300,000)
Principal payments on other indebtedness	(6,154)	(7,736)	(10,070)
Repurchase of convertible senior subordinated notes	0	0	(247,760)
Prepayment penalty on long-term debt	0	0	(31,496)
Sale of mandatorily redeemable preferred shares	0	0	60,000
Redemption of mandatorily redeemable preferred shares	0	0	(60,000)
Deferred financing fees	(57,773)	(500)	(125,111)
Payments for contingent consideration	(85,037)	(55,896)	(29,786)
Payments of tax withholding for restricted shares	(2,078)	(11,500)	(15,398)
Exercise of options	0	1,952	27,217
Repurchase of ordinary shares	0	0	(250,088)
Issuance of ordinary shares related to the employee stock purchase plan	0	5,119	4,299
Issuance of ordinary shares	0	0	2,300,000
Payments related to the issuance of ordinary shares	0	0	(66,956)
Cash buy-out of noncontrolling interests	0	0	(39,608)
Net cash (used in) provided by financing activities	(166,993)	(397,186)	6,001,992
Effect of foreign exchange rate	2,515	436	(11,269)
Movement in cash held for sale	11,744	(11,744)	997
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS	505,834	(57,903)	(73,543)
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD	805,180	863,083	936,626
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD	1,311,014	805,180	863,083
SUPPLEMENTAL INFORMATION:
Cash paid for interest	467,017	429,172	284,985
Cash paid for income taxes	28,675	63,983	42,700
Cash received from U.S. Federal tax refunds	29,825	759,950	162,821
Cash paid into Qualified Settlement Funds for mesh legal settlements	668,306	831,131	743,132
Cash paid out of Qualified Settlement Funds for mesh legal settlements	632,176	1,134,734	649,391
Other cash distributions for mesh legal settlements	19,243	7,830	27,380
SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Accrual for purchases of property, plant and equipment	5,723	2,676	4,476
Acquisition financed by ordinary shares	0	0	2,844,568
Repurchase of convertible senior subordinated notes financed by ordinary shares	$ 0	$ 0	$ 625,483

Description of Business	12 Months Ended
Description of Business	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	NOTE 1. DESCRIPTION OF BUSINESS Endo International plc is an Ireland-domiciled, global specialty pharmaceutical company focused on generic and branded pharmaceuticals. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of generic and branded drugs to meet patients’ needs. Unless otherwise indicated or required by the context, references throughout to “Endo,” the “Company,” “we,” “our” or “us” refer to financial information and transactions of Endo International plc and its subsidiaries. The accompanying Consolidated Financial Statements of Endo International plc and its subsidiaries have been prepared in accordance with United States (U.S.) generally accepted accounting principles (GAAP).

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Consolidation and Basis of Presentation. The Consolidated Financial Statements include the accounts of wholly owned subsidiaries after the elimination of intercompany accounts and transactions.

Reclassifications. Certain prior period amounts have been reclassified to conform to the current period presentation. Additionally, as further discussed below under the heading “Recent Accounting Pronouncements Adopted or Otherwise Effective as of December 31, 2017,” the Company adopted Accounting Standards Update (ASU) No. 2016-09 “Compensation - Stock Compensation” (ASU 2016-09), ASU No. 2016-15 “Classification of Certain Cash Receipts and Cash Payments” (ASU 2016-15) and ASU No. 2016-18 “Statement of Cash Flows (Topic 230) - Restricted Cash” (ASU 2016-18) during 2017. The table below presents the effects of these ASUs on the Company’s Consolidated Statements of Cash Flows for each of the years ended December 31, 2016 and 2015 (in thousands):



	Prior to Adoption			Impact of Adoption of:									Subsequent to Adoption
	Prior to Adoption			ASU 2016-09			ASU 2016-15			ASU 2016-18			Subsequent to Adoption
For the year ended December 31, 2016:
Net cash provided by operating activities	$	524,439		$	3,204		$	—		$	500		$	528,143
Net cash provided by (used in) investing activities	125,861			—			—			(303,413		)	(177,552		)
Net cash used in financing activities	(393,982		)	(3,204		)	—			—			(397,186		)
Effect of foreign exchange rate	328			—			—			108			436
Movement in cash held for sale	(11,744		)	—			—			—			(11,744		)
Net change (1)	$	244,902		$	—		$	—		$	(302,805	)	$	(57,903	)
Beginning-of-period balance (2)	272,348			—			—			590,735			863,083
End-of-period balance (2)	$	517,250		$	—		$	—		$	287,930		$	805,180
For the year ended December 31, 2015:
Net cash provided by operating activities	$	62,026		$	21,979		$	31,496		$	3,000		$	118,501
Net cash used in investing activities	(6,244,770		)	—			—			61,006			(6,183,764		)
Net cash provided by financing activities	6,055,467			(21,979		)	(31,496		)	—			6,001,992
Effect of foreign exchange rate	(7,068		)	—			—			(4,201		)	(11,269		)
Movement in cash held for sale	997			—			—			—			997
Net change (1)	$	(133,348	)	$	—		$	—		$	59,805		$	(73,543	)
Beginning-of-period balance (2)	405,696			—			—			530,930			936,626
End-of-period balance (2)	$	272,348		$	—		$	—		$	590,735		$	863,083

__________


(1)	This line refers to the “Net increase (decrease) in cash and cash equivalents” prior to the adoption of ASU 2016-18 and the “Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents” after the adoption.


(2)	These lines refer to the beginning or end of period amounts of “Cash and cash equivalents” prior to the adoption of ASU 2016-18 and the beginning or end of periods amounts of “Cash, cash equivalents, restricted cash and restricted cash equivalents” after the adoption.

The adoption of ASU 2016-09 and ASU 2016-15 did not affect the Company’s Consolidated Statement of Cash Flows for the year ended December 31, 2017. The primary impact of adopting ASU 2016-18 on the Company’s 2017 Consolidated Statement of Cash Flows was to exclude the cash flow effect of $36.2 million of net increases in restricted cash and cash equivalents from net cash provided by investing activities for the year ended December 31, 2017.

Use of Estimates. The preparation of our Consolidated Financial Statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts and disclosures in our Consolidated Financial Statements, including the notes thereto, and elsewhere in this report. For example, we are required to make significant estimates and assumptions related to revenue recognition, including sales deductions, financial instruments, long-lived assets, goodwill, other intangibles, income taxes, contingencies and share-based compensation, among others. Some of these estimates can be subjective and complex. Although we believe that our estimates and assumptions are reasonable, there may be other reasonable estimates or assumptions that differ significantly from ours. Further, our estimates and assumptions are based upon information available at the time they were made. Actual results may differ significantly from our estimates.

We regularly evaluate our estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Market conditions, such as illiquid credit markets, volatile equity markets, dramatic fluctuations in foreign currency rates and economic downturn, can increase the uncertainty already inherent in our estimates and assumptions. We also are subject to other risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. We adjust our estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our Consolidated Financial Statements on a prospective basis.

Customer, Product and Supplier Concentration. We primarily sell our generic and branded pharmaceuticals to wholesalers, retail drug store chains, supermarket chains, mass merchandisers, distributors, mail order accounts, hospitals and government agencies. Our wholesalers and distributors purchase products from us and, in turn, supply products to retail drug store chains, independent pharmacies and managed health care organizations. Customers in the managed health care market include health maintenance organizations, nursing homes, hospitals, clinics, pharmacy benefit management companies and mail order customers. Total revenues from direct customers that accounted for 10% or more of our total consolidated revenues during the years ended December 31, 2017, 2016 and 2015 are as follows:



	2017		2016		2015
Cardinal Health, Inc.	25	%	26	%	21	%
McKesson Corporation	25	%	27	%	31	%
AmerisourceBergen Corporation	25	%	25	%	23	%

Revenues from these customers are included within each of our segments.

VASOSTRICT^® accounted for 12% of our 2017 total revenues. No other products accounted for 10% or more of our total revenues during the years ended December 31, 2017, 2016 or 2015.

We have agreements with certain third parties for the manufacture, supply and processing of certain of our existing pharmaceutical products. See Note 14. Commitments and Contingencies for information on material manufacturing, supply and other service agreements.

We are subject to risks and uncertainties associated with these concentrations that could have a material adverse effect on our financial position and results of operations in future periods, including in the near term.

Revenue Recognition. Our revenue consists almost entirely of sales of our pharmaceutical products to customers, whereby we ship product to a customer pursuant to a purchase order, which typically corresponds and/or makes reference to a master agreement with that customer, and invoice the customer upon shipment. For sales such as these, we recognize revenue when title and risk of loss has passed to the customer, which is typically upon delivery to the customer, when estimated provisions for revenue reserves are reasonably determinable and when collectability is reasonably confirmed. The amount of revenue we recognize is equal to the selling price, adjusted for our estimates of a number of significant sales deductions, which are further described below.

Revenue from the launch of a new or significantly unique product may be deferred until such time that the product has achieved market acceptance. For these products, revenue is typically recognized based on dispensed prescription data and other information obtained prior to and during the period following launch.

Sales Deductions. When we recognize revenue from the sale of our products, we simultaneously record an adjustment to revenue for estimated chargebacks, rebates, sales incentives and allowances, DSA and other fees for services, returns and allowances. These sales deductions are estimated based on historical experience, estimated future trends, estimated customer inventory levels, current contract sales terms with our direct and indirect customers and other competitive factors. We subsequently review our provisions for our various sales deductions based on new or revised information that becomes available to us and make revisions to our estimates if and when appropriate. If the assumptions we used to calculate our provisions for sales deductions do not appropriately reflect future activity, our financial position, results of operations and cash flows could be materially impacted.

Research and Development (R&D). Expenditures for research and development are expensed as incurred. Total R&D expenses include the costs of discovery research, preclinical development, early- and late-clinical development and drug formulation, clinical trials, medical support of marketed products, upfront, milestone and other payments under third-party collaborations and contracts and other costs. R&D spending also includes enterprise-wide costs which support our overall R&D infrastructure. Property, plant and equipment that are acquired or constructed for research and development activities and that have alternate future uses are capitalized and depreciated over their estimated useful lives on a straight-line basis. Contractual upfront and milestone payments made to third parties are generally: (i) expensed as incurred up to the point of regulatory approval and (ii) capitalized and amortized over the related product’s remaining useful life subsequent to regulatory approval. Amounts capitalized for such payments are included in Other intangibles, net in the Consolidated Balance Sheets.

Cash and Cash Equivalents. The Company considers all highly liquid money market instruments with an original maturity of three months or less when purchased to be cash equivalents. At December 31, 2017, cash equivalents were deposited in financial institutions and consisted of immediately available fund balances and time deposits. The Company maintains its cash deposits and cash equivalents with financial institutions it believes to be well-known and stable.

Restricted Cash and Cash Equivalents. Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are excluded from Cash and cash equivalents in the Consolidated Balance Sheets. For additional information see Note 7. Fair Value Measurements.

Marketable Securities. The Company has equity securities, which consist of investments in the stock of publicly traded companies. For additional information see Note 7. Fair Value Measurements.

Accounts Receivable. Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. In addition, accounts receivable is reduced by certain sales deduction reserves where we have the right of offset with the customer.

Concentrations of Credit Risk. Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents, restricted cash equivalents, marketable debt securities and accounts receivable. We invest our excess cash in high-quality, liquid money market instruments and time deposits maintained by major banks and financial institutions. We have not experienced any losses on our cash equivalents.

We perform ongoing credit evaluations of our customers and generally do not require collateral. We have no history of significant losses from uncollectible accounts. Approximately 89% and 84% of our gross trade accounts receivable balances represent amounts due from three customers (Cardinal Health, Inc., McKesson Corporation and AmerisourceBergen Corporation) at December 31, 2017 and 2016, respectively.

We do not expect our current or future exposures to credit risk to have a significant impact on our operations. However, there can be no assurance that any of these risks will not have an adverse effect on our business.

Inventories. Inventories consist of raw materials, work-in-process and finished goods. Inventory that is in excess of the amount expected to be sold within one year is classified as long-term inventory and is recorded in Other assets in the Consolidated Balance Sheets. The Company capitalizes inventory costs associated with certain generic products prior to regulatory approval and product launch when it is reasonably certain, based on management’s judgment of future commercial use and net realizable value, that the pre-launch inventories will be saleable. The determination to capitalize is made on a product-by-product basis once: (i) the Company (or its third party development partners) has filed an ANDA that has been acknowledged by the FDA as containing sufficient information to allow the FDA to conduct its review in an efficient and timely manner and (ii) management is reasonably certain that all regulatory and legal requirements will be cleared. The Company could be required to write down previously capitalized costs related to pre-launch inventories upon a change in such judgment, a denial or delay of approval by regulatory bodies, a delay in commercialization or other potential factors. Our inventories are stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out method and includes materials, direct labor and an allocation of overhead. Net realizable value is determined by the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. When necessary, we write-down inventories to net realizable value based on forecasted demand and market and regulatory conditions, which may differ from actual results.

Property, Plant and Equipment. Property, plant and equipment is generally stated at cost less accumulated depreciation. Major improvements are capitalized, while routine maintenance and repairs are expensed as incurred. Costs incurred during the construction or development of property plant and equipment are capitalized as assets under construction. Once an asset has been put into service, depreciation expense is taken over the estimated useful life of the related assets or, in the case of leasehold improvements and capital lease assets, over the shorter of the estimated useful life or the lease term. Depreciation expense is recorded on a straight-line basis. Depreciation expense is not recorded on Assets held for sale. Gains and losses on disposals are included in Other (income) expense, net in the Consolidated Statements of Operations. Depreciation is based on the following estimated useful lives, as of December 31, 2017:



	Range of Useful Lives (1), from:
Buildings	10 years	to	30 years
Machinery and equipment	2 years	to	15 years
Leasehold improvements	2 years	to	10 years
Computer equipment and software	1 year	to	7 years
Assets under capital lease	Shorter of useful life or lease term
Furniture and fixtures	3 years	to	10 years

__________


(1)	The useful lives for certain fixed assets have been reduced in connection with our 2017 U.S. Generic Pharmaceuticals Restructuring Initiative, which is further described in Note 4. Restructuring. The ranges of useful lives above do not include such assets.

Computer Software. The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software, including external direct costs of material and services, and payroll costs for employees directly involved with the software development. Capitalized software costs are included in Property, plant and equipment, net in the Consolidated Balance Sheets and depreciated beginning when the software project is substantially complete and the asset is ready for its intended use. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.

Lease Accounting. The Company accounts for operating lease transactions by recording rent expense on a straight-line basis over the expected life of the lease, commencing on the date it gains possession of leased property. The Company includes tenant improvement allowances and rent holidays received from landlords and the effect of any rent escalation clauses as adjustments to straight-line rent expense over the expected life of the lease.

Capital lease transactions are reflected as a liability at the inception of the lease based on the present value of the minimum lease payments or, if lower, the fair value of the property. Assets under capital leases are recorded in Property, plant and equipment, net in the Consolidated Balance Sheets and depreciated in a manner similar to other Property, plant and equipment.

Certain construction projects may be accounted for as direct financing arrangements, whereby the Company records, over the construction period, the full cost of the asset in Property, plant and equipment, net in the Consolidated Balance Sheets. A corresponding liability is also recorded, net of leasehold improvements paid for by the Company, and is amortized over the expected lease term through monthly rental payments using an effective interest method. Assets recorded under direct financing arrangements are depreciated over the lease term.

Finite-Lived Intangible Assets. Our finite-lived intangible assets, which consist of license rights and developed technology, are initially recorded at fair value upon acquisition. There are several methods that can be used to determine fair value. For intangible assets, we typically use the income method. This method starts with our forecast of all of the expected future net cash flows. Revenues are estimated based on relevant market size and growth factors, expected industry trends, individual project life cycles and, if applicable, the life of any estimated period of marketing exclusivity, such as that granted by a patent. The pricing, margins and expense levels of similar products are considered if available. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams.

To the extent an intangible asset is deemed to have a finite life, it is then amortized over its estimated useful life using either the straight-line method or, in the case of certain developed technology assets, the economic benefit model. The values of these various assets are subject to continuing scientific, medical and marketplace uncertainty. Factors giving rise to our initial estimate of useful lives are subject to change. Significant changes to any of these factors may result in a reduction in the useful life of the asset and an acceleration of related amortization expense, which could cause our operating income, net income and net income per share to decrease. Amortization expense is not recorded on assets held for sale.

License Rights. Our license rights have useful lives ranging from 3 years to 15 years, with a weighted average useful life of approximately 12 years. We determine amortization periods for licenses based on our assessment of various factors including the expected launch date of the product, the strength of the intellectual property protection of the product, contractual terms and various other competitive, developmental and regulatory issues.

Developed Technology. Our developed technology assets have useful lives ranging from 1 year to 20 years, with a weighted average useful life of approximately 11 years. We determine amortization periods and method of amortization for developed technology assets based on our assessment of various factors impacting estimated useful lives and timing and extent of estimated cash flows of the acquired assets including the strength of the intellectual property protection of the product, contractual terms and various other competitive and regulatory issues.

Long-Lived Asset Impairment Testing. Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are assessed for impairment whenever events or changes in circumstances indicate the carrying amounts of the assets may not be recoverable. Recoverability of an asset that will continue to be used in our operations is measured by comparing the carrying amount of the asset to the forecasted undiscounted future cash flows related to the asset. In the event the carrying amount of the asset exceeds its undiscounted future cash flows and the carrying amount is not considered recoverable, impairment may exist. An impairment loss, if any, is measured as the excess of the asset’s carrying amount over its fair value, generally based on a discounted future cash flow method, independent appraisals or preliminary offers from prospective buyers. An impairment loss would be recognized in the Consolidated Statements of Operations in the period that the impairment occurs.

In-Process Research and Development Assets (IPR&D). IPR&D assets are considered indefinite-lived intangible assets. Similar to finite-lived intangible assets, IPR&D assets are initially recorded at fair value. While amortization expense is not initially recorded for IPR&D assets, these assets are subject to impairment reviews. Impairment tests for an IPR&D asset occur at least annually on October 1^st of each year, but also whenever events or changes in circumstances indicate that the asset might be impaired. If the fair value of the intangible assets is less than its carrying amount, an impairment loss is recognized for the difference. For those assets that reach commercialization, the assets are reclassified as finite-lived intangible assets and amortized over the expected useful lives.

Goodwill. Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. While amortization expense is not recorded on goodwill, goodwill is subject to impairment reviews. Impairment tests for goodwill occur at least annually on October 1^st of each year, but also whenever events or changes in circumstances indicate that the asset might be impaired.

As further described below under the heading “Recent Accounting Pronouncements Adopted or Otherwise Effective as of December 31, 2017,” effective January 1, 2017, we early adopted Accounting Standards Update (ASU) No. 2017-04 “Intangibles - Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment” (ASU 2017-04). Subsequent to adoption, we perform our goodwill impairment tests by comparing the fair value of each of our reporting units with the carrying amount. Any goodwill impairment charge we recognize for a reporting unit is equal to the lesser of (i) the total goodwill allocated to that reporting unit and (ii) the amount by which that reporting unit’s carrying amount exceeds its fair value.

Contingencies. The Company is subject to various patent challenges, product liability claims, government investigations and other legal proceedings in the ordinary course of business. Legal fees and other expenses related to litigation are expensed as incurred and included in Selling, general and administrative expenses or Discontinued operations, net of tax in the Consolidated Statements of Operations. Contingent accruals and legal settlements are recorded in the Consolidated Statements of Operations as Litigation-related and other contingencies, net (or Discontinued operations, net in the case of vaginal mesh matters) when the Company determines that a loss is both probable and reasonably estimable. Due to the fact that legal proceedings and other contingencies are inherently unpredictable, our estimates of the probability and amount of any such liabilities involve significant judgment regarding future events. The Company records a receivable from its product liability insurance carriers only when the resolution of any dispute has been reached and realization of the potential claim for recovery is considered probable.

Contingent Consideration. Certain of the Company’s business acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of operational and commercial milestones and royalty payments on future product sales. The fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period, the Company remeasures its contingent consideration liability to its current fair value, with changes recorded in earnings. Changes to any of the inputs used in determining fair value may result in a significantly different fair value adjustment.

Share Repurchases. The Company accounts for the repurchase of ordinary shares at par value. Under applicable Irish law, ordinary shares repurchased are retired and not displayed separately as treasury stock. Upon retirement of the ordinary shares, the Company records the difference between the weighted average cost of such ordinary shares and the par value of the ordinary shares as an adjustment to Accumulated deficit in the Consolidated Balance Sheets.

Advertising Costs. Advertising costs are expensed as incurred and included in Selling, general and administrative expenses in the Consolidated Statements of Operations. Advertising costs amounted to $42.0 million, $47.9 million and $57.9 million for the years ended December 31, 2017, 2016 and 2015, respectively.

Cost of Revenues. Cost of revenues includes all costs directly related to bringing both purchased and manufactured products to their final selling destination. Amounts include purchasing and receiving costs, direct and indirect costs to manufacture products including direct materials, direct labor and direct overhead expenses necessary to acquire and convert purchased materials and supplies into finished goods, royalties paid or owed by Endo on certain in-licensed products, inspection costs, depreciation of certain property, plant and equipment, amortization of intangible assets, warehousing costs, freight charges, costs to operate our equipment and other shipping and handling costs, among others.

Share-Based Compensation. The Company grants share-based compensation awards to certain employees and non-employee directors. Generally, the grant-date fair value of each award is recognized as expense over the requisite service period. However, expense recognition differs in the case of certain performance share units where the ultimate payout is performance-based. For these awards, at each reporting period, the Company estimates the ultimate payout and adjusts the cumulative expense based on its estimate and the percent of the requisite service period that has elapsed. Share-based compensation expense is reduced for estimated future forfeitures. These estimates are revised in future periods if actual forfeitures differ from the estimates. Changes in forfeiture estimates impact compensation expense in the period in which the change in estimate occurs. New ordinary shares are generally issued upon the exercise of stock options or vesting of stock awards by employees and non-employee directors.

Foreign Currency. The Company operates in various jurisdictions both inside and outside of the U.S. While the Company’s reporting currency is the U.S. dollar (USD), the Company has concluded that certain of its distinct and separable operations have functional currencies other than the USD. Further, certain of the Company’s operations hold assets and liabilities and recognize income and expenses denominated in various local currencies, which may differ from their functional currencies.

Assets and liabilities are first remeasured from local currency to functional currency, generally using end-of-period exchange rates. Foreign currency income and expenses are generally remeasured using average exchange rates in effect during the year. In the case of nonmonetary assets and liabilities such as inventories, prepaid expenses, property, plant and equipment, goodwill and other intangible assets, and related income statement amounts, such as depreciation expense, historical exchange rates are used for remeasurement. The net effect of remeasurement is included in Other (income) expense, net in the Consolidated Statements of Operations.

As part of the Company’s consolidation process, assets and liabilities of entities with functional currencies other than the USD are translated into USD at end-of-period exchange rates. Income and expenses are translated using average exchange rates in effect during the year. The net effect of translation is included as foreign currency translation, a component of Other comprehensive income (loss). Upon the sale or liquidation of an investment in a foreign operation, the Company records a reclassification adjustment out of Other comprehensive income (loss) for the accumulated amount of currency translation.

Income Taxes. The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company records net deferred tax assets to the extent it believes these assets will more likely than not be realized. In making such a determination, the Company considers all available positive and negative evidence, including projected future taxable income, tax-planning strategies and results of recent operations. In the event that the Company were to determine that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income tax.

The Company records uncertain tax positions on the basis of a two-step process whereby the Company first determines whether it is more likely than not that the tax positions will be sustained based on the technical merits of the position and then measures those tax positions that meet the more-likely-than-not recognition threshold. The Company recognizes the largest amount of tax benefit that is greater than 50% likely to be realized upon ultimate settlement with the tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within the Income tax expense (benefit) line in the Consolidated Statements of Operations. Accrued interest and penalties are included within the related tax liability line in the Consolidated Balance Sheets.

Comprehensive Income. Comprehensive income or loss includes all changes in equity during a period except those that resulted from investments by or distributions to a company’s shareholders. Other comprehensive income or loss refers to revenues, expenses, gains and losses that are included in comprehensive income, but excluded from net income as these amounts are recorded directly as an adjustment to shareholders’ equity.

Recent Accounting Pronouncements

Recently Issued Accounting Pronouncements Not Yet Adopted at December 31, 2017

In May 2014, the Financial Accounting Standards Board (FASB) issued ASU No. 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09). ASU 2014-09 represents a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which a company expects to be entitled to receive in exchange for those goods or services. This ASU sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed. In August 2015, the FASB issued ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” which defers the effective date of ASU 2014-09 by one year, but permits companies to adopt one year earlier if they choose (i.e., the original effective date). As such, ASU 2014-09 will be effective for annual and interim reporting periods beginning after December 15, 2017. In March and April 2016, the FASB issued ASU No. 2016-08 “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Consideration (Reporting Revenue Gross versus Net)” and ASU No. 2016-10 “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,” respectively, which clarifies the guidance on reporting revenue as a principal versus agent, identifying performance obligations and accounting for intellectual property licenses. In addition, in May 2016, the FASB issued ASU No. 2016-12 “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients,” which amends certain narrow aspects of Topic 606, and in December 2016, the FASB issued ASU No. 2016-20 “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,” which amends certain narrow aspects of Topic 606.

The new revenue recognition standard is effective for the Company on January 1, 2018. The Company is currently finalizing its analysis of the impact of ASU 2014-09 on its consolidated results of operations and financial position. The Company established a cross-functional implementation team consisting of representatives from across its business segments, which has substantially completed a diagnostic assessment of the impact of the standard on its contract portfolio, including review of customer contracts, as well as the Company’s current accounting policies and practices to identify potential differences that would result from applying the requirements of the new standard to its revenue contracts. Based on this assessment, the Company does not expect the impact to be material to its consolidated financial statements. The Company is also finalizing its evaluation of the internal control implications associated with the adoption of the new standard, including the identification and implementation, if necessary, of changes to its business processes, systems and controls to support recognition and disclosure under the new standard.

The majority of the Company’s revenue is generated from product sales and the Company currently does not anticipate a significant impact to revenue related to these arrangements. In certain limited situations, under current GAAP, the Company has deferred revenue for certain product sales because the sales price was not deemed to be fixed or determinable. Under the new standard, the Company will be required to estimate the variable consideration associated with these transactions and record revenue at the point of sale.

The Company also generates revenue from certain less significant transactions, including certain licensing arrangements. The Company has substantially completed its preliminary evaluation of the impact of the new standard on these other transactions and does not anticipate a significant impact on revenue related to these arrangements; however, this analysis is preliminary and remains subject to change.

The two permitted transition methods under the new standard are the full retrospective method, in which case the standard would be applied to each prior reporting period presented and the cumulative effect of applying the standard would be recognized at the earliest period shown, or the modified retrospective method, in which case the cumulative effect of applying the standard would be recognized at the date of initial application. The Company will utilize the modified retrospective method of adoption.

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (ASU 2016-02). ASU 2016-02 establishes the principles to report transparent and economically neutral information about the assets and liabilities that arise from leases. This guidance requires lessees to recognize the lease assets and lease liabilities that arise from leases in the statement of financial position and to disclose qualitative and quantitative information about lease transactions, such as information about variable lease payments and options to renew and terminate leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2016-02 on the Company’s consolidated results of operations and financial position.

In May 2017, the FASB issued ASU No. 2017-09 “Compensation - Stock Compensation” (ASU 2017-09). ASU 2017-09 provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. It is intended to reduce both (1) diversity in practice and (2) cost and complexity when accounting for changes to the terms or conditions of share-based payment awards. ASU 2017-09 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. The Company adopted the new standard on January 1, 2018 and the amendments in this update will be applied prospectively to any award modified on or after the adoption date.

In February 2018, the FASB issued ASU No. 2018-02 “Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income” (ASU 2018-02). ASU 2018-02 allows for a reclassification from accumulated other comprehensive income or loss to retained earnings or accumulated deficit for stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017 (TCJA). ASU 2018-02 also requires certain related disclosures. ASU 2018-02 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2018 and should be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the U.S. federal corporate income tax rate in the TCJA is recognized. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-02.

Recent Accounting Pronouncements Adopted or Otherwise Effective as of December 31, 2017

In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory” (ASU 2015-11). ASU 2015-11 states that an entity should measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. For public entities, ASU 2015-11 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company adopted ASU 2015-11 on January 1, 2017 and the adoption did not impact the Company’s consolidated results of operations and financial position.

As discussed above under the heading “Reclassifications,” in March 2016, the FASB issued ASU 2016-09. ASU 2016-09 changes how companies account for certain aspects of share-based payments to employees including: (i) requiring all income tax effects of awards to be recognized in the income statement, rather than in additional paid in capital, when the awards vest or are settled, (ii) eliminating the requirement that excess tax benefits be realized before companies can recognize them, (iii) requiring companies to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity, (iv) increasing the amount an employer can withhold to cover income taxes on awards and still qualify for the exception to liability classification for shares used to satisfy the employer’s statutory income tax withholding obligation, (v) requiring an employer to classify the cash paid to a tax authority when shares are withheld to satisfy its statutory income tax withholding obligation as a financing activity on its statement of cash flows and (vi) electing whether to account for forfeitures of share-based payments by (a) recognizing forfeitures of awards as they occur or (b) estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change, as is currently required. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company adopted the new guidance on January 1, 2017 on a prospective basis, except for the provision requiring companies to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity, which was adopted retrospectively. As a result of the adoption, during the year ended December 31, 2017, the Company did not recognize any tax expense in its Consolidated Statement of Operations that would have been recorded as additional paid-in capital prior to adoption. The table above under the heading “Reclassifications” presents the retrospective effects of the adoption of ASU 2016-09 on the Company’s Consolidated Statements of Cash Flows, which related to the reclassification of excess tax benefits. The adoption of ASU 2016-09 did not impact beginning retained earnings and the Company will continue to estimate forfeitures to determine the amount of compensation cost to be recognized in each period. None of the other provisions in this amended guidance had a significant impact on the Company’s consolidated financial statements.

As discussed above under the heading “Reclassifications,” in August 2016, the FASB issued ASU 2016-15. ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. One of the provisions of ASU 2016-15 is that cash outflows for debt prepayment or debt extinguishment costs should be classified as cash outflows for financing activities, rather than operating activities. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted in any interim or annual period, but all of ASU 2016-15 must be adopted in the same period. All updates should be applied using a retrospective transition method. The Company early adopted ASU 2016-15 on December 31, 2017. The table above under the heading “Reclassifications” presents the retrospective effects of the adoption of ASU 2016-15 on the Company’s Consolidated Statements of Cash Flows, which related to the reclassification of cash outflows for debt prepayment costs.

In October 2016, the FASB issued ASU No. 2016-16 “Intra-Entity Transfers of Assets Other Than Inventory” (ASU 2016-16). ASU 2016-16 states that an entity should recognize the income tax consequences when an intra-entity transfer of an asset other than inventory occurs. ASU 2016-16 is effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years. Early adoption is permitted as long as it is adopted in the first interim period of a fiscal year beginning after December 15, 2016. The Company early adopted ASU 2016-16 on January 1, 2017, resulting in the elimination of previously recorded deferred charges that were established in 2016. Specifically, the Company eliminated a $24.1 million current deferred charge and a $348.8 million non-current deferred charge that were reflected in our Consolidated Balance Sheet at December 31, 2016 as Prepaid expenses and other current assets and Other assets, respectively. The eliminations of these deferred charges were recorded as adjustments to retained earnings as of January 1, 2017. On adoption, the Company also recorded net deferred tax assets, primarily related to certain intangible assets and tax deductible goodwill, of $479.7 million, fully offset by a corresponding valuation allowance.

As discussed above under the heading “Reclassifications,” in November 2016, the FASB issued ASU 2016-18. ASU 2016-18 states that a statement of cash flows should explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period, and all updates should be applied using a retrospective transition method. The Company early adopted ASU 2016-18 on December 31, 2017. The table above under the heading “Reclassifications” presents the retrospective effects of the adoption of ASU 2016-18 on the Company’s Consolidated Statements of Cash Flows.

In January 2017, the FASB issued ASU No. 2017-01 “Business Combinations (Topic 805) - Clarifying the Definition of a Business” (ASU 2017-01). ASU 2017-01 clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The amendments in this update provide a screen to determine when an integrated set of assets and activities (collectively referred to as a “set”), is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. ASU 2017-01 is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. The amendments in this update should be applied prospectively on or after the effective date. Early application of the amendments in this update is allowed. The Company early adopted this new standard on January 1, 2017.

In January 2017, the FASB issued ASU 2017-04. ASU 2017-04 simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. In computing the implied fair value of goodwill under Step 2, an entity had to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities (including unrecognized assets and liabilities) following the procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Instead, under ASU 2017-04, an entity should perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider the income tax effects of any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019 and an entity should apply the amendments of ASU 2017-04 on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company early adopted this standard on January 1, 2017. Refer to Note 10. Goodwill and Other Intangibles for a description of goodwill impairment charges taken during the year ended December 31, 2017.

Discontinued Operations and Assets and Liabilities Held For Sale

12 Months Ended

Dec. 31, 2017

Discontinued Operations and Disposal Groups [Abstract]

DISCONTINUED OPERATIONS AND ASSETS AND LIABILITIES HELD FOR SALE

NOTE 3. DISCONTINUED OPERATIONS AND ASSETS AND LIABILITIES HELD FOR SALE

American Medical Systems

On February 24, 2015, the Company’s Board of Directors (Board of Directors) approved a plan to sell the Company’s American Medical Systems Holdings, Inc. (AMS) business. The AMS business included the Men’s Health and Prostate Health and Women’s Health (Astora) businesses. The Men’s Health and Prostate Health businesses were sold to Boston Scientific Corporation (Boston Scientific) on August 3, 2015 for $1.6 billion in cash. In addition, Boston Scientific paid $60.0 million in exchange for 60,000 shares of AMS Series B Non-Voting Preferred Stock (the Series B Senior Preferred Stock) sold by our subsidiary Endo Pharmaceuticals Inc. (EPI). On December 11, 2015, the Company repurchased the Series B Senior Preferred Stock from Boston Scientific Corporation for $61.6 million.

On February 24, 2016, the Company’s Board of Directors resolved to wind-down the remaining Astora business as it did not align with the Company’s strategic direction and to reduce Astora’s exposure to mesh-related product liability. Astora ceased business operations on March 31, 2016.

The operating results of AMS are reported as Discontinued operations, net of tax in the Consolidated Statements of Operations for all periods presented. The assets and liabilities of the AMS disposal groups were classified as held for sale until they were sold in the case of the Men’s Health and Prostate Health businesses, or until the Company determined it would wind-down the remaining business in the case of Astora.

In connection with classifying AMS as held for sale during 2015, the Company was required to compare the estimated fair values of the underlying disposal groups, less the costs to sell, to the respective carrying amounts. The Company performed this analysis for each unsold AMS disposal group during each reporting period in 2015. As a result of these analyses, the Company recorded combined asset impairment charges of $230.7 million in 2015, which were classified as Discontinued operations, net of tax in the Consolidated Statements of Operations. We estimated the fair value of the Men’s Health and Prostate Health businesses based on the agreed-upon purchase price with Boston Scientific. The fair value of Astora was estimated based on contemporaneous expressions of interest from third parties.

Subsequently, at the time of the sale of the Men’s Health and Prostate Health businesses in August 2015, the Company recorded a gain based on the difference between the net proceeds received and the net book value of the assets sold of approximately $13.6 million, which included an adjustment of $25.7 million relating to amounts transferred from foreign currency translation adjustments and included in the determination of net income for the period as a result of the sale, which decreased the gain. This amount is included in Discontinued operations, net of tax in the Consolidated Statements of Operations for the year ended December 31, 2015.

In addition, as a result of determining that the sale of the AMS disposal groups was probable as of December 31, 2015, the Company re-assessed its permanent reinvestment assertion for certain components of the AMS business and recognized a corresponding tax benefit of $161.8 million during the year ended December 31, 2015, which was recorded as Income tax benefit (a component of Loss from continuing operations) in the Consolidated Statements of Operations. In addition, due to the overall differences between the book and tax basis of the underlying assets sold during the third quarter of 2015, the Company recognized a tax benefit of $157.4 million during the year ended December 31, 2015 from Discontinued operations.

As a result of the Astora wind-down initiative announced in the first quarter of 2016, the Company incurred asset impairment charges of $21.3 million during the year ended December 31, 2016. See below for discussion of our material wind-down initiatives.

The following table provides the operating results of AMS Discontinued operations, net of tax for the years ended December 31, 2017, 2016 and 2015 (in thousands):



	2017			2016			2015
Revenue	$	338		$	30,101		$	305,256
Litigation-related and other contingencies, net	$	775,474		$	20,115		$	1,107,752
Asset impairment charges	$	—		$	21,328		$	230,703
Gain on sale of business	$	—		$	—		$	13,550
Loss from discontinued operations before income taxes	$	(816,426	)	$	(123,164	)	$	(1,352,344	)
Income tax benefit	$	(13,704	)	$	—		$	(157,418	)
Discontinued operations, net of tax	$	(802,722	)	$	(123,164	)	$	(1,194,926	)

Amounts reported in the table above as Litigation-related and other contingencies, net primarily relate to charges for vaginal-mesh-related matters, which are further described in Note 14. Commitments and Contingencies.

The cash flows from discontinued operating activities related to AMS included the impact of net losses of $802.7 million, $123.2 million and $1,194.9 million for the years ended December 31, 2017, 2016 and 2015, respectively, and the impact of cash activity related to vaginal mesh cases, which is further described in Note 14. Commitments and Contingencies. Net cash used in discontinued investing activities related to AMS consisted of purchases of property, plant and equipment of $0.1 million and $2.7 million for the years ended December 31, 2016 and 2015, with no comparable amount during the year ended December 31, 2017. There was no depreciation or amortization during the years ended December 31, 2017 or 2016 related to AMS. Depreciation and amortization during the year ended December 31, 2015 was $11.6 million.

Astora Restructuring Initiative

The Astora wind-down process included a restructuring initiative implemented during the three months ended March 31, 2016, which included a reduction of the Astora workforce consisting of approximately 250 employees (the Astora Restructuring Initiative).

The Company did not incur any pre-tax charges during the year ended December 31, 2017 as a result of the Astora Restructuring Initiative. A summary of expenses related to the Astora Restructuring Initiative is included below for the year ended December 31, 2016 (in thousands):



	2016
Employee separation, retention and other benefit-related costs	$	20,476
Asset impairment charges	21,328
Contract termination-related items	8,074
Other wind down costs	10,972
Total	$	60,850

The Company anticipates there will be no significant additional pre-tax restructuring expenses related to this initiative. The majority of these actions were completed as of September 30, 2016 and substantially all cash payments were made by June 30, 2017. These restructuring costs are included in Discontinued operations in the Consolidated Statements of Operations.

The liability related to the Astora Restructuring Initiative is included in Accounts payable and accrued expenses in the Consolidated Balance Sheets. Changes to this liability during the years ended December 31, 2017 and 2016 were as follows (in thousands):



	Employee Separation and Other Benefit-Related Costs			Contract Termination Charges			Other Restructuring Costs			Total
Liability balance as of January 1, 2016	$	—		$	—		$	—		$	—
Expenses	20,476			8,074			5,798			34,348
Cash distributions	(16,621		)	(6,413		)	(5,798		)	(28,832		)
Liability balance as of January 1, 2017	$	3,855		$	1,661		$	—		$	5,516
Cash distributions	(3,855		)	(1,208		)	—			(5,063		)
Liability balance as of December 31, 2017	$	—		$	453		$	—		$	453

Litha

During the fourth quarter of 2016, the Company initiated a process to sell its Litha Healthcare Group Limited and related Sub-Sahara African business assets (Litha) and, on February 27, 2017, the Company entered into a definitive agreement to sell Litha to Acino Pharma AG (Acino). The sale closed on July 3, 2017 and the Company received net cash proceeds of approximately $94.2 million, after giving effect to cash and net working capital purchase price adjustments, as well as a short-term receivable of $4.4 million, which was subsequently collected in October 2017. No additional gain or loss was recognized upon sale. However, in December 2017, Acino became obligated to pay $10.1 million of additional consideration to the Company related to the settlement of certain contingencies set forth in the purchase agreement, which was subsequently paid to the Company in January 2018. In December 2017, the Company recorded a short-term receivable and a gain on the sale of Litha for this amount. The gain is included in Other (income) expense, net in the Consolidated Statements of Operations. The purchase agreement contains an additional contingency that could result in a decrease in the purchase price of up to $26 million as a result of additional payments to Acino, which would result in a loss on the sale. This contingency is expected to be resolved by June 30, 2018.

The assets and liabilities of Litha are classified as held for sale in the Consolidated Balance Sheets as of December 31, 2016. Litha was part of the Company’s International Pharmaceuticals segment.

The following table provides the components of Assets and Liabilities held for sale of Litha as of and December 31, 2016 (in thousands):



	December 31, 2016
Current assets	$	50,167
Property, plant and equipment	3,527
Other intangibles, net	29,950
Other assets	11,343
Assets held for sale	$	94,987
Current liabilities	18,642
Other liabilities	5,696
Liabilities held for sale	$	24,338

Litha does not meet the requirements for treatment as a discontinued operation.

Somar

On June 30, 2017, the Company entered into a definitive agreement to sell Somar and all of the securities thereof, to AI Global Investments (Netherlands) PCC Limited acting for and on behalf of the Soar Cell (the Purchaser). The sale closed on October 25, 2017 and the Purchaser paid an aggregate purchase price of approximately $124 million in cash, after giving effect to estimated cash, debt and net working capital purchase price adjustments. The Company recognized a $1.3 million loss upon sale. Somar was part of the Company’s International Pharmaceuticals segment. Somar does not meet the requirements for treatment as a discontinued operation.

Restructuring

12 Months Ended

Dec. 31, 2017

Restructuring and Related Activities [Abstract]

RESTRUCTURING

NOTE 4. RESTRUCTURING

Auxilium Restructuring Initiative

In connection with the acquisition of Auxilium Pharmaceuticals, Inc. (subsequently converted to Auxilium Pharmaceuticals LLC hereafter referred to as Auxilium) on January 29, 2015, the Company implemented cost-rationalization and integration initiatives to capture operating synergies and generate cost savings across the Company (the Auxilium Restructuring Initiative). These measures included realigning our sales, sales support, management activities and staffing, which included separation benefits to former Auxilium employees, in addition to the closing of duplicative facilities. The cost reduction initiatives included a reduction in headcount of approximately 40% of the former Auxilium workforce. For former Auxilium employees that agreed to continue employment with the Company for a merger transition period, the separation costs payable upon completion of their retention period were expensed over their respective retention period.

As a result of the Auxilium Restructuring Initiative, the Company incurred $1.1 million of restructuring expenses during the year ended December 31, 2017, primarily related to its Chesterbrook, Pennsylvania facility. There were no significant restructuring expenses related to this initiative during the year ended December 31, 2016. The Company incurred restructuring expenses of $41.9 million during the year ended December 31, 2015, primarily consisting of $26.7 million of employee severance and other benefit-related costs. Other restructuring expenses related primarily to our Auxilium subsidiary’s former corporate headquarters in Chesterbrook, Pennsylvania, including $7.0 million of asset impairment charges on certain related leasehold improvements and $7.9 million recorded upon the facility’s cease use date, representing the liability for our remaining obligations under the respective lease agreement, net of estimated sublease income. These restructuring costs were included in the U.S. Branded Pharmaceuticals segment, and were primarily included in Selling, general and administrative costs and expenses in the Consolidated Statements of Operations. The Company does not anticipate any additional pre-tax restructuring expenses.

The liability related to the Auxilium Restructuring Initiative is included in Accounts payable and accrued expenses and Other liabilities in the Consolidated Balance Sheets. Changes to this accrual during the years ended December 31, 2017 and 2016 were as follows (in thousands):



	Employee Separation and Other Benefit-Related Costs			Other Restructuring Costs			Total
Liability balance as of January 1, 2016	$	5,353		$	6,910		$	12,263
Cash distributions	(5,353		)	(1,406		)	(6,759		)
Liability balance as of January 1, 2017	$	—		$	5,504		$	5,504
Expenses	—			1,058			1,058
Cash distributions	—			(1,937		)	(1,937		)
Liability balance as of December 31, 2017	$	—		$	4,625		$	4,625

The remainder of the cash payments will be made over the remaining lease term of the Chesterbrook facility, which extends until December 2023.

2015 U.S. Generic Pharmaceuticals Restructuring Initiative

In connection with the acquisition of Par Pharmaceutical Holdings, Inc. and its subsidiaries (together herein Par) on September 25, 2015, we implemented cost-rationalization and integration initiatives to capture operating synergies and generate cost savings across the Company. These measures included realigning the Company’s U.S. Generic Pharmaceuticals segment sales, sales support, management activities and staffing, which resulted in separation benefits to certain U.S. Generic Pharmaceuticals employees. The cost reduction initiatives included a reduction in headcount of approximately 6% of the U.S. Generic Pharmaceuticals workforces. Under this restructuring initiative (the 2015 U.S. Generic Pharmaceuticals Restructuring Initiative), separation costs were expensed over the requisite service period, if any, while retention was expensed ratably over the respective retention period.

There were no significant restructuring expenses related to this initiative during the year ended December 31, 2017. The Company incurred restructuring expenses of $5.0 million and $23.6 million during the years ended December 31, 2016 and 2015, respectively, consisting of employee separation, retention and other benefit-related costs. These actions were completed by October 31, 2016. These restructuring costs were allocated to the U.S. Generic Pharmaceuticals segment, and were primarily included in Selling, general and administrative expenses in the Consolidated Statements of Operations.

The liability related to the 2015 U.S. Generic Pharmaceuticals Restructuring Initiative is included in Accounts payable and accrued expenses in the Consolidated Balance Sheets. Changes to this accrual during the years ended December 31, 2017 and 2016 were as follows (in thousands):



	Total
Liability balance as of January 1, 2016	$	17,914
Expenses	5,010
Cash distributions	(19,655		)
Liability balance as of January 1, 2017	$	3,269
Expenses	63
Cash distributions	(3,332		)
Liability balance as of December 31, 2017	$	—

2016 U.S. Generic Pharmaceuticals Restructuring Initiative

As part of the ongoing U.S. Generic Pharmaceuticals integration efforts initiated in connection with the acquisition of Par in September 2015, the Company announced a restructuring initiative in May 2016 to optimize its product portfolio and rationalize its manufacturing sites to expand product margins (the 2016 U.S. Generic Pharmaceuticals Restructuring Initiative). These measures included certain cost savings initiatives, including a reduction in headcount and the disposal of our Charlotte, North Carolina manufacturing facility (the Charlotte facility). On October 31, 2016, we entered into a definitive agreement to sell the Charlotte facility for cash proceeds of $14 million. The transaction closed in January 2017. The assets of the Charlotte facility were classified as held for sale in the accompanying Consolidated Balance Sheet as of December 31, 2016.

As a result of the 2016 U.S. Generic Pharmaceuticals Restructuring Initiative, the Company incurred pre-tax charges of $1.0 million and $173.9 million during the years ended December 31, 2017 and 2016, respectively. The 2017 charges related primarily to employee separation and other benefit-related costs.

The 2016 charges consisted of certain asset impairment charges of $107.2 million, charges to increase excess inventory reserves of $33.3 million, charges related to employee separation, retention and other benefit-related costs of $17.0 million, accelerated depreciation of $10.2 million and other charges of $6.2 million. These charges are included in the U.S. Generic Pharmaceuticals segment and are included in Asset impairment charges, Cost of revenues and Selling, general and administrative expenses in the Consolidated Statements of Operations. The Company does not expect to incur additional significant expenses related to this restructuring initiative. Substantially all related cash payments were made by the end of 2017. Under this restructuring initiative, separation costs were expensed ratably over the requisite service period, if any, while retention was expensed ratably over the respective retention period.

The liability related to the 2016 U.S. Generic Pharmaceuticals Restructuring Initiative is included in Accounts payable and accrued expenses in the Consolidated Balance Sheets and related entirely to employee separation and other benefit-related costs. Changes to this liability during the years ended December 31, 2017 and 2016 were as follows (in thousands):



	Total
Liability balance as of January 1, 2016	$	—
Expenses	16,983
Cash distributions	(7,044		)
Liability balance as of January 1, 2017	$	9,939
Expenses	984
Cash distributions	(10,672		)
Liability balance as of December 31, 2017	$	251

2016 U.S. Branded Pharmaceuticals Restructuring Initiative

In December 2016, the Company announced that it was terminating its worldwide license and development agreement with BioDelivery Sciences International, Inc. (BDSI) for BELBUCA™ and returning the product to BDSI. This termination was completed on January 6, 2017. As a result of this announcement and a comprehensive assessment of its product portfolio, the Company restructured its U.S. Branded Pharmaceuticals segment sales organization during the fourth quarter of 2016 (the 2016 U.S. Branded Pharmaceuticals Restructuring Initiative), which included the elimination of an approximate 375-member U.S. Branded Pharmaceuticals pain field sales force and the termination of certain contracts.

The Company did not incur any significant pre-tax charges during the year ended December 31, 2017 as a result of the 2016 U.S. Branded Pharmaceuticals Restructuring Initiative. The Company incurred total pre-tax charges of approximately $61.5 million during the fourth quarter of 2016. These charges consisted of a non-cash intangible asset impairment charge of approximately $36.8 million, employee separation and other benefit-related costs of $16.5 million, early contract termination fees of $5.2 million and $3.0 million of inventory write-offs. Actions related to this initiative were completed by December 31, 2016 and substantially all of the cash payments were made by the end of 2017. These charges are included in the U.S. Branded Pharmaceuticals segment and are included in Asset impairment charges, Cost of revenues, and Selling, general and administrative expenses in the Consolidated Statements of Operations. The Company does not expect to incur any additional material pre-tax restructuring expenses related to this initiative.

The liability related to the 2016 U.S. Branded Pharmaceuticals Restructuring Initiative is included in Accounts payable and accrued expenses in the Consolidated Balance Sheets. Changes to this liability during the years ended December 31, 2017 and 2016 were as follows (in thousands):



	Employee Separation and Other Benefit-Related Costs			Contract Termination Charges			Total
Liability balance as of January 1, 2016	$	—		$	—		$	—
Expenses	16,544			5,224			21,768
Cash distributions	—			—			—
Liability balance as of January 1, 2017	$	16,544		$	5,224		$	21,768
Cash distributions	(16,544		)	(5,224		)	(21,768		)
Liability balance as of December 31, 2017	$	—		$	—		$	—

January 2017 Restructuring Initiative

On January 26, 2017, the Company announced a restructuring initiative implemented as part of its ongoing organizational review (the January 2017 Restructuring Initiative). This restructuring is intended to further integrate, streamline and optimize the Company’s operations by aligning certain corporate and R&D functions with its recently restructured U.S. Generic Pharmaceuticals and U.S. Branded Pharmaceuticals business units in order to create efficiencies and cost savings. As part of this restructuring, the Company undertook certain cost reduction initiatives, including a reduction of approximately 90 positions of its workforce, primarily related to corporate and U.S. Branded Pharmaceuticals R&D functions in Malvern, PA and Chestnut Ridge, NY, a streamlining of general and administrative expenses, an optimization of commercial spend and a refocusing of research and development efforts.

As a result of the January 2017 Restructuring Initiative, the Company incurred total pre-tax charges of approximately $15.1 million during the year ended December 31, 2017 related to employee separation and other benefit-related costs. Of the total charges incurred, $6.9 million are included in the U.S. Branded Pharmaceuticals segment, $4.9 million are included in Corporate unallocated costs and $3.3 million are included in the U.S. Generic Pharmaceuticals segment for the year ended December 31, 2017, respectively. These charges are included in Selling, general and administrative expenses in the Consolidated Statements of Operations. The Company does not expect to incur additional material pre-tax restructuring-related expenses. Substantially all cash payments were made by the end of 2017 and substantially all of the actions associated with this restructuring were completed by the end of April 2017.

The liability related to the January 2017 Restructuring Initiative is included in Accounts payable and accrued expenses in the Consolidated Balance Sheets and is entirely related to employee separation and other benefit-related costs. Changes to this liability during the year ended December 31, 2017 were as follows (in thousands):



	2017
Liability balance as of January 1, 2017	$	—
Expenses	15,072
Cash distributions	(12,391		)
Liability balance as of December 31, 2017	$	2,681

2017 U.S. Generic Pharmaceuticals Restructuring Initiative

On July 21, 2017, the Company announced that after completing a comprehensive review of its manufacturing network, the Company will be ceasing operations and closing its manufacturing and distribution facilities in Huntsville, Alabama (the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative). The closure of the facilities is expected to occur by the end of 2018.

As a result of the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative, the Company’s workforce is expected to be reduced by approximately 815 employees and the Company expects total pre-tax charges related to this initiative to be approximately $345 million, including total estimated cash outlays of approximately $70 million, substantially all of which will be paid by the end of 2018. The estimated restructuring charges consist of accelerated depreciation charges of approximately $155 million, asset impairment charges related to identifiable intangible assets and certain property, plant and equipment of approximately $105 million, charges to increase excess inventory reserves of approximately $10 million, employee separation, retention and other benefit-related costs of approximately $40 million and certain other charges of approximately $35 million. Employee separation, retention and certain other employee benefit-related costs are expensed ratably over the requisite service period. Other costs including, but not limited to, contract termination fees and product technology transfer costs, will be expensed as incurred.

As a result of the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative, the Company incurred pre-tax charges of $286.7 million during the year ended December 31, 2017. These expenses consisted of charges relating to accelerated depreciation of $123.3 million, employee separation, retention and other benefit-related costs of $29.6 million, charges to increase excess inventory reserves of $12.1 million, certain intangible asset and property, plant and equipment impairment charges of $104.7 million and certain other charges of $17.0 million.

These charges are included in the U.S. Generic Pharmaceuticals segment. Intangible asset and property, plant and equipment impairment charges are included in Asset impairment charges. Charges to increase excess inventory reserves are included in Cost of revenues. Employee separation, retention and other benefit-related costs are included in Cost of revenues. Certain other charges are included in both Cost of revenues and Selling, general and administrative expenses in the Consolidated Statements of Operations.

The liability related to the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative is included in Accounts payable and accrued expenses in the Consolidated Balance Sheets. Changes to this liability during the year ended December 31, 2017 were as follows (in thousands):



	Employee Separation and Other Benefit-Related Costs			Other Restructuring Costs			Total
Liability balance as of January 1, 2017	$	—		$	—		$	—
Expenses	29,553			13,724			43,277
Cash distributions	(6,578		)	(12,114		)	(18,692		)
Liability balance as of December 31, 2017	$	22,975		$	1,610		$	24,585

January 2018 Restructuring Initiative

In January 2018, the Company initiated a restructuring initiative that included a reorganization of its U.S. Generic Pharmaceuticals segment’s research and development network, a further simplification of the Company’s manufacturing networks and a company-wide unification of certain corporate functions (the January 2018 Restructuring Initiative).

As a result of the January 2018 Restructuring Initiative, the Company expects total related pre-tax charges of approximately $30 million, including total estimated cash outlays of approximately $25 million, substantially all of which will be paid by March 31, 2019. The estimated restructuring charges consist of employee separation, retention and other benefit-related costs of approximately $25 million and certain other charges of approximately $5 million. Employee separation, retention and certain other employee benefit-related costs are expensed ratably over the requisite service period. Other costs will be expensed as incurred.

As a result of the January 2018 Restructuring Initiative, the Company incurred pre-tax charges of $2.6 million during the year ended December 31, 2017. These expenses consisted of certain property, plant and equipment impairment charges of $2.0 million and certain other charges of $0.6 million. These charges are included in the U.S. Generic Pharmaceuticals segment. Impairment charges are included in Asset impairment charges in the Consolidated Statements of Operations. Certain other charges are included in Selling, general and administrative expenses in the Consolidated Statements of Operations.

Acquisitions

12 Months Ended

Dec. 31, 2017

Business Combinations [Abstract]

ACQUISITIONS

NOTE 5. ACQUISITIONS

For each of the acquisitions described below, the estimates of the fair values of the net assets acquired have been finalized and all measurement period adjustments are complete.

Auxilium Pharmaceuticals, Inc.

On January 29, 2015 (the Auxilium Acquisition Date), the Company acquired all of the outstanding shares of common stock of Auxilium, a fully integrated specialty biopharmaceutical company in the men’s healthcare sector with a strategically focused product portfolio and pipeline in orthopedics, dermatology and other therapeutic areas, in a cash and stock transaction valued at $2.6 billion. The consideration included 18,609,835 ordinary shares valued at $1.52 billion.

The operating results of Auxilium are included in the accompanying Consolidated Statements of Operations for the years ended December 31, 2017 and 2016 and the operating results from the acquisition date of January 29, 2015 are included in the accompanying Consolidated Statements of Operations for the year ended December 31, 2015. The Consolidated Balance Sheets as of December 31, 2017 and 2016 reflect the acquisition of Auxilium. Our measurement period adjustments for Auxilium were complete as of December 31, 2015.

The Company recognized no acquisition-related transaction costs associated with the Auxilium acquisition during the years ended December 31, 2017 and 2016. The Company recognized acquisition-related transaction costs associated with the Auxilium acquisition during the year ended December 31, 2015 totaling $23.1 million. These costs, which related primarily to bank fees, legal and accounting services and fees for other professional services, are included in Acquisition-related and integration items in the accompanying Consolidated Statements of Operations.

The amounts of Auxilium Revenue and Net loss included in the Company’s Consolidated Statements of Operations from and including January 29, 2015 to December 31, 2015 are as follows (in thousands, except per share data):



Revenue	$	341,520
Net loss attributable to Endo International plc (1)	$	(469,986	)
Basic and diluted net loss per share	$	(2.38	)

__________


(1)	Net loss attributable to Endo International plc does not include any portion of the goodwill impairment charges recorded during 2015 since it is not possible to distinguish the amount of the charges directly attributable to Auxilium.

The following supplemental unaudited pro forma information presents the financial results as if the acquisition of Auxilium had occurred on January 1, 2015 for the year ended December 31, 2015. This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2015, nor is it indicative of any future results.



	2015
Unaudited pro forma consolidated results (in thousands, except per share data):
Revenue	$	3,292,293
Net loss attributable to Endo International plc	$	(1,513,625	)
Basic and diluted net loss per share	$	(7.68	)

These amounts have been calculated after applying the Company’s accounting policies and adjusting the results of Auxilium to reflect factually supportable adjustments that give effect to events that are directly attributable to the Auxilium acquisition assuming the Auxilium acquisition had occurred on January 1, 2015. These adjustments mainly include adjustments to interest expense and additional intangible amortization. The adjustments to interest expense, net of tax, related to borrowings to finance the acquisition increased the expense by $1.1 million for the year ended December 31, 2015. In addition, the adjustments include additional intangible amortization, net of tax, which would have been charged assuming the Company’s estimated fair value of the intangible assets. The adjustment to the amortization expense for the year ended December 31, 2015 increased the expense by $6.2 million.

Acquisition of Par Pharmaceutical Holdings, Inc.

On September 25, 2015 (Par Acquisition Date), the Company acquired Par Pharmaceutical Holdings, Inc., a specialty pharmaceutical company that develops, licenses, manufactures, markets and distributes innovative and cost-effective pharmaceuticals with a focus on high-barrier-to-entry products and first-to-file or first-to-market opportunities, for total consideration of $8.14 billion, including the assumption of Par debt. The consideration included 18,069,899 of the Company’s ordinary shares valued at $1.33 billion.

The operating results of Par are included in the accompanying Consolidated Statements of Operations for the years ended December 31, 2017 and 2016 and the operating results from the acquisition date of September 25, 2015 are included in the accompanying Consolidated Statements of Operations for the year ended December 31, 2015. The Consolidated Balance Sheets as of December 31, 2017 and 2016 reflect the acquisition of Par. Our measurement period adjustments for Par were complete as of September 30, 2016.

The Company recognized acquisition-related transaction costs associated with the Par acquisition during the year ended December 31, 2015 totaling $46.3 million. These costs, which related primarily to bank fees, legal and accounting services and fees for other professional services, are included in Acquisition-related and integration items in the accompanying Consolidated Statements of Operations.

The amounts of Par revenue and Net loss attributable to Endo International plc included in the Company’s Consolidated Statements of Operations for the year ended December 31, 2015 from and including September 25, 2015 to December 31, 2015 are as follows (in thousands, except per share data):



Revenue	$	401,238
Net loss attributable to Endo International plc	$	(4,348	)
Basic and diluted net loss per share	$	(0.02	)

The following supplemental unaudited pro forma information presents the financial results as if the acquisition of Par had occurred on January 1, 2015 for the year ended December 31, 2015. This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2015, nor is it indicative of any future results.



	2015
Unaudited pro forma consolidated results (in thousands, except per share data):
Revenue	$	4,268,110
Net loss attributable to Endo International plc	$	(1,594,130	)
Basic and diluted net loss per share	$	(8.09	)

These amounts have been calculated after applying the Company’s accounting policies and adjusting the results of Par to reflect factually supportable adjustments that give effect to events that are directly attributable to the Par acquisition assuming the Par acquisition had occurred on January 1, 2015. These adjustments mainly include adjustments to interest expense and additional intangible amortization. The adjustments to interest expense, net of tax, related to borrowings to finance the acquisition increased the expense by $11.7 million for the year ended December 31, 2015. In addition, the adjustments include additional intangible amortization, net of tax, which would have been charged assuming the Company’s estimated fair value of the intangible assets. The adjustment to the amortization expense for the year ended December 31, 2015 increased the expense by $129.2 million.

Aspen Holdings

On October 1, 2015, the Company acquired a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutic areas from a subsidiary of Aspen Pharmacare Holdings Ltd, a leading publicly-traded South African company that supplies branded and generic products in more than 150 countries, and from GlaxoSmithKline plc (GSK) for total consideration of approximately $135.6 million. The Company accounted for this transaction as a business combination in accordance with the relevant accounting literature. The transaction expanded the Company’s presence in South Africa. These products were incorporated into our Litha business, which was subsequently sold in July 2017.

Until sold, the operating results of the Aspen Asset Acquisition were included in the accompanying Consolidated Statements of Operations for the years ended December 31, 2017 and 2016 and the operating results from the acquisition date of October 1, 2015 are included in the accompanying Consolidated Statements of Operations for the year ended December 31, 2015. Our measurement period adjustments for the Aspen Asset Acquisition were complete as of September 30, 2016.

Pro forma results of operations have not been presented because the effect of the Aspen Asset Acquisition was not material.

VOLTAREN^® Gel

The Company had exclusive U.S. marketing rights to VOLTAREN^® Gel through June 30, 2016 pursuant to a License and Supply Agreement entered into in 2008 with and among Novartis AG and Novartis Consumer Health, Inc. (the 2008 VOLTAREN^® Gel Agreement). On December 11, 2015, the Company, Novartis AG and Sandoz Inc. entered into a new License and Supply Agreement (the 2015 VOLTAREN^® Gel Agreement) whereby the Company licensed exclusive U.S. marketing and license rights to commercialize VOLTAREN^® Gel and to launch an authorized generic of VOLTAREN^® Gel effective July 1, 2016. Pursuant to the 2015 VOLTAREN^® Gel Agreement, the former 2008 VOLTAREN^® Gel Agreement expired on June 30, 2016 in accordance with its terms.

The Company accounted for this transaction as a business combination as of the effective date in accordance with the relevant accounting literature. The Company acquired the product for consideration of approximately $162.7 million, consisting of an upfront payment of $16.2 million and contingent cash consideration with an acquisition-date fair value of approximately $146 million, including the impact of a measurement period adjustment recorded during the fourth quarter of 2016. See Note 7. Fair Value Measurements for further discussion of this contingent consideration.

The preliminary fair values of the net identifiable assets acquired totaled approximately $162.7 million, resulting in no goodwill. The amount of net identifiable assets acquired in connection with the VOLTAREN^® Gel acquisition includes approximately $162.7 million of identifiable developed technology intangible assets to be amortized over an average life of approximately 7 years. Our measurement period adjustments for the acquisition of VOLTAREN^® Gel were complete as of December 31, 2016.

The operating results of VOLTAREN^® Gel under business combination accounting are included in the accompanying Consolidated Statements of Operations for the year ended December 31, 2017 and for the six months ended December 31, 2016. The results included in the accompanying Consolidated Statements of Operations for the year ended December 31, 2015 and for the six months ended June 30, 2016, were accounted for under the previous license and supply agreement, which was not treated as a business combination.

Pro forma results of operations have not been presented because the effect of the 2015 VOLTAREN^® Gel Agreement was not material.

Segment Results

12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

SEGMENT RESULTS

NOTE 6. SEGMENT RESULTS

Beginning with our first quarter 2018 Quarterly Report on Form 10-Q, the four reportable business segments in which we now operate are: (1) U.S. Branded - Specialty & Established Pharmaceuticals, (2) U.S. Branded - Sterile Injectables, (3) U.S. Generic Pharmaceuticals and (4) International Pharmaceuticals. Prior to that, the Company had three reportable segments: (1) U.S. Generic Pharmaceuticals, (2) U.S. Branded Pharmaceuticals and (3) International Pharmaceuticals. Our new U.S. Branded - Sterile Injectables segment consists of our sterile injectables product portfolio, which was previously part of our former U.S. Generic Pharmaceuticals segment. Our new U.S. Generic Pharmaceuticals segment represents the remainder of our former U.S. Generic Pharmaceuticals segment. Additionally, our former U.S. Branded Pharmaceuticals segment has been renamed “U.S. Branded - Specialty & Established Pharmaceuticals.” The information in this Note 6. Segment Results has been retrospectively adjusted to reflect this change in reportable segments.

Our segments reflect the level at which the chief operating decision maker regularly reviews financial information to assess performance and to make decisions about resources to be allocated. Each segment derives revenue from the sales or licensing of its respective products and is discussed in more detail below.

We evaluate segment performance based on each segment’s adjusted income from continuing operations before income tax, which we define as Loss from continuing operations before income tax and before certain upfront and milestone payments to partners; acquisition-related and integration items, including transaction costs, earn-out payments or adjustments, changes in the fair value of contingent consideration and bridge financing costs; cost reduction and integration-related initiatives such as separation benefits, retention payments, other exit costs and certain costs associated with integrating an acquired company’s operations; excess costs that will be eliminated pursuant to integration plans; asset impairment charges; amortization of intangible assets; inventory step-up recorded as part of our acquisitions; certain non-cash interest expense; litigation-related and other contingent matters; gains or losses from early termination of debt; foreign currency gains or losses on intercompany financing arrangements; and certain other items.

Certain of the corporate general and administrative expenses incurred by the Company are not attributable to any specific segment. Accordingly, these costs are not allocated to any of the Company’s segments and are included in the results below as “Corporate unallocated costs.” Interest income and expense are also considered corporate items and not allocated to any of the Company’s segments. The Company’s consolidated adjusted income from continuing operations before income tax is equal to the combined results of each of its segments less these unallocated corporate items.

U.S. Branded - Specialty & Established Pharmaceuticals

Our U.S. Branded - Specialty & Established Pharmaceuticals segment includes a variety of branded prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The products that are included in this segment include XIAFLEX^®, SUPPRELIN^®LA, TESTOPEL^®, NASCOBAL^® Nasal Spray, AVEED^®, OPANA^®ER, PERCOCET^®, VOLTAREN^®Gel, LIDODERM^®, TESTIM^® and FORTESTA^®Gel, among others.

U.S. Branded - Sterile Injectables

Our U.S. Branded - Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT^®, ADRENALIN^® and APLISOL^®, among others, and certain generic sterile injectable products, including ephedrine sulfate injection and neostigmine methylsulfate injection, among others.

U.S. Generic Pharmaceuticals

Our U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health and cardiovascular disease markets, among others.

International Pharmaceuticals

Our International Pharmaceuticals segment includes a variety of specialty pharmaceutical products sold outside the U.S., primarily in Canada through our operating company Paladin Labs Inc. (Paladin). This segment’s key products serve growing therapeutic areas, including attention deficit hyperactivity disorder (ADHD), pain, women’s health and oncology. This segment also included: (i) our South African business, which was sold in July 2017 and consisted of Litha Healthcare Group Limited and certain assets acquired from Aspen Holdings in October 2015 and (ii) our Latin American business consisting of Grupo Farmacéutico Somar, S.A.P.I. de C.V. (Somar), which was sold in October 2017.

The following represents selected information for the Company’s reportable segments for the years ended December 31, 2017, 2016 and 2015 (in thousands):



	2017		2016		2015
Net revenues to external customers:
U.S. Branded - Specialty & Established Pharmaceuticals	$	957,525	$	1,166,294	$	1,284,607
U.S. Branded - Sterile Injectables	750,471		576,399		114,719
U.S. Generic Pharmaceuticals	1,530,530		1,988,214		1,557,697
International Pharmaceuticals (1)	230,332		279,367		311,695
Total net revenues to external customers	$	3,468,858	$	4,010,274	$	3,268,718
Adjusted income from continuing operations before income tax:
U.S. Branded - Specialty & Established Pharmaceuticals	$	485,515	$	553,806	$	694,440
U.S. Branded - Sterile Injectables	563,103		426,170		76,627
U.S. Generic Pharmaceuticals	501,249		653,309		665,140
International Pharmaceuticals	58,308		84,337		81,789
Total segment adjusted income from continuing operations before income tax	$	1,608,175	$	1,717,622	$	1,517,996

__________


(1)	Revenues generated by our International Pharmaceuticals segment are primarily attributable to external customers located in Canada and, prior to the sale of Litha on July 3, 2017 and Somar on October 25, 2017, South Africa and Latin America.

There were no material revenues from external customers attributed to an individual country outside of the United States during the years ended December 31, 2017, 2016 and 2015. There were no material tangible long-lived assets in an individual country other than the United States as of December 31, 2017 or December 31, 2016.

The table below provides reconciliations of our consolidated Loss from continuing operations before income tax, which is determined in accordance with U.S. GAAP, to our total segment adjusted income from continuing operations before income tax for the years ended December 31, 2017, 2016 and 2015 (in thousands):



	2017			2016			2015
Total consolidated loss from continuing operations before income tax	$	(1,483,004	)	$	(3,923,856	)	$	(1,437,864	)
Interest expense, net	488,228			452,679			373,214
Corporate unallocated costs (1)	165,298			189,043			171,242
Amortization of intangible assets	773,766			876,451			561,302
Inventory step-up and certain manufacturing costs that will be eliminated pursuant to integration plans	390			125,699			249,464
Upfront and milestone payments to partners	9,483			8,330			16,155
Separation benefits and other cost reduction initiatives (2)	212,448			107,491			125,407
Impact of VOLTAREN® Gel generic competition	—			(7,750		)	—
Acceleration of Auxilium employee equity awards at closing	—			—			37,603
Certain litigation-related and other contingencies, net (3)	185,990			23,950			37,082
Asset impairment charges (4)	1,154,376			3,781,165			1,140,709
Acquisition-related and integration items (5)	58,086			87,601			105,250
Loss on extinguishment of debt	51,734			—			67,484
Costs associated with unused financing commitments	—			—			78,352
Other-than-temporary impairment of equity investment	—			—			18,869
Foreign currency impact related to the remeasurement of intercompany debt instruments	(1,403		)	366			(25,121		)
Other, net	(7,217		)	(3,547		)	(1,152		)
Total segment adjusted income from continuing operations before income tax	$	1,608,175		$	1,717,622		$	1,517,996

__________


(1)	Amounts include certain corporate overhead costs, such as headcount and facility expenses and certain other income and expenses.

(2)

Amounts primarily relate to employee separation costs of $53.0 million, $57.9 million and $60.2 million in 2017, 2016 and 2015, respectively. Other amounts in 2017 include accelerated depreciation of $123.7 million, charges to increase excess inventory reserves of $13.7 million and other charges of $22.0 million, each of which related primarily to the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative. Other amounts in 2016 primarily consist of charges to increase excess inventory reserves of $24.5 million and other restructuring costs of $25.1 million, consisting primarily of contract termination fees and building costs. Other amounts in 2015 primarily consist of $41.2 million of inventory write-offs and $13.3 million of building costs, including a $7.9 million charge recorded upon the cease use date of our Auxilium subsidiary’s former corporate headquarters. See Note 4. Restructuring for discussion of our material restructuring initiatives.


(3)	Amounts include adjustments for Litigation-related and other contingencies, net as further described in Note 14. Commitments and Contingencies.


(4)	Amounts primarily relate to charges to impair goodwill and intangible assets as further described in Note 10. Goodwill and Other Intangibles as well as charges to write down certain property, plant and equipment as further described in Note 4. Restructuring, Note 7. Fair Value Measurements and Note 9. Property, Plant and Equipment.

(5)

Amounts in 2017, 2016 and 2015 include costs directly associated with previous acquisitions of $8.1 million, $63.8 million and $170.9 million, respectively. In addition, in 2017 and 2016, there were charges due to changes in the fair value of contingent consideration of $49.9 million and $23.8 million, respectively. In 2015, there was a benefit due to changes in the fair value of contingent consideration of $65.6 million.

The following represents depreciation expense for our reportable segments for the years ended December 31, 2017, 2016 and 2015 (in thousands):



	2017		2016		2015
U.S. Branded - Specialty & Established Pharmaceuticals	$	16,957	$	16,294	$	19,884
U.S. Branded - Sterile Injectables	8,411		9,023		2,333
U.S. Generic Pharmaceuticals	174,652		70,816		26,860
International Pharmaceuticals	3,332		2,557		3,147
Corporate unallocated	6,647		8,168		7,674
Total depreciation expense	$	209,999	$	106,858	$	59,898

Asset information is not reviewed or included within our internal management reporting. Therefore, the Company has not disclosed asset information for each reportable segment.

Fair Value Measurements

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

NOTE 7. FAIR VALUE MEASUREMENTS

Financial Instruments

The financial instruments recorded in our Consolidated Balance Sheets include cash and cash equivalents (including money market funds and time deposits), restricted cash and cash equivalents, accounts receivable, marketable securities, equity and cost method investments, accounts payable and accrued expenses, acquisition-related contingent consideration and debt obligations. Included in cash and cash equivalents and restricted cash and cash equivalents are money market funds representing a type of mutual fund required by law to invest in low-risk securities (for example, U.S. government bonds, U.S. Treasury Bills and commercial paper). Money market funds pay dividends that generally reflect short-term interest rates. Due to their short-term maturity, the carrying amounts of non-restricted and restricted cash and cash equivalents (including money market funds and time deposits), accounts receivable, accounts payable and accrued expenses approximate their fair values.

At December 31, 2017 and 2016, the Company had combined restricted cash and cash equivalents of $324.4 million and $287.9 million, respectively, of which $320.5 million and $282.1 million, respectively, are classified as current assets and reported in our Consolidated Balance Sheets as Restricted cash and cash equivalents. The remaining amounts, which are classified as non-current assets, are reported in our Consolidated Balance Sheets as Other assets. Approximately $313.8 million and $276.0 million of our restricted cash and cash equivalents are held in QSFs for mesh-related matters at December 31, 2017 and 2016, respectively. See Note 14. Commitments and Contingencies for further information relating to the vaginal mesh liability.

Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:


•	Level 1—Quoted prices in active markets for identical assets or liabilities.


•	Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.


•	Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Marketable Securities

Equity securities consist of investments in the stock of publicly traded companies, the values of which are based on quoted market prices and thus represent Level 1 measurements within the above-defined fair value hierarchy. These securities are not held to support current operations and are therefore classified as non-current assets. Equity securities are included in Marketable securities in our Consolidated Balance Sheets at December 31, 2017 and December 31, 2016.

At the time of purchase, we classify our marketable securities as either available-for-sale securities or trading securities, depending on our intent at that time. Available-for-sale and trading securities are carried at fair value with unrealized holding gains and losses recorded within other comprehensive income or net income, respectively. The Company reviews any unrealized losses associated with available-for-sale securities to determine the classification as a “temporary” or “other-than-temporary” impairment. A temporary impairment results in an unrealized loss being recorded in other comprehensive income. An impairment that is viewed as other-than-temporary is recognized in net income. The Company considers various factors in determining the classification, including the length of time and extent to which the fair value has been less than the Company’s cost basis, the financial condition and near-term prospects of the issuer or investee, and the Company’s ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.

Acquisition-Related Contingent Consideration

The fair value of contingent consideration liabilities is determined using unobservable inputs; hence these instruments represent Level 3 measurements within the above-defined fair value hierarchy. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period, the contingent consideration liability is remeasured at current fair value with changes recorded in earnings. Changes in any of the inputs may result in a significant adjustment to fair value. See Recurring Fair Value Measurements below for additional information on acquisition-related contingent consideration.

Recurring Fair Value Measurements

The Company’s financial assets and liabilities measured at fair value on a recurring basis at December 31, 2017 and December 31, 2016 were as follows (in thousands):



	Fair Value Measurements at Reporting Date using:
December 31, 2017	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets:
Money market funds	$	439,831	$	—	$	—	$	439,831
Time deposits	—		303,410		—		303,410
Equity securities	1,456		—		—		1,456
Total	$	441,287	$	303,410	$	—	$	744,697
Liabilities:
Acquisition-related contingent consideration—short-term	$	—	$	—	$	70,543	$	70,543
Acquisition-related contingent consideration—long-term	—		—		119,899		119,899
Total	$	—	$	—	$	190,442	$	190,442



	Fair Value Measurements at Reporting Date using:
December 31, 2016	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets:
Money market funds	$	26,210	$	—	$	—	$	26,210
Time deposits	—		100,000		—		100,000
Equity securities	2,267		—		—		2,267
Total	$	28,477	$	100,000	$	—	$	128,477
Liabilities:
Acquisition-related contingent consideration—short-term	$	—	$	—	$	109,373	$	109,373
Acquisition-related contingent consideration—long-term	—		—		152,740		152,740
Total	$	—	$	—	$	262,113	$	262,113

At December 31, 2017 and December 31, 2016, money market funds include $35.6 million and $26.2 million, respectively, in QSFs to be disbursed to mesh-related or other product liability claimants. Amounts in QSFs are considered restricted cash equivalents. See Note 14. Commitments and Contingencies for further discussion of our product liability cases. Our money market funds and equity securities are considered available-for-sale securities. The differences between the amortized cost and fair value of such securities were not material, individually or in the aggregate, at December 31, 2017 or December 31, 2016, nor were any of the related gross unrealized gains or losses.

Fair Value Measurements Using Significant Unobservable Inputs

The following table presents changes to the Company’s liability for acquisition-related contingent consideration, which was measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended December 31, 2017 and 2016 (in thousands):



	2017			2016
Beginning of period	$	262,113		$	143,502
Amounts acquired	—			146,866
Amounts settled	(122,559		)	(55,896		)
Measurement period adjustments	—			3,700
Changes in fair value recorded in earnings	49,949			23,823
Effect of currency translation	939			118
End of period	$	190,442		$	262,113

At December 31, 2017, the fair value measurements of the contingent consideration obligations were determined using risk-adjusted discount rates ranging from 10% to 22%. Changes in fair value recorded in earnings related to acquisition-related contingent consideration are included in our Consolidated Statements of Operations as Acquisition-related and integration items, and amounts recorded for the short-term and long-term portions of acquisition-related contingent consideration are included in Accounts payable and accrued expenses and Other liabilities, respectively, in our Consolidated Balance Sheets.

The following table presents changes to the Company’s liability for acquisition-related contingent consideration during the year ended December 31, 2017 by acquisition (in thousands):



	Balance as of December 31, 2016		Acquisitions		Fair Value Adjustments and Accretion			Payments and Other			Balance as of December 31, 2017
Auxilium acquisition	$	21,097	$	—	$	467		$	(8,503	)	$	13,061
Lehigh Valley Technologies, Inc. acquisitions	96,000		—		40,016			(73,015		)	63,001
VOLTAREN^® Gel acquisition	118,395		—		18,586			(38,857		)	98,124
Other	26,621		—		(9,120		)	(1,245		)	16,256
Total	$	262,113	$	—	$	49,949		$	(121,620	)	$	190,442

The following table presents changes to the Company’s liability for acquisition-related contingent consideration during the year ended December 31, 2016 by acquisition (in thousands):



	Balance as of December 31, 2015		Acquisitions		Fair Value Adjustments and Accretion			Payments and Other			Balance as of December 31, 2016
Qualitest acquisition	$	1,137	$	—	$	(1,137	)	$	—		$	—
Sumavel acquisition	631		—		(631		)	—			—
Auxilium acquisition	26,435		—		8,952			(14,290		)	21,097
Lehigh Valley Technologies, Inc. acquisitions	97,003		—		30,676			(31,679		)	96,000
VOLTAREN^® Gel acquisition	—		146,055		(18,807		)	(8,853		)	118,395
Other	18,296		4,511		4,770			(956		)	26,621
Total	$	143,502	$	150,566	$	23,823		$	(55,778	)	$	262,113

Nonrecurring Fair Value Measurements

The Company’s financial assets and liabilities measured at fair value on a nonrecurring basis during the year ended December 31, 2017 were as follows (in thousands):



	Fair Value Measurements at Reporting Date using:						Total Expense for the Year Ended December 31, 2017
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Expense for the Year Ended December 31, 2017
Assets:
Certain U.S. Branded Pharmaceuticals intangible assets (Note 10)	$	—	$	—	$	34,326	$	(76,674	)
Certain U.S. Generic Pharmaceuticals intangible assets (Note 10)	—		—		367,160		(577,923		)
Certain International Pharmaceuticals intangible assets (Note 10)	—		—		21,772		(145,360		)
Certain property, plant and equipment (1)	—		—		—		(65,676		)
Total	$	—	$	—	$	423,258	$	(865,633	)

__________

(1)

Amounts relate primarily to an aggregate charge of $47.2 million recorded in connection with the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative, which is described further in Note 4. Restructuring, and $11.9 million recorded following the initiation of held-for-sale accounting resulting from the Company’s June 30, 2017 definitive agreement to sell Somar, which is described in Note 3. Discontinued Operations and Assets and Liabilities Held for Sale.

Additionally, the Company recorded aggregate goodwill impairment charges during the year ended December 31, 2017 of $288.7 million. Refer to Note 10. Goodwill and Other Intangibles for further description of the impairment charges taken, including the valuation methodologies utilized.

The Company’s financial assets and liabilities measured at fair value on a nonrecurring basis during the year ended December 31, 2016 were as follows (in thousands):



	Fair Value Measurements at Measurement Date using:						Total Expense for the Year Ended December 31, 2016
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Expense for the Year Ended December 31, 2016
Assets:
Certain Astora property, plant and equipment (Note 3)	$	—	$	—	$	—	$	(5,041	)
Certain U.S. Generic Pharmaceuticals property, plant and equipment	—		—		11,360		(13,679		)
Certain U.S. Branded Pharmaceuticals intangible assets (Note 10)	—		—		4,621		(110,430		)
Certain U.S. Generic Pharmaceuticals intangible assets (Note 10)	—		—		872,474		(676,776		)
Certain International Pharmaceuticals intangible assets (Note 10)	—		—		139,313		(301,698		)
Certain Astora intangible assets (Note 3)	—		—		—		(16,287		)
Generics reporting unit goodwill (Note 10)	—		—		3,531,301		(2,342,549		)
Paladin reporting unit goodwill (Note 10)	—		—		170,572		(272,578		)
Somar reporting unit goodwill (Note 10)	—		—		24,044		(33,000		)
Litha reporting unit goodwill (Note 10)	—		—		—		(26,343		)
Other asset impairment charges	—		—		—		(4,112		)
Total	$	—	$	—	$	4,753,685	$	(3,802,493	)

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Inventories

12 Months Ended

Dec. 31, 2017

Inventory Disclosure [Abstract]

INVENTORIES

NOTE 8. INVENTORIES

Inventories consist of the following at December 31, 2017 and December 31, 2016 (in thousands):



	December 31, 2017		December 31, 2016
Raw materials (1)	$	124,685	$	175,240
Work-in-process (1)	109,897		100,494
Finished goods (1)	156,855		279,937
Total	$	391,437	$	555,671

__________

(1) The components of inventory shown in the table above are net of allowance for obsolescence.

Inventory that is in excess of the amount expected to be sold within one year, which relates primarily to XIAFLEX^® inventory, is classified as long-term inventory and is not included in the table above. At December 31, 2017 and December 31, 2016, $17.1 million and $22.9 million, respectively, of long-term inventory was included in Other assets in the Consolidated Balance Sheets. As of December 31, 2017 and December 31, 2016, the Company’s Consolidated Balance Sheets included approximately $5.9 million and $16.8 million, respectively, of capitalized pre-launch inventories related to generic products that were not yet available to be sold.

Property, Plant And Equipment

12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT AND EQUIPMENT

NOTE 9. PROPERTY, PLANT AND EQUIPMENT

Changes in the amount of Property, plant and equipment for the year ended December 31, 2017 are set forth in the table below (in thousands). This table excludes changes related to businesses classified as held for sale, to the extent such changes occurred after the business was classified as held for sale.



Cost:	Land and Buildings			Machinery and Equipment			Leasehold Improve- ments			Computer Equipment and Software			Assets under Capital Lease			Furniture and Fixtures			Assets under Construc- tion			Total
At January 1, 2017	$	322,537		$	227,833		$	50,359		$	118,928		$	9,155		$	21,086		$	129,102		$	879,000
Additions	19,871			49,088			11,067			21,626			—			684			26,043			128,379
Disposals, transfers, impairments and other	(12,333		)	(9,939		)	(1,271		)	(9,459		)	(4,259		)	(8,770		)	(36,186		)	(82,217		)
Effect of currency translation	1,391			836			309			356			—			124			76			3,092
At December 31, 2017	$	331,466		$	267,818		$	60,464		$	131,451		$	4,896		$	13,124		$	119,035		$	928,254
Accumulated Depreciation:
At January 1, 2017	$	(50,770	)	$	(64,319	)	$	(21,263	)	$	(62,836	)	$	(5,773	)	$	(4,443	)	$	—		$	(209,404	)
Additions	(93,633		)	(76,986		)	(6,607		)	(27,121		)	(2,645		)	(3,007		)	—			(209,999		)
Disposals, transfers and other	(4,656		)	6,964			1,088			7,354			4,257			1,201			—			16,208
Effect of currency translation	(343		)	(400		)	(85		)	(189		)	—			(71		)	—			(1,088		)
At December 31, 2017	$	(149,402	)	$	(134,741	)	$	(26,867	)	$	(82,792	)	$	(4,161	)	$	(6,320	)	$	—		$	(404,283	)
Net Book Amount:
At December 31, 2017	$	182,064		$	133,077		$	33,597		$	48,659		$	735		$	6,804		$	119,035		$	523,971
At December 31, 2016	$	271,767		$	163,514		$	29,096		$	56,092		$	3,382		$	16,643		$	129,102		$	669,596

Depreciation expense, including expense related to assets under capital lease, was $210.0 million, $106.9 million and $59.9 million for the years ended December 31, 2017, 2016 and 2015, respectively.

During the years ended December 31, 2017, 2016 and 2015, the Company recorded impairment charges totaling $65.7 million, $15.9 million and $10.8 million, respectively, which amounts exclude $5.0 million in 2016 related to AMS, which was classified as a discontinued operation. Impairment charges in 2017 primarily relate to an aggregate charge of $47.2 million recorded in connection with the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative, which is described further in Note 4. Restructuring, and $11.9 million recorded following the initiation of held-for-sale accounting resulting from the Company’s June 30, 2017 definitive agreement to sell Somar, which is described in Note 3. Discontinued Operations and Assets and Liabilities Held for Sale. In 2016 and 2015, impairment charges reflect the write off of certain property, plant and equipment amounts that were abandoned or sold as part of our ongoing efforts to improve our operating efficiency and consolidate certain locations, including our generics manufacturing and research and development operations. These charges are included in the Asset impairment charges line item in our Consolidated Statement of Operations.

Goodwill And Other Intangibles

12 Months Ended

Dec. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLES

NOTE 10. GOODWILL AND OTHER INTANGIBLES

Goodwill

Changes in the carrying amount of our goodwill for the years ended December 31, 2017 and 2016 were as follows (in thousands):



	Carrying Amount
	U.S. Generic Pharmaceuticals			U.S. Branded Pharmaceuticals			International Pharmaceuticals			Total
Goodwill as of December 31, 2015	$	5,789,934		$	1,002,776		$	506,644		$	7,299,354
Measurement period adjustments	83,916			8,352			1,366			93,634
Effect of currency translation on gross balance	—			—			3,336			3,336
Effect of currency translation on accumulated impairment	—			—			9,421			9,421
Goodwill impairment charges	(2,342,549		)	(1,880		)	(331,921		)	(2,676,350		)
Goodwill as of December 31, 2016	$	3,531,301		$	1,009,248		$	188,846		$	4,729,395
Effect of currency translation on gross balance	—			—			40,454			40,454
Effect of currency translation on accumulated impairment	—			—			(31,023		)	(31,023		)
Goodwill impairment charges	—			(180,430		)	(108,314		)	(288,744		)
Goodwill as of December 31, 2017	$	3,531,301		$	828,818		$	89,963		$	4,450,082

The carrying amounts of goodwill at December 31, 2017 and December 31, 2016 are net of the following accumulated impairments:



	Accumulated Impairment
	U.S. Generic Pharmaceuticals		U.S. Branded Pharmaceuticals		International Pharmaceuticals		Total
Accumulated impairment losses as of December 31, 2016	$	2,342,549	$	675,380	$	408,280	$	3,426,209
Accumulated impairment losses as of December 31, 2017 (1)	$	2,342,549	$	855,810	$	463,545	$	3,661,904

__________


(1)	During the year ended December 31, 2017, we sold our Litha and Somar businesses. Accordingly, we removed $84.1 million of accumulated impairments from the International Pharmaceuticals segment.

Other Intangible Assets

Changes in the amount of other intangible assets for the year ended December 31, 2017 are set forth in the table below (in thousands). This table excludes changes related to businesses classified as held for sale, to the extent such changes occurred after the business was classified as held for sale. As such, this table excludes asset impairment charges of $9.6 million related to our Litha business, assets derecognized upon the divestitures of Litha, Somar and BELBUCA™ with a combined carrying amount of $26.4 million and net increases resulting from currency translation of $1.5 million related to our Litha and Somar businesses.



Cost basis:	Balance as of December 31, 2016			Acquisitions			Impairments (1)			Other (1) (2)			Effect of Currency Translation (1)			Balance as of December 31, 2017
Indefinite-lived intangibles:
In-process research and development	$	1,123,581		$	—		$	(334,490	)	$	(442,100	)	$	209		$	347,200
Total indefinite-lived intangibles	$	1,123,581		$	—		$	(334,490	)	$	(442,100	)	$	209		$	347,200
Finite-lived intangibles:
Licenses (weighted average life of 12 years)	$	465,720		$	—		$	(8,178	)	$	(140	)	$	—		$	457,402
Tradenames	7,345			—			(808		)	(262		)	134			6,409
Developed technology (weighted average life of 11 years)	6,223,004			—			(446,835		)	378,811			32,784			6,187,764
Total finite-lived intangibles (weighted average life of 11 years)	$	6,696,069		$	—		$	(455,821	)	$	378,409		$	32,918		$	6,651,575
Total other intangibles	$	7,819,650		$	—		$	(790,311	)	$	(63,691	)	$	33,127		$	6,998,775

Accumulated amortization:	Balance as of December 31, 2016			Amortization			Impairments			Other (2)			Effect of Currency Translation			Balance as of December 31, 2017
Finite-lived intangibles:
Licenses	$	(341,600	)	$	(28,761	)	$	—		$	140		$	—		$	(370,221	)
Tradenames	(6,599		)	(42		)	—			262			(30		)	(6,409		)
Developed technology	(1,612,154		)	(744,963		)	—			63,289			(10,633		)	(2,304,461		)
Total other intangibles	$	(1,960,353	)	$	(773,766	)	$	—		$	63,691		$	(10,663	)	$	(2,681,091	)
Net other intangibles	$	5,859,297														$	4,317,684

__________


(1)	Additional information on the changes in the total gross carrying amount of our other intangible assets is presented below (in thousands):



	Gross Carrying Amount
December 31, 2016	$	7,819,650
Impairment of certain U.S. Branded Pharmaceuticals intangible assets	(76,674		)
Impairment of certain U.S. Generic Pharmaceuticals intangible assets	(577,923		)
Impairment of certain International Pharmaceuticals intangible assets	(135,714		)
Transfer of intangible assets to Assets held for sale (NOTE 3)	(33,304		)
Removal of certain fully amortized intangible assets	(30,387		)
Effect of currency translation	33,127
December 31, 2017	$	6,998,775


(2)	Includes reclassification adjustments of $442.1 million for certain developed technology intangible assets, previously classified as in-process research and development, that were placed in service during the year ended December 31, 2017, the removal of certain fully amortized intangible assets and the transfer of Somar intangible assets to Assets held for sale.

Amortization expense for the years ended December 31, 2017, 2016 and 2015 totaled $773.8 million, $876.5 million, and $561.3 million respectively. Amortization expense is included in Cost of revenues in the Consolidated Statements of Operations. Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2017 is as follows (in thousands):



2018	$	598,603
2019	$	506,857
2020	$	469,339
2021	$	450,854
2022	$	436,811

Impairments

Endo tests goodwill and indefinite-lived intangible assets for impairment annually, or more frequently whenever events or changes in circumstances indicate that the asset might be impaired. Our annual assessment is performed as of October 1st.

As part of our goodwill and intangible asset impairment assessments, we estimate the fair values of our reporting units and our intangible assets using an income approach that utilizes a discounted cash flow model, or, where appropriate, a market approach. The discounted cash flow models are dependent upon our estimates of future cash flows and other factors. These estimates of future cash flows involve assumptions concerning (i) future operating performance, including future sales, long-term growth rates, operating margins, variations in the amount and timing of cash flows and the probability of achieving the estimated cash flows and (ii) future economic conditions. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The discount rates applied to the estimated cash flows for the Company’s October 1, 2017, 2016 and 2015 annual goodwill and indefinite-lived intangible assets impairment test ranged from 9.5% to 12.5%, 8.5% to 11.0% and from 9.0% to 16.0%, respectively, depending on the overall risk associated with the particular assets and other market factors. We believe the discount rates and other inputs and assumptions are consistent with those that a market participant would use. Any impairment charges resulting from annual or interim goodwill and intangible asset impairment assessments are recorded to Asset impairment charges in our Consolidated Statements of Operations.

A summary of significant goodwill and other intangible asset impairment charges by reportable segment for the years ended December 31, 2017, 2016 and 2015 is included below.

As a result of our annual test performed as of October 1, 2017, the Company determined that the estimated fair values of its Branded, Generics and International reporting units exceeded their carrying amounts; therefore, a goodwill impairment charge was not required for the three months ended December 31, 2017.

Certain of our 2016 impairment charges discussed below related to our 2016 annual goodwill impairment test. After performing this test, we concluded that the carrying amounts of our Generics, Paladin, Somar and Litha reporting units each exceeded their respective estimated fair values and recorded goodwill impairment charges of $2,342.5 million, $272.6 million, $33.0 million and $26.3 million, respectively. The impairments were a result of a combination of factors, including increased buying power from the continued consolidation of our generic business customer base, a significant change in the value derived from the level and frequency of anticipated future pricing opportunities and increased levels of competition, particularly in our Generics reporting unit, due to the entry of new low cost competitors and accelerated FDA ANDA approvals. These factors were exacerbated by an increase in the risk factor included in the discount rate used to calculate the Generics discounted cash flows from the date of our last interim test. The increase in the discount rate was due to the implied control premium resulting from recent trading values of our stock. On a combined basis, these factors reduced the estimated fair value of our reporting units.

Additionally, our 2015 Paladin goodwill impairment charge discussed below related to our 2015 annual goodwill impairment test. After performing this test, we concluded that the carrying amount of our Paladin reporting unit exceeded its estimated fair values and recorded goodwill impairment charges of $85.8 million. The impairment was primarily due to the loss of exclusivity on certain products sold in Canada.

U.S. Generic Pharmaceuticals Segment

During each quarter of 2017, the Company identified certain market conditions impacting the recoverability of certain indefinite and finite-lived intangible assets in its U.S. Generic Pharmaceuticals segment. Accordingly, the Company tested these assets for impairment and determined that their carrying amounts were no longer fully recoverable, resulting in pre-tax, non-cash asset impairment charges totaling $72.7 million, $268.2 million, $54.2 million and $125.3 million during the three months ended March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017, respectively. In addition, as further described in Note 4. Restructuring, we announced the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative in July 2017, which includes the discontinuation of certain commercial products. As a result, we assessed the recoverability of the impacted products, resulting in 2017 pre-tax, non-cash intangible asset impairment charges of approximately $57.5 million.

During the three months ended March 31, 2016 and June 30, 2016, the Company identified certain market and regulatory conditions impacting the commercial potential of certain indefinite and finite-lived intangible assets in our U.S. Generic Pharmaceuticals segment. Accordingly, we tested these assets for impairment and determined that the carrying amounts of certain of these assets were no longer fully recoverable, resulting in pre-tax, non-cash asset impairment charges of $29.3 million and $40.0 million during the first and second quarters of 2016, respectively. In addition, during the first quarter of 2016, the Company recognized pre-tax, non-cash asset impairment charges of $100.3 million related to the 2016 U.S. Generic Pharmaceuticals Restructuring Initiative, which resulted from the discontinuation of certain commercial products and the abandonment of certain IPR&D projects. See Note 4. Restructuring for discussion of our material restructuring initiatives. During the fourth quarter of 2016, the Company recognized pre-tax, non-cash intangible asset impairment charges of $507.2 million in its U.S. Generic Pharmaceuticals segment resulting from certain market conditions, including price erosion and increased competition, impacting the commercial potential of finite and indefinite-lived intangible assets, including higher than expected erosion rates in the U.S. Generic Pharmaceuticals base business. Also during the fourth quarter of 2016, we recognized a pre-tax, non-cash goodwill asset impairment charge of $2,342.5 million. The goodwill impairment charge related to our 2016 annual test, as described above.

During the year ended December 31, 2015, we identified certain market conditions impacting the commercial potential of certain indefinite and finite-lived intangible assets in our U.S. Generic Pharmaceuticals segment. Accordingly, we tested these assets for impairment and determined that the carrying amounts of certain of these assets were no longer fully recoverable, resulting in 2015 pre-tax, non-cash intangible asset impairment charges of $181.0 million.

U.S. Branded Pharmaceuticals Segment

In March 2017, we announced that the Food and Drug Administration’s (FDA) Drug Safety and Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees voted that the benefits of reformulated OPANA^®ER (oxymorphone hydrochloride extended release) no longer outweigh its risks. In June 2017, we became aware of the FDA’s request that we voluntarily withdraw OPANA^®ER from the market, and in July 2017, after careful consideration and consultation with the FDA, we decided to voluntarily remove OPANA^®ER from the market. As a result of our decision, we determined that the carrying amount of our OPANA^® ER intangible asset was no longer recoverable, resulting in a pre-tax, non-cash impairment charge of $20.6 million in the second quarter of 2017, representing the remaining carrying amount. In addition, during the second, third and fourth quarters of 2017, we identified certain market conditions impacting the recoverability of certain other finite-lived intangible assets in our U.S. Branded Pharmaceuticals segment. Accordingly, we tested these assets for impairment and determined that their carrying amounts were no longer fully recoverable, resulting in pre-tax, non-cash asset impairment charges totaling $31.5 million, $24.1 million and $0.5 million during the three months ended June 30, 2017, September 30, 2017 and December 31, 2017, respectively.

In addition, as a result of the actions taken with respect to OPANA^® ER and the continued erosion of our U.S. Branded Pharmaceuticals segment’s Established Products portfolio, we initiated an interim goodwill impairment analysis of our Branded reporting unit during the second quarter of 2017. Based on the provisions of ASU 2017-04, which we adopted as of January 1, 2017, we recorded a pre-tax, non-cash goodwill impairment charge of $180.4 million during the three months ended June 30, 2017 for the amount by which the carrying amount exceeded the reporting unit’s fair value. We estimated the fair value of the Branded reporting unit using an income approach that utilizes a discounted cash flow model. The discount rate applied to the estimated cash flows for our Branded goodwill impairment test was 9.5%.

As a result of unfavorable formulary changes and generic competition for sumatriptan, we experienced a downturn in the performance of our SUMAVEL^® DOSEPRO^® product, a needle-free delivery system for sumatriptan acquired from Zogenix, Inc. in 2014. As a result of this underperformance, we concluded during the third quarter of 2016 that an impairment assessment was required to evaluate the recoverability of SUMAVEL^® DOSEPRO^®. After performing this assessment, we recorded a pre-tax, non-cash impairment charge of $72.8 million during the third quarter of 2016, representing the remaining carrying amount. During the fourth quarter of 2016, we recognized pre-tax, non-cash goodwill and intangible asset impairment charges of $1.9 million and $37.6 million, respectively, resulting primarily from the termination of our BELBUCA™ product and the return of this product to BDSI.

In 2015, a sustained downturn in the short-acting testosterone replacement therapy (TRT) market caused underperformance across several of our TRT products, including TESTIM^® and NATESTO™. In addition, we also experienced underperformance with respect to STENDRA^®. As a result of this underperformance and a re-alignment of investment priorities towards higher growth and higher value assets such as XIAFLEX^®, we concluded during the third quarter of 2015 that an impairment assessment was required to evaluate the recoverability of certain finite-lived intangible assets associated with these products. After performing this assessment, we recorded a pre-tax, non-cash impairment charge of approximately $152.0 million during the third quarter of 2015, representing a full impairment of our Natesto™ intangible asset and a partial impairment of our TESTIM^® and STENDRA^® intangible assets. As a result of providing written notice to VIVUS Inc. on December 30, 2015 that we were terminating the STENDRA^® License Agreement effective June 30, 2016, we recorded an additional pre-tax, non-cash impairment charge of approximately $9.5 million, representing the remaining carrying amount of our STENDRA^® intangible asset. Additionally, during the fourth quarter of 2015, we determined that the fair value of certain U.S. Branded Pharmaceuticals IPR&D assets were less than their respective carrying amounts, and we recorded a pre-tax, non-cash impairment charge of $5.5 million representing the full carrying amount of the assets.

Given the results of our intangible asset assessment during the third quarter of 2015 for STENDRA^®and certain TRT products, we initiated an interim goodwill impairment analysis of our Urology, Endocrinology and Oncology (UEO) reporting unit as of September 30, 2015. As a result of this interim analysis, we determined that the net book value of our UEO reporting unit exceeded its estimated fair value. We prepared this analysis on a preliminary basis to estimate the amount of a provisional impairment charge as of September 30, 2015, and determined that an impairment was probable and reasonably estimable. We performed the preliminary fair value assessments taking into consideration a number of factors, based upon the latest available information, including the preliminary results of a hypothetical purchase price allocation. As a result of the preliminary analysis, during the three months ended September 30, 2015, we recorded a provisional pre-tax, non-cash goodwill impairment charge of $680.0 million, representing the difference between the estimated implied fair value of the UEO reporting unit’s goodwill and its respective carrying amount. We completed our UEO goodwill impairment analysis during the fourth quarter of 2015 and reduced the provisional pre-tax, non-cash goodwill impairment charge by $6.5 million, resulting in a net 2015 charge of $673.5 million.

International Pharmaceuticals Segment

Pursuant to an existing agreement with a wholly owned subsidiary of Novartis AG (Novartis), Paladin licensed the Canadian rights to commercialize serelaxin, an investigational drug for the treatment of acute heart failure (AHF). In March 2017, Novartis announced that a Phase 3 study of serelaxin in patients with AHF failed to meet its primary endpoints. As a result, we concluded that the full carrying amount of our serelaxin IPR&D intangible asset was impaired, resulting in a $45.5 million pre-tax non-cash impairment charge for the three months ended March 31, 2017.

In addition and as a result of the serelaxin impairment discussed above, we assessed the recoverability of our Paladin goodwill balance and determined that the estimated fair value of the Paladin reporting unit was below its carrying amount. We recorded a pre-tax, non-cash asset impairment charge of $82.6 million during the three months ended March 31, 2017 for the amount by which the carrying amount exceeded the reporting unit’s fair value. We estimated the fair value of the Paladin reporting unit using an income approach that utilizes a discounted cash flow model. The discount rate applied to the estimated cash flows for our Paladin goodwill impairment test was 10.0%.

As further discussed in Note 3. Discontinued Operations and Assets and Liabilities Held for Sale, we entered into a definitive agreement to sell Somar on June 30, 2017, which resulted in Somar’s assets and liabilities being classified as held for sale. The initiation of held-for-sale accounting, together with the agreed upon sale price, triggered an impairment review. Accordingly, we performed an impairment analysis using a market approach and determined that impairment charges were required. We recorded 2017 pre-tax, non-cash impairment charges of $25.7 million and $89.5 million related to Somar’s goodwill and other intangible assets, respectively. The goodwill and other intangible asset impairment charges each represented the remaining carrying amounts of the corresponding assets.

As described above, as part of the 2016 annual goodwill impairment test, we recorded pre-tax, non-cash goodwill impairment charges related to our Paladin, Somar and Litha reporting units of $272.6 million, $33.0 million and $26.3 million, respectively.

During the three months ended September 30, 2016, we determined that we would not pursue commercialization of a product in certain international markets. Accordingly, we tested the finite-lived intangible asset associated with this product for impairment and determined that the carrying amount was no longer fully recoverable, resulting in a pre-tax, non-cash intangible asset impairment charge of $16.2 million during the third quarter of 2016. During the fourth quarter of 2016, we recognized pre-tax, non-cash intangible asset impairment charges of $285.5 million in our International Pharmaceuticals segment resulting from certain market conditions impacting the commercial potential of finite and indefinite-lived intangible assets.

As described above, as part of the 2015 annual goodwill impairment test, we recorded a pre-tax, non-cash goodwill impairment charge of $85.8 million related to our Paladin reporting unit.

As part of our finite-lived intangible asset impairment review processes for 2015, we recorded pre-tax, non-cash intangible asset impairment charges of approximately $14.6 million in our International Pharmaceuticals segment, representing the difference between the carrying amount of certain intangible assets and their estimated fair value.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Accounts Payable And Accrued Expenses

12 Months Ended

Dec. 31, 2017

Accrued Liabilities [Abstract]

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

NOTE 12. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses include the following at December 31, 2017 and December 31, 2016 (in thousands):



	December 31, 2017		December 31, 2016
Trade accounts payable	$	85,348	$	126,712
Returns and allowances	291,034		332,455
Rebates	168,333		227,706
Chargebacks	14,604		33,092
Accrued interest	130,257		128,254
Accrued payroll and related benefits	113,908		115,224
Accrued royalties and other distribution partner payables	63,114		191,433
Acquisition-related contingent consideration—short-term	70,543		109,373
Other	159,684		189,835
Total	$	1,096,825	$	1,454,084

License And Collaboration Agreements	12 Months Ended
License And Collaboration Agreements	Dec. 31, 2017
License And Collaboration Agreements [Abstract]
LICENSE AND COLLABORATION AGREEMENTS	NOTE 11. LICENSE AND COLLABORATION AGREEMENTS Our subsidiaries have entered into certain license, collaboration and discovery agreements with third parties for product development. These agreements require our subsidiaries to share in the development costs of such products and the third parties grant marketing rights to our subsidiaries for such products. Generally, under these agreements: (i) we are required to make upfront payments and other payments upon successful completion of regulatory or sales milestones, (ii) we are required to pay royalties on sales of the products arising from these agreements and (iii) termination is permitted with no significant continuing obligation. BioSpecifics Technologies Corp. The Company, through an affiliate, is party to a development and license agreement, as amended (the BioSpecifics Agreement) with BioSpecifics Technologies Corp. (BioSpecifics). The BioSpecifics Agreement was originally entered into in June 2004 to obtain exclusive worldwide rights to develop, market and sell certain products containing BioSpecifics’ enzyme collagenase clostridium histolyticum (CCH), which we market for approved indications under the trademark XIAFLEX^®. The Company’s licensed rights concern the development and commercialization of products, other than dermal formulations labeled for topical administration, and currently, the Company’s licensed rights cover the indications of Dupuytren’s contracture (DC), Dupuytren’s nodules, Peyronie’s disease (PD), adhesive capsulitis, cellulite, canine and human lipomas, plantar fibromatosis and lateral hip fat. The Company may further expand the BioSpecifics Agreement, at its option, to cover other indications as they are developed by the Company or BioSpecifics. Under the BioSpecifics Agreement, we are responsible, at our own cost and expense, for developing the formulation and finished dosage form of products and arranging for the clinical supply of products. BioSpecifics is currently conducting exploratory clinical trials evaluating CCH as a treatment for a number of conditions, including uterine fibroids. The Company has the option to license development and marketing rights to these indications based on a full analysis of the data from the clinical trials, which would transfer responsibility for the future development costs to the Company and trigger opt-in payments and potential future milestone and royalty payments to BioSpecifics. The BioSpecifics Agreement extends, on a country-by-country and product-by-product basis, for the longer of the patent life, the expiration of any regulatory exclusivity period or twelve years from the effective date. Either party may terminate the BioSpecifics Agreement as a result of the other party’s breach or bankruptcy. We may terminate the BioSpecifics Agreement with 90 days’ written notice. We must pay BioSpecifics on a country-by-country and product-by-product basis a specified percentage within a range of 5% to 15% of net sales for products covered by the BioSpecifics Agreement. This royalty applies to net sales by the Company or its sublicensees, including Asahi Kasei Pharma Corporation (Asahi Kasei) and Swedish Orphan Biovitrum AB (Sobi). We are also obligated to pay a percentage of any future regulatory or commercial milestone payments received from such sublicensees. In addition, the Company and its affiliates pay BioSpecifics an amount equal to a specified mark-up on certain cost of goods related to supply of XIAFLEX^® (which mark-up is capped at a specified percentage within the range of 5% to 15% of the cost of goods of XIAFLEX^®) for products sold by the Company and its affiliates.

Debt

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

DEBT

NOTE 13. DEBT

The following table presents information about the Company’s total indebtedness at December 31, 2017 and December 31, 2016 (in thousands):



	December 31, 2017						December 31, 2016
	Effective Interest Rate		Principal Amount		Carrying Amount		Effective Interest Rate		Principal Amount		Carrying Amount
7.25% Senior Notes due 2022	7.91	%	$	400,000	$	390,974	7.91	%	$	400,000	$	389,150
5.75% Senior Notes due 2022	6.04	%	700,000		692,855		6.04	%	700,000		691,339
5.375% Senior Notes due 2023	5.62	%	750,000		742,048		5.62	%	750,000		740,733
6.00% Senior Notes due 2023	6.28	%	1,635,000		1,613,446		6.28	%	1,635,000		1,610,280
5.875% Senior Secured Notes due 2024	6.14	%	300,000		295,513		—		—		—
6.00% Senior Notes due 2025	6.27	%	1,200,000		1,181,243		6.27	%	1,200,000		1,179,203
Term Loan A Facility Due 2019	—		—		—		2.95	%	941,875		932,824
Term Loan B Facility Due 2022	—		—		—		4.06	%	2,772,000		2,728,919
Term Loan B Facility Due 2024	5.46	%	3,397,925		3,360,103		—		—		—
Other debt	1.50	%	55		55		1.50	%	55		55
Total long-term debt, net			$	8,382,980	$	8,276,237			$	8,398,930	$	8,272,503
Less current portion, net			34,205		34,205				131,125		131,125
Total long-term debt, less current portion, net			$	8,348,775	$	8,242,032			$	8,267,805	$	8,141,378

The senior unsecured notes are unsecured and effectively subordinated in right of priority to the 2017 Credit Agreement and our senior secured notes, in each case to the extent of the value of the collateral securing such instruments, which collateral represents substantially all of the assets of the issuers or borrowers and the guarantors party thereto.

The aggregate estimated fair value of the Company’s long-term debt, which was estimated using inputs based on quoted market prices for the same or similar debt issuances, was $7.5 billion and $7.8 billion at December 31, 2017 and December 31, 2016, respectively. Based on this valuation methodology, we determined these debt instruments represent Level 2 measurements within the fair value hierarchy.

Credit Facility

We have $996.8 million of remaining credit available through our Revolving Credit Facility as of December 31, 2017. As of December 31, 2017, we were in compliance with all covenants contained in our 2017 Credit Agreement. Our 2017 Credit Agreement is described below under the heading “April 2017 Refinancing.”

Senior Notes and Senior Secured Notes

Our various senior notes and our senior secured notes mature between 2022 and 2025. The indentures governing these notes generally allow for redemption prior to maturity, in whole or in part, subject to certain restrictions and limitations described therein. Generally, until a date specified in each indenture (which, as of December 31, 2017, has occurred only for the 7.25% Senior Notes due 2022, 5.75% Senior Notes due 2022 and 5.375% Senior Notes due 2023), the notes may either: (i) be redeemed, in part or in full, by paying the sum of: (a) 100% of the principal amount being redeemed, (b) an applicable make-whole premium as described in each indenture and (c) accrued and unpaid interest or (ii) be redeemed in part (up to 35% of the principal amount outstanding) with the net cash proceeds from specified equity offerings at redemption prices ranging from 105.875% to 106.000% (with respect to the notes for which the specified date described above has not yet occurred as of December 31, 2017) of the principal amount being redeemed, plus accrued and unpaid interest. After the specified date described above, the notes may generally be redeemed, in whole or in part, at redemption prices ranging from 100.000% to 104.500% of the principal amount being redeemed plus accrued and unpaid interest.

Other than the 5.875% Senior Secured Notes due 2024, these notes are senior unsecured obligations of the Company’s subsidiaries party to the applicable indenture governing such notes. These notes are issued by certain of our subsidiaries and are guaranteed on a senior unsecured basis by the subsidiaries of Endo International plc that also guarantee the 2017 Credit Agreement, except for a de minimis amount of the 7.25% Senior Notes due 2022, which are issued by Endo Health Solutions Inc. (EHSI). and guaranteed on a senior unsecured basis by the guarantors named in the Fifth Supplemental Indenture relating to such notes. The 5.875% Senior Secured Notes due 2024 are senior secured obligations of Endo International plc and its subsidiaries that are party to the indenture governing such notes. These notes are issued by certain of our subsidiaries and are guaranteed on a senior secured basis by Endo International plc and its subsidiaries that also guarantee our 2017 Credit Agreement.

The indentures governing our various senior notes contain affirmative and negative covenants that the Company believes to be usual and customary for similar indentures. The negative covenants, among other things, restrict the Company’s ability and the ability of its restricted subsidiaries to incur certain additional indebtedness and issue preferred stock, make certain investments and restricted payments, sell certain assets, enter into sale and leaseback transactions, agree to payment restrictions on the ability of restricted subsidiaries to make certain payments to Endo International plc or any of its restricted subsidiaries, create certain liens, merge, consolidate or sell all or substantially all of the Company’s assets or enter into certain transactions with affiliates. As of December 31, 2017, we were in compliance with all covenants. Additionally, pursuant to the terms of the indentures governing certain of our senior unsecured notes, the restricted subsidiaries of Endo International plc, whose assets comprise substantially all of the Company’s consolidated total assets after intercompany eliminations, are subject to various restrictions limiting their ability to transfer assets in excess of certain thresholds to Endo International plc.

April 2017 Refinancing

On April 27, 2017, Endo International plc entered into a new credit agreement (the 2017 Credit Agreement) as a guarantor, together with its subsidiaries Endo Luxembourg Finance Company I S.à r.l., and Endo LLC, as borrowers (the Borrowers), the other guarantors party thereto, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent, issuing bank and swingline lender. The 2017 Credit Agreement provides for (i) a five-year senior secured revolving credit facility in a principal amount of $1,000.0 million (the 2017 Revolving Credit Facility) (up to $50.0 million (which amount may be increased to up to $75.0 million with the consent of the administrative agent and certain issuing banks) of which is available for letters of credit and up to $50.0 million (which amount may be increased to up to $75.0 million with the consent of the administrative agent) of which is available for swing line loans) and (ii) a seven-year senior secured term loan facility in a principal amount of $3,415.0 million (the 2017 Term Loan Facility and, together with the 2017 Revolving Credit Facility, the 2017 Credit Facility). Any outstanding amounts borrowed pursuant to the 2017 Term Loan Facility will immediately mature if the 7.25% Senior Notes due 2022 are not refinanced or repaid in full prior to the date that is 91 days prior to the stated maturity date thereof. Any outstanding amounts borrowed pursuant to the 2017 Credit Facility will immediately mature if any of the following of our senior notes (other than, in the case of the 2017 Revolving Credit Facility, the 5.375% Senior notes due 2023 and the 6.00% Senior Notes due 2023) are not refinanced or repaid in full prior to the date that is 91 days prior to the stated maturity date thereof:



Instrument		Maturity Date
7.25% Senior Notes due 2022		January 15, 2022
5.75% Senior Notes due 2022		January 15, 2022
5.375% Senior Notes due 2023		January 15, 2023
6.00% Senior Notes due 2023		July 15, 2023

The proceeds of the 2017 Term Loan Facility were used, together with cash on hand, to repay our outstanding obligations under our prior credit facilities and to pay related fees and expenses. The proceeds of the 2017 Revolving Credit Facility will be used for working capital, capital expenditures and general corporate purposes. The obligations under the 2017 Credit Agreement are guaranteed by Endo International plc and its subsidiaries from time to time (with certain exceptions) (together with the Borrowers, the Loan Parties). The obligations under the 2017 Credit Agreement and the obligations under the indenture governing the 5.875% Senior Secured Notes due 2024 are secured on a pari passu basis by a first priority (subject to permitted liens) lien on substantially all the assets (with certain exceptions) of the Loan Parties. The 2017 Credit Agreement contains affirmative and negative covenants that the Company believes to be usual and customary for a senior secured credit facility of this type. The negative covenants include, among other things, limitations on asset sales, mergers and acquisitions, indebtedness, liens, dividends and other restricted payments, investments and transactions with the Company’s affiliates. In addition, on an annual basis commencing with the year ended December 31, 2018, the Company is required to perform a calculation of excess cash flow (as defined in the 2017 Credit Agreement) and a portion of the principal amount of the 2017 Term Loan Facility may be required to be prepaid in accordance with the terms of the 2017 Credit Agreement. No such payment is required at December 31, 2017.

The 2017 Credit Agreement provides that the Borrowers may incur incremental revolving commitments and/or incremental term loans in an aggregate principal amount of up to (i) up to $1.0 billion plus (ii) an unlimited amount if the pro forma first lien net leverage ratio at the time of incurrence of such incremental commitments or loans after giving effect thereto is less than or equal to 2.50 to 1.00 (assuming for purposes of such calculation that any incremental revolving commitments being incurred are fully drawn and without netting cash proceeds of any incremental facilities or incremental equivalent debt) or, in lieu of incremental facilities under the 2017 Credit Agreement, the incurrence of incremental equivalent debt consisting of pari passu notes or loans (subject to pro forma compliance with a first lien net leverage ratio of 2.50 to 1.00), junior secured notes or loans (subject to pro forma compliance with a secured net leverage ratio of 3.50 to 1.00) or unsecured notes or loans (subject to pro forma compliance with a total net leverage ratio of 6.50 to 1.00) from one or more of the existing lenders (or their affiliates) or other lenders (with the consent of the administrative agent) and, subject to compliance by the Borrowers with the documentation and other requirements under the 2017 Credit Agreement, without the need for consent from any of the existing lenders under the 2017 Credit Agreement.

Borrowings under the 2017 Revolving Credit Facility bear interest, at the borrower’s election, at a rate equal to (i) an applicable margin between 1.50% and 3.00% depending on the Company’s total net leverage ratio plus the London Interbank Offered Rate (LIBOR) or (ii) an applicable margin between 0.50% and 2.00% depending on the Company’s total net leverage ratio plus the Alternate Base Rate (as defined in the 2017 Credit Agreement). In addition, borrowings under our 2017 Term Loan Facility bear interest, at the borrower’s election, at a rate equal to (i) 4.25% plus LIBOR, subject to a LIBOR floor of 0.75%, or (ii) 3.75% plus the Alternate Base Rate, subject to an Alternate Base Rate floor of 1.75%.

Also on April 27, 2017, Endo Designated Activity Company (Endo DAC), Endo Finance LLC and Endo Finco Inc. (collectively, the Issuers) issued $300.0 million in aggregate principal amount of 5.875% Senior Secured Notes due 2024 (the 2024 Notes). The 2024 Notes were issued in a private offering for resale to “qualified institutional buyers” (as defined in Rule 144A under the Securities Act) and outside the United States to non-U.S. persons in compliance with Regulation S under the Securities Act. The 2024 Notes are senior secured obligations of the Issuers and are: (i) guaranteed by Endo International plc and its subsidiaries that also guarantee the 2017 Credit Agreement and certain other material indebtedness and (ii) secured by a lien on the same collateral that secures the 2017 Credit Agreement. Interest on the 2024 Notes is payable semiannually in arrears on April 15 and October 15 of each year, beginning on October 15, 2017. The 2024 Notes will mature on October 15, 2024, subject to earlier repurchase or redemption in accordance with the terms of the 2024 Notes indenture. On or after April 15, 2020, the Issuers may on any one or more occasions redeem all or a part of the 2024 Notes, at the redemption prices (expressed as percentages of principal amount) set forth below, plus accrued and unpaid interest and additional interest, if any, on the notes redeemed if such notes are redeemed during the twelve-month period beginning on April 15 of the years indicated below:



Year	Percentage
2020	102.938	%
2021	101.469	%
2022 and thereafter	100.000	%

At any time prior to April 15, 2020, the Issuers may on any one or more occasions redeem all or a part of the 2024 Notes at a redemption price equal to 100% of the principal amount of the notes redeemed, plus the applicable make-whole premium as described in the 2024 Notes indenture, plus accrued and unpaid interest and additional interest, if any. In addition, prior to April 15, 2020, the Issuers may, subject to certain restrictions and limitations, redeem up to 35% of the aggregate principal amount of the 2024 Notes with the net cash proceeds from specified equity offerings at a redemption price equal to 105.875% of the aggregate principal amount of the 2024 Notes redeemed, plus accrued and unpaid interest and additional interest, if any. If the Company experiences certain change of control events, the Issuers must offer to repurchase the 2024 Notes at 101% of their principal amount, plus accrued and unpaid interest and additional interest, if any. The 2024 Notes indenture contains covenants that, among other things, restrict the Company’s ability and the ability of its restricted subsidiaries to incur certain additional indebtedness and issue preferred stock, make certain dividends, distributions, investments and restricted payments, sell certain assets, enter into sale and leaseback transactions, agree to payment restrictions on the ability of restricted subsidiaries to make certain payments to Endo International plc or any of its restricted subsidiaries, create certain liens, merge, consolidate or sell all or substantially all of the Company’s assets, enter into certain transactions with affiliates or designate subsidiaries as unrestricted subsidiaries. These covenants are subject to a number of exceptions and qualifications, including the fall away or revision of certain of these covenants and release of the collateral upon the 2024 Notes receiving investment grade credit ratings.

The Company used the net proceeds under the 2017 Term Loan Facility, together with the net proceeds of the 2024 Notes and cash on hand, to repay all of its outstanding loans under its prior credit facilities and to pay related fees and expenses. The Company intends to use the proceeds of the 2017 Revolving Credit Facility from time to time for working capital, capital expenditures and general corporate purposes.

In connection with the April 2017 Refinancing, we incurred new debt issuance costs of approximately $56.7 million, which were allocated among the new debt instruments as follows: (i) $41.3 million to the 2017 Term Loan Facility, (ii) $10.5 million to the 2017 Revolving Credit Facility and (iii) $4.9 million to the 2024 Notes. These costs, together with $10.1 million of the previously deferred debt issuance costs associated with our prior revolving credit facility, have been deferred and will be amortized as interest expense over the terms of the respective instruments. The remaining $51.7 million of deferred debt issuance costs associated with our prior revolving and term loan facilities were charged to expense in the second quarter of 2017. These expenses were included in the Consolidated Statements of Operations as Loss on extinguishment of debt.

Maturities

The following table presents, subsequent to the closing of the April 2017 Refinancing, the maturities on our long-term debt for each of the five fiscal years subsequent to December 31, 2017 (in thousands):



	Maturities (1)
2018	$	34,205
2019	$	34,150
2020	$	34,150
2021	$	34,150
2022	$	1,134,150

__________

(1)

Any outstanding amounts borrowed pursuant to the 2017 Credit Facility will immediately mature if certain of our senior notes (enumerated above under the heading “April 2017 Refinancing”) (other than, in the case of the 2017 Revolving Credit Facility, the 5.375% Senior Notes due 2023 and the 6.00% Senior Notes due 2023) are not refinanced or repaid in full prior to the date that is 91 days prior to the respective stated maturity dates thereof. Accordingly, we may be required to repay or refinance senior notes with an aggregate principal amount of $1,100.0 million in 2021, despite such notes having stated maturities in 2022. Similarly, we may be required to repay or refinance senior notes with an aggregate principal amount of $750.0 million in 2022, despite such notes having stated maturities in 2023. The amounts in this maturities table do not reflect any such early payment; rather, they reflect stated maturity dates.

Commitments And Contingencies

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 14. COMMITMENTS AND CONTINGENCIES

Manufacturing, Supply and Other Service Agreements

Our subsidiaries contract with various third party manufacturers, suppliers and service providers to provide raw materials used in our subsidiaries’ products and semi-finished and finished goods, as well as certain packaging, labeling services, customer service support, warehouse and distribution services. If, for any reason, we are unable to obtain sufficient quantities of any of the finished goods or raw materials or components required for our products or services needed to conduct our business, it could have an adverse effect on our business, financial condition, results of operations and cash flows.

In addition to the manufacturing and supply agreements described above, we have agreements with various companies for clinical development services. Although we have no reason to believe that the parties to these agreements will not meet their obligations, failure by any of these third parties to honor their contractual obligations may have a material adverse effect on our business, financial condition, results of operations and cash flows.

Jubilant HollisterStier Laboratories LLC (JHS)

During the second quarter of 2016, we entered into a new agreement with JHS (JHS Agreement). Pursuant to the JHS Agreement, JHS fills and lyophilizes the XIAFLEX^®bulk drug substance, which is manufactured by the Company, and produces sterile diluent. The initial term of the JHS agreement is three years, with automatic renewal provisions thereafter for subsequent one-year terms, unless or until either party provides notification prior to expiration of the then current term of the contract. The Company is required to purchase a specified percentage of its total forecasted volume of XIAFLEX^®from JHS each year, unless JHS is unable to supply XIAFLEX^®within the timeframe established under such forecasts. Amounts purchased pursuant to the JHS Agreement were $5.6 million and $6.3 million for the years ended December 31, 2017 and 2016. Amounts purchased in 2015 were not material.

Milestones and Royalties

See Note 11. License and Collaboration Agreements for a description of future milestone and royalty commitments pursuant to our material acquisitions, license and collaboration agreements.

Legal Proceedings and Investigations

We and certain of our subsidiaries are involved in various claims, legal proceedings, internal and governmental investigations (collectively, proceedings) that arise from time to time in the ordinary course of our business, including, among others, those relating to product liability, intellectual property, regulatory compliance, consumer protection and commercial matters. While we cannot predict the outcome of these proceedings and we intend to vigorously prosecute or defend our position as appropriate, there can be no assurance that we will be successful or obtain any requested relief and an adverse outcome in any of these proceedings could have a material adverse effect on our current and future financial position, results of operations and cash flows. Matters that are not being disclosed herein are, in the opinion of our management, immaterial both individually and in the aggregate with respect to our financial position, results of operations and cash flows. If and when such matters, in the opinion of our management, become material either individually or in the aggregate, we will disclose such matters.

We believe that certain settlements and judgments, as well as legal defense costs, relating to certain product liability or other matters are or may be covered in whole or in part under our insurance policies with a number of insurance carriers. In certain circumstances, insurance carriers reserve their rights to contest or deny coverage. We intend to contest vigorously any and all such disputes with our insurance carriers and to enforce our rights under the terms of our insurance policies. Accordingly, we will record receivables with respect to amounts due under these policies only when the resolution of any dispute has been reached and realization of the potential claim for recovery is considered probable. Amounts recovered under our insurance policies will likely be less than the stated coverage limits and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers will pay claims or that coverage will otherwise be available.

As of December 31, 2017, our reserve for loss contingencies totaled $1,298.2 million, of which $1,087.2 million relates to our liability accrual for vaginal mesh cases and other mesh-related matters. During the fourth quarter of 2017, the Company recorded a total increase to its legal reserves of approximately $200 million related to testosterone-related product liability matters and LIDODERM^®-related antitrust matters, which reflects the Company’s conclusion that a loss is probable with respect to these matters. The reserve for LIDODERM^®-related matters includes an estimated loss for, among other matters, a settlement in principle of all remaining claims filed against EPI in multidistrict litigation (MDL) No. 2521, which is further discussed below under the heading “Other Antitrust Matters.” The testosterone-related reserve includes an estimated loss for, among other matters, all testosterone-related product liability cases filed in MDL No. 2545 and in other courts. These cases are further discussed below under the heading “Product Liability and Related Matters.” Although we believe there is a reasonable possibility that a loss in excess of the amount recognized exists, we are unable to estimate the possible loss or range of loss in excess of the amount recognized at this time.

Product Liability and Related Matters

We and certain of our subsidiaries have been named as defendants in numerous lawsuits in various U.S. federal and state courts, as well as in Canada and other countries, alleging personal injury resulting from the use of certain products of our subsidiaries. These and other related matters are described below in more detail.

Vaginal Mesh. In October 2008, the FDA issued a Public Health Notification (October 2008 Public Health Notification) regarding potential complications associated with transvaginal placement of surgical mesh to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI). The notification provided recommendations and encouraged physicians to seek specialized training in mesh procedures, to advise their patients about the risks associated with these procedures and to be diligent in diagnosing and reporting complications.

In July 2011, the FDA issued an update to the October 2008 Public Health Notification to further advise the public and the medical community of the potential complications associated with transvaginal placement of surgical mesh to treat POP and SUI. In the July 2011 update, the FDA stated that adverse events are not rare and questioned the relative effectiveness of transvaginal mesh as a treatment for POP as compared to non-mesh surgical repair. The July 2011 update continued to encourage physicians to seek specialized training in mesh procedures, to consider and to advise their patients about the risks associated with these procedures and to be diligent in diagnosing and reporting complications. In January 2016, the FDA issued a statement reclassifying surgical mesh for transvaginal POP repair from Class II to Class III. Surgical mesh for SUI repair remains a Class II device.

Since 2008, we and certain of our subsidiaries, including AMS and/or Astora, have been named as defendants in multiple lawsuits in the U.S. in various state and federal courts (including a federal MDL pending in the U.S. District Court for the Southern District of West Virginia (MDL No. 2325)), and in Canada and other countries, alleging personal injury resulting from the use of transvaginal surgical mesh products designed to treat POP and SUI. In January 2018, a representative proceeding (class action) was filed in the Federal Court of Australia against American Medical Systems, LLC. In the various class action and individual complaints, plaintiffs claim a variety of personal injuries, including chronic pain, incontinence, inability to control bowel function and permanent deformities, and seek compensatory and punitive damages, where available.

We and certain plaintiffs’ counsel representing mesh-related product liability claimants have entered into various Master Settlement Agreements (MSAs) and other agreements to resolve up to approximately 71,000 filed and unfiled mesh claims handled or controlled by the participating counsel. These MSAs and other agreements were entered into at various times between June 2013 and the present, were solely by way of compromise and settlement and were not in any way an admission of liability or fault by us or any of our subsidiaries.

All MSAs are subject to a process that includes guidelines and procedures for administering the settlements and the release of funds. In certain cases, the MSAs provide for the creation of qualified settlement funds (QSFs) into which funds may be deposited pursuant to certain schedules set forth in those agreements. All MSAs have participation requirements regarding the claims represented by each law firm party to the MSA. In addition, one agreement gives us a unilateral right of approval regarding which claims may be eligible to participate under that settlement. To the extent fewer claims than are authorized under an agreement participate, the total settlement payment under that agreement will be reduced by an agreed-upon amount for each such non-participating claim. Funds deposited in QSFs are included in restricted cash and cash equivalents in the Consolidated Balance Sheets.

Distribution of funds to any individual claimant is conditioned upon the receipt of documentation substantiating the validity of the claim, a full release and dismissal of the entire action or claim as to all AMS parties and affiliates. Prior to receiving funds, an individual claimant is required to represent and warrant that liens, assignment rights or other claims identified in the claims administration process have been or will be satisfied by the individual claimant. Confidentiality provisions apply to the amount of settlement awards to participating claimants, the claims evaluation process and procedures used in conjunction with award distributions, and the negotiations leading to the settlements.

In June 2017, the MDL court entered a case management order which, among other things, requires plaintiffs in newly-filed MDL cases to provide expert disclosures on specific causation within one hundred twenty (120) days of filing a claim (the Order). Under the Order, a plaintiff's failure to meet the foregoing deadline may be grounds for the entry of judgment against such plaintiff. In July 2017, a similar order was entered in Minnesota state court.

Beginning in the second quarter of 2017, the Company aggressively pursued a settlement strategy in connection with the mesh litigation. Consequently, the Company increased its mesh liability accrual by $775.5 million in the second quarter of 2017, which is expected to cover approximately 22,000 known U.S. mesh claims, subject to a claims validation process for all resolved claims, as well as all of the international mesh liability claims of which the Company is aware and other mesh-related matters. This increase reflected the Company’s conclusion that a loss was probable with respect to all unsettled mesh-related matters of which we were aware, and our current liability accrual applies to such matters. Although the Company believes it has appropriately estimated the probable total amount of loss associated with all matters as of the date of this report, it is reasonably possible that further claims may be filed or asserted and adjustments to our liability accrual may be required. This could have a material adverse effect on our business, financial condition, results of operations and cash flows.

The following table presents the changes in the QSFs and mesh liability accrual balance during the year ended December 31, 2017 (in thousands):



	Qualified Settlement Funds			Mesh Liability Accrual
Balance as of January 1, 2017	$	275,987		$	963,117
Additional charges	—			775,474
Cash contributions to Qualified Settlement Funds	668,306			—
Cash distributions to settle disputes from Qualified Settlement Funds	(632,176		)	(632,176		)
Cash distributions to settle disputes	—			(19,243		)
Other	1,697			—
Balance as of December 31, 2017	$	313,814		$	1,087,172

As of December 31, 2017, $876.7 million of the mesh liability accrual amount shown above is classified in the Current portion of the legal settlement accrual in the Consolidated Balance Sheets, with the remainder classified as Long-term legal settlement accrual, less current portion. Charges related to vaginal mesh liability and associated legal fees and other expenses for all periods presented are reported in Discontinued operations, net of tax in our Consolidated Statements of Operations.

To date, the Company has made total mesh liability payments of approximately $2.9 billion, $313.8 million of which remains in the QSFs as of December 31, 2017. We expect to fund into the QSFs the remaining payments under all settlement agreements during 2018 and 2019. As the funds are disbursed out of the QSFs from time to time, the liability accrual will be reduced accordingly with a corresponding reduction to restricted cash and cash equivalents. In addition, we may pay cash distributions to settle disputes separate from the QSFs, which will also decrease the liability accrual and decrease cash and cash equivalents.

We were contacted in October 2012 regarding a civil investigation initiated by a number of state attorneys general into mesh products, including transvaginal surgical mesh products designed to treat POP and SUI. In November 2013, we received a subpoena relating to this investigation from the state of California, and we have subsequently received additional subpoenas from California and other states. We are currently cooperating with these investigations.

We will continue to vigorously defend any unresolved claims and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any additional losses that could be incurred.

Testosterone. Various manufacturers of prescription medications containing testosterone, including our subsidiaries Endo Pharmaceuticals Inc. (EPI) and Auxilium Pharmaceuticals, Inc. (subsequently converted to Auxilium Pharmaceuticals, LLC and hereinafter referred to as Auxilium), have been named as defendants in multiple lawsuits alleging personal injury resulting from the use of such medications, including FORTESTA^® Gel, DELATESTRYL^®, TESTIM^®, TESTOPEL^®, AVEED^® and STRIANT^®. Plaintiffs in these suits generally allege various personal injuries, including pulmonary embolism, stroke or other vascular and/or cardiac injuries, and seek compensatory and/or punitive damages, where available.

As of February 20, 2018, we were aware of approximately 1,300 testosterone cases (some of which may have been filed on behalf of multiple plaintiffs) pending against one or more of our subsidiaries. Many of these cases have been coordinated in a federal MDL pending in the U.S. District Court for the Northern District of Illinois (MDL No. 2545). In addition, there are cases pending against EPI and/or Auxilium in the Philadelphia Court of Common Pleas (PCCP) and in certain other state courts.

In November 2015, the MDL court entered an order granting defendants’ motion to dismiss claims involving certain testosterone products that were approved pursuant to Abbreviated New Drug Applications (ANDAs), including TESTOPEL^®. Plaintiffs filed a motion for reconsideration and clarification of this order. In March 2016, the MDL court granted plaintiffs’ motion in part and entered an order permitting certain claims to go forward to the extent they are based on allegations of fraudulent off-label marketing.

The first MDL trial against Auxilium involving TESTIM^® took place in November 2017 and resulted in a defense verdict. The first PCCP trial against Auxilium involving TESTIM^® was scheduled for January 2018 but resolved prior to trial. The next PCCP trial against Auxilium involving TESTIM^® is set for July 2018, with approximately fourteen other PCCP trials involving one or more of our subsidiaries scheduled to follow by January 2019; in some of these cases, another pharmaceutical manufacturer is also named as a defendant.

In February 2018, counsel for plaintiffs and counsel for Auxilium and EPI signed a memorandum of understanding regarding a potential settlement, subject to certain contingencies and conditions. The MDL court subsequently entered a case management order directing that proceedings involving these parties be temporarily stayed so that the parties may devote their efforts to finalizing a master settlement agreement. A fourth quarter 2017 increase to the Company’s legal reserves includes, among other things, an estimated loss for all testosterone-related product liability claims filed in MDL No. 2545 and in other courts. Although the Company believes it has appropriately estimated the probable total amount of loss associated with testosterone-related product liability matters as of the date of this report, it is reasonably possible that further claims may be filed or asserted and adjustments to our liability accrual may be required. This could have a material adverse effect on our business, financial condition, results of operations and cash flows.

The MDL also includes a lawsuit filed in November 2014 in the U.S. District for the Northern District of Illinois against EPI, Auxilium and various other manufacturers of testosterone products on behalf of a proposed class of health insurance companies and other third party payers that claim to have paid for certain testosterone products. After a series of motions to dismiss, plaintiffs filed a third amended complaint in April 2016, asserting civil claims for alleged violations of the Racketeer Influenced and Corrupt Organizations Act (RICO) and for negligent misrepresentation based on defendants’ marketing of certain testosterone products. The court denied a motion to dismiss this complaint in August 2016 and the case is currently in discovery. In November 2017, plaintiff filed a motion to certify a nationwide class of third party payers. This lawsuit is not part of the potential settlement described above.

Unapproved Drug Litigation

In September 2013, the State of Louisiana filed a petition for damages against certain of our subsidiaries, including EPI, and more than 50 other pharmaceutical companies in Louisiana state court (19th Judicial District) alleging that the defendants or their subsidiaries marketed products that were not approved by the FDA and seeking damages, fines, penalties, attorneys’ fees and costs under various causes of action. In October 2015, the district court entered judgment for defendants on their exception for no right of action. The State appealed, and in October 2016 the Louisiana First Circuit Court of Appeals reversed the dismissal as to the State’s Medicaid Assistance Program Integrity Law (MAPIL) and Louisiana Unfair Trade Practices Act (LUTPA) claims but affirmed the dismissal as to the State’s other claims. The State’s petition for rehearing was denied in December 2016. Both sides applied to the Louisiana Supreme Court for a writ of certiorari to review the First Circuit’s decision. Those writs were denied in March 2017. In May 2017, defendants filed exceptions for no cause of action in the district court. In August 2017, the court sustained defendants’ exception as to the MAPIL claim but overruled defendants’ exception as to the LUTPA claim. The State then filed a motion seeking reconsideration with respect to the MAPIL claim, and defendants filed a motion for clarification with respect to the court’s ruling on the LUTPA claim. In October 2017, the court denied the State’s motion and entered final judgment against the State with respect to the MAPIL claim. The court also granted defendants’ motion for clarification and dismissed the State’s LUTPA claim insofar as it sought civil penalties for alleged violations occurring before June 2, 2006. In October 2017, defendants applied for a supervisory writ to the Louisiana First Circuit Court of Appeals on the district court’s August 2017 order overruling defendants’ exception on the State’s LUTPA claim.

In March 2017, the State of Mississippi filed a complaint against our subsidiary EPI in Mississippi state court (Hinds County Chancery Court) alleging that EPI marketed products that were not approved by the FDA and seeking damages, penalties, attorneys’ fees, costs and other relief under various causes of action. In April 2017, EPI removed the case to the U.S. District Court for the Southern District of Mississippi. In May 2017, the State moved to remand the case to state court, and that motion was granted in October 2017. In November 2017, EPI filed a motion to dismiss the State’s complaint on various grounds. In January 2018, the State filed a motion for leave to amend its complaint. In February 2018, following an unopposed motion by the State, the court consolidated the State’s case against EPI with five substantially similar cases brought by the State against other defendants. The consolidation is solely for purposes of coordinated pretrial proceedings and discovery, not for trial.

We will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.

Opioid-Related Matters

Since 2014, multiple U.S. states, counties, other governmental persons or entities and private plaintiffs have filed suit against our subsidiaries EHSI and EPI, in some instances the Company and/or our subsidiary Par Pharmaceutical, Inc. (PPI), and/or various other manufacturers, distributors and/or others, asserting claims relating to defendants’ alleged sales, marketing and/or distribution practices with respect to prescription opioid medications, including certain of our products. As of February 20, 2018, the cases of which we were aware include, but are not limited to, cases filed by the states of Delaware, Kentucky, Mississippi, Missouri, New Mexico and Ohio; approximately 465 cases filed by counties, cities, Native American tribes and/or other government-related persons or entities in Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Washington, West Virginia, Wisconsin and Puerto Rico; approximately 25 cases filed by hospitals, health systems, unions, health and welfare funds or other third-party payers; and approximately eight cases alleging personal injury and/or wrongful death. We will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.

Many of these cases have been coordinated in a federal MDL pending in the U.S. District Court for the Northern District of Ohio (MDL No. 2804). Other cases remain pending in various state courts. Certain cases filed in Connecticut, Illinois and New York state courts have been transferred to a single court within their respective state court systems for coordinated pretrial proceedings. Defendants have filed motions seeking similar relief in Pennsylvania.

The complaints in the cases assert a variety of claims including, but not limited to, claims for alleged violations of public nuisance, consumer protection, unfair trade practices, racketeering, Medicaid fraud and/or drug dealer liability statutes and/or common law claims for public nuisance, fraud/misrepresentation, strict liability, negligence and/or unjust enrichment. The claims are generally based on alleged misrepresentations and/or omissions in connection with the sale and marketing of prescription opioid medications and/or an alleged failure to take adequate steps to prevent abuse and diversion. Plaintiffs generally seek declaratory and/or injunctive relief; compensatory, punitive and/or treble damages; restitution, disgorgement, civil penalties, abatement, attorneys’ fees, costs and/or other relief. Certain of the cases are brought as putative class actions.

Defendants, including the company’s subsidiaries, have filed motions to dismiss in certain cases. For the most part, these motions remain pending. In a case filed by the City of Chicago in June 2014, defendants have answered the city’s claims for consumer fraud (deceptive practices) and misrepresentation; defendants’ motion to dismiss other claims remains pending. The case is now part of MDL 2804. In a case filed in May 2014 in California state court (Orange County) in the name of the People of the State of California, acting by and through County Counsel for Santa Clara County and the Orange County District Attorney, following a hearing in January 2018, the court denied defendants’ motions to dismiss the fourth amended complaint but struck certain material from that complaint. In February 2018, plaintiffs filed a motion for leave to file a fifth amended complaint.

In March 2017, the Boone County Commission filed suit in the U.S. District Court for the Southern District of West Virginia against multiple defendants, including our subsidiary Generics Bidco I, LLC, for the alleged violation of federal and state safety laws designed to monitor, detect and prevent the diversion of controlled substances. The complaint generally seeks compensatory and punitive damages for the alleged creation of a public nuisance. In December 2017, the case was transferred to MDL 2804 for pretrial purposes.

In addition to the lawsuits described above, the Company and/or its subsidiaries have received certain subpoenas, civil investigative demands (CIDs) and informal requests for information concerning the sale, marketing and/or distribution of prescription opioid medications, including the following:

In September 2017, the Department of Justice for the State of Oregon and the Office of the Attorney General for the Commonwealth of Massachusetts issued CIDs to EHSI and EPI on behalf of a multistate group which we understand currently includes the District of Columbia and the following additional states: Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois, Iowa, Kansas, Louisiana, Maine, Maryland, Michigan, Minnesota, Nebraska, Nevada, New York, North Carolina, North Dakota, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, West Virginia, Wisconsin and Wyoming. Our subsidiaries are currently cooperating with this investigation. We understand that these recent CIDs superseded prior subpoenas and/or CIDs issued by certain of the foregoing states.

Other states are conducting their own investigations outside of the multistate group. For example, in August 2015, our subsidiary EPI received a subpoena from the New Hampshire Attorney General’s office seeking documents and information regarding sales and marketing of opioids, including OPANA^® ER. We were cooperating with the investigation until we learned that the Attorney General was being assisted by outside counsel hired on a contingency fee basis. The Attorney General initiated an action in New Hampshire Superior Court to enforce the subpoena despite this contingency fee arrangement, and we (along with other companies that had received similar subpoenas) responded by filing a motion for protective order to preclude the use of contingency fee counsel. In addition, we filed a separate motion seeking declaratory relief. In March 2016, the Superior Court granted the motion for protective order on the grounds that the contingency fee agreement was invalid as ultra vires and that the Attorney General’s office had acted outside of its statutory authority in entering into the agreement with the contingency fee counsel. In April 2016, both the Attorney General and the companies that had received subpoenas, including EPI, appealed, in part, the March 2016 Superior Court order to the New Hampshire Supreme Court. In June 2017, the New Hampshire Supreme Court reversed the Superior Court’s protective order ruling and remanded the case to the Superior Court. We resumed cooperation with the investigation and in December 2017, the Attorney General issued a second subpoena to EPI seeking additional documents and information regarding sales and marketing of opioids. In October 2017, we filed a petition for certiorari seeking U.S. Supreme Court review of the New Hampshire Supreme Court’s decision. Other states investigating outside of the multistate group include New Jersey (subpoena received by EPI in March 2017); Washington (CID received by the Company, EHSI and EPI in August 2017); Indiana (CID received by EHSI and EPI in November 2017); Montana (CID received by EHSI and EPI in January 2018); Alaska (CID received by EPI in February 2018); and South Carolina (CID received by EHSI and EPI in February 2018). We are cooperating with these investigations.

In January 2018, our subsidiary EPI received a federal grand jury subpoena from the U.S. District Court for the Southern District of Florida in connection with an investigation being conducted by the U.S. Attorney’s Office for the Southern District of Florida in conjunction with the U.S. Food and Drug Administration. The subpoena seeks information related to OPANA^® ER and other oxymorphone products. EPI is cooperating with the investigation.

Similar investigations may be brought by others or the foregoing matters may be expanded or result in litigation. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.

Generic Drug Pricing Matters

In December 2014, our subsidiary Par received a grand jury subpoena from the Antitrust Division of the DOJ issued by the U.S. District Court for the Eastern District of Pennsylvania. The subpoena requested documents and information focused primarily on product and pricing information relating to Par’s authorized generic version of Lanoxin (digoxin) oral tablets and Par’s generic doxycycline products, and on communications with competitors and others regarding those products. Par is cooperating with the investigation.

In December 2015, EPI received interrogatories and a subpoena from the Connecticut Attorney General’s Office requesting documents and information regarding pricing of certain of generic products, including doxycycline hyclate, amitriptyline hydrochloride, doxazosin mesylate, methotrexate sodium and oxybutynin chloride. EPI is cooperating with this investigation.

We are unable to predict the outcome of the foregoing investigations, which may involve additional requests for information or result in litigation. In addition, investigations or litigations similar to these matters described above may be brought by others or the foregoing matters may be expanded. We are also unable to predict the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for these matters but will explore all options as appropriate in our best interests.

Since April 2017, certain private plaintiff cases alleging price-fixing and other anticompetitive conduct with respect to at least 18 different generic pharmaceutical products have been consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Eastern District of Pennsylvania under the caption In re Generic Pharmaceuticals Pricing Antitrust Litigation (MDL No. 2724). The various cases included in the MDL involve different groups of defendants. Our subsidiary PPI is named as a defendant in proposed class actions relating to six of these products: digoxin, doxycycline hyclate, divalproex ER, propranolol, baclofen and amitriptyline hydrochloride. Among the private plaintiff lawsuits now consolidated and/or coordinated in the MDL, the earliest lawsuits naming the Company and/or its subsidiaries were filed in November 2016 and related to digoxin and doxycycline.

The private plaintiffs in the MDL include alleged direct purchasers, end-payers, and indirect purchaser resellers, and they purport to represent not only themselves but also all others similarly situated. At the MDL court’s direction, in August 2017, private plaintiffs filed separate consolidated amended class action complaints as to each product and each type of purchaser (direct purchasers, end-payers and indirect purchaser resellers), except the propranolol direct purchaser plaintiffs are attempting to proceed on a consolidated amended complaint filed in the U.S. District Court for the Southern District of New York prior to MDL transfer (the Southern District of New York had denied a motion to dismiss this complaint). The MDL court has divided the various cases into three separate tranches for certain administrative and scheduling purposes, including briefing on motions to dismiss. As to the six products in the first tranche (which include digoxin, doxycycline hyclate and divalproex ER), defendants filed motions to dismiss in October 2017; those motions remain pending. Defendants have also asserted that they are entitled to move the MDL court to dismiss the propranolol direct purchaser consolidated amended complaint; the MDL court has taken this issue under advisement. Defendants moved to stay discovery in all cases pending rulings on their motions to dismiss; in February 2018, the Court denied that motion with certain exceptions.

In December 2016, the Attorney General for the State of Connecticut, leading a coalition of 20 state attorneys general, filed a complaint in the U.S. District Court for the District of Connecticut alleging price-fixing and other anticompetitive conduct with respect to doxycycline hyclate delayed release and glyburide against certain manufacturers of those products. The Company and its subsidiaries were not named in that complaint, or in an amended complaint filed on behalf of 40 states in March 2017, or in a separate lawsuit filed by four more states and the District of Columbia in the same court in July 2017. In August 2017, the state cases were transferred to MDL No. 2724. In October 2017, the state plaintiffs filed a motion for leave to (1) consolidate their two cases, (2) add Alaska and the Commonwealth of Puerto Rico as plaintiffs, and (3) assert additional claims against existing and new defendants. The proposed amended complaint would add new allegations and claims against 14 new defendants, including our subsidiary Par Pharmaceutical Companies, Inc. (subsequently renamed Endo Generics Holding, Inc. but referred to as Par in this Commitments and Contingencies note), relating to 13 additional products. As to our subsidiary, the proposed amended complaint alleges anticompetitive conduct with respect to doxycycline monohydrate. The proposed amended complaint also alleges that the defendants engaged in an overarching conspiracy to restrain trade across the generic pharmaceutical industry and seeks to hold all defendants, including our subsidiary, jointly and severally liable for harm caused by the alleged anticompetitive activity concerning the 15 drugs at issue. The proposed amended complaint seeks declaratory and injunctive relief, disgorgement and other equitable relief, compensatory and treble damages, civil penalties, costs and attorneys’ fees. Defendants have opposed the states’ motion for leave to file their proposed consolidated amended complaint, and the court has not yet ruled on the issue.

In January 2018, The Kroger Co., Albertsons Companies, LLC, and H.E. Butt Grocery Company LP filed a lawsuit in the U.S. District Court for the Eastern District of Pennsylvania against PPI, as well as numerous other manufacturers of generic pharmaceuticals, alleging anticompetitive conduct relating to thirty separate generic pharmaceutical products, including seven products allegedly manufactured by PPI: digoxin, doxycycline hyclate, doxycycline monohydrate, divalproex ER, propranolol, baclofen and amitriptyline hydrochloride. The complaint alleges an overarching conspiracy among all named defendants to engage in price-fixing for all thirty products, as well as product-specific conspiracies relating to each individual product, in violation of federal antitrust law. The complaint seeks monetary damages, including treble damages, attorneys’ fees, and injunctive relief.

Other Pricing Matters

Beginning in December 2015, two complaints, including a class action complaint, were filed in the PCCP against us and certain of our subsidiaries, including Par, along with other manufacturers of generic pharmaceutical products, seeking compensatory and punitive or treble damages, as well as injunctive relief, and alleging that certain marketing and pricing practices by the defendant companies violated state law, including consumer protection law. The class action complaint was subsequently removed to the U.S. District Court for the Eastern District of Pennsylvania, and the plaintiff filed an amended complaint. In September 2017, the district court dismissed the amended complaint with prejudice. The case in the PCCP has been stayed pending final resolution of the class action. We will continue to vigorously defend this matter and to explore other options as appropriate in our best interests.

In March 2016, EPI received a CID from the U.S. Attorney’s Office for the Southern District of New York. The CID requested documents and information regarding contracts with pharmacy benefit managers regarding FROVA^®. We are cooperating with this investigation.

Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.

Other Antitrust Matters

Beginning in November 2013, multiple direct and indirect purchasers of LIDODERM^® filed a number of cases against our subsidiary EPI and co-defendants Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. (collectively, Teikoku), and Actavis plc and certain of its subsidiaries (collectively, Actavis), which was subsequently acquired by Teva Pharmaceuticals Industries Ltd and its subsidiaries from Allergan plc. Plaintiffs generally alleged that EPI, Teikoku and Actavis entered into an anticompetitive conspiracy to restrain trade through the settlement of patent infringement litigation concerning U.S. Patent No. 5,827,529 (the ‘529 patent) and other patents. Some complaints also alleged that Teikoku wrongfully listed the ‘529 patent in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) as related to LIDODERM^®,that EPI and Teikoku commenced sham patent litigation against Actavis and that EPI abused the FDA citizen petition process by filing a citizen petition and amendments solely to interfere with generic companies’ efforts to obtain FDA approval of their versions of LIDODERM^®. The complaints asserted claims under Sections 1 and 2 of the Sherman Act (15 U.S.C. §§ 1, 2), and/or various state antitrust and consumer protection statutes, as well as common law claims, and generally sought damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys’ fees. The cases were consolidated and/or coordinated in April 2014 in a federal MDL in the U.S. District Court for the Northern District of California (MDL No. 2521). The MDL court certified classes of direct and indirect purchasers in February 2017. In June 2017, defendants moved for summary judgment on all claims, and plaintiffs also moved for partial summary judgment on certain elements of their claims. In November 2017, the court granted defendants’ motion in part, ruling in defendants’ favor on the issues of infringement and derivation and also limiting the time period at issue. Defendants’ motions for summary judgment were denied in all other respects. The court also granted plaintiffs’ motions for summary judgment on the issues of agreement and relevant market. EPI settled with certain plaintiffs in October 2017 and reached an agreement in principle with all remaining plaintiffs in February 2018. Settlements with the direct and indirect purchaser classes will be subject to court approval.

Beginning in June 2014, multiple direct and indirect purchasers of OPANA^® ER filed cases against our subsidiaries EHSI and EPI and other pharmaceutical companies, including Impax Laboratories Inc. (Impax) and Penwest Pharmaceuticals Co., which our subsidiary EPI had acquired. Some cases were filed on behalf of putative classes of direct and indirect purchasers, while others were filed on behalf of individual retailers or health care benefit plans. All cases have been consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Northern District of Illinois (MDL No. 2580). Plaintiffs generally allege that an agreement reached by EPI and Impax to settle patent infringement litigation concerning multiple patents pertaining to OPANA^® ER and EPI’s introduction of the re-formulation of OPANA^® ER violated antitrust laws. The complaints assert claims under Sections 1 and 2 of the Sherman Act, various state antitrust and consumer protection statutes and state common law. Plaintiffs generally seek damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys’ fees. In February 2016, the MDL court issued orders (i) denying defendants’ motion to dismiss the claims of the direct purchasers, (ii) denying in part and granting in part defendants’ motion to dismiss the claims of the indirect purchasers, but giving them permission to file amended complaints and (iii) granting defendants’ motion to dismiss the complaints filed by certain retailers, but giving them permission to file amended complaints. In response to the MDL court’s orders, the indirect purchasers filed an amended complaint to which the defendants filed a renewed motion to dismiss certain claims, and certain retailers also filed amended complaints. The court has dismissed the indirect purchaser unjust enrichment claims arising under the laws of the states of California, Rhode Island and Illinois. The cases are currently in discovery. We will continue to vigorously defend these matters and to explore other options as appropriate in our best interests.

Beginning in February 2009, the FTC and certain private plaintiffs, including distributors and retailers, filed suit against our subsidiary, Par, and others alleging violations of antitrust law arising out of Par’s settlement of certain patent litigation concerning the generic version of AndroGel^®. Generally, the complaints seek damages, treble damages, equitable relief, and attorneys’ fees and costs. The cases have been consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Northern District of Georgia (MDL No. 2084). In September 2012, the district court granted summary judgment to defendants on plaintiffs’ claims of sham litigation. In May 2016, plaintiffs representing a putative class of indirect purchasers voluntarily dismissed their case against Par with prejudice. In February 2017, the FTC voluntarily dismissed its claims against Par with prejudice. Claims by a putative class of direct purchasers and certain specific alleged direct purchasers or their assignees are still pending. In September 2017, Par moved for summary judgment on all remaining claims. We will continue to vigorously defend these matters and to explore other options as appropriate in our best interests.

In February 2018, an alleged indirect purchaser filed a proposed class action against our subsidiary PPI and others alleging a conspiracy to delay generic competition and monopolize the market for Zetia^® (ezetimibe) and its generic equivalents. The complaint asserts claims under Sections 1 and 2 of the Sherman Act, various state antitrust and consumer protection statutes and state common law and seeks injunctive relief, damages, treble damages, attorneys’ fees and costs. We intend to vigorously defend this matter and to explore other options as appropriate in our best interests.

In November 2014, EPI received a CID from Florida’s Office of the Attorney General seeking documents and other information concerning EPI’s agreement with Actavis settling the LIDODERM^® patent litigation, as well as information concerning marketing and sales of LIDODERM^®. EPI received similar CIDs from South Carolina’s Office of the Attorney General in February 2016 and from Alaska’s Office of the Attorney General in February 2015. The Alaska CID was also directed to EHSI and included requests for documents and information concerning agreements with Actavis and Impax settling the OPANA^® ER patent litigation.

In February 2015, Par and affiliates received a CID from the Office of the Attorney General for the State of Alaska seeking production of certain documents and information regarding Par’s settlement of the AndroGel^® patent litigation as well as documents produced in the aforementioned litigation filed by the FTC.

We are cooperating with each of the foregoing investigations.

A fourth quarter 2017 increase to the Company’s legal reserves includes, among other things, an estimated loss for certain LIDODERM^®-related claims. We will continue to vigorously defend any unresolved claims and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any additional losses that could be incurred.

False Claims Act Litigation

Beginning in July 2006, the Attorneys General of Florida, Indiana and Virginia and the U.S. Office of Personnel Management (the USOPM) issued subpoenas, and the Attorneys General of Michigan, Tennessee, Texas and Utah issued CIDs, to our subsidiary Par, among other companies. The demands generally requested documents and information pertaining to allegations that certain of Par’s sales and marketing practices caused pharmacies to substitute ranitidine capsules for ranitidine tablets, fluoxetine tablets for fluoxetine capsules and two 7.5 mg buspirone tablets for one 15 mg buspirone tablet, under circumstances in which some state Medicaid programs at various times reimbursed the new dosage form at a higher rate than the dosage form being substituted. The aforementioned subpoenas and CIDs culminated in a qui tam action by Bernard Lisitza asserting claims under federal and state law on behalf of the U.S. and several states. The complaint was unsealed in August 2011. Lisitza’s corrected second amended complaint generally sought (i) a finding that defendants violated, and an order that they be enjoined from future violations of, the federal False Claims Act and state false claims acts; (ii) treble damages and maximum civil penalties for each violation of the federal False Claims Act and state false claims acts; (iii) an applicable percentage share of the proceeds; and (iv) expenses, fees and costs. The U.S. intervened in this action and filed a separate complaint in September 2011, alleging claims for violations of the federal False Claims Act and common law fraud. The U.S.’s second corrected complaint generally sought (i) treble damages and civil penalties for violations under the federal False Claims Act and (ii) compensatory and punitive damages for common law fraud. The states of Michigan and Indiana also intervened, asserting claims under their respective state false claim acts, as well as common law fraud and unjust enrichment claims. Michigan’s complaint generally sought treble damages, civil penalties and common law compensatory and punitive damages. Indiana’s amended complaint generally sought treble damages, costs and attorneys’ fees. In August 2017, the court granted summary judgment against Lisitza, precluding him from serving as the relator and entering judgment against all plaintiffs on whose behalf he had filed suit. The court also granted summary judgment as to the intervenors’ claims for violation of the federal False Claims Act and for common law fraud and declined to exercise supplemental jurisdiction over the remaining claims. Lisitza appealed the court’s summary judgment rulings in September 2017 but dismissed his appeal in October 2017. All remaining claims by Lisitza and the intervening states have since been resolved and the matter is now concluded.

Securities Litigation

In May 2016, a putative class action entitled Craig Friedman v. Endo International plc, Rajiv Kanishka Liyanaarchchie de Silva and Suketu P. Upadhyay was filed in the U.S. District Court for the Southern District of New York by an individual shareholder on behalf of himself and all similarly situated shareholders. In August 2016, the court appointed Steamfitters’ Industry Pension Fund and Steamfitters’ Industry Security Benefit Fund as lead plaintiffs in the action. In October 2016, plaintiffs filed a second amended complaint that, among other things, added Paul Campanelli as a defendant, and we filed a motion to dismiss. In response, and without resolving the motion, the Court permitted lead plaintiffs to file a third amended complaint. The amended complaint alleged violations of Sections 10(b) and 20(a) of the Exchange Act based on the Company’s revision of its 2016 earnings guidance and certain disclosures about its generics business, the integration of Par and its subsidiaries, certain other alleged business issues and the receipt of a CID from the U.S. Attorney’s Office for the Southern District of New York regarding contracts with pharmacy benefit managers concerning FROVA^®. Lead plaintiffs sought class certification, damages in an unspecified amount and attorneys’ fees and costs. We filed a motion to dismiss the third amended complaint in December 2016. In January 2018, the Court granted our motion and dismissed the case with prejudice. In February 2018, lead plaintiffs filed a motion for relief from the judgment and leave to file a fourth amended complaint.

In February 2017, a putative class action entitled Public Employees’ Retirement System of Mississippi v. Endo International plc was filed in the Court of Common Pleas of Chester County, Pennsylvania by an institutional purchaser of shares in our June 2, 2015 public offering, on behalf of itself and all similarly situated purchasers. The lawsuit alleges violations of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 against Endo, certain of its current and former directors and officers, and the underwriters who participated in the offering, based on certain disclosures about Endo’s generics business. In March 2017, defendants removed the case to the U.S. District Court for the Eastern District of Pennsylvania. In August 2017, the court remanded the case back to the Chester County Court of Common Pleas. In October 2017, plaintiff filed an amended complaint, and defendants moved to partially stay the case pending the resolution of a pending U.S. Supreme Court case that could impact the state court’s jurisdiction. Defendants’ motion for a partial stay was granted in November 2017. In December 2017, defendants filed preliminary objections to the amended complaint.

In April 2017, a putative class action entitled Phaedra A. Makris v. Endo International plc, Rajiv Kanishka Liyanaarchchie de Silva and Suketu P. Upadhyay was filed in the Superior Court of Justice in Ontario, Canada by an individual shareholder on behalf of herself and similarly-situated Canadian-based investors who purchased Endo’s securities between January 11 and May 5, 2016. The statement of claim generally seeks class certification, declaratory relief, damages, interest and costs based on alleged violations of the Ontario Securities Act. The statement of claim alleges negligent misrepresentations concerning the Company’s revenues, profit margins and earnings per share; its receipt of a subpoena from the State of Connecticut regarding doxycycline hyclate, amitriptyline hydrochloride, doxazosin mesylate, methotrexate sodium and oxybutynin chloride; and the erosion of the Company’s U.S. generic pharmaceuticals business.

In August 2017, a putative class action entitled Bier v. Endo International plc, et al. was filed in the U.S. District Court for the Eastern District of Pennsylvania by an individual shareholder on behalf of himself and all similarly situated shareholders. The original complaint alleged violations of Section 10(b) and 20(a) of the Exchange Act against Endo and four current and former directors and officers, based on the Company’s decision to remove reformulated OPANA^® ER from the market. In December 2017, SEB Investment Management AB was appointed lead plaintiff in the action. In February 2018, the lead plaintiff filed an amended complaint, which added claims alleging violations of Sections 11 and 15 of the Securities Act in connection with the June 2015 offering. The amended complaint named the Company, EHSI and twenty current and former directors, officers and employees of Endo as defendants. Defendants have not yet responded to the amended complaint.

In November 2017, a putative class action entitled Pelletier v. Endo International plc, Rajiv Kanishka Liyanaarchchie De Silva, Suketu P. Upadhyay, and Paul V. Campanelli was filed in the U.S. District Court for the Eastern District of Pennsylvania by an individual shareholder on behalf of himself and all similarly situated shareholders. The lawsuit alleges violations of Section 10(b) and 20(a) of the Exchange Act in connection with the allegations of anticompetitive conduct asserted in In re Generic Pharmaceuticals Pricing Antitrust Litigation, MDL No. 2724. In January 2018, the Chief Judge of the Eastern District of Pennsylvania designated Pelletier as related to Bier and reassigned Pelletier to the judge overseeing Bier. A lead plaintiff has not yet been selected.

VASOSTRICT^®Related Matters

In July 2016, Fresenius Kabi USA, LLC (Fresenius) filed a complaint against Par and its affiliate Par Sterile Products, LLC in the U.S. District Court for the District of New Jersey alleging that Par and its affiliate engaged in an anticompetitive scheme to exclude competition from the market for vasopressin solution for intravenous injection in view of Par’s VASOSTRICT^® (vasopressin) product. The complaint alleges violations of Sections 1 and 2 of the Sherman Antitrust Act, as well as state antitrust and common law, based on assertions that Par and its affiliate entered into exclusive supply agreements with one or more active pharmaceutical ingredient (API) manufacturers and that, as a result, Fresenius has been unable to obtain vasopressin API in order to file an ANDA to obtain FDA approval for its own vasopressin product. Fresenius seeks actual, treble and punitive damages, attorneys’ fees and costs, and injunctive relief. In September 2016, Par and its affiliate filed a motion to dismiss, which the district court denied in February 2017. The case is currently in discovery.

In August 2017, our subsidiaries PPI and Par Sterile Products, LLC filed a complaint for actual, exemplary and punitive damages, injunctive relief and other relief against QuVa Pharma, Inc. (QuVa), Stuart Hinchen, Peter Jenkins, and Mike Rutkowski in the U.S. District Court for the District of New Jersey. The complaint alleges misappropriation in violation of the federal Defend Trade Secrets Act, New Jersey’s Trade Secrets Act and New Jersey common law, as well as unfair competition, breach of contract, breach of fiduciary duty, breach of the duty of loyalty, tortious interference with contractual relations and breach of the duty of confidence in connection with VASOSTRICT^®, a vasopressin-based cardiopulmonary drug. In October 2017, defendants answered the complaint and QuVa asserted counterclaims against PPI and Par Sterile Products, LLC alleging unfair competition under New Jersey common law and seeking declaratory judgment of non-infringement as to five U.S. Patents assigned to PPI that are listed in FDA’s Orange Book for VASOSTRICT^®. The counterclaims seek actual, exemplary, and punitive damages, injunctive relief and other relief. We filed a motion to dismiss the unfair competition counterclaim in November 2017. Briefing on that motion has been completed but no ruling has been issued. Also in November 2017, we filed a motion for preliminary injunction seeking various forms of relief, including an order prohibiting defendants, and all persons working in concert with them, from selling or offering for sale any product that competes with a Par product and was developed and/or is manufactured using Par’s trade secrets. Briefing on that motion has been completed and a hearing on that motion was held in February 2018. In January 2018, we filed a first amended complaint adding five former employees of Par Sterile Products, LLC as defendants and numerous causes of action against some or all of those former employees, including misappropriation under the federal Defend Trade Secrets Act, New Jersey’s Trade Secrets Act and New Jersey common law, as well as breach of contract, breach of the duty of loyalty and breach of the duty of confidence.

In October 2017, Endo Par Innovation Company, LLC (EPIC) and Par Sterile Products, LLC (PSP) filed a complaint in the United States District Court for the District of Columbia challenging the legality of the FDA’s Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act (January 2017) with respecting to listing of vasopressin in Category 1 of the Interim Policy. The complaint contends that the Interim Policy is unlawful because it is inconsistent with the Federal, Food, Drug, and Cosmetic Act, including, but not limited to, Section 503B of that Act. The complaint seeks (i) a declaration that FDA’s Interim Policy and its listing of vasopressin in Category 1 of the Interim Policy are unlawful, and (ii) an order enjoining and vacating the Interim Policy and FDA’s listing of vasopressin in Category 1 of the Interim Policy. In January 2018, EPIC and PSP agreed to a temporary stay of the litigation in light of the FDA’s announcement that forthcoming guidance will address the concerns set forth in the Company’s complaint.

We will continue to vigorously defend or prosecute the foregoing matters as appropriate, to protect our intellectual property rights, to pursue all available legal and regulatory avenues and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.

Paragraph IV Certifications on OPANA^® ER

In late 2012, two patents (U.S. Patent Nos. 8,309,122 and 8,329,216) were issued to EPI covering OPANA^® ER (oxymorphone hydrochloride extended-release tablets CII). In December 2012, EPI filed a complaint against Actavis in U.S. District Court for the Southern District of New York for patent infringement based on its ANDA for a non-INTAC^® technology version of OPANA^® ER. In May 2013 and June 2013, EPI filed similar suits in the U.S. District Court for the Southern District of New York against the following applicants for non-INTAC^® technology OPANA^® ER: Roxane Laboratories, Inc. (Roxane) and Ranbaxy Laboratories Limited, which was acquired by Sun Pharmaceutical Industries Ltd. (Ranbaxy). Those suits allege infringement of U.S. Patent Nos. 7,851,482, 8,309,122 and 8,329,216. In July 2013, Actavis and Roxane were granted FDA approval to market all strengths of their respective non-INTAC^® technology formulations of OPANA^® ER. In September 2013, Actavis launched its generic version of non-crush-resistant OPANA^® ER 5, 10, 20, 30 and 40 mg tablets. A trial in this case was held from March 2015 through April 2015 in the U.S. District Court for the Southern District of New York. In August 2015, the District Court ruled that all defendants infringed the claims of U.S. Patent Nos. 8,309,122 and 8,329,216. The District Court also ruled that the defendants failed to show that U.S. Patent Nos. 8,309,122 and 8,329,216 were invalid, enjoined the defendants from launching their generic products until the expiration of those patents and directed Actavis to withdraw its generic product within 60 days. In October 2015, the District Court tolled the 60-day period until it decided two pending post-trial motions. In April 2016, the District Court issued an order upholding its August 2015 ruling in EPI’s favor and confirming the prior injunction against the manufacture or sale of the generic version of the non-INTAC^® technology OPANA^® ER currently offered by Actavis and the additional approved but not yet marketed generic version of the product developed by Roxane. The defendants filed appeals to the Court of Appeals for the Federal Circuit. EPI continued its suit for damages for Actavis’s sales of its infringing generic version of OPANA^® ER. In August 2017, EPI settled the damages portion of this suit with Actavis. As a result of that settlement, EPI received $25 million from Actavis in August 2017. We intend to continue vigorously asserting our intellectual property rights and to oppose any such appeal.

From September 21, 2012 through October 30, 2013, EPI and its partner Grünenthal received Paragraph IV Notices from each of Teva Pharmaceuticals USA, Inc., Amneal Pharmaceuticals, LLC (Amneal), ThoRx Laboratories, Inc. (ThoRx), Actavis, Impax and Ranbaxy (now Sun Pharmaceutical Industries Ltd.), advising of the filing by each such company of an ANDA for a generic version of the formulation of OPANA^® ER with INTAC^® technology. These Paragraph IV Notices refer to U.S. Patent Nos. 7,851,482, 8,075,872, 8,114,383, 8,192,722, 8,309,060, 8,309,122 and 8,329,216, which variously cover the formulation of OPANA^® ER, a highly pure version of the active pharmaceutical ingredient and the release profile of OPANA^® ER. EPI filed lawsuits against each of these filers in the U.S. District Court for the Southern District of New York. Each lawsuit was filed within the 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme. A trial in this case was held from March 2015 through April 2015 in the U.S. District Court for the Southern District of New York against the remaining filers. In August 2015, the District Court issued an Opinion holding that all defendants infringed the claims of U.S. Patent Nos. 8,309,060, 8,309,122 and 8,329,216. The Opinion also held that the defendants had shown that U.S. Patent No. 8,309,060 was invalid, but that the defendants had failed to show that U.S. Patent Nos. 8,309,122 and 8,329,216 were invalid. The District Court also issued an Order enjoining the defendants from launching their generic products until the expiration of U.S. Patent Nos. 8,309,122 and 8,329,216. The defendants filed appeals to the Court of Appeals for the Federal Circuit. An argument was held at the Federal Circuit on this appeal in December 2017. No opinion has yet been issued. We intend to continue to vigorously assert our intellectual property and oppose appeals by the defendants. However, there can be no assurance that we and/or Grünenthal will be successful. If we are unsuccessful and Teva, Amneal, ThoRx, Actavis or Impax is able to obtain FDA approval of its product, generic versions of OPANA^® ER INTAC^® technology may be launched prior to the applicable patents’ expirations in 2023. Additionally, we cannot predict or determine the timing or outcome of this defense but will explore all options as appropriate in our best interests.

In August 2014 and October 2014, the U.S. Patent Office issued U.S. Patent Nos. 8,808,737 and 8,871,779 respectively, which cover a method of using OPANA^® ER and a highly pure version of the active pharmaceutical ingredient of OPANA^® ER. In November 2014, EPI filed lawsuits against Teva, ThoRx, Actavis, Impax, Ranbaxy, Roxane, Amneal and Sandoz Inc. based on their ANDAs filed against both the INTAC^® technology and non-INTAC^® technology versions of OPANA^® ER. Those lawsuits were filed in the U.S. District Court for the District of Delaware alleging infringement of these new patents, which expire in 2027 and 2029, respectively. On November 17, 2015, the District Court held the ‘737 patent invalid for claiming unpatentable subject matter. That patent has been dismissed from all suits and the suits administratively closed as to that patent, subject to appeal at the end of the case on the ‘779 patent. In July 2016, a three-day trial was held in the U.S. District Court for the District of Delaware against Teva and Amneal for infringement of the ‘779 patent. In October 2016, the District Court issued an Opinion holding that the defendants infringed the claims of U.S. Patent No. 8,871,779. The Opinion also held that the defendants had failed to show that U.S. Patent No. 8,871,779 was invalid. The District Court issued an Order enjoining the defendants from launching their generic products until the expiration of U.S. Patent No. 8,871,779 in November 2029. A trial for infringement of the ‘799 patent by Actavis was held in February 2017 in the same court (U.S. District Court for the District of Delaware) in front of the same judge. In August 2017, the District Court issued an Opinion holding that Actavis infringed the claims of U.S. Patent No. 8,871,779, and that Actavis had failed to show that U.S. Patent No. 8,871,779 was invalid. Teva, Amneal and Actavis have appealed these holdings. We have appealed the holding that the ‘737 patent is invalid.

We will continue to vigorously defend or prosecute the foregoing matters as appropriate, to protect our intellectual property rights, to pursue all available legal and regulatory avenues and to explore other options as appropriate in our best interests in defense of both the non-INTAC^® technology formulation OPANA^® ER and the INTAC^® technology formulation OPANA^® ER, including enforcement of the product’s intellectual property rights and approved labeling. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.

Other Proceedings and Investigations

Proceedings similar to those described above may also be brought in the future. Additionally, we are involved in, or have been involved in, arbitrations or various other proceedings that arise from the normal course of our business. We cannot predict the timing or outcome of these other proceedings. Currently, neither we nor our subsidiaries are involved in any other proceedings that we expect to have a material effect on our business, financial condition, results of operations and cash flows.

Leases

We lease certain fixed assets under capital leases that expire through 2024. We lease automobiles, machinery and equipment and facilities under certain noncancelable operating leases that expire through 2028. These leases are renewable at our option.

On October 28, 2011, our subsidiary EPI entered into a lease agreement for a new Company headquarters in Malvern, Pennsylvania. The initial term of the lease was through 2024 and includes three renewal options, each for an additional 60-month period. This lease is accounted for as a direct financing arrangement whereby the Company recorded, over the construction period, the full cost of the asset in Property, plant and equipment, net. A corresponding liability was also recorded, net of leasehold improvements paid for by the Company, and is being amortized over the expected lease term through monthly rental payments using an effective interest method. At December 31, 2017, there was a liability of $38.4 million related to this arrangement, $4.6 million of which is included in Accounts payable and accrued expenses and $33.8 million of which is included in Other liabilities in the accompanying Consolidated Balance Sheet.

A summary of minimum future rental payments required under capital and operating leases as of December 31, 2017 are as follows (in thousands):



	Capital Leases (1)(2)		Operating Leases
2018	$	6,713	$	13,888
2019	6,633		14,120
2020	6,564		13,505
2021	6,681		11,758
2022	6,831		11,212
Thereafter	14,126		23,703
Total minimum lease payments	$	47,548	$	88,186
Less: Amount representing interest	4,168
Total present value of minimum payments	$	43,380
Less: Current portion of such obligations	6,713
Long-term capital lease obligations	$	36,667

__________


(1)	The direct financing arrangement is included under Capital Leases.

(2)

We have entered into agreements to sublease certain properties. Most significantly, we sublease approximately 90,000 square feet of our Malvern, Pennsylvania headquarters and substantially all of our Chesterbrook, Pennsylvania facility. As of December 31, 2017, we expect to receive approximately $25.2 million in future minimum rental payments over the remaining terms of the Malvern and Chesterbrook subleases from 2018 until 2024. Amounts included in this table have not been reduced by the minimum sublease rentals.

Expenses incurred under operating leases were $18.7 million, $22.2 million and $20.1 million for the years ended December 31, 2017, 2016 and 2015, respectively.

Other Comprehensive Loss

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

OTHER COMPREHENSIVE INCOME (LOSS)

NOTE 15. OTHER COMPREHENSIVE LOSS

The following table presents the tax effects allocated to each component of Other comprehensive income (loss) for the years ended December 31, 2017, 2016 and 2015 (in thousands):



	2017								2016								2015
	Before-Tax Amount			Tax Benefit (Expense)		Net-of-Tax Amount			Before-Tax Amount			Tax Benefit (Expense)		Net-of-Tax Amount			Before-Tax Amount			Tax (Expense) Benefit			Net-of-Tax Amount
Net unrealized (loss) gain on securities:
Unrealized (loss) gain arising during the period	$	(811	)	$	296	$	(515	)	$	(1,588	)	$	674	$	(914	)	$	2,349		$	(50	)	$	2,299
Less: reclassification adjustments for gain realized in net loss	—			—		—			(6		)	—		(6		)	—			—			—
Net unrealized (losses) gains	$	(811	)	$	296	$	(515	)	$	(1,594	)	$	674	$	(920	)	$	2,349		$	(50	)	$	2,299
Net unrealized gain (loss) on foreign currency:
Foreign currency translation gain (loss) arising during the period	31,202			—		31,202			18,267			13,462		31,729			(263,425		)	(21,297		)	(284,722		)
Less: reclassification adjustments for loss realized in net loss	112,926			—		112,926			—			—		—			25,557			158			25,715
Foreign currency translation gain (loss)	$	144,128		$	—	$	144,128		$	18,267		$	13,462	$	31,729		$	(237,868	)	$	(21,139	)	$	(259,007	)
Other comprehensive income (loss)	$	143,317		$	296	$	143,613		$	16,673		$	14,136	$	30,809		$	(235,519	)	$	(21,189	)	$	(256,708	)

Reclassification adjustments out of Other comprehensive income (loss) related to foreign currency translation were recorded upon the liquidation of Litha and Somar during 2017 and the AMS Men’s Health and Prostate Health businesses during 2015.

The following is a summary of the accumulated balances related to each component of Other comprehensive income (loss), net of taxes, at December 31, 2017 and December 31, 2016 (in thousands):



	December 31, 2017			December 31, 2016
Net unrealized gains	$	380		$	895
Foreign currency translation loss	(210,201		)	(354,329		)
Accumulated other comprehensive loss	$	(209,821	)	$	(353,434	)

Shareholders' Equity

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

SHAREHOLDERS' EQUITY

NOTE 16. SHAREHOLDERS' EQUITY

On February 11, 2014, the Company issued 4,000,000 euro deferred shares of $0.01 each at par. The euro deferred shares are held by nominees in order to satisfy an Irish legislative requirement to maintain a minimum level of issued share capital denominated in euro and to have at least seven registered shareholders. The euro deferred shares carry no voting rights and are not entitled to receive any dividend or distribution.

On January 29, 2015, the Company acquired Auxilium for total consideration of $2.6 billion. The consideration included 18,609,835 ordinary shares valued at $1.52 billion. The acquisition is described in more detail in Note 5. Acquisitions.

On June 10, 2015, we completed the sale of 27,627,628 ordinary shares, including 3,603,603 ordinary shares sold upon the exercise in full by the underwriters of their option to purchase additional ordinary shares from us, at a price of $83.25 per share, for aggregate gross proceeds to us of $2.30 billion, before fees, in order to finance a portion of the Par acquisition, which is described in more detail in Note 5. Acquisitions. On September 25, 2015, the Company acquired Par for total consideration of $8.14 billion. The consideration included 18,069,899 ordinary shares valued at $1.33 billion.

During the year ended December 31, 2015, the Company completed a buy-out of the noncontrolling interest associated with its Litha subsidiary. The following table reflects the effect on the Company’s equity for the year ended December 31, 2015 (in thousands):



	2015
Adjustment to Accumulated other comprehensive loss related to the reallocation (from noncontrolling to controlling interests) of foreign currency translation loss attributable to our noncontrolling interest in Litha	$	(3,904	)
Decrease in noncontrolling interests for buy-out of Litha	(32,732		)
Decrease in additional paid-in capital for buy-out of Litha	(2,972		)
Total cash consideration paid related to buy-out of Litha	$	(39,608	)

Share Repurchase Program

The Company has broad shareholder authority pursuant to Article 11 of the Company’s Articles of Association to conduct repurchase by way of redemptions of its ordinary shares.

Pursuant to the 2014 Share Buyback Authority, in April 2015, our Board of Directors approved a share buyback program (the 2015 Share Buyback Program). The 2015 Share Buyback Program authorized the Company to redeem in the aggregate $2.5 billion of its outstanding ordinary shares. As permitted by Irish Law and the Company’s Articles of Association, all ordinary shares redeemed under the 2015 Share Buyback Program shall be cancelled upon redemption.

In November 2015, the Company entered into a program to repurchase by way of redemption up to $250.0 million of its ordinary shares under the 2015 Share Buyback Program. The Company redeemed and cancelled approximately 4.4 million of its ordinary shares during November 2015 totaling $250.0 million, not including related fees.

Shared-based Compensation

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Shared-based Compensation

NOTE 17. SHARE-BASED COMPENSATION

As discussed in Note 3. Discontinued Operations and Assets and Liabilities Held for Sale, the operating results of the Company’s AMS businesses are reported as Discontinued operations, net of tax in the Consolidated Statements of Operations for all periods presented. However, as share-based compensation is not material for these businesses, amounts in this Note 17. Share-based Compensation have not been adjusted to exclude the impact of these businesses.

Stock Incentive Plans

In June 2015, the Company’s shareholders approved the 2015 Stock Incentive Plan (the 2015 Plan). As of the effective date of the 2015 Plan, 10.0 million ordinary shares, including the transfer of 5.0 million ordinary shares available to be granted under the previous 2010 Stock Incentive Plan, were reserved for the granting of stock options (including incentive stock options), stock appreciation rights, restricted stock awards, performance awards and other share-based awards, which may be issued at the discretion of the Company’s board of directors from time to time. Upon the approval of the 2015 Plan, no additional ordinary shares were to be granted under the previously approved plans, including the Company’s 2000, 2004, 2007, 2010 and Assumed Stock Incentive Plans. All awards previously granted and outstanding under the prior plans remain subject to the terms of those prior plans.

During the second quarter of 2017, the Company’s shareholders approved an amendment to the 2015 Plan. The plan was amended and restated to increase the number of the Company’s ordinary shares that may be issued with respect to awards under the Plan by 10.0 million ordinary shares and to make certain other changes to the Plan’s terms. The shares were registered in August 2017.

During the third quarter of 2017, the Company issued approximately 1.0 million stock options and 0.1 million restricted stock units for which a grant date has not been established as the awards are subject to shareholder approval at the Company’s 2018 Annual General Meeting of Shareholders. If approved, the options will have an exercise price equal to the closing share price on their issuance date in August 2017. Additionally, at December 31, 2017, there are 0.3 million performance share units, representing target amounts, for which a grant date has not yet been established.

At December 31, 2017, approximately 8.8 million ordinary shares were reserved for future grants under the 2015 Plan. Options and awards which have been issued but for which a grant date has not yet been established are excluded from this amount.

As of December 31, 2017, stock options, restricted stock awards, performance stock units and restricted stock units have been granted under the stock incentive plans.

Generally, the grant-date fair value of each award is recognized as expense over the requisite service period. However, expense recognition differs in the case of certain performance share units where the ultimate payout is performance-based. For these awards, at each reporting period, the Company estimates the ultimate payout and adjusts the cumulative expense based on its estimate and the percent of the requisite service period that has elapsed.

The Company recognized share-based compensation expense of $50.1 million, $59.8 million and $98.8 million during the years ended December 31, 2017, 2016 and 2015, respectively. The share-based compensation expense recognized during the year ended December 31, 2015 includes a charge related to the acceleration of Auxilium employee equity awards at closing of $37.6 million and $11.4 million of expense related to certain AMS equity awards modified in conjunction with the anticipated sale of the business. The AMS amounts are recorded in Discontinued Operations, net of tax. As of December 31, 2017, the total remaining unrecognized compensation cost related to all non-vested share-based compensation awards for which a grant date has been established as of December 31, 2017 amounted to $58.2 million.

Presented below is the allocation of share-based compensation as recorded in our Consolidated Statements of Operations for the years ended December 31, 2017, 2016 and 2015 (in thousands).



	2017		2016		2015
Selling, general and administrative expenses	$	38,292	$	54,176	$	79,928
Research and development expenses	4,197		2,440		2,388
Cost of revenues	7,660		2,040		2,241
Discontinued operations (Note 3)	—		1,113		14,231
Total share-based compensation expense	$	50,149	$	59,769	$	98,788

Stock Options

During the years ended December 31, 2017, 2016 and 2015, the Company granted stock options to employees of the Company as part of their annual share compensation award and, in certain circumstances, on an ad hoc basis or upon their commencement of service with the Company. For options for which a grant date has not yet occurred, no fair value has been established and these options are not reflected in any of the amounts in this “Stock Options” section.

Employee stock options generally vest ratably, in equal amounts, over a three or four-year service period and expire ten years from the grant date. The fair value of option grants is estimated at the date of grant using the Black-Scholes option-pricing model. This model utilizes assumptions related to volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero as the Company has not paid cash dividends to date and does not currently expect to pay cash dividends) and the expected term of the option. Expected volatilities utilized in the model are based mainly on the historical volatility of the Company’s share price over a period commensurate with the expected life of the share option as well as other factors. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. We estimate the expected term of options granted based on our historical experience with our employees’ exercise of stock options and other factors.

A summary of the activity for each of the years ended December 31, 2017, 2016 and 2015 is presented below:



	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value (1)
Outstanding as of January 1, 2015	3,063,352		$	40.15
Granted	794,757		$	77.27
Exercised	(880,885	)	$	30.93
Forfeited	(201,397	)	$	72.24
Expired	(7,260	)	$	45.20
Outstanding as of December 31, 2015	2,768,567		$	51.56
Granted	2,578,105		$	35.45
Exercised	(62,589	)	$	31.19
Forfeited	(858,556	)	$	52.27
Expired	(100,318	)	$	60.71
Outstanding as of December 31, 2016	4,325,209		$	41.70
Granted	5,288,675		$	10.42
Forfeited	(623,987	)	$	28.32
Expired	(741,767	)	$	40.29
Outstanding as of December 31, 2017	8,248,130		$	22.79	7.87	$	493,979
Vested and expected to vest as of December 31, 2017	7,633,410		$	23.46	7.76	$	435,456
Exercisable as of December 31, 2017	1,826,250		$	42.39	3.99	$	—

__________


(1)	The intrinsic value of a stock option is the excess, if any, of the closing price of the Company’s ordinary shares on the last trading day of the fiscal year over the exercise price. The aggregate intrinsic values presented in the table above represent sum of the intrinsic values of all corresponding stock options that are “in-the-money.”

The range of exercise prices for the above stock options outstanding at December 31, 2017 is from $7.55 to $89.68.

No options were exercised during the year ended December 31, 2017. The total intrinsic value of options exercised during the years ended December 31, 2016 and 2015 was $1.3 million and $27.2 million, respectively. No tax benefits from stock option exercises were realized during the years ended December 31, 2017 and 2016. Tax benefits from stock option exercises during the year ended December 31, 2015 were $11.7 million. The weighted average grant date fair value of the stock options granted in the years ended December 31, 2017, 2016 and 2015 was $4.73, $11.46 and $21.09 per option, respectively, determined using the following average assumptions:



	2017		2016		2015
Expected term (years)	4.0		4.0		4.0
Risk-free interest rate	1.7	%	1.1	%	1.3	%
Dividend yield	—		—		—
Expected volatility	58	%	43	%	32	%

As of December 31, 2017, the weighted average remaining requisite service period of the non-vested stock options was 2.5 years and the total remaining unrecognized compensation cost related to non-vested stock options amounted to $21.1 million.

Restricted Stock Units and Performance Share Units

During the years ended December 31, 2017, 2016 and 2015, the Company granted restricted stock units (RSUs) and performance share units (PSUs) to employees of the Company as part of their annual share compensation award and, in certain circumstances, on an ad hoc basis or upon their commencement of service with the Company. For RSUs and PSUs for which a grant date has not yet occurred, no fair value has been established and these awards are not reflected in any of the amounts in this “Restricted Stock Units and Performance Share Units” section.

RSUs vest ratably, in equal amounts, over a three or four-year service period. PSUs vest in full after a three-year service period and are conditional upon the achievement of performance or market conditions established by the compensation committee of the Board of Directors.

PSUs granted in 2017 were based upon two discrete measures: relative total shareholder return (TSR) and a free cash flow performance metric. The free cash flow performance metric, which accounts for 50% of the PSU award at grant, will be measured annually over a 3-year performance cycle. The remaining 50% of the PSU award is tied exclusively to relative TSR performance, which will be measured against the 3-year TSR of a custom index of companies. The actual number of shares awarded is adjusted to between zero and 200% of the target award amount based upon achievement of certain goals. In addition to meeting the conditions required by both the TSR and free cash flow portions of the awards, grant recipients are also subject to being employed by the Company following the completion of the 3-year period in order to receive the awards. TSR relative to peers is considered a market condition under applicable authoritative guidance, while the free cash flow measure is considered performance condition.

In 2016, PSU grants are tied to relative TSR performance, which will be measured against the 3-year TSR of a custom index of companies, with maximum payout levels also based on absolute compounded annual growth rate (CAGR) stock price objectives. Each award covered a 3-year performance cycle. The actual number of shares awarded is adjusted to between zero and 300% of the target award amount based upon achievement of pre-determined relative TSR and CAGR stock price goals. TSR relative to peers is considered a market condition under applicable authoritative guidance.

Starting in 2014 and continuing in 2015, PSU grants are tied to the attainment of absolute CAGR for the Company’s ordinary share price, which is considered a market condition under applicable authoritative guidance. Each award covers a 3-year performance cycle. The actual number of shares awarded is adjusted to between zero and 300% of the target award amount based upon achievement of pre-determined CAGR goals.

RSUs are valued based on the closing price of Endo’s ordinary shares on the date of grant. PSUs with TSR conditions are valued using a Monte-Carlo variant valuation model, while those with adjusted free cash flow conditions are valued taking into consideration the probability of achieving the specified performance goal. The Monte-Carlo variant valuation model considered a variety of potential future share prices for Endo as well as our peer companies in a selected market index.

A summary of our nonvested RSUs and PSUs for the years ended December 31, 2017, 2016 and 2015 is presented below:



	Number of Shares		Aggregate Intrinsic Value (1)
Nonvested as of January 1, 2015	1,654,753
Granted	927,214
Forfeited	(251,351	)
Vested	(523,763	)
Nonvested as of December 31, 2015	1,806,853
Granted	1,582,429
Forfeited	(975,994	)
Vested	(728,228	)
Nonvested as of December 31, 2016	1,685,060
Granted	4,168,477
Forfeited	(552,981	)
Vested	(575,883	)
Nonvested as of December 31, 2017	4,724,673		$	36,616,216
Vested and expected to vest as of December 31, 2017	4,337,839		$	33,618,256

__________


(1)	The aggregate intrinsic values of RSUs and PSUs presented in the table above are calculated by multiplying the closing price of the Company’s ordinary shares on the last trading day of the fiscal year by the corresponding number of RSUs and PSUs.

As of December 31, 2017, the weighted average remaining requisite service period of these units was 2.1 years. The weighted average grant date fair value of the units granted during the years ended December 31, 2017, 2016 and 2015 was $11.42, $43.52 and $72.34 per unit, respectively. As of December 31, 2017, the total remaining unrecognized compensation cost related to non-vested RSUs and PSUs amounted to $30.8 million and $6.3 million, respectively.

Other Expense (Income), Net

12 Months Ended

Dec. 31, 2017

Component of Operating Income [Abstract]

OTHER EXPENSE (INCOME), NET

NOTE 18. OTHER EXPENSE (INCOME), NET

The components of Other (income) expense, net for the for the years ended December 31, 2017, 2016 and 2015 are as follows (in thousands):



	2017			2016			2015
Foreign currency (gain) loss, net	$	(2,801	)	$	2,991		(23,058		)
Equity loss (earnings) from investments accounted for under the equity method, net	898			(1,190		)	3,217
Other-than-temporary impairment of equity investment	—			—			18,869
Legal settlement	—			—			(12,500		)
Costs associated with unused financing commitments	—			—			78,352
Other miscellaneous, net	(15,120		)	(2,139		)	(1,189		)
Other (income) expense, net	$	(17,023	)	$	(338	)	$	63,691

Foreign currency (gain) loss, net results from the remeasurement of the Company’s foreign currency denominated assets and liabilities. In 2017, other miscellaneous, net includes a $10.1 million gain resulting from the sale of Litha, as further described in Note 3. Discontinued Operations and Assets and Liabilities Held for Sale. During 2015, the Company recognized an other-than-temporary impairment of its Litha joint venture investment, totaling $18.9 million, reflecting the excess carrying amount of this investment over its estimated fair value. In addition, the Company incurred $78.4 million during 2015 related to unused commitment fees primarily associated with financing for the Par acquisition.

Income Taxes

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 19. INCOME TAXES

Tax Reform

The TCJA, which was signed into law on December 22, 2017, has resulted in significant changes to the U.S. corporate income tax system. In addition to the reduction of the U.S. statutory federal corporate income tax rate from 35% to 21% effective January 1, 2018, the TCJA contains a broad range of provisions, many of which differ significantly from those contained in previous U.S. tax law. Key provisions of the TCJA, which generally became effective January 1, 2018, include expanded limitations on the deductibility of interest, immediate expensing of capital expenditures, the creation of a new anti-base erosion minimum tax system that among other things limits the deductibility of certain payments made to related foreign entities, the introduction of a territorial tax system beginning in 2018, a one-time deemed repatriation of foreign earnings subject to a transition tax and the modification or repeal of many business deductions and credits. Although the rate of U.S. federal income tax will be reduced in the future, changes in tax rates and laws are accounted for in the period of enactment. Therefore, during the year ended December 31, 2017, we recorded a benefit of $36.2 million as our current estimate of the provisions of the TCJA. This benefit, which is primarily related to remeasurement of deferred tax liabilities related to tax deductible goodwill, has been recorded in our Consolidated Statements of Operations as Income tax benefit.

We have recorded the aforementioned net benefit based on currently available information and interpretations of the TCJA. In accordance with authoritative guidance issued by the SEC, the income tax effect for certain aspects of the TCJA may represent provisional amounts for which our accounting is incomplete but a reasonable estimate could be determined and recorded during the fourth quarter of 2017. We consider amounts related to the various transition rules and interpretations of the TCJA to be provisional. Accordingly, we will continue to evaluate the impacts of the TCJA, including administrative and regulatory guidance as it becomes available. The measurement and existence of current and non-current income tax payables and/or the remeasurement of deferred tax assets and liabilities may change upon finalization of our analysis, which is expected to occur no later than one year from the date of the TCJA’s enactment. Any adjustment to a provisional amount identified during the one-year measurement period will be recorded as an income tax expense or benefit in the period the adjustment is determined.

Income (Loss) Before Income Taxes

Our operations are conducted through our various subsidiaries in numerous jurisdictions throughout the world. We have provided for income taxes based upon the tax laws and rates in the countries in which our operations are conducted.

The components of our Loss from continuing operations before income tax by geography for the years ended December 31, 2017, 2016 and 2015 are as follows (in thousands):



	2017			2016			2015
United States	$	(1,866,222	)	$	(4,309,211	)	$	(626,740	)
International	383,218			385,355			(811,124		)
Total (loss) income from continuing operations before income tax	$	(1,483,004	)	$	(3,923,856	)	$	(1,437,864	)

Income tax from continuing operations consists of the following for the years ended December 31, 2017, 2016 and 2015 (in thousands):



	2017			2016			2015
Current:
U.S. Federal	$	(86,478	)	$	18,369		$	(308,909	)
U.S. State	(6,462		)	9,501			(5,600		)
International	(1,224		)	22,851			16,722
Total current income tax	$	(94,164	)	$	50,721		$	(297,787	)
Deferred:
U.S. Federal	$	(124,682	)	$	(661,484	)	$	(779,757	)
U.S. State	(3,225		)	(239		)	(70,221		)
International	(28,222		)	(83,619		)	(9,376		)
Total deferred income tax	$	(156,129	)	$	(745,342	)	$	(859,354	)
Excess tax benefits of stock compensation exercised	$	—		$	(5,463	)	$	19,676
Valuation allowance	—			—			—
Total income tax	$	(250,293	)	$	(700,084	)	$	(1,137,465	)

Tax Rate

A reconciliation of income tax from continuing operations at the U.S. federal statutory income tax rate to the total income tax provision from continuing operations for the years ended December 31, 2017, 2016 and 2015 is as follows (in thousands):



	2017			2016			2015
Notional U.S. federal income tax provision at the statutory rate	$	(519,051	)	$	(1,373,350	)	$	(503,271	)
State income tax, net of federal benefit	(11,473		)	5,182			(45,823		)
U.S. tax reform impact	(36,216		)	—			—
Uncertain tax positions	58,120			(18,111		)	30,974
Residual tax on non-U.S. net earnings	(1,350,811		)	(301,666		)	(359,831		)
Effects of outside basis differences	—			(636,134		)	(786,130		)
Non-deductible goodwill impairment	60,808			926,881			248,403
Change in valuation allowance	1,648,836			762,604			278,339
Intra-entity transfers of assets	(53,509		)	(92,859		)	—
International Pharmaceuticals segment divestitures	(56,092		)	—			—
Other	9,095			27,369			(126		)
Income tax	$	(250,293	)	$	(700,084	)	$	(1,137,465	)

During the year ended December 31, 2017, the tax benefit primarily related to pre-tax losses incurred by certain U.S. subsidiaries. During the year ended December 31, 2016, the Company recorded a $636.1 million net tax benefit related to worthless stock deductions that are reflected as a component of benefits from outside basis differences. During the year ended December 31, 2015, the Company recorded a $674.2 million net tax benefit predominately related to a worthless stock deduction directly attributable to mesh product liability losses that is reflected as a component of benefits from outside basis differences. The Company claimed the worthless stock deduction on its 2015 U.S. Federal and State income tax returns.

Deferred Tax Assets and Liabilities

Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes. Excluding assets and liabilities held for sale, the significant components of the net deferred income tax liability shown on the balance sheets as of December 31, 2017 and 2016 are as follows (in thousands):



	2017			2016
Deferred tax assets:
Accrued expenses and customer allowances	$	299,142		$	232,101
Compensation related to stock options	20,108			24,246
Deferred interest expense	46,230			57,440
Fixed assets and intangible assets	484,313			55,473
Loss on capital assets	49,585			9,904
Net operating loss carryforward	7,183,651			4,410,386
Other	32,356			30,262
Research and development credit carryforward	4,838			4,244
Tax credit carryforwards	1,516			4,520
Uncertain tax positions	4,364			10,562
Total gross deferred income tax assets	$	8,126,103		$	4,839,138
Deferred tax liabilities:
Other	$	(2,042	)	$	—
Outside basis difference	(92,635		)	(182,409		)
Total gross deferred income tax liabilities	$	(94,677	)	$	(182,409	)
Valuation allowance	(8,062,975		)	(4,841,209		)
Net deferred income tax liability	$	(31,549	)	$	(184,480	)

At December 31, 2017, the Company had the following significant deferred tax assets for net operating and capital loss carryforwards, net of unrecognized tax benefits (in thousands):



Jurisdiction	2017		Begin to Expire
Ireland	$	43,965	indefinite
Luxembourg	$	6,847,805	2034
United States:
Federal-ordinary losses	$	115,518	2020
Federal-capital losses	$	27,114	2022
State-ordinary losses	$	172,439	2018
State-capital losses	$	20,920	2026

A valuation allowance is required when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased, or if objective negative evidence, in the form of cumulative losses, is no longer present and additional weight may be given to subjective evidence, such as projections for growth.

The Company has recorded a valuation allowance against certain jurisdictional net operating loss carryforwards and other tax attributes. As of December 31, 2017 and 2016, the total valuation allowance, including amounts classified as held for sale, was $8,063.0 million and $4,841.2 million, respectively. During the years ended December 31, 2017 and 2016, the Company increased its valuation allowance in the amount of $3,221.8 million and $4,414.2 million, respectively. The net increase in the Company’s valuation allowance in 2017 was primarily driven by: (i) $3,310.8 million related to losses within jurisdictions unable to support recognition of a deferred tax asset, of which the largest jurisdiction was Luxembourg, where the Company recognized a significant loss on its investment in the equity of consolidated subsidiaries, (ii) the establishment of a $479.7 million valuation allowance offsetting net deferred tax assets created in connection with the adoption of ASU 2016-16 that primarily related to certain intangibles and tax deductible goodwill, which is further described in Note 2. Summary of Significant Accounting Policies and (iii) $21.5 million relating to state tax benefits. This increase was partially offset by a $590.2 million reduction related to remeasurement of certain deferred tax assets resulting from the TCJA.

The net increase in the Company’s valuation allowance in 2016 was primarily split into three main components: (i) $3,950.1 million related to losses within jurisdictions unable to support recognition of a deferred tax asset, the largest jurisdiction of which was Luxembourg, where the Company recognized a material loss on its investment in the equity of consolidated subsidiaries, (ii) $67.1 million relating to state tax benefits and (iii) $400.8 million related to recording a valuation allowance on U.S. deferred tax assets.

At December 31, 2017, the Company had the following significant valuation allowances (in thousands):



Jurisdiction	2017
Canada	$	2,228
Ireland	$	99,194
Luxembourg	$	6,847,805
United States	$	1,110,172

We have provided income taxes for earnings that are currently distributed as well as the taxes associated with certain earnings that are expected to be distributed in the future. No additional provision has been made for Irish and non-Irish income taxes on the undistributed earnings of subsidiaries or for unrecognized deferred tax liabilities for temporary differences related to basis differences in investments in subsidiaries as such earnings are expected to be indefinitely reinvested, the investments are essentially permanent in duration. As of December 31, 2017, certain subsidiaries had approximately $169.8 million of cumulative undistributed earnings that have been permanently reinvested because our plans do not demonstrate a need to repatriate such earnings. A liability could arise if our intention to indefinitely reinvest such earnings were to change and amounts are distributed by such subsidiaries or if such subsidiaries are ultimately disposed. It is not practicable to estimate the additional income taxes related to indefinitely reinvested earnings or the basis differences related to investments in subsidiaries.

Uncertain Tax Positions

The Company and its subsidiaries are subject to income taxes in the U.S., various states and numerous foreign jurisdictions with varying statutes as to which tax years are subject to examination by the tax authorities. The Company has taken positions on its tax returns that may be challenged by various tax authorities for which reserves have been established for tax-related uncertainties. These accruals for tax-related uncertainties are based on the Company’s best estimate of the potential tax exposures. When particular matters arise, a number of years may elapse before such matters are audited and finally resolved. Favorable resolution of such matters could be recognized as a reduction of the Company’s effective tax rate in the year of resolution. Resolution of any particular issue could increase the effective tax rate and may require the use of cash in the year of resolution.

As of December 31, 2017, the Company had total unrecognized income tax benefits of $435.1 million. If recognized in future years, $289.9 million of these currently unrecognized income tax benefits would impact the income tax provision and effective tax rate. As of December 31, 2016, the Company had total unrecognized tax benefits of $443.6 million. If recognized in future years, $435.4 million of these unrecognized income tax benefits would have impacted the income tax provision and effective tax rate. The following table summarizes the activity related to unrecognized income tax benefits (in thousands):



	Unrecognized Tax Benefit Federal, State, and Foreign Tax
UTB Balance at January 1, 2015	$	105,330
Gross additions for current year positions	65,439
Gross reductions for prior period positions	(234		)
Gross additions for prior period positions	3,460
Decrease due to lapse of statute of limitations	(75		)
Additions related to acquisitions	150,152
Currency translation adjustment	(7,825		)
UTB Balance at December 31, 2015	$	316,247
Gross additions for current year positions	142,778
Gross reductions for prior period positions	(35,888		)
Gross additions for prior period positions	2,111
Decrease due to lapse of statute of limitations	(3,085		)
Additions related to acquisitions	2,350
Currency translation adjustment	88
UTB Balance at December 31, 2016	$	424,601
Gross additions for current year positions	44,293
Gross reductions for prior period positions	(64,887		)
Gross additions for prior period positions	22,765
Decrease due to lapse of statute of limitations	(13,151		)
Additions related to acquisitions	—
Currency translation adjustment	2,330
UTB Balance at December 31, 2017	$	415,951
Accrued interest and penalties	19,185
Total UTB balance including accrued interest and penalties	$	435,136
Current portion	$	17,100
Non-current portion	$	418,036

The Company records accrued interest as well as penalties related to uncertain tax positions as part of the provision for income taxes. As of December 31, 2017, we had recorded $19.2 million of accrued interest and penalties related to uncertain tax positions on the Consolidated Balance Sheet, all of which was recorded in income taxes. As of December 31, 2016, the balance of accrued interest and penalties was $19.0 million, all of which was recorded in income taxes. During the years ended December 31, 2017, 2016, and 2015, we recognized expense of $1.4 million, $5.1 million and $1.6 million, respectively, related to interest and penalties. The current and non-current portions of our UTB balance are included in our Consolidated Balance Sheet as Accounts payable and accrued expenses, Other liabilities or, if appropriate, as a reduction to Deferred tax assets.

Our subsidiaries file income tax returns in the countries in which they have operations. Generally, these countries have statutes of limitations ranging from 3 to 10 years. Certain subsidiary tax returns are currently under examination by taxing authorities, including U.S. tax returns for the 2011 through 2015 tax years by the Internal Revenue Service.

It is expected that the amount of unrecognized tax benefits will change during the next twelve months; however, the Company does not anticipate any adjustments that would lead to a material impact on our results of operations or our financial position.

As of December 31, 2017, we may be subject to examination in the major tax jurisdictions:



Jurisdiction		Open Years
Canada		2013 through 2017
India		2012 through 2017
Ireland		2014 through 2017
Luxembourg		2013 through 2017
United States - federal, state and local		2006 through 2017

Net Loss Per Share

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

NET LOSS PER SHARE

NOTE 20. NET LOSS PER SHARE

The following is a reconciliation of the numerator and denominator of basic and diluted net loss per share for the years ended December 31, 2017, 2016 and 2015 (in thousands):



	2017			2016			2015
Numerator:
Loss from continuing operations	$	(1,232,711	)	$	(3,223,772	)	$	(300,399	)
Less: Net income (loss) from continuing operations attributable to noncontrolling interests	—			16			(283		)
Loss from continuing operations attributable to Endo International plc ordinary shareholders	$	(1,232,711	)	$	(3,223,788	)	$	(300,116	)
Loss from discontinued operations attributable to Endo International plc ordinary shareholders, net of tax	(802,722		)	(123,278		)	(1,194,926		)
Net loss attributable to Endo International plc ordinary shareholders	$	(2,035,433	)	$	(3,347,066	)	$	(1,495,042	)
Denominator:
For basic per share data—weighted average shares	223,198			222,651			197,100
Dilutive effect of ordinary share equivalents	—			—			—
Dilutive effect of various convertible notes and warrants	—			—			—
For diluted per share data—weighted average shares	223,198			222,651			197,100

Basic net loss per share data is computed based on the weighted average number of ordinary shares outstanding during the period. Diluted loss per share data is computed based on the weighted average number of ordinary shares outstanding and, if there is net income from continuing operations attributable to Endo ordinary shareholders during the period, the dilutive impact of ordinary share equivalents outstanding during the period.

The dilutive effect of ordinary share equivalents are measured under the treasury stock method. Due to the Company’s adoption of ASU 2016-09, effective January 1, 2017, the Company no longer considers excess tax benefits resulting from share-based compensation awards when applying the treasury stock method to calculate diluted weighted average shares outstanding. Therefore, the adoption of this ASU will have the effect of increasing dilution in periods where there is net income from continuing operations attributable to Endo ordinary shareholders and there are weighted average dilutive awards outstanding. Stock options and awards that have been issued but for which a grant date has not yet been established, such as those discussed in Note 17. Share-based Compensation, are not considered in the calculation of basic of diluted weighted average shares.

All potentially dilutive items were excluded from the diluted share calculation for the years ended December 31, 2017, 2016 and 2015 because their effect would have been anti-dilutive, as the Company was in a loss position.

Savings And Investment Plan And Deferred Compensation Plans	12 Months Ended
	Dec. 31, 2017
Savings And Investment Plan And Deferred Compensation Plans [Abstract]
Savings And Investment Plan And Deferred Compensation Plans	NOTE 21. SAVINGS AND INVESTMENT PLAN AND DEFERRED COMPENSATION PLANS Savings and Investment Plan The Company maintains a defined contribution Savings and Investment Plan (the Endo 401(k) Plan) covering all U.S.-based eligible employees. The Company matches 100% of the first 3% of eligible cash compensation that a participant contributes to the Endo 401(k) Plan plus 50% of the next 2% for a total of up to 4%, subject to statutory limitations. Participants are immediately vested with respect to their own contributions and the Company’s matching contributions. Costs incurred for contributions made by the Company to the Endo 401(k) Plan amounted to $9.4 million, $11.5 million and $8.6 million for the years ended December 31, 2017, 2016 and 2015, respectively. Directors Stock Election Plan The Company maintains a directors stock election plan. The purpose of this plan is to provide non-employee directors the opportunity to have their retainer fees, or a portion thereof, delivered in the form of Endo ordinary shares. The amount of shares will be determined by dividing the portion of cash fees elected to be received as shares by the closing price of the shares on the day the payment would have otherwise been paid in cash.

Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2017

Quarterly Financial Data [Abstract]

Quarterly Financial Data (Unaudited)

NOTE 22. QUARTERLY FINANCIAL DATA (UNAUDITED)

The following table presents select unaudited financial data for each of the three-month periods ending March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017, as well as the comparable 2016 periods (in thousands, except per share data):



	Quarter Ended
	March 31,			June 30,			September 30,			December 31,
2017 (1)
Total revenues	$	1,037,600		$	875,731		$	786,887		$	768,640
Gross profit	$	368,638		$	336,330		$	272,365		$	262,995
Loss from continuing operations	$	(165,423	)	$	(696,020	)	$	(99,687	)	$	(271,581	)
Discontinued operations, net of tax	$	(8,405	)	$	(700,498	)	$	3,017		$	(96,836	)
Net loss attributable to Endo International plc	$	(173,828	)	$	(1,396,518	)	$	(96,670	)	$	(368,417	)
Net loss per share attributable to Endo International plc ordinary shareholders—Basic:
Continuing operations	$	(0.74	)	$	(3.12	)	$	(0.45	)	$	(1.22	)
Discontinued operations	(0.04		)	(3.14		)	0.02			(0.43		)
Basic	$	(0.78	)	$	(6.26	)	$	(0.43	)	$	(1.65	)
Net loss per share attributable to Endo International plc ordinary shareholders—Diluted:
Continuing operations	$	(0.74	)	$	(3.12	)	$	(0.45	)	$	(1.22	)
Discontinued operations	(0.04		)	(3.14		)	0.02			(0.43		)
Diluted	$	(0.78	)	$	(6.26	)	$	(0.43	)	$	(1.65	)
Weighted average shares—Basic	223,014			223,158			223,299			223,322
Weighted average shares—Diluted	223,014			223,158			223,299			223,322
2016 (2)
Total revenues	$	963,539		$	920,887		$	884,335		$	1,241,513
Gross profit	$	274,834		$	288,669		$	326,863		$	484,935
(Loss) income from continuing operations	$	(88,763	)	$	389,812		$	(191,496	)	$	(3,333,325	)
Discontinued operations, net of tax	$	(45,108	)	$	(46,216	)	$	(27,423	)	$	(4,531	)
Net (loss) income attributable to Endo International plc	$	(133,869	)	$	343,578		$	(218,919	)	$	(3,337,856	)
Net (loss) income per share attributable to Endo International plc ordinary shareholders—Basic:
Continuing operations	$	(0.40	)	$	1.75		$	(0.86	)	$	(14.96	)
Discontinued operations	(0.20		)	(0.21		)	(0.12		)	(0.02		)
Basic	$	(0.60	)	$	1.54		$	(0.98	)	$	(14.98	)
Net (loss) income per share attributable to Endo International plc ordinary shareholders—Diluted:
Continuing operations	$	(0.40	)	$	1.75		$	(0.86	)	$	(14.96	)
Discontinued operations	(0.20		)	(0.21		)	(0.12		)	(0.02		)
Diluted	$	(0.60	)	$	1.54		$	(0.98	)	$	(14.98	)
Weighted average shares—Basic	222,302			222,667			222,767			222,870
Weighted average shares—Diluted	222,302			222,863			222,767			222,870

__________

(1)

Loss from continuing operations for the year ended December 31, 2017 was impacted by (1) acquisition-related and integration items of $10.9 million, $4.2 million, $16.6 million and $26.4 million during the first, second, third and fourth quarters, respectively, including charges due to changes in the fair value of contingent consideration of $6.2 million, $2.0 million, $15.4 million and $26.4 million, respectively; (2) asset impairment charges of $204.0 million, $725.0 million, $94.9 million and $130.4 million during the first, second, third and fourth quarters, respectively; (3) certain cost reductions and separation benefits incurred in connection with continued efforts to enhance the Company’s operations and other miscellaneous costs of $22.7 million, $24.6 million, $80.7 million and $84.5 million during the first, second, third and fourth quarters, respectively; (4) charges/(benefits) related to litigation-related and other contingent matters totaling $0.9 million, $(2.6) million, $(12.4) million and $200.0 million during the first, second, third and fourth quarters, respectively, and (5) loss on extinguishment of debt of $51.7 million during the second quarter. As previously reported in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, the third quarter numbers above reflect a $14.2 million correcting entry to increase asset impairment charges resulting from certain assets that should have been impaired during the second quarter.

(2)

(Loss) income from continuing operations for the year ended December 31, 2016 was impacted by (1) acquisition-related and integration items of $12.6 million, $48.2 million, $19.5 million and $7.4 million during the first, second, third and fourth quarters, respectively, including charges/(benefits) of $(10.7) million, $23.9 million, $11.6 million and $(1.0) million during the first, second, third and fourth quarters, respectively; (2) asset impairment charges of $129.6 million, $40.0 million, $93.5 million and $3,518.1 million during the first, second, third and fourth quarters, respectively; (3) inventory step-up and certain manufacturing costs that will be eliminated pursuant to integration plans of $68.5 million, $29.1 million, $14.2 million and $13.9 million during the first, second, third and fourth quarters, respectively; (4) certain cost reductions and separation benefits incurred in connection with continued efforts to enhance the Company’s operations and other miscellaneous costs of $38.5 million, $22.2 million, $9.8 million and $37.1 million during the first, second, third and fourth quarters, respectively, and (5) charges/(benefits) related to litigation-related and other contingent matters totaling $5.2 million, $5.3 million, $18.3 million and $(4.8) million during the first, second, third and fourth quarters, respectively.

Quarterly and year-to-date computations of per share amounts are made independently, therefore, the sum of the per share amounts for the quarters may not equal the per share amounts for the year.

As further described in Note 3. Discontinued Operations and Assets and Liabilities Held for Sale, we sold our Litha business on July 3, 2017 and our Somar business on October 25, 2017. Both of these businesses were part of our International Pharmaceuticals segment. Neither business met the requirements for presentation as discontinued operations. The operating results of the AMS business are reported as Discontinued operations, net of tax in the Consolidated Statements of Operations for all periods presented. For additional information, see Note 3. Discontinued Operations and Assets and Liabilities Held for Sale.

SCHEDULE II--Valuation and Qualifying Accounts

12 Months Ended

Dec. 31, 2017

Valuation and Qualifying Accounts [Abstract]

SCHEDULE II--Valuation and Qualifying Accounts

SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS

(in thousands)



	Balance at Beginning of Period		Additions, Costs and Expenses		Deductions, Write-offs			Other (1)			Balance at End of Period
Valuation Allowance For Deferred Tax Assets:
Year Ended December 31, 2015	$	40,646	$	386,087	$	(17,106	)	$	17,364		$	426,991
Year Ended December 31, 2016	$	426,991	$	4,416,478	$	(2,039	)	$	(221	)	$	4,841,209
Year Ended December 31, 2017	$	4,841,209	$	3,811,982	$	—		$	(590,216	)	$	8,062,975

__________


(1)	Represents opening balances of businesses acquired in the period and, for the year ended December 31, 2017, changes in the statutory U.S. Federal corporate income tax rate.

All other financial statement schedules have been omitted because they are not applicable or the required information is included in the Consolidated Financial Statements or notes thereto.


3.	Exhibits:

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2017
Accounting Policies [Abstract]
Consolidation and Basis of Presentation	Consolidation and Basis of Presentation. The Consolidated Financial Statements include the accounts of wholly owned subsidiaries after the elimination of intercompany accounts and transactions.
Reclassifications	Reclassifications. Certain prior period amounts have been reclassified to conform to the current period presentation.
Use of Estimates	Use of Estimates. The preparation of our Consolidated Financial Statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts and disclosures in our Consolidated Financial Statements, including the notes thereto, and elsewhere in this report. For example, we are required to make significant estimates and assumptions related to revenue recognition, including sales deductions, financial instruments, long-lived assets, goodwill, other intangibles, income taxes, contingencies and share-based compensation, among others. Some of these estimates can be subjective and complex. Although we believe that our estimates and assumptions are reasonable, there may be other reasonable estimates or assumptions that differ significantly from ours. Further, our estimates and assumptions are based upon information available at the time they were made. Actual results may differ significantly from our estimates. We regularly evaluate our estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Market conditions, such as illiquid credit markets, volatile equity markets, dramatic fluctuations in foreign currency rates and economic downturn, can increase the uncertainty already inherent in our estimates and assumptions. We also are subject to other risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations.
Customer, Product And Supplier Concentration	Customer, Product and Supplier Concentration. We primarily sell our generic and branded pharmaceuticals to wholesalers, retail drug store chains, supermarket chains, mass merchandisers, distributors, mail order accounts, hospitals and government agencies. Our wholesalers and distributors purchase products from us and, in turn, supply products to retail drug store chains, independent pharmacies and managed health care organizations. Customers in the managed health care market include health maintenance organizations, nursing homes, hospitals, clinics, pharmacy benefit management companies and mail order customers.
Revenue Recognition	Revenue Recognition. Our revenue consists almost entirely of sales of our pharmaceutical products to customers, whereby we ship product to a customer pursuant to a purchase order, which typically corresponds and/or makes reference to a master agreement with that customer, and invoice the customer upon shipment. For sales such as these, we recognize revenue when title and risk of loss has passed to the customer, which is typically upon delivery to the customer, when estimated provisions for revenue reserves are reasonably determinable and when collectability is reasonably confirmed. The amount of revenue we recognize is equal to the selling price, adjusted for our estimates of a number of significant sales deductions, which are further described below. Revenue from the launch of a new or significantly unique product may be deferred until such time that the product has achieved market acceptance. For these products, revenue is typically recognized based on dispensed prescription data and other information obtained prior to and during the period following launch.
Sales Deductions	Sales Deductions. When we recognize revenue from the sale of our products, we simultaneously record an adjustment to revenue for estimated chargebacks, rebates, sales incentives and allowances, DSA and other fees for services, returns and allowances. These sales deductions are estimated based on historical experience, estimated future trends, estimated customer inventory levels, current contract sales terms with our direct and indirect customers and other competitive factors. We subsequently review our provisions for our various sales deductions based on new or revised information that becomes available to us and make revisions to our estimates if and when appropriate. If the assumptions we used to calculate our provisions for sales deductions do not appropriately reflect future activity, our financial position, results of operations and cash flows could be materially impacted.
Research and Development (R&D)	Research and Development (R&D). Expenditures for research and development are expensed as incurred. Total R&D expenses include the costs of discovery research, preclinical development, early- and late-clinical development and drug formulation, clinical trials, medical support of marketed products, upfront, milestone and other payments under third-party collaborations and contracts and other costs. R&D spending also includes enterprise-wide costs which support our overall R&D infrastructure. Property, plant and equipment that are acquired or constructed for research and development activities and that have alternate future uses are capitalized and depreciated over their estimated useful lives on a straight-line basis. Contractual upfront and milestone payments made to third parties are generally: (i) expensed as incurred up to the point of regulatory approval and (ii) capitalized and amortized over the related product’s remaining useful life subsequent to regulatory approval. Amounts capitalized for such payments are included in Other intangibles, net in the Consolidated Balance Sheets.
Cash and Cash Equivalents	Cash and Cash Equivalents. The Company considers all highly liquid money market instruments with an original maturity of three months or less when purchased to be cash equivalents. At December 31, 2017, cash equivalents were deposited in financial institutions and consisted of immediately available fund balances and time deposits. The Company maintains its cash deposits and cash equivalents with financial institutions it believes to be well-known and stable.
Restricted Cash and Cash Equivalents	Restricted Cash and Cash Equivalents. Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are excluded from Cash and cash equivalents in the Consolidated Balance Sheets.
Marketable Securities	Marketable Securities. The Company has equity securities, which consist of investments in the stock of publicly traded companies.
Accounts Receivable	Accounts Receivable. Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. In addition, accounts receivable is reduced by certain sales deduction reserves where we have the right of offset with the customer.
Concentrations Of Credit Risk	Concentrations of Credit Risk. Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents, restricted cash equivalents, marketable debt securities and accounts receivable. We invest our excess cash in high-quality, liquid money market instruments and time deposits maintained by major banks and financial institutions. We have not experienced any losses on our cash equivalents.
Inventories	Inventories. Inventories consist of raw materials, work-in-process and finished goods. Inventory that is in excess of the amount expected to be sold within one year is classified as long-term inventory and is recorded in Other assets in the Consolidated Balance Sheets. The Company capitalizes inventory costs associated with certain generic products prior to regulatory approval and product launch when it is reasonably certain, based on management’s judgment of future commercial use and net realizable value, that the pre-launch inventories will be saleable. The determination to capitalize is made on a product-by-product basis once: (i) the Company (or its third party development partners) has filed an ANDA that has been acknowledged by the FDA as containing sufficient information to allow the FDA to conduct its review in an efficient and timely manner and (ii) management is reasonably certain that all regulatory and legal requirements will be cleared. The Company could be required to write down previously capitalized costs related to pre-launch inventories upon a change in such judgment, a denial or delay of approval by regulatory bodies, a delay in commercialization or other potential factors. Our inventories are stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out method and includes materials, direct labor and an allocation of overhead. Net realizable value is determined by the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. When necessary, we write-down inventories to net realizable value based on forecasted demand and market and regulatory conditions, which may differ from actual results.
Property, Plant and Equipment	Property, Plant and Equipment. Property, plant and equipment is generally stated at cost less accumulated depreciation. Major improvements are capitalized, while routine maintenance and repairs are expensed as incurred. Costs incurred during the construction or development of property plant and equipment are capitalized as assets under construction. Once an asset has been put into service, depreciation expense is taken over the estimated useful life of the related assets or, in the case of leasehold improvements and capital lease assets, over the shorter of the estimated useful life or the lease term. Depreciation expense is recorded on a straight-line basis. Depreciation expense is not recorded on Assets held for sale. Gains and losses on disposals are included in Other (income) expense, net in the Consolidated Statements of Operations.
Computer Software	Computer Software. The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software, including external direct costs of material and services, and payroll costs for employees directly involved with the software development. Capitalized software costs are included in Property, plant and equipment, net in the Consolidated Balance Sheets and depreciated beginning when the software project is substantially complete and the asset is ready for its intended use. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred. Developed Technology. Our developed technology assets have useful lives ranging from 1 year to 20 years, with a weighted average useful life of approximately 11 years. We determine amortization periods and method of amortization for developed technology assets based on our assessment of various factors impacting estimated useful lives and timing and extent of estimated cash flows of the acquired assets including the strength of the intellectual property protection of the product, contractual terms and various other competitive and regulatory issues.
Lease Accounting	Lease Accounting. The Company accounts for operating lease transactions by recording rent expense on a straight-line basis over the expected life of the lease, commencing on the date it gains possession of leased property. The Company includes tenant improvement allowances and rent holidays received from landlords and the effect of any rent escalation clauses as adjustments to straight-line rent expense over the expected life of the lease. Capital lease transactions are reflected as a liability at the inception of the lease based on the present value of the minimum lease payments or, if lower, the fair value of the property. Assets under capital leases are recorded in Property, plant and equipment, net in the Consolidated Balance Sheets and depreciated in a manner similar to other Property, plant and equipment. Certain construction projects may be accounted for as direct financing arrangements, whereby the Company records, over the construction period, the full cost of the asset in Property, plant and equipment, net in the Consolidated Balance Sheets. A corresponding liability is also recorded, net of leasehold improvements paid for by the Company, and is amortized over the expected lease term through monthly rental payments using an effective interest method. Assets recorded under direct financing arrangements are depreciated over the lease term.
Finite-Lived Intangible Assets	Finite-Lived Intangible Assets. Our finite-lived intangible assets, which consist of license rights and developed technology, are initially recorded at fair value upon acquisition. There are several methods that can be used to determine fair value. For intangible assets, we typically use the income method. This method starts with our forecast of all of the expected future net cash flows. Revenues are estimated based on relevant market size and growth factors, expected industry trends, individual project life cycles and, if applicable, the life of any estimated period of marketing exclusivity, such as that granted by a patent. The pricing, margins and expense levels of similar products are considered if available. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams. To the extent an intangible asset is deemed to have a finite life, it is then amortized over its estimated useful life using either the straight-line method or, in the case of certain developed technology assets, the economic benefit model. The values of these various assets are subject to continuing scientific, medical and marketplace uncertainty. Factors giving rise to our initial estimate of useful lives are subject to change. Significant changes to any of these factors may result in a reduction in the useful life of the asset and an acceleration of related amortization expense, which could cause our operating income, net income and net income per share to decrease. Amortization expense is not recorded on assets held for sale.
License Rights	License Rights. Our license rights have useful lives ranging from 3 years to 15 years, with a weighted average useful life of approximately 12 years. We determine amortization periods for licenses based on our assessment of various factors including the expected launch date of the product, the strength of the intellectual property protection of the product, contractual terms and various other competitive, developmental and regulatory issues.
Long-Lived Asset Impairment Testing	Long-Lived Asset Impairment Testing. Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are assessed for impairment whenever events or changes in circumstances indicate the carrying amounts of the assets may not be recoverable. Recoverability of an asset that will continue to be used in our operations is measured by comparing the carrying amount of the asset to the forecasted undiscounted future cash flows related to the asset. In the event the carrying amount of the asset exceeds its undiscounted future cash flows and the carrying amount is not considered recoverable, impairment may exist. An impairment loss, if any, is measured as the excess of the asset’s carrying amount over its fair value, generally based on a discounted future cash flow method, independent appraisals or preliminary offers from prospective buyers. An impairment loss would be recognized in the Consolidated Statements of Operations in the period that the impairment occurs.
In-Process Research and Development Assets (IPR&D)	In-Process Research and Development Assets (IPR&D). IPR&D assets are considered indefinite-lived intangible assets. Similar to finite-lived intangible assets, IPR&D assets are initially recorded at fair value. While amortization expense is not initially recorded for IPR&D assets, these assets are subject to impairment reviews. Impairment tests for an IPR&D asset occur at least annually on October 1^st of each year, but also whenever events or changes in circumstances indicate that the asset might be impaired. If the fair value of the intangible assets is less than its carrying amount, an impairment loss is recognized for the difference. For those assets that reach commercialization, the assets are reclassified as finite-lived intangible assets and amortized over the expected useful lives.
Goodwill	Goodwill. Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. While amortization expense is not recorded on goodwill, goodwill is subject to impairment reviews. Impairment tests for goodwill occur at least annually on October 1^st of each year, but also whenever events or changes in circumstances indicate that the asset might be impaired. As further described below under the heading “Recent Accounting Pronouncements Adopted or Otherwise Effective as of December 31, 2017,” effective January 1, 2017, we early adopted Accounting Standards Update (ASU) No. 2017-04 “Intangibles - Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment” (ASU 2017-04). Subsequent to adoption, we perform our goodwill impairment tests by comparing the fair value of each of our reporting units with the carrying amount. Any goodwill impairment charge we recognize for a reporting unit is equal to the lesser of (i) the total goodwill allocated to that reporting unit and (ii) the amount by which that reporting unit’s carrying amount exceeds its fair value.
Contingencies	Contingencies. The Company is subject to various patent challenges, product liability claims, government investigations and other legal proceedings in the ordinary course of business. Legal fees and other expenses related to litigation are expensed as incurred and included in Selling, general and administrative expenses or Discontinued operations, net of tax in the Consolidated Statements of Operations. Contingent accruals and legal settlements are recorded in the Consolidated Statements of Operations as Litigation-related and other contingencies, net (or Discontinued operations, net in the case of vaginal mesh matters) when the Company determines that a loss is both probable and reasonably estimable. Due to the fact that legal proceedings and other contingencies are inherently unpredictable, our estimates of the probability and amount of any such liabilities involve significant judgment regarding future events. The Company records a receivable from its product liability insurance carriers only when the resolution of any dispute has been reached and realization of the potential claim for recovery is considered probable.
Contingent Consideration	Contingent Consideration. Certain of the Company’s business acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of operational and commercial milestones and royalty payments on future product sales. The fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period, the Company remeasures its contingent consideration liability to its current fair value, with changes recorded in earnings. Changes to any of the inputs used in determining fair value may result in a significantly different fair value adjustment.
Share Repurchases	Share Repurchases. The Company accounts for the repurchase of ordinary shares at par value. Under applicable Irish law, ordinary shares repurchased are retired and not displayed separately as treasury stock. Upon retirement of the ordinary shares, the Company records the difference between the weighted average cost of such ordinary shares and the par value of the ordinary shares as an adjustment to Accumulated deficit in the Consolidated Balance Sheets.
Advertising Costs	Advertising Costs. Advertising costs are expensed as incurred and included in Selling, general and administrative expenses in the Consolidated Statements of Operations.
Cost of Revenues	Cost of Revenues. Cost of revenues includes all costs directly related to bringing both purchased and manufactured products to their final selling destination. Amounts include purchasing and receiving costs, direct and indirect costs to manufacture products including direct materials, direct labor and direct overhead expenses necessary to acquire and convert purchased materials and supplies into finished goods, royalties paid or owed by Endo on certain in-licensed products, inspection costs, depreciation of certain property, plant and equipment, amortization of intangible assets, warehousing costs, freight charges, costs to operate our equipment and other shipping and handling costs, among others.
Share-Based Compensation	Share-Based Compensation. The Company grants share-based compensation awards to certain employees and non-employee directors. Generally, the grant-date fair value of each award is recognized as expense over the requisite service period. However, expense recognition differs in the case of certain performance share units where the ultimate payout is performance-based. For these awards, at each reporting period, the Company estimates the ultimate payout and adjusts the cumulative expense based on its estimate and the percent of the requisite service period that has elapsed. Share-based compensation expense is reduced for estimated future forfeitures. These estimates are revised in future periods if actual forfeitures differ from the estimates. Changes in forfeiture estimates impact compensation expense in the period in which the change in estimate occurs. New ordinary shares are generally issued upon the exercise of stock options or vesting of stock awards by employees and non-employee directors.
Foreign Currency Translation	Foreign Currency. The Company operates in various jurisdictions both inside and outside of the U.S. While the Company’s reporting currency is the U.S. dollar (USD), the Company has concluded that certain of its distinct and separable operations have functional currencies other than the USD. Further, certain of the Company’s operations hold assets and liabilities and recognize income and expenses denominated in various local currencies, which may differ from their functional currencies. Assets and liabilities are first remeasured from local currency to functional currency, generally using end-of-period exchange rates. Foreign currency income and expenses are generally remeasured using average exchange rates in effect during the year. In the case of nonmonetary assets and liabilities such as inventories, prepaid expenses, property, plant and equipment, goodwill and other intangible assets, and related income statement amounts, such as depreciation expense, historical exchange rates are used for remeasurement. The net effect of remeasurement is included in Other (income) expense, net in the Consolidated Statements of Operations. As part of the Company’s consolidation process, assets and liabilities of entities with functional currencies other than the USD are translated into USD at end-of-period exchange rates. Income and expenses are translated using average exchange rates in effect during the year. The net effect of translation is included as foreign currency translation, a component of Other comprehensive income (loss). Upon the sale or liquidation of an investment in a foreign operation, the Company records a reclassification adjustment out of Other comprehensive income (loss) for the accumulated amount of currency translation.
Income Taxes	Income Taxes. The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company records net deferred tax assets to the extent it believes these assets will more likely than not be realized. In making such a determination, the Company considers all available positive and negative evidence, including projected future taxable income, tax-planning strategies and results of recent operations. In the event that the Company were to determine that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income tax. The Company records uncertain tax positions on the basis of a two-step process whereby the Company first determines whether it is more likely than not that the tax positions will be sustained based on the technical merits of the position and then measures those tax positions that meet the more-likely-than-not recognition threshold. The Company recognizes the largest amount of tax benefit that is greater than 50% likely to be realized upon ultimate settlement with the tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within the Income tax expense (benefit) line in the Consolidated Statements of Operations. Accrued interest and penalties are included within the related tax liability line in the Consolidated Balance Sheets.
Comprehensive Income	Comprehensive Income. Comprehensive income or loss includes all changes in equity during a period except those that resulted from investments by or distributions to a company’s shareholders. Other comprehensive income or loss refers to revenues, expenses, gains and losses that are included in comprehensive income, but excluded from net income as these amounts are recorded directly as an adjustment to shareholders’ equity.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Issued Accounting Pronouncements Not Yet Adopted at December 31, 2017 In May 2014, the Financial Accounting Standards Board (FASB) issued ASU No. 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09). ASU 2014-09 represents a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which a company expects to be entitled to receive in exchange for those goods or services. This ASU sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed. In August 2015, the FASB issued ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” which defers the effective date of ASU 2014-09 by one year, but permits companies to adopt one year earlier if they choose (i.e., the original effective date). As such, ASU 2014-09 will be effective for annual and interim reporting periods beginning after December 15, 2017. In March and April 2016, the FASB issued ASU No. 2016-08 “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Consideration (Reporting Revenue Gross versus Net)” and ASU No. 2016-10 “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,” respectively, which clarifies the guidance on reporting revenue as a principal versus agent, identifying performance obligations and accounting for intellectual property licenses. In addition, in May 2016, the FASB issued ASU No. 2016-12 “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients,” which amends certain narrow aspects of Topic 606, and in December 2016, the FASB issued ASU No. 2016-20 “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,” which amends certain narrow aspects of Topic 606. The new revenue recognition standard is effective for the Company on January 1, 2018. The Company is currently finalizing its analysis of the impact of ASU 2014-09 on its consolidated results of operations and financial position. The Company established a cross-functional implementation team consisting of representatives from across its business segments, which has substantially completed a diagnostic assessment of the impact of the standard on its contract portfolio, including review of customer contracts, as well as the Company’s current accounting policies and practices to identify potential differences that would result from applying the requirements of the new standard to its revenue contracts. Based on this assessment, the Company does not expect the impact to be material to its consolidated financial statements. The Company is also finalizing its evaluation of the internal control implications associated with the adoption of the new standard, including the identification and implementation, if necessary, of changes to its business processes, systems and controls to support recognition and disclosure under the new standard. The majority of the Company’s revenue is generated from product sales and the Company currently does not anticipate a significant impact to revenue related to these arrangements. In certain limited situations, under current GAAP, the Company has deferred revenue for certain product sales because the sales price was not deemed to be fixed or determinable. Under the new standard, the Company will be required to estimate the variable consideration associated with these transactions and record revenue at the point of sale. The Company also generates revenue from certain less significant transactions, including certain licensing arrangements. The Company has substantially completed its preliminary evaluation of the impact of the new standard on these other transactions and does not anticipate a significant impact on revenue related to these arrangements; however, this analysis is preliminary and remains subject to change. The two permitted transition methods under the new standard are the full retrospective method, in which case the standard would be applied to each prior reporting period presented and the cumulative effect of applying the standard would be recognized at the earliest period shown, or the modified retrospective method, in which case the cumulative effect of applying the standard would be recognized at the date of initial application. The Company will utilize the modified retrospective method of adoption. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (ASU 2016-02). ASU 2016-02 establishes the principles to report transparent and economically neutral information about the assets and liabilities that arise from leases. This guidance requires lessees to recognize the lease assets and lease liabilities that arise from leases in the statement of financial position and to disclose qualitative and quantitative information about lease transactions, such as information about variable lease payments and options to renew and terminate leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2016-02 on the Company’s consolidated results of operations and financial position. In May 2017, the FASB issued ASU No. 2017-09 “Compensation - Stock Compensation” (ASU 2017-09). ASU 2017-09 provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. It is intended to reduce both (1) diversity in practice and (2) cost and complexity when accounting for changes to the terms or conditions of share-based payment awards. ASU 2017-09 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. The Company adopted the new standard on January 1, 2018 and the amendments in this update will be applied prospectively to any award modified on or after the adoption date. In February 2018, the FASB issued ASU No. 2018-02 “Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income” (ASU 2018-02). ASU 2018-02 allows for a reclassification from accumulated other comprehensive income or loss to retained earnings or accumulated deficit for stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017 (TCJA). ASU 2018-02 also requires certain related disclosures. ASU 2018-02 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2018 and should be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the U.S. federal corporate income tax rate in the TCJA is recognized. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-02. Recent Accounting Pronouncements Adopted or Otherwise Effective as of December 31, 2017 In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory” (ASU 2015-11). ASU 2015-11 states that an entity should measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. For public entities, ASU 2015-11 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company adopted ASU 2015-11 on January 1, 2017 and the adoption did not impact the Company’s consolidated results of operations and financial position. As discussed above under the heading “Reclassifications,” in March 2016, the FASB issued ASU 2016-09. ASU 2016-09 changes how companies account for certain aspects of share-based payments to employees including: (i) requiring all income tax effects of awards to be recognized in the income statement, rather than in additional paid in capital, when the awards vest or are settled, (ii) eliminating the requirement that excess tax benefits be realized before companies can recognize them, (iii) requiring companies to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity, (iv) increasing the amount an employer can withhold to cover income taxes on awards and still qualify for the exception to liability classification for shares used to satisfy the employer’s statutory income tax withholding obligation, (v) requiring an employer to classify the cash paid to a tax authority when shares are withheld to satisfy its statutory income tax withholding obligation as a financing activity on its statement of cash flows and (vi) electing whether to account for forfeitures of share-based payments by (a) recognizing forfeitures of awards as they occur or (b) estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change, as is currently required. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company adopted the new guidance on January 1, 2017 on a prospective basis, except for the provision requiring companies to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity, which was adopted retrospectively. As a result of the adoption, during the year ended December 31, 2017, the Company did not recognize any tax expense in its Consolidated Statement of Operations that would have been recorded as additional paid-in capital prior to adoption. The table above under the heading “Reclassifications” presents the retrospective effects of the adoption of ASU 2016-09 on the Company’s Consolidated Statements of Cash Flows, which related to the reclassification of excess tax benefits. The adoption of ASU 2016-09 did not impact beginning retained earnings and the Company will continue to estimate forfeitures to determine the amount of compensation cost to be recognized in each period. None of the other provisions in this amended guidance had a significant impact on the Company’s consolidated financial statements. As discussed above under the heading “Reclassifications,” in August 2016, the FASB issued ASU 2016-15. ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. One of the provisions of ASU 2016-15 is that cash outflows for debt prepayment or debt extinguishment costs should be classified as cash outflows for financing activities, rather than operating activities. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted in any interim or annual period, but all of ASU 2016-15 must be adopted in the same period. All updates should be applied using a retrospective transition method. The Company early adopted ASU 2016-15 on December 31, 2017. The table above under the heading “Reclassifications” presents the retrospective effects of the adoption of ASU 2016-15 on the Company’s Consolidated Statements of Cash Flows, which related to the reclassification of cash outflows for debt prepayment costs. In October 2016, the FASB issued ASU No. 2016-16 “Intra-Entity Transfers of Assets Other Than Inventory” (ASU 2016-16). ASU 2016-16 states that an entity should recognize the income tax consequences when an intra-entity transfer of an asset other than inventory occurs. ASU 2016-16 is effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years. Early adoption is permitted as long as it is adopted in the first interim period of a fiscal year beginning after December 15, 2016. The Company early adopted ASU 2016-16 on January 1, 2017, resulting in the elimination of previously recorded deferred charges that were established in 2016. Specifically, the Company eliminated a $24.1 million current deferred charge and a $348.8 million non-current deferred charge that were reflected in our Consolidated Balance Sheet at December 31, 2016 as Prepaid expenses and other current assets and Other assets, respectively. The eliminations of these deferred charges were recorded as adjustments to retained earnings as of January 1, 2017. On adoption, the Company also recorded net deferred tax assets, primarily related to certain intangible assets and tax deductible goodwill, of $479.7 million, fully offset by a corresponding valuation allowance. As discussed above under the heading “Reclassifications,” in November 2016, the FASB issued ASU 2016-18. ASU 2016-18 states that a statement of cash flows should explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period, and all updates should be applied using a retrospective transition method. The Company early adopted ASU 2016-18 on December 31, 2017. The table above under the heading “Reclassifications” presents the retrospective effects of the adoption of ASU 2016-18 on the Company’s Consolidated Statements of Cash Flows. In January 2017, the FASB issued ASU No. 2017-01 “Business Combinations (Topic 805) - Clarifying the Definition of a Business” (ASU 2017-01). ASU 2017-01 clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The amendments in this update provide a screen to determine when an integrated set of assets and activities (collectively referred to as a “set”), is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. ASU 2017-01 is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. The amendments in this update should be applied prospectively on or after the effective date. Early application of the amendments in this update is allowed. The Company early adopted this new standard on January 1, 2017. In January 2017, the FASB issued ASU 2017-04. ASU 2017-04 simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. In computing the implied fair value of goodwill under Step 2, an entity had to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities (including unrecognized assets and liabilities) following the procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Instead, under ASU 2017-04, an entity should perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider the income tax effects of any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019 and an entity should apply the amendments of ASU 2017-04 on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company early adopted this standard on January 1, 2017.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Schedule of new accounting pronouncements

The table below presents the effects of these ASUs on the Company’s Consolidated Statements of Cash Flows for each of the years ended December 31, 2016 and 2015 (in thousands):



	Prior to Adoption			Impact of Adoption of:									Subsequent to Adoption
	Prior to Adoption			ASU 2016-09			ASU 2016-15			ASU 2016-18			Subsequent to Adoption
For the year ended December 31, 2016:
Net cash provided by operating activities	$	524,439		$	3,204		$	—		$	500		$	528,143
Net cash provided by (used in) investing activities	125,861			—			—			(303,413		)	(177,552		)
Net cash used in financing activities	(393,982		)	(3,204		)	—			—			(397,186		)
Effect of foreign exchange rate	328			—			—			108			436
Movement in cash held for sale	(11,744		)	—			—			—			(11,744		)
Net change (1)	$	244,902		$	—		$	—		$	(302,805	)	$	(57,903	)
Beginning-of-period balance (2)	272,348			—			—			590,735			863,083
End-of-period balance (2)	$	517,250		$	—		$	—		$	287,930		$	805,180
For the year ended December 31, 2015:
Net cash provided by operating activities	$	62,026		$	21,979		$	31,496		$	3,000		$	118,501
Net cash used in investing activities	(6,244,770		)	—			—			61,006			(6,183,764		)
Net cash provided by financing activities	6,055,467			(21,979		)	(31,496		)	—			6,001,992
Effect of foreign exchange rate	(7,068		)	—			—			(4,201		)	(11,269		)
Movement in cash held for sale	997			—			—			—			997
Net change (1)	$	(133,348	)	$	—		$	—		$	59,805		$	(73,543	)
Beginning-of-period balance (2)	405,696			—			—			530,930			936,626
End-of-period balance (2)	$	272,348		$	—		$	—		$	590,735		$	863,083

__________


(1)	This line refers to the “Net increase (decrease) in cash and cash equivalents” prior to the adoption of ASU 2016-18 and the “Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents” after the adoption.


(2)	These lines refer to the beginning or end of period amounts of “Cash and cash equivalents” prior to the adoption of ASU 2016-18 and the beginning or end of periods amounts of “Cash, cash equivalents, restricted cash and restricted cash equivalents” after the adoption.

Schedules of concentration of risk, by risk factor

Total revenues from direct customers that accounted for 10% or more of our total consolidated revenues during the years ended December 31, 2017, 2016 and 2015 are as follows:



	2017		2016		2015
Cardinal Health, Inc.	25	%	26	%	21	%
McKesson Corporation	25	%	27	%	31	%
AmerisourceBergen Corporation	25	%	25	%	23	%

Estimated useful lives

Depreciation is based on the following estimated useful lives, as of December 31, 2017:



	Range of Useful Lives (1), from:
Buildings	10 years	to	30 years
Machinery and equipment	2 years	to	15 years
Leasehold improvements	2 years	to	10 years
Computer equipment and software	1 year	to	7 years
Assets under capital lease	Shorter of useful life or lease term
Furniture and fixtures	3 years	to	10 years

__________


(1)	The useful lives for certain fixed assets have been reduced in connection with our 2017 U.S. Generic Pharmaceuticals Restructuring Initiative, which is further described in Note 4. Restructuring. The ranges of useful lives above do not include such assets.

This table excludes changes related to businesses classified as held for sale, to the extent such changes occurred after the business was classified as held for sale.



Cost:	Land and Buildings			Machinery and Equipment			Leasehold Improve- ments			Computer Equipment and Software			Assets under Capital Lease			Furniture and Fixtures			Assets under Construc- tion			Total
At January 1, 2017	$	322,537		$	227,833		$	50,359		$	118,928		$	9,155		$	21,086		$	129,102		$	879,000
Additions	19,871			49,088			11,067			21,626			—			684			26,043			128,379
Disposals, transfers, impairments and other	(12,333		)	(9,939		)	(1,271		)	(9,459		)	(4,259		)	(8,770		)	(36,186		)	(82,217		)
Effect of currency translation	1,391			836			309			356			—			124			76			3,092
At December 31, 2017	$	331,466		$	267,818		$	60,464		$	131,451		$	4,896		$	13,124		$	119,035		$	928,254
Accumulated Depreciation:
At January 1, 2017	$	(50,770	)	$	(64,319	)	$	(21,263	)	$	(62,836	)	$	(5,773	)	$	(4,443	)	$	—		$	(209,404	)
Additions	(93,633		)	(76,986		)	(6,607		)	(27,121		)	(2,645		)	(3,007		)	—			(209,999		)
Disposals, transfers and other	(4,656		)	6,964			1,088			7,354			4,257			1,201			—			16,208
Effect of currency translation	(343		)	(400		)	(85		)	(189		)	—			(71		)	—			(1,088		)
At December 31, 2017	$	(149,402	)	$	(134,741	)	$	(26,867	)	$	(82,792	)	$	(4,161	)	$	(6,320	)	$	—		$	(404,283	)
Net Book Amount:
At December 31, 2017	$	182,064		$	133,077		$	33,597		$	48,659		$	735		$	6,804		$	119,035		$	523,971
At December 31, 2016	$	271,767		$	163,514		$	29,096		$	56,092		$	3,382		$	16,643		$	129,102		$	669,596

Discontinued Operations and Assets and Liabilities Held For Sale (Tables)

12 Months Ended

Dec. 31, 2017

Discontinued Operations and Disposal Groups [Abstract]

Schedule of disposal groups, including discontinued operations, income statement, balance sheet and additional disclosures

The following table provides the operating results of AMS Discontinued operations, net of tax for the years ended December 31, 2017, 2016 and 2015 (in thousands):



	2017			2016			2015
Revenue	$	338		$	30,101		$	305,256
Litigation-related and other contingencies, net	$	775,474		$	20,115		$	1,107,752
Asset impairment charges	$	—		$	21,328		$	230,703
Gain on sale of business	$	—		$	—		$	13,550
Loss from discontinued operations before income taxes	$	(816,426	)	$	(123,164	)	$	(1,352,344	)
Income tax benefit	$	(13,704	)	$	—		$	(157,418	)
Discontinued operations, net of tax	$	(802,722	)	$	(123,164	)	$	(1,194,926	)

The following table provides the components of Assets and Liabilities held for sale of Litha as of and December 31, 2016 (in thousands):



	December 31, 2016
Current assets	$	50,167
Property, plant and equipment	3,527
Other intangibles, net	29,950
Other assets	11,343
Assets held for sale	$	94,987
Current liabilities	18,642
Other liabilities	5,696
Liabilities held for sale	$	24,338

Restructuring and related costs

A summary of expenses related to the Astora Restructuring Initiative is included below for the year ended December 31, 2016 (in thousands):



	2016
Employee separation, retention and other benefit-related costs	$	20,476
Asset impairment charges	21,328
Contract termination-related items	8,074
Other wind down costs	10,972
Total	$	60,850

Schedule of restructuring reserve by type of cost

Changes to this liability during the years ended December 31, 2017 and 2016 were as follows (in thousands):



	Employee Separation and Other Benefit-Related Costs			Contract Termination Charges			Other Restructuring Costs			Total
Liability balance as of January 1, 2016	$	—		$	—		$	—		$	—
Expenses	20,476			8,074			5,798			34,348
Cash distributions	(16,621		)	(6,413		)	(5,798		)	(28,832		)
Liability balance as of January 1, 2017	$	3,855		$	1,661		$	—		$	5,516
Cash distributions	(3,855		)	(1,208		)	—			(5,063		)
Liability balance as of December 31, 2017	$	—		$	453		$	—		$	453

Changes to this accrual during the years ended December 31, 2017 and 2016 were as follows (in thousands):



	Employee Separation and Other Benefit-Related Costs			Other Restructuring Costs			Total
Liability balance as of January 1, 2016	$	5,353		$	6,910		$	12,263
Cash distributions	(5,353		)	(1,406		)	(6,759		)
Liability balance as of January 1, 2017	$	—		$	5,504		$	5,504
Expenses	—			1,058			1,058
Cash distributions	—			(1,937		)	(1,937		)
Liability balance as of December 31, 2017	$	—		$	4,625		$	4,625

Changes to this liability during the year ended December 31, 2017 were as follows (in thousands):



	Employee Separation and Other Benefit-Related Costs			Other Restructuring Costs			Total
Liability balance as of January 1, 2017	$	—		$	—		$	—
Expenses	29,553			13,724			43,277
Cash distributions	(6,578		)	(12,114		)	(18,692		)
Liability balance as of December 31, 2017	$	22,975		$	1,610		$	24,585

Changes to this liability during the years ended December 31, 2017 and 2016 were as follows (in thousands):



	Total
Liability balance as of January 1, 2016	$	—
Expenses	16,983
Cash distributions	(7,044		)
Liability balance as of January 1, 2017	$	9,939
Expenses	984
Cash distributions	(10,672		)
Liability balance as of December 31, 2017	$	251

Changes to this accrual during the years ended December 31, 2017 and 2016 were as follows (in thousands):



	Total
Liability balance as of January 1, 2016	$	17,914
Expenses	5,010
Cash distributions	(19,655		)
Liability balance as of January 1, 2017	$	3,269
Expenses	63
Cash distributions	(3,332		)
Liability balance as of December 31, 2017	$	—

Changes to this liability during the years ended December 31, 2017 and 2016 were as follows (in thousands):



	Employee Separation and Other Benefit-Related Costs			Contract Termination Charges			Total
Liability balance as of January 1, 2016	$	—		$	—		$	—
Expenses	16,544			5,224			21,768
Cash distributions	—			—			—
Liability balance as of January 1, 2017	$	16,544		$	5,224		$	21,768
Cash distributions	(16,544		)	(5,224		)	(21,768		)
Liability balance as of December 31, 2017	$	—		$	—		$	—

Changes to this liability during the year ended December 31, 2017 were as follows (in thousands):



	2017
Liability balance as of January 1, 2017	$	—
Expenses	15,072
Cash distributions	(12,391		)
Liability balance as of December 31, 2017	$	2,681

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=84176398&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84176398&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

+ Details

Restructuring (Tables)

12 Months Ended

Dec. 31, 2017

Restructuring and Related Activities [Abstract]

Schedule of restructuring reserve by type of cost

Changes to this liability during the years ended December 31, 2017 and 2016 were as follows (in thousands):



	Employee Separation and Other Benefit-Related Costs			Contract Termination Charges			Other Restructuring Costs			Total
Liability balance as of January 1, 2016	$	—		$	—		$	—		$	—
Expenses	20,476			8,074			5,798			34,348
Cash distributions	(16,621		)	(6,413		)	(5,798		)	(28,832		)
Liability balance as of January 1, 2017	$	3,855		$	1,661		$	—		$	5,516
Cash distributions	(3,855		)	(1,208		)	—			(5,063		)
Liability balance as of December 31, 2017	$	—		$	453		$	—		$	453

Changes to this accrual during the years ended December 31, 2017 and 2016 were as follows (in thousands):



	Employee Separation and Other Benefit-Related Costs			Other Restructuring Costs			Total
Liability balance as of January 1, 2016	$	5,353		$	6,910		$	12,263
Cash distributions	(5,353		)	(1,406		)	(6,759		)
Liability balance as of January 1, 2017	$	—		$	5,504		$	5,504
Expenses	—			1,058			1,058
Cash distributions	—			(1,937		)	(1,937		)
Liability balance as of December 31, 2017	$	—		$	4,625		$	4,625

Changes to this liability during the year ended December 31, 2017 were as follows (in thousands):



	Employee Separation and Other Benefit-Related Costs			Other Restructuring Costs			Total
Liability balance as of January 1, 2017	$	—		$	—		$	—
Expenses	29,553			13,724			43,277
Cash distributions	(6,578		)	(12,114		)	(18,692		)
Liability balance as of December 31, 2017	$	22,975		$	1,610		$	24,585

Changes to this liability during the years ended December 31, 2017 and 2016 were as follows (in thousands):



	Total
Liability balance as of January 1, 2016	$	—
Expenses	16,983
Cash distributions	(7,044		)
Liability balance as of January 1, 2017	$	9,939
Expenses	984
Cash distributions	(10,672		)
Liability balance as of December 31, 2017	$	251

Changes to this accrual during the years ended December 31, 2017 and 2016 were as follows (in thousands):



	Total
Liability balance as of January 1, 2016	$	17,914
Expenses	5,010
Cash distributions	(19,655		)
Liability balance as of January 1, 2017	$	3,269
Expenses	63
Cash distributions	(3,332		)
Liability balance as of December 31, 2017	$	—

Changes to this liability during the years ended December 31, 2017 and 2016 were as follows (in thousands):



	Employee Separation and Other Benefit-Related Costs			Contract Termination Charges			Total
Liability balance as of January 1, 2016	$	—		$	—		$	—
Expenses	16,544			5,224			21,768
Cash distributions	—			—			—
Liability balance as of January 1, 2017	$	16,544		$	5,224		$	21,768
Cash distributions	(16,544		)	(5,224		)	(21,768		)
Liability balance as of December 31, 2017	$	—		$	—		$	—

Changes to this liability during the year ended December 31, 2017 were as follows (in thousands):



	2017
Liability balance as of January 1, 2017	$	—
Expenses	15,072
Cash distributions	(12,391		)
Liability balance as of December 31, 2017	$	2,681

Acquisitions (Tables)

12 Months Ended

Dec. 31, 2017

Business Combinations [Abstract]

Schedule of revenue and net loss of acquired included in Condensed Consolidated Statements of Operations



Revenue	$	401,238
Net loss attributable to Endo International plc	$	(4,348	)
Basic and diluted net loss per share	$	(0.02	)



Revenue	$	341,520
Net loss attributable to Endo International plc (1)	$	(469,986	)
Basic and diluted net loss per share	$	(2.38	)

__________


(1)	Net loss attributable to Endo International plc does not include any portion of the goodwill impairment charges recorded during 2015 since it is not possible to distinguish the amount of the charges directly attributable to Auxilium.

Schedule of pro forma consolidated results

This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2015, nor is it indicative of any future results.



	2015
Unaudited pro forma consolidated results (in thousands, except per share data):
Revenue	$	3,292,293
Net loss attributable to Endo International plc	$	(1,513,625	)
Basic and diluted net loss per share	$	(7.68	)



	2015
Unaudited pro forma consolidated results (in thousands, except per share data):
Revenue	$	4,268,110
Net loss attributable to Endo International plc	$	(1,594,130	)
Basic and diluted net loss per share	$	(8.09	)

Segment Results (Tables)

12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Schedule of reportable segments information

The following represents selected information for the Company’s reportable segments for the years ended December 31, 2017, 2016 and 2015 (in thousands):



	2017		2016		2015
Net revenues to external customers:
U.S. Branded - Specialty & Established Pharmaceuticals	$	957,525	$	1,166,294	$	1,284,607
U.S. Branded - Sterile Injectables	750,471		576,399		114,719
U.S. Generic Pharmaceuticals	1,530,530		1,988,214		1,557,697
International Pharmaceuticals (1)	230,332		279,367		311,695
Total net revenues to external customers	$	3,468,858	$	4,010,274	$	3,268,718
Adjusted income from continuing operations before income tax:
U.S. Branded - Specialty & Established Pharmaceuticals	$	485,515	$	553,806	$	694,440
U.S. Branded - Sterile Injectables	563,103		426,170		76,627
U.S. Generic Pharmaceuticals	501,249		653,309		665,140
International Pharmaceuticals	58,308		84,337		81,789
Total segment adjusted income from continuing operations before income tax	$	1,608,175	$	1,717,622	$	1,517,996

__________


(1)	Revenues generated by our International Pharmaceuticals segment are primarily attributable to external customers located in Canada and, prior to the sale of Litha on July 3, 2017 and Somar on October 25, 2017, South Africa and Latin America.

Schedule of reconciliations of consolidated loss from continuing operations before income tax



	2017			2016			2015
Total consolidated loss from continuing operations before income tax	$	(1,483,004	)	$	(3,923,856	)	$	(1,437,864	)
Interest expense, net	488,228			452,679			373,214
Corporate unallocated costs (1)	165,298			189,043			171,242
Amortization of intangible assets	773,766			876,451			561,302
Inventory step-up and certain manufacturing costs that will be eliminated pursuant to integration plans	390			125,699			249,464
Upfront and milestone payments to partners	9,483			8,330			16,155
Separation benefits and other cost reduction initiatives (2)	212,448			107,491			125,407
Impact of VOLTAREN® Gel generic competition	—			(7,750		)	—
Acceleration of Auxilium employee equity awards at closing	—			—			37,603
Certain litigation-related and other contingencies, net (3)	185,990			23,950			37,082
Asset impairment charges (4)	1,154,376			3,781,165			1,140,709
Acquisition-related and integration items (5)	58,086			87,601			105,250
Loss on extinguishment of debt	51,734			—			67,484
Costs associated with unused financing commitments	—			—			78,352
Other-than-temporary impairment of equity investment	—			—			18,869
Foreign currency impact related to the remeasurement of intercompany debt instruments	(1,403		)	366			(25,121		)
Other, net	(7,217		)	(3,547		)	(1,152		)
Total segment adjusted income from continuing operations before income tax	$	1,608,175		$	1,717,622		$	1,517,996

__________


(1)	Amounts include certain corporate overhead costs, such as headcount and facility expenses and certain other income and expenses.

(2)


(3)	Amounts include adjustments for Litigation-related and other contingencies, net as further described in Note 14. Commitments and Contingencies.


(4)	Amounts primarily relate to charges to impair goodwill and intangible assets as further described in Note 10. Goodwill and Other Intangibles as well as charges to write down certain property, plant and equipment as further described in Note 4. Restructuring, Note 7. Fair Value Measurements and Note 9. Property, Plant and Equipment.

(5)

Schedule Of Additional Selected Financial Information For Reportable Segments

The following represents depreciation expense for our reportable segments for the years ended December 31, 2017, 2016 and 2015 (in thousands):



	2017		2016		2015
U.S. Branded - Specialty & Established Pharmaceuticals	$	16,957	$	16,294	$	19,884
U.S. Branded - Sterile Injectables	8,411		9,023		2,333
U.S. Generic Pharmaceuticals	174,652		70,816		26,860
International Pharmaceuticals	3,332		2,557		3,147
Corporate unallocated	6,647		8,168		7,674
Total depreciation expense	$	209,999	$	106,858	$	59,898

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Financial assets and liabilities measured at fair value on recurring basis

The Company’s financial assets and liabilities measured at fair value on a recurring basis at December 31, 2017 and December 31, 2016 were as follows (in thousands):



	Fair Value Measurements at Reporting Date using:
December 31, 2017	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets:
Money market funds	$	439,831	$	—	$	—	$	439,831
Time deposits	—		303,410		—		303,410
Equity securities	1,456		—		—		1,456
Total	$	441,287	$	303,410	$	—	$	744,697
Liabilities:
Acquisition-related contingent consideration—short-term	$	—	$	—	$	70,543	$	70,543
Acquisition-related contingent consideration—long-term	—		—		119,899		119,899
Total	$	—	$	—	$	190,442	$	190,442



	Fair Value Measurements at Reporting Date using:
December 31, 2016	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets:
Money market funds	$	26,210	$	—	$	—	$	26,210
Time deposits	—		100,000		—		100,000
Equity securities	2,267		—		—		2,267
Total	$	28,477	$	100,000	$	—	$	128,477
Liabilities:
Acquisition-related contingent consideration—short-term	$	—	$	—	$	109,373	$	109,373
Acquisition-related contingent consideration—long-term	—		—		152,740		152,740
Total	$	—	$	—	$	262,113	$	262,113

Changes to liability for acquisition-related contingent consideration

The following table presents changes to the Company’s liability for acquisition-related contingent consideration during the year ended December 31, 2017 by acquisition (in thousands):



	Balance as of December 31, 2016		Acquisitions		Fair Value Adjustments and Accretion			Payments and Other			Balance as of December 31, 2017
Auxilium acquisition	$	21,097	$	—	$	467		$	(8,503	)	$	13,061
Lehigh Valley Technologies, Inc. acquisitions	96,000		—		40,016			(73,015		)	63,001
VOLTAREN^® Gel acquisition	118,395		—		18,586			(38,857		)	98,124
Other	26,621		—		(9,120		)	(1,245		)	16,256
Total	$	262,113	$	—	$	49,949		$	(121,620	)	$	190,442



	2017			2016
Beginning of period	$	262,113		$	143,502
Amounts acquired	—			146,866
Amounts settled	(122,559		)	(55,896		)
Measurement period adjustments	—			3,700
Changes in fair value recorded in earnings	49,949			23,823
Effect of currency translation	939			118
End of period	$	190,442		$	262,113

The following table presents changes to the Company’s liability for acquisition-related contingent consideration during the year ended December 31, 2016 by acquisition (in thousands):



	Balance as of December 31, 2015		Acquisitions		Fair Value Adjustments and Accretion			Payments and Other			Balance as of December 31, 2016
Qualitest acquisition	$	1,137	$	—	$	(1,137	)	$	—		$	—
Sumavel acquisition	631		—		(631		)	—			—
Auxilium acquisition	26,435		—		8,952			(14,290		)	21,097
Lehigh Valley Technologies, Inc. acquisitions	97,003		—		30,676			(31,679		)	96,000
VOLTAREN^® Gel acquisition	—		146,055		(18,807		)	(8,853		)	118,395
Other	18,296		4,511		4,770			(956		)	26,621
Total	$	143,502	$	150,566	$	23,823		$	(55,778	)	$	262,113

Summary of nonrecurring fair value measurements

The Company’s financial assets and liabilities measured at fair value on a nonrecurring basis during the year ended December 31, 2017 were as follows (in thousands):



	Fair Value Measurements at Reporting Date using:						Total Expense for the Year Ended December 31, 2017
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Expense for the Year Ended December 31, 2017
Assets:
Certain U.S. Branded Pharmaceuticals intangible assets (Note 10)	$	—	$	—	$	34,326	$	(76,674	)
Certain U.S. Generic Pharmaceuticals intangible assets (Note 10)	—		—		367,160		(577,923		)
Certain International Pharmaceuticals intangible assets (Note 10)	—		—		21,772		(145,360		)
Certain property, plant and equipment (1)	—		—		—		(65,676		)
Total	$	—	$	—	$	423,258	$	(865,633	)

__________

(1)

The Company’s financial assets and liabilities measured at fair value on a nonrecurring basis during the year ended December 31, 2016 were as follows (in thousands):



	Fair Value Measurements at Measurement Date using:						Total Expense for the Year Ended December 31, 2016
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Expense for the Year Ended December 31, 2016
Assets:
Certain Astora property, plant and equipment (Note 3)	$	—	$	—	$	—	$	(5,041	)
Certain U.S. Generic Pharmaceuticals property, plant and equipment	—		—		11,360		(13,679		)
Certain U.S. Branded Pharmaceuticals intangible assets (Note 10)	—		—		4,621		(110,430		)
Certain U.S. Generic Pharmaceuticals intangible assets (Note 10)	—		—		872,474		(676,776		)
Certain International Pharmaceuticals intangible assets (Note 10)	—		—		139,313		(301,698		)
Certain Astora intangible assets (Note 3)	—		—		—		(16,287		)
Generics reporting unit goodwill (Note 10)	—		—		3,531,301		(2,342,549		)
Paladin reporting unit goodwill (Note 10)	—		—		170,572		(272,578		)
Somar reporting unit goodwill (Note 10)	—		—		24,044		(33,000		)
Litha reporting unit goodwill (Note 10)	—		—		—		(26,343		)
Other asset impairment charges	—		—		—		(4,112		)
Total	$	—	$	—	$	4,753,685	$	(3,802,493	)

Inventories (Tables)

12 Months Ended

Dec. 31, 2017

Inventory Disclosure [Abstract]

Schedule of inventory

Inventories consist of the following at December 31, 2017 and December 31, 2016 (in thousands):



	December 31, 2017		December 31, 2016
Raw materials (1)	$	124,685	$	175,240
Work-in-process (1)	109,897		100,494
Finished goods (1)	156,855		279,937
Total	$	391,437	$	555,671

__________

(1) The components of inventory shown in the table above are net of allowance for obsolescence.

Property, Plant And Equipment (Tables)

12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Schedule of property, plant and equipment

Depreciation is based on the following estimated useful lives, as of December 31, 2017:



	Range of Useful Lives (1), from:
Buildings	10 years	to	30 years
Machinery and equipment	2 years	to	15 years
Leasehold improvements	2 years	to	10 years
Computer equipment and software	1 year	to	7 years
Assets under capital lease	Shorter of useful life or lease term
Furniture and fixtures	3 years	to	10 years

__________


(1)	The useful lives for certain fixed assets have been reduced in connection with our 2017 U.S. Generic Pharmaceuticals Restructuring Initiative, which is further described in Note 4. Restructuring. The ranges of useful lives above do not include such assets.

This table excludes changes related to businesses classified as held for sale, to the extent such changes occurred after the business was classified as held for sale.



Cost:	Land and Buildings			Machinery and Equipment			Leasehold Improve- ments			Computer Equipment and Software			Assets under Capital Lease			Furniture and Fixtures			Assets under Construc- tion			Total
At January 1, 2017	$	322,537		$	227,833		$	50,359		$	118,928		$	9,155		$	21,086		$	129,102		$	879,000
Additions	19,871			49,088			11,067			21,626			—			684			26,043			128,379
Disposals, transfers, impairments and other	(12,333		)	(9,939		)	(1,271		)	(9,459		)	(4,259		)	(8,770		)	(36,186		)	(82,217		)
Effect of currency translation	1,391			836			309			356			—			124			76			3,092
At December 31, 2017	$	331,466		$	267,818		$	60,464		$	131,451		$	4,896		$	13,124		$	119,035		$	928,254
Accumulated Depreciation:
At January 1, 2017	$	(50,770	)	$	(64,319	)	$	(21,263	)	$	(62,836	)	$	(5,773	)	$	(4,443	)	$	—		$	(209,404	)
Additions	(93,633		)	(76,986		)	(6,607		)	(27,121		)	(2,645		)	(3,007		)	—			(209,999		)
Disposals, transfers and other	(4,656		)	6,964			1,088			7,354			4,257			1,201			—			16,208
Effect of currency translation	(343		)	(400		)	(85		)	(189		)	—			(71		)	—			(1,088		)
At December 31, 2017	$	(149,402	)	$	(134,741	)	$	(26,867	)	$	(82,792	)	$	(4,161	)	$	(6,320	)	$	—		$	(404,283	)
Net Book Amount:
At December 31, 2017	$	182,064		$	133,077		$	33,597		$	48,659		$	735		$	6,804		$	119,035		$	523,971
At December 31, 2016	$	271,767		$	163,514		$	29,096		$	56,092		$	3,382		$	16,643		$	129,102		$	669,596

Goodwill And Other Intangibles (Tables)

12 Months Ended

Dec. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of changes in the carrying amount of goodwill

The carrying amounts of goodwill at December 31, 2017 and December 31, 2016 are net of the following accumulated impairments:



	Accumulated Impairment
	U.S. Generic Pharmaceuticals		U.S. Branded Pharmaceuticals		International Pharmaceuticals		Total
Accumulated impairment losses as of December 31, 2016	$	2,342,549	$	675,380	$	408,280	$	3,426,209
Accumulated impairment losses as of December 31, 2017 (1)	$	2,342,549	$	855,810	$	463,545	$	3,661,904

__________


(1)	During the year ended December 31, 2017, we sold our Litha and Somar businesses. Accordingly, we removed $84.1 million of accumulated impairments from the International Pharmaceuticals segment.

Changes in the carrying amount of our goodwill for the years ended December 31, 2017 and 2016 were as follows (in thousands):



	Carrying Amount
	U.S. Generic Pharmaceuticals			U.S. Branded Pharmaceuticals			International Pharmaceuticals			Total
Goodwill as of December 31, 2015	$	5,789,934		$	1,002,776		$	506,644		$	7,299,354
Measurement period adjustments	83,916			8,352			1,366			93,634
Effect of currency translation on gross balance	—			—			3,336			3,336
Effect of currency translation on accumulated impairment	—			—			9,421			9,421
Goodwill impairment charges	(2,342,549		)	(1,880		)	(331,921		)	(2,676,350		)
Goodwill as of December 31, 2016	$	3,531,301		$	1,009,248		$	188,846		$	4,729,395
Effect of currency translation on gross balance	—			—			40,454			40,454
Effect of currency translation on accumulated impairment	—			—			(31,023		)	(31,023		)
Goodwill impairment charges	—			(180,430		)	(108,314		)	(288,744		)
Goodwill as of December 31, 2017	$	3,531,301		$	828,818		$	89,963		$	4,450,082

Schedule of other intangible assets

As such, this table excludes asset impairment charges of $9.6 million related to our Litha business, assets derecognized upon the divestitures of Litha, Somar and BELBUCA™ with a combined carrying amount of $26.4 million and net increases resulting from currency translation of $1.5 million related to our Litha and Somar businesses.



Cost basis:	Balance as of December 31, 2016			Acquisitions			Impairments (1)			Other (1) (2)			Effect of Currency Translation (1)			Balance as of December 31, 2017
Indefinite-lived intangibles:
In-process research and development	$	1,123,581		$	—		$	(334,490	)	$	(442,100	)	$	209		$	347,200
Total indefinite-lived intangibles	$	1,123,581		$	—		$	(334,490	)	$	(442,100	)	$	209		$	347,200
Finite-lived intangibles:
Licenses (weighted average life of 12 years)	$	465,720		$	—		$	(8,178	)	$	(140	)	$	—		$	457,402
Tradenames	7,345			—			(808		)	(262		)	134			6,409
Developed technology (weighted average life of 11 years)	6,223,004			—			(446,835		)	378,811			32,784			6,187,764
Total finite-lived intangibles (weighted average life of 11 years)	$	6,696,069		$	—		$	(455,821	)	$	378,409		$	32,918		$	6,651,575
Total other intangibles	$	7,819,650		$	—		$	(790,311	)	$	(63,691	)	$	33,127		$	6,998,775

Accumulated amortization:	Balance as of December 31, 2016			Amortization			Impairments			Other (2)			Effect of Currency Translation			Balance as of December 31, 2017
Finite-lived intangibles:
Licenses	$	(341,600	)	$	(28,761	)	$	—		$	140		$	—		$	(370,221	)
Tradenames	(6,599		)	(42		)	—			262			(30		)	(6,409		)
Developed technology	(1,612,154		)	(744,963		)	—			63,289			(10,633		)	(2,304,461		)
Total other intangibles	$	(1,960,353	)	$	(773,766	)	$	—		$	63,691		$	(10,663	)	$	(2,681,091	)
Net other intangibles	$	5,859,297														$	4,317,684

__________


(1)	Additional information on the changes in the total gross carrying amount of our other intangible assets is presented below (in thousands):



	Gross Carrying Amount
December 31, 2016	$	7,819,650
Impairment of certain U.S. Branded Pharmaceuticals intangible assets	(76,674		)
Impairment of certain U.S. Generic Pharmaceuticals intangible assets	(577,923		)
Impairment of certain International Pharmaceuticals intangible assets	(135,714		)
Transfer of intangible assets to Assets held for sale (NOTE 3)	(33,304		)
Removal of certain fully amortized intangible assets	(30,387		)
Effect of currency translation	33,127
December 31, 2017	$	6,998,775


(2)	Includes reclassification adjustments of $442.1 million for certain developed technology intangible assets, previously classified as in-process research and development, that were placed in service during the year ended December 31, 2017, the removal of certain fully amortized intangible assets and the transfer of Somar intangible assets to Assets held for sale.

Schedule of changes in gross carrying amount of other intangible assets

Additional information on the changes in the total gross carrying amount of our other intangible assets is presented below (in thousands):



	Gross Carrying Amount
December 31, 2016	$	7,819,650
Impairment of certain U.S. Branded Pharmaceuticals intangible assets	(76,674		)
Impairment of certain U.S. Generic Pharmaceuticals intangible assets	(577,923		)
Impairment of certain International Pharmaceuticals intangible assets	(135,714		)
Transfer of intangible assets to Assets held for sale (NOTE 3)	(33,304		)
Removal of certain fully amortized intangible assets	(30,387		)
Effect of currency translation	33,127
December 31, 2017	$	6,998,775

Schedule of future amortization expense

Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2017 is as follows (in thousands):



2018	$	598,603
2019	$	506,857
2020	$	469,339
2021	$	450,854
2022	$	436,811

Accounts Payable And Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2017

Accrued Liabilities [Abstract]

Schedule of accounts payable and accrued expenses

Accounts payable and accrued expenses include the following at December 31, 2017 and December 31, 2016 (in thousands):



	December 31, 2017		December 31, 2016
Trade accounts payable	$	85,348	$	126,712
Returns and allowances	291,034		332,455
Rebates	168,333		227,706
Chargebacks	14,604		33,092
Accrued interest	130,257		128,254
Accrued payroll and related benefits	113,908		115,224
Accrued royalties and other distribution partner payables	63,114		191,433
Acquisition-related contingent consideration—short-term	70,543		109,373
Other	159,684		189,835
Total	$	1,096,825	$	1,454,084

Debt (Tables)

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Schedule of long-term debt instruments

The following table presents information about the Company’s total indebtedness at December 31, 2017 and December 31, 2016 (in thousands):



	December 31, 2017						December 31, 2016
	Effective Interest Rate		Principal Amount		Carrying Amount		Effective Interest Rate		Principal Amount		Carrying Amount
7.25% Senior Notes due 2022	7.91	%	$	400,000	$	390,974	7.91	%	$	400,000	$	389,150
5.75% Senior Notes due 2022	6.04	%	700,000		692,855		6.04	%	700,000		691,339
5.375% Senior Notes due 2023	5.62	%	750,000		742,048		5.62	%	750,000		740,733
6.00% Senior Notes due 2023	6.28	%	1,635,000		1,613,446		6.28	%	1,635,000		1,610,280
5.875% Senior Secured Notes due 2024	6.14	%	300,000		295,513		—		—		—
6.00% Senior Notes due 2025	6.27	%	1,200,000		1,181,243		6.27	%	1,200,000		1,179,203
Term Loan A Facility Due 2019	—		—		—		2.95	%	941,875		932,824
Term Loan B Facility Due 2022	—		—		—		4.06	%	2,772,000		2,728,919
Term Loan B Facility Due 2024	5.46	%	3,397,925		3,360,103		—		—		—
Other debt	1.50	%	55		55		1.50	%	55		55
Total long-term debt, net			$	8,382,980	$	8,276,237			$	8,398,930	$	8,272,503
Less current portion, net			34,205		34,205				131,125		131,125
Total long-term debt, less current portion, net			$	8,348,775	$	8,242,032			$	8,267,805	$	8,141,378

Any outstanding amounts borrowed pursuant to the 2017 Credit Facility will immediately mature if any of the following of our senior notes (other than, in the case of the 2017 Revolving Credit Facility, the 5.375% Senior notes due 2023 and the 6.00% Senior Notes due 2023) are not refinanced or repaid in full prior to the date that is 91 days prior to the stated maturity date thereof:



Instrument		Maturity Date
7.25% Senior Notes due 2022		January 15, 2022
5.75% Senior Notes due 2022		January 15, 2022
5.375% Senior Notes due 2023		January 15, 2023
6.00% Senior Notes due 2023		July 15, 2023

Outstanding principal balance of non-recourse notes percentage

On or after April 15, 2020, the Issuers may on any one or more occasions redeem all or a part of the 2024 Notes, at the redemption prices (expressed as percentages of principal amount) set forth below, plus accrued and unpaid interest and additional interest, if any, on the notes redeemed if such notes are redeemed during the twelve-month period beginning on April 15 of the years indicated below:



Year	Percentage
2020	102.938	%
2021	101.469	%
2022 and thereafter	100.000	%

Schedule of maturities of long-term debt



	Maturities (1)
2018	$	34,205
2019	$	34,150
2020	$	34,150
2021	$	34,150
2022	$	1,134,150

__________

(1)

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644

+ Details

Commitments And Contingencies (Tables)

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Changes in Qualified Settlement Funds accounts and product liability balance

The following table presents the changes in the QSFs and mesh liability accrual balance during the year ended December 31, 2017 (in thousands):



	Qualified Settlement Funds			Mesh Liability Accrual
Balance as of January 1, 2017	$	275,987		$	963,117
Additional charges	—			775,474
Cash contributions to Qualified Settlement Funds	668,306			—
Cash distributions to settle disputes from Qualified Settlement Funds	(632,176		)	(632,176		)
Cash distributions to settle disputes	—			(19,243		)
Other	1,697			—
Balance as of December 31, 2017	$	313,814		$	1,087,172

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

A summary of minimum future rental payments required under capital and operating leases as of December 31, 2017 are as follows (in thousands):



	Capital Leases (1)(2)		Operating Leases
2018	$	6,713	$	13,888
2019	6,633		14,120
2020	6,564		13,505
2021	6,681		11,758
2022	6,831		11,212
Thereafter	14,126		23,703
Total minimum lease payments	$	47,548	$	88,186
Less: Amount representing interest	4,168
Total present value of minimum payments	$	43,380
Less: Current portion of such obligations	6,713
Long-term capital lease obligations	$	36,667

__________


(1)	The direct financing arrangement is included under Capital Leases.

(2)

- Definition

Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14472-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913245&loc=d3e12021-110248

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14453-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82913245&loc=d3e12053-110248

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14394-108349

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14615-108349

+ Details

Other Comprehensive Income (Loss) (Tables)

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Schedule of tax effects allocated to each component of other comprehensive income

The following table presents the tax effects allocated to each component of Other comprehensive income (loss) for the years ended December 31, 2017, 2016 and 2015 (in thousands):



	2017								2016								2015
	Before-Tax Amount			Tax Benefit (Expense)		Net-of-Tax Amount			Before-Tax Amount			Tax Benefit (Expense)		Net-of-Tax Amount			Before-Tax Amount			Tax (Expense) Benefit			Net-of-Tax Amount
Net unrealized (loss) gain on securities:
Unrealized (loss) gain arising during the period	$	(811	)	$	296	$	(515	)	$	(1,588	)	$	674	$	(914	)	$	2,349		$	(50	)	$	2,299
Less: reclassification adjustments for gain realized in net loss	—			—		—			(6		)	—		(6		)	—			—			—
Net unrealized (losses) gains	$	(811	)	$	296	$	(515	)	$	(1,594	)	$	674	$	(920	)	$	2,349		$	(50	)	$	2,299
Net unrealized gain (loss) on foreign currency:
Foreign currency translation gain (loss) arising during the period	31,202			—		31,202			18,267			13,462		31,729			(263,425		)	(21,297		)	(284,722		)
Less: reclassification adjustments for loss realized in net loss	112,926			—		112,926			—			—		—			25,557			158			25,715
Foreign currency translation gain (loss)	$	144,128		$	—	$	144,128		$	18,267		$	13,462	$	31,729		$	(237,868	)	$	(21,139	)	$	(259,007	)
Other comprehensive income (loss)	$	143,317		$	296	$	143,613		$	16,673		$	14,136	$	30,809		$	(235,519	)	$	(21,189	)	$	(256,708	)

Schedule of accumulated other comprehensive income (loss)

The following is a summary of the accumulated balances related to each component of Other comprehensive income (loss), net of taxes, at December 31, 2017 and December 31, 2016 (in thousands):



	December 31, 2017			December 31, 2016
Net unrealized gains	$	380		$	895
Foreign currency translation loss	(210,201		)	(354,329		)
Accumulated other comprehensive loss	$	(209,821	)	$	(353,434	)

Shareholders' Equity (Tables)

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Schedule of changes in stockholders' equity

The following table reflects the effect on the Company’s equity for the year ended December 31, 2015 (in thousands):



	2015
Adjustment to Accumulated other comprehensive loss related to the reallocation (from noncontrolling to controlling interests) of foreign currency translation loss attributable to our noncontrolling interest in Litha	$	(3,904	)
Decrease in noncontrolling interests for buy-out of Litha	(32,732		)
Decrease in additional paid-in capital for buy-out of Litha	(2,972		)
Total cash consideration paid related to buy-out of Litha	$	(39,608	)

Shared-based Compensation (Tables)

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of allocation of stock-based compensation

Presented below is the allocation of share-based compensation as recorded in our Consolidated Statements of Operations for the years ended December 31, 2017, 2016 and 2015 (in thousands).



	2017		2016		2015
Selling, general and administrative expenses	$	38,292	$	54,176	$	79,928
Research and development expenses	4,197		2,440		2,388
Cost of revenues	7,660		2,040		2,241
Discontinued operations (Note 3)	—		1,113		14,231
Total share-based compensation expense	$	50,149	$	59,769	$	98,788

Summary of activity under stock incentive plans

A summary of the activity for each of the years ended December 31, 2017, 2016 and 2015 is presented below:



	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value (1)
Outstanding as of January 1, 2015	3,063,352		$	40.15
Granted	794,757		$	77.27
Exercised	(880,885	)	$	30.93
Forfeited	(201,397	)	$	72.24
Expired	(7,260	)	$	45.20
Outstanding as of December 31, 2015	2,768,567		$	51.56
Granted	2,578,105		$	35.45
Exercised	(62,589	)	$	31.19
Forfeited	(858,556	)	$	52.27
Expired	(100,318	)	$	60.71
Outstanding as of December 31, 2016	4,325,209		$	41.70
Granted	5,288,675		$	10.42
Forfeited	(623,987	)	$	28.32
Expired	(741,767	)	$	40.29
Outstanding as of December 31, 2017	8,248,130		$	22.79	7.87	$	493,979
Vested and expected to vest as of December 31, 2017	7,633,410		$	23.46	7.76	$	435,456
Exercisable as of December 31, 2017	1,826,250		$	42.39	3.99	$	—

__________


(1)	The intrinsic value of a stock option is the excess, if any, of the closing price of the Company’s ordinary shares on the last trading day of the fiscal year over the exercise price. The aggregate intrinsic values presented in the table above represent sum of the intrinsic values of all corresponding stock options that are “in-the-money.”

Stock option assumption

The weighted average grant date fair value of the stock options granted in the years ended December 31, 2017, 2016 and 2015 was $4.73, $11.46 and $21.09 per option, respectively, determined using the following average assumptions:



	2017		2016		2015
Expected term (years)	4.0		4.0		4.0
Risk-free interest rate	1.7	%	1.1	%	1.3	%
Dividend yield	—		—		—
Expected volatility	58	%	43	%	32	%

Summary of restricted and performance stock units activity

A summary of our nonvested RSUs and PSUs for the years ended December 31, 2017, 2016 and 2015 is presented below:



	Number of Shares		Aggregate Intrinsic Value (1)
Nonvested as of January 1, 2015	1,654,753
Granted	927,214
Forfeited	(251,351	)
Vested	(523,763	)
Nonvested as of December 31, 2015	1,806,853
Granted	1,582,429
Forfeited	(975,994	)
Vested	(728,228	)
Nonvested as of December 31, 2016	1,685,060
Granted	4,168,477
Forfeited	(552,981	)
Vested	(575,883	)
Nonvested as of December 31, 2017	4,724,673		$	36,616,216
Vested and expected to vest as of December 31, 2017	4,337,839		$	33,618,256

__________


(1)	The aggregate intrinsic values of RSUs and PSUs presented in the table above are calculated by multiplying the closing price of the Company’s ordinary shares on the last trading day of the fiscal year by the corresponding number of RSUs and PSUs.

Other (Income) Expense, Net (Tables)

12 Months Ended

Dec. 31, 2017

Component of Operating Income [Abstract]

Schedule of components of other income, net

The components of Other (income) expense, net for the for the years ended December 31, 2017, 2016 and 2015 are as follows (in thousands):



	2017			2016			2015
Foreign currency (gain) loss, net	$	(2,801	)	$	2,991		(23,058		)
Equity loss (earnings) from investments accounted for under the equity method, net	898			(1,190		)	3,217
Other-than-temporary impairment of equity investment	—			—			18,869
Legal settlement	—			—			(12,500		)
Costs associated with unused financing commitments	—			—			78,352
Other miscellaneous, net	(15,120		)	(2,139		)	(1,189		)
Other (income) expense, net	$	(17,023	)	$	(338	)	$	63,691

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Components Of Income Before Income Tax By Geography

The components of our Loss from continuing operations before income tax by geography for the years ended December 31, 2017, 2016 and 2015 are as follows (in thousands):



	2017			2016			2015
United States	$	(1,866,222	)	$	(4,309,211	)	$	(626,740	)
International	383,218			385,355			(811,124		)
Total (loss) income from continuing operations before income tax	$	(1,483,004	)	$	(3,923,856	)	$	(1,437,864	)

Schedule of Income Tax

Income tax from continuing operations consists of the following for the years ended December 31, 2017, 2016 and 2015 (in thousands):



	2017			2016			2015
Current:
U.S. Federal	$	(86,478	)	$	18,369		$	(308,909	)
U.S. State	(6,462		)	9,501			(5,600		)
International	(1,224		)	22,851			16,722
Total current income tax	$	(94,164	)	$	50,721		$	(297,787	)
Deferred:
U.S. Federal	$	(124,682	)	$	(661,484	)	$	(779,757	)
U.S. State	(3,225		)	(239		)	(70,221		)
International	(28,222		)	(83,619		)	(9,376		)
Total deferred income tax	$	(156,129	)	$	(745,342	)	$	(859,354	)
Excess tax benefits of stock compensation exercised	$	—		$	(5,463	)	$	19,676
Valuation allowance	—			—			—
Total income tax	$	(250,293	)	$	(700,084	)	$	(1,137,465	)

Schedule Of Reconciliation Of Income Tax At Federal Statutory Income Tax Rate To Total Income Tax Provision



	2017			2016			2015
Notional U.S. federal income tax provision at the statutory rate	$	(519,051	)	$	(1,373,350	)	$	(503,271	)
State income tax, net of federal benefit	(11,473		)	5,182			(45,823		)
U.S. tax reform impact	(36,216		)	—			—
Uncertain tax positions	58,120			(18,111		)	30,974
Residual tax on non-U.S. net earnings	(1,350,811		)	(301,666		)	(359,831		)
Effects of outside basis differences	—			(636,134		)	(786,130		)
Non-deductible goodwill impairment	60,808			926,881			248,403
Change in valuation allowance	1,648,836			762,604			278,339
Intra-entity transfers of assets	(53,509		)	(92,859		)	—
International Pharmaceuticals segment divestitures	(56,092		)	—			—
Other	9,095			27,369			(126		)
Income tax	$	(250,293	)	$	(700,084	)	$	(1,137,465	)

Schedule of Deferred Tax Assets and Liabilities

Excluding assets and liabilities held for sale, the significant components of the net deferred income tax liability shown on the balance sheets as of December 31, 2017 and 2016 are as follows (in thousands):



	2017			2016
Deferred tax assets:
Accrued expenses and customer allowances	$	299,142		$	232,101
Compensation related to stock options	20,108			24,246
Deferred interest expense	46,230			57,440
Fixed assets and intangible assets	484,313			55,473
Loss on capital assets	49,585			9,904
Net operating loss carryforward	7,183,651			4,410,386
Other	32,356			30,262
Research and development credit carryforward	4,838			4,244
Tax credit carryforwards	1,516			4,520
Uncertain tax positions	4,364			10,562
Total gross deferred income tax assets	$	8,126,103		$	4,839,138
Deferred tax liabilities:
Other	$	(2,042	)	$	—
Outside basis difference	(92,635		)	(182,409		)
Total gross deferred income tax liabilities	$	(94,677	)	$	(182,409	)
Valuation allowance	(8,062,975		)	(4,841,209		)
Net deferred income tax liability	$	(31,549	)	$	(184,480	)

Summary of Tax Credit Carryforwards

At December 31, 2017, the Company had the following significant deferred tax assets for net operating and capital loss carryforwards, net of unrecognized tax benefits (in thousands):



Jurisdiction	2017		Begin to Expire
Ireland	$	43,965	indefinite
Luxembourg	$	6,847,805	2034
United States:
Federal-ordinary losses	$	115,518	2020
Federal-capital losses	$	27,114	2022
State-ordinary losses	$	172,439	2018
State-capital losses	$	20,920	2026

Summary of Valuation Allowance



	Balance at Beginning of Period		Additions, Costs and Expenses		Deductions, Write-offs			Other (1)			Balance at End of Period
Valuation Allowance For Deferred Tax Assets:
Year Ended December 31, 2015	$	40,646	$	386,087	$	(17,106	)	$	17,364		$	426,991
Year Ended December 31, 2016	$	426,991	$	4,416,478	$	(2,039	)	$	(221	)	$	4,841,209
Year Ended December 31, 2017	$	4,841,209	$	3,811,982	$	—		$	(590,216	)	$	8,062,975

__________


(1)	Represents opening balances of businesses acquired in the period and, for the year ended December 31, 2017, changes in the statutory U.S. Federal corporate income tax rate.

At December 31, 2017, the Company had the following significant valuation allowances (in thousands):



Jurisdiction	2017
Canada	$	2,228
Ireland	$	99,194
Luxembourg	$	6,847,805
United States	$	1,110,172

Schedule Of Reconciliation Of Change In Uncertain Tax Benefits

The following table summarizes the activity related to unrecognized income tax benefits (in thousands):



	Unrecognized Tax Benefit Federal, State, and Foreign Tax
UTB Balance at January 1, 2015	$	105,330
Gross additions for current year positions	65,439
Gross reductions for prior period positions	(234		)
Gross additions for prior period positions	3,460
Decrease due to lapse of statute of limitations	(75		)
Additions related to acquisitions	150,152
Currency translation adjustment	(7,825		)
UTB Balance at December 31, 2015	$	316,247
Gross additions for current year positions	142,778
Gross reductions for prior period positions	(35,888		)
Gross additions for prior period positions	2,111
Decrease due to lapse of statute of limitations	(3,085		)
Additions related to acquisitions	2,350
Currency translation adjustment	88
UTB Balance at December 31, 2016	$	424,601
Gross additions for current year positions	44,293
Gross reductions for prior period positions	(64,887		)
Gross additions for prior period positions	22,765
Decrease due to lapse of statute of limitations	(13,151		)
Additions related to acquisitions	—
Currency translation adjustment	2,330
UTB Balance at December 31, 2017	$	415,951
Accrued interest and penalties	19,185
Total UTB balance including accrued interest and penalties	$	435,136
Current portion	$	17,100
Non-current portion	$	418,036

Summary of Income Tax Examinations

As of December 31, 2017, we may be subject to examination in the major tax jurisdictions:



Jurisdiction		Open Years
Canada		2013 through 2017
India		2012 through 2017
Ireland		2014 through 2017
Luxembourg		2013 through 2017
United States - federal, state and local		2006 through 2017

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Reconciliation of the numerator and denominator of basic and diluted net loss per share

The following is a reconciliation of the numerator and denominator of basic and diluted net loss per share for the years ended December 31, 2017, 2016 and 2015 (in thousands):



	2017			2016			2015
Numerator:
Loss from continuing operations	$	(1,232,711	)	$	(3,223,772	)	$	(300,399	)
Less: Net income (loss) from continuing operations attributable to noncontrolling interests	—			16			(283		)
Loss from continuing operations attributable to Endo International plc ordinary shareholders	$	(1,232,711	)	$	(3,223,788	)	$	(300,116	)
Loss from discontinued operations attributable to Endo International plc ordinary shareholders, net of tax	(802,722		)	(123,278		)	(1,194,926		)
Net loss attributable to Endo International plc ordinary shareholders	$	(2,035,433	)	$	(3,347,066	)	$	(1,495,042	)
Denominator:
For basic per share data—weighted average shares	223,198			222,651			197,100
Dilutive effect of ordinary share equivalents	—			—			—
Dilutive effect of various convertible notes and warrants	—			—			—
For diluted per share data—weighted average shares	223,198			222,651			197,100

Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2017

Quarterly Financial Data [Abstract]

Schedule of Quarterly Financial Information



	Quarter Ended
	March 31,			June 30,			September 30,			December 31,
2017 (1)
Total revenues	$	1,037,600		$	875,731		$	786,887		$	768,640
Gross profit	$	368,638		$	336,330		$	272,365		$	262,995
Loss from continuing operations	$	(165,423	)	$	(696,020	)	$	(99,687	)	$	(271,581	)
Discontinued operations, net of tax	$	(8,405	)	$	(700,498	)	$	3,017		$	(96,836	)
Net loss attributable to Endo International plc	$	(173,828	)	$	(1,396,518	)	$	(96,670	)	$	(368,417	)
Net loss per share attributable to Endo International plc ordinary shareholders—Basic:
Continuing operations	$	(0.74	)	$	(3.12	)	$	(0.45	)	$	(1.22	)
Discontinued operations	(0.04		)	(3.14		)	0.02			(0.43		)
Basic	$	(0.78	)	$	(6.26	)	$	(0.43	)	$	(1.65	)
Net loss per share attributable to Endo International plc ordinary shareholders—Diluted:
Continuing operations	$	(0.74	)	$	(3.12	)	$	(0.45	)	$	(1.22	)
Discontinued operations	(0.04		)	(3.14		)	0.02			(0.43		)
Diluted	$	(0.78	)	$	(6.26	)	$	(0.43	)	$	(1.65	)
Weighted average shares—Basic	223,014			223,158			223,299			223,322
Weighted average shares—Diluted	223,014			223,158			223,299			223,322
2016 (2)
Total revenues	$	963,539		$	920,887		$	884,335		$	1,241,513
Gross profit	$	274,834		$	288,669		$	326,863		$	484,935
(Loss) income from continuing operations	$	(88,763	)	$	389,812		$	(191,496	)	$	(3,333,325	)
Discontinued operations, net of tax	$	(45,108	)	$	(46,216	)	$	(27,423	)	$	(4,531	)
Net (loss) income attributable to Endo International plc	$	(133,869	)	$	343,578		$	(218,919	)	$	(3,337,856	)
Net (loss) income per share attributable to Endo International plc ordinary shareholders—Basic:
Continuing operations	$	(0.40	)	$	1.75		$	(0.86	)	$	(14.96	)
Discontinued operations	(0.20		)	(0.21		)	(0.12		)	(0.02		)
Basic	$	(0.60	)	$	1.54		$	(0.98	)	$	(14.98	)
Net (loss) income per share attributable to Endo International plc ordinary shareholders—Diluted:
Continuing operations	$	(0.40	)	$	1.75		$	(0.86	)	$	(14.96	)
Discontinued operations	(0.20		)	(0.21		)	(0.12		)	(0.02		)
Diluted	$	(0.60	)	$	1.54		$	(0.98	)	$	(14.98	)
Weighted average shares—Basic	222,302			222,667			222,767			222,870
Weighted average shares—Diluted	222,302			222,863			222,767			222,870

__________

(1)

(2)

SCHEDULE II--Valuation and Qualifying Accounts - Valuation Allowance (Tables)

12 Months Ended

Dec. 31, 2017

Valuation and Qualifying Accounts [Abstract]

Summary of Valuation Allowance



	Balance at Beginning of Period		Additions, Costs and Expenses		Deductions, Write-offs			Other (1)			Balance at End of Period
Valuation Allowance For Deferred Tax Assets:
Year Ended December 31, 2015	$	40,646	$	386,087	$	(17,106	)	$	17,364		$	426,991
Year Ended December 31, 2016	$	426,991	$	4,416,478	$	(2,039	)	$	(221	)	$	4,841,209
Year Ended December 31, 2017	$	4,841,209	$	3,811,982	$	—		$	(590,216	)	$	8,062,975

__________


(1)	Represents opening balances of businesses acquired in the period and, for the year ended December 31, 2017, changes in the statutory U.S. Federal corporate income tax rate.

At December 31, 2017, the Company had the following significant valuation allowances (in thousands):



Jurisdiction	2017
Canada	$	2,228
Ireland	$	99,194
Luxembourg	$	6,847,805
United States	$	1,110,172

Summary of Significant Accounting Policies Reclassifications due to new Accounting Pronouncements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net cash provided by operating activities	$ 553,985	$ 528,143	$ 118,501
Net cash provided by investing activities	104,583	(177,552)	(6,183,764)
Net cash used in financing activities	(166,993)	(397,186)	6,001,992
Effect of foreign exchange rate	2,515	436	(11,269)
Movement in cash held for sale	11,744	(11,744)	997
Net change	505,834	(57,903)	(73,543)
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD	805,180	863,083	936,626
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD	1,311,014	805,180	863,083
Accounting Standards Update 2016-18
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net cash provided by investing activities	36,200
Prior to Adoption
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net cash provided by operating activities		524,439	62,026
Net cash provided by investing activities		125,861	(6,244,770)
Net cash used in financing activities		(393,982)	6,055,467
Effect of foreign exchange rate		328	(7,068)
Movement in cash held for sale		(11,744)	997
Net change		244,902	(133,348)
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD	517,250	272,348	405,696
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD		517,250	272,348
Impact of Adoption of: \| Accounting Standards Update 2016-09
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net cash provided by operating activities		3,204	21,979
Net cash provided by investing activities		0	0
Net cash used in financing activities		(3,204)	(21,979)
Effect of foreign exchange rate		0	0
Movement in cash held for sale		0	0
Net change		0	0
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD	0	0	0
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD		0	0
Impact of Adoption of: \| Accounting Standards Update 2016-15
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net cash provided by operating activities		0	31,496
Net cash provided by investing activities		0	0
Net cash used in financing activities		0	(31,496)
Effect of foreign exchange rate		0	0
Movement in cash held for sale		0	0
Net change		0	0
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD	0	0	0
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD		0	0
Impact of Adoption of: \| Accounting Standards Update 2016-18
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net cash provided by operating activities		500	3,000
Net cash provided by investing activities		(303,413)	61,006
Net cash used in financing activities		0	0
Effect of foreign exchange rate		108	(4,201)
Movement in cash held for sale		0	0
Net change		(302,805)	59,805
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD	$ 287,930	590,735	530,930
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD		$ 287,930	$ 590,735

Schedule of Concentration Risk, By Risk Factor, Customer (Details) - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cardinal Health, Inc.
Concentration Risk [Line Items]
Percentage of trade accounts receivable from major customers	25.00%	26.00%	21.00%
McKesson Corporation
Concentration Risk [Line Items]
Percentage of trade accounts receivable from major customers	25.00%	27.00%	31.00%
AmerisourceBergen Corporation
Concentration Risk [Line Items]
Percentage of trade accounts receivable from major customers	25.00%	25.00%	23.00%

Summary of Significant Accounting Policies (Narrative) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($) customer	Dec. 31, 2015 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Net cash provided by investing activities	$ 104,583	$ (177,552)	$ (6,183,764)
Advertising costs	$ 42,000	$ 47,900	$ 57,900
Weighted Average
Summary Of Significant Accounting Policies [Line Items]
Intangible life (years)	11 years
Licensing Agreements \| Minimum
Summary Of Significant Accounting Policies [Line Items]
Intangible life (years)	3 years
Licensing Agreements \| Maximum
Summary Of Significant Accounting Policies [Line Items]
Intangible life (years)	15 years
Licensing Agreements \| Weighted Average
Summary Of Significant Accounting Policies [Line Items]
Intangible life (years)	12 years
Developed technology \| Minimum
Summary Of Significant Accounting Policies [Line Items]
Intangible life (years)	1 year
Developed technology \| Maximum
Summary Of Significant Accounting Policies [Line Items]
Intangible life (years)	20 years
Developed technology \| Weighted Average
Summary Of Significant Accounting Policies [Line Items]
Intangible life (years)	11 years
Trade Accounts Receivable
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	89.00%	84.00%
Number of customers \| customer		3
Accounting Standards Update 2016-18
Summary Of Significant Accounting Policies [Line Items]
Net cash provided by investing activities	$ 36,200
Sales Revenue, Net [Member] \| Product Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	12.00%	0.00%	0.00%

Schedule of Estimated Useful Lives (Details)	12 Months Ended
Schedule of Estimated Useful Lives (Details)	Dec. 31, 2017
Buildings \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years
Buildings \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	30 years
Machinery and equipment \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	2 years
Machinery and equipment \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	15 years
Leasehold improvements \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	2 years
Leasehold improvements \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years
Computer equipment and software \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	1 year
Computer equipment and software \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years
Furniture and fixtures \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Furniture and fixtures \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years

Changes in Accounting Pronouncements (Details) - Accounting Standards Update 2016-16 - New Accounting Pronouncement, Early Adoption, Effect $ in Millions	Dec. 31, 2017 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Current deferred charge	$ 24.1
Non-current deferred charge	348.8
Accounting Standards Update 2016-16
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net deferred tax asset	$ 479.7

Discontinued Operations and Assets and Liabilities Held For Sale - American Medical Systems (Narrative) (Details) - USD ($)			12 Months Ended
	Dec. 11, 2015	Aug. 03, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of business and other assets, net			$ 223,237,000	$ 10,870,000	$ 1,588,779,000
Less: reclassification adjustments for loss realized in net loss			112,926,000	0	25,715,000
Purchases of property, plant and equipment			125,654,000	138,856,000	81,774,000
AMS
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of business and other assets, net		$ 1,600,000,000
Asset impairment charges				21,300,000
Less: reclassification adjustments for loss realized in net loss					25,700,000
Tax (expense) benefit from (gain) loss on disposal					161,800,000
Discontinued Operations, Disposed of by Sale \| AMS
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset impairment charges			0	21,328,000	230,703,000
Gain on sale of business			0	0	13,550,000
Income tax benefit			13,704,000	0	157,418,000
Net loss			802,722,000	123,164,000	1,194,926,000
Purchases of property, plant and equipment				100,000	2,700,000
Depreciation and amortization			$ 0	$ 0	$ 11,600,000
Series B Preferred Stock \| AMS
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Expected proceeds from issuance of preferred stock		$ 60,000,000
Expected shares to be issued		60,000
Payment for redeemable preferred stock	$ 61,600,000

Discontinued Operations and Assets and Liabilities Held For Sale - Operating Results of Discontinued Operations (Details) - AMS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset impairment charges		$ 21,300
Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue	$ 338	30,101	$ 305,256
Litigation-related and other contingencies, net	775,474	20,115	1,107,752
Asset impairment charges	0	21,328	230,703
Gain on sale of business	0	0	13,550
Loss from discontinued operations before income taxes	(816,426)	(123,164)	(1,352,344)
Income tax benefit	(13,704)	0	(157,418)
Discontinued operations, net of tax	$ (802,722)	$ (123,164)	$ (1,194,926)

Discontinued Operations and Assets and Liabilities Held For Sale - Astora Restructuring (Narrative) (Details) - Astora Restructuring	3 Months Ended
	Mar. 31, 2016 employee	Dec. 31, 2017 USD ($)
Restructuring Cost and Reserve [Line Items]
Number of positions reduced \| employee	250
Expected restructuring costs remaining \| $		$ 0

Discontinued Operations and Assets and Liabilities Held For Sale - Summary of Astora Restructuring Expenses (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Other wind down costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	$ 22,000,000	$ 25,100,000
Astora Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	$ 0	60,850,000
Astora Restructuring \| Employee separation, retention and other benefit-related costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		20,476,000
Astora Restructuring \| Asset impairment charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		21,328,000
Astora Restructuring \| Contract termination-related items
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		8,074,000
Astora Restructuring \| Other wind down costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		$ 10,972,000

Discontinued Operations and Assets and Liabilities Held For Sale - Changes to Liabilty Related to Astora Restructuring Initiative (Details) - Astora Restructuring - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Restructuring Reserve [Roll Forward]
Beginning liability balance	$ 5,516	$ 0
Expenses		34,348
Cash distributions	(5,063)	(28,832)
Ending liability balance	453	5,516
Employee Separation and Other Benefit-Related Costs
Restructuring Reserve [Roll Forward]
Beginning liability balance	3,855	0
Expenses		20,476
Cash distributions	(3,855)	(16,621)
Ending liability balance	0	3,855
Contract Termination Charges
Restructuring Reserve [Roll Forward]
Beginning liability balance	1,661	0
Expenses		8,074
Cash distributions	(1,208)	(6,413)
Ending liability balance	453	1,661
Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Beginning liability balance	0	0
Expenses		5,798
Cash distributions	0	(5,798)
Ending liability balance	$ 0	$ 0

Discontinued Operations and Assets and Liabilities Held For Sale - Litha Healthcare Group Sale (Details) - USD ($)		1 Months Ended	12 Months Ended
	Jul. 03, 2017	Oct. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of business, net			$ 223,237,000	$ 10,870,000	$ 1,588,779,000
Liabilities held for sale			0	24,338,000
Litha Joint Venture Investment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of business			$ 10,100,000
International Pharmaceuticals \| Litha Healthcare Group Limited \| Disposal Group, Held-for-sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of business, net	$ 94,200,000
Additional contingent consideration receivable		$ 4,400,000
Gain on sale of business	0
Additional contingent consideration payable	$ 26,000,000
Current assets				50,167,000
Property, plant and equipment				3,527,000
Other intangibles, net				29,950,000
Other assets				11,343,000
Assets held for sale				94,987,000
Current liabilities				18,642,000
Other liabilities				5,696,000
Liabilities held for sale				$ 24,338,000

Discontinued Operations and Assets and Liabilities Held For Sale - Somar Sale (Details) - Somar - Disposal Group, Held-for-sale, Not Discontinued Operations - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Oct. 25, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Aggregate purchase price		$ 124.0
Gain on sale of business	$ 1.3

Restructuring (Narrative) (Details)				1 Months Ended	3 Months Ended					12 Months Ended
Restructuring (Narrative) (Details)	Jul. 21, 2017 USD ($) position	Jan. 26, 2017 position	Oct. 31, 2016 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($) position	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Jan. 31, 2018 USD ($)	Sep. 25, 2015	Jan. 29, 2015
Restructuring Cost and Reserve [Line Items]
Impairment of intangible assets										$ 790,311,000
U.S. Generic Pharmaceuticals
Restructuring Cost and Reserve [Line Items]
Impairment of intangible assets					$ 125,300,000	$ 54,200,000	$ 268,200,000	$ 72,700,000	$ 507,200,000
Excess Inventory Reserve Write-Offs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										13,700,000	$ 24,500,000	$ 41,200,000
Other Restructuring Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										22,000,000	25,100,000
Auxilium Restructuring
Restructuring Cost and Reserve [Line Items]
Expected positions eliminated (percent)															40.00%
Restructuring expenses										1,058,000	0	41,900,000
Auxilium Restructuring \| Asset Impairment Charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses												7,000,000
Auxilium Restructuring \| Facility Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses												7,900,000
Auxilium Restructuring \| Other Restructuring Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										1,058,000
Auxilium Restructuring \| Employee separation, retention and other benefit-related costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										0		26,700,000
US Generic Pharmaceuticals Restructuring 2015
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										63,000	5,010,000	$ 23,600,000
Percent of positions eliminated														6.00%
2016 US Generic Pharmaceuticals Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										984,000	16,983,000
Restructuring costs incurred										1,000,000	173,900,000
2016 US Generic Pharmaceuticals Restructuring \| Asset Impairment Charges
Restructuring Cost and Reserve [Line Items]
Impairment of intangible assets											107,200,000
2016 US Generic Pharmaceuticals Restructuring \| Excess Inventory Reserve Write-Offs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses											33,300,000
2016 US Generic Pharmaceuticals Restructuring \| Employee Separation, Retention, and Other Benefit Related Costs \| U.S. Generic Pharmaceuticals
Restructuring Cost and Reserve [Line Items]
Restructuring expenses											17,000,000
2016 US Generic Pharmaceuticals Restructuring \| Accelerated Depreciation \| U.S. Generic Pharmaceuticals
Restructuring Cost and Reserve [Line Items]
Restructuring expenses											10,200,000
2016 US Generic Pharmaceuticals Restructuring \| Other Restructuring Costs \| U.S. Generic Pharmaceuticals
Restructuring Cost and Reserve [Line Items]
Restructuring expenses											6,200,000
2016 US Generic Pharmaceuticals Restructuring \| Charlotte, North Carolina Facility
Restructuring Cost and Reserve [Line Items]
Proceeds from sale of property			$ 14,000,000
2016 US Branded Pharmaceutical Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring expenses									$ 61,500,000		21,768,000
Number of positions reduced \| position									375
Expected restructuring costs remaining					0					0
2016 US Branded Pharmaceutical Restructuring \| Asset Impairment Charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses									$ 36,800,000
2016 US Branded Pharmaceutical Restructuring \| Excess Inventory Reserve Write-Offs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses									3,000,000
2016 US Branded Pharmaceutical Restructuring \| Employee separation, retention and other benefit-related costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses									16,500,000		16,544,000
2016 US Branded Pharmaceutical Restructuring \| Contract Termination Charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses									$ 5,200,000		$ 5,224,000
January 2017 Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										15,072,000
Expected number of positions to be eliminated \| position		90
Expected restructuring costs remaining					$ 0					0
January 2017 Restructuring \| Corporate unallocated costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										4,900,000
January 2017 Restructuring \| U.S. Generic Pharmaceuticals \| Operating Segments
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										3,300,000
January 2017 Restructuring \| U.S. Branded Pharmaceuticals \| Operating Segments
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										6,900,000
2017 US Generic Pharmaceuticals Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										43,277,000
Expected number of positions to be eliminated \| position	815
Restructuring and related cost, expected cost	$ 345,000,000
Estimated cash outlays	70,000,000
2017 US Generic Pharmaceuticals Restructuring \| U.S. Generic Pharmaceuticals
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										286,700,000
2017 US Generic Pharmaceuticals Restructuring \| Asset Impairment Charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										104,700,000
Restructuring and related cost, expected cost	105,000,000
2017 US Generic Pharmaceuticals Restructuring \| Excess Inventory Reserve Write-Offs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										12,100,000
Restructuring and related cost, expected cost	10,000,000
2017 US Generic Pharmaceuticals Restructuring \| Employee Separation, Retention, and Other Benefit Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										29,600,000
Restructuring and related cost, expected cost	40,000,000
2017 US Generic Pharmaceuticals Restructuring \| Accelerated Depreciation
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										123,300,000
Restructuring and related cost, expected cost	155,000,000
2017 US Generic Pharmaceuticals Restructuring \| Other Restructuring Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										13,724,000
Restructuring and related cost, expected cost	$ 35,000,000
Restructuring charges										17,000,000
2017 US Generic Pharmaceuticals Restructuring \| Employee separation, retention and other benefit-related costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										29,553,000
January 2018 Restructuring Member \| U.S. Generic Pharmaceuticals
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										2,600,000
January 2018 Restructuring Member \| Asset Impairment Charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										2,000,000
January 2018 Restructuring Member \| Other Restructuring Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges										$ 600,000
Scenario, Forecast \| January 2018 Restructuring Member
Restructuring Cost and Reserve [Line Items]
Estimated cash outlays				$ 25,000,000
Subsequent Event \| January 2018 Restructuring Member \| U.S. Generic Pharmaceuticals
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected cost													$ 30,000,000
Subsequent Event \| January 2018 Restructuring Member \| Employee Separation, Retention, and Other Benefit Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected cost													25,000,000
Subsequent Event \| January 2018 Restructuring Member \| Other Restructuring Costs
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected cost													$ 5,000,000

Restructuring (Changes to Restructuring Accrual) (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Expenses		$ 22,000,000	$ 25,100,000
Auxilium Restructuring
Restructuring Reserve [Roll Forward]
Beginning liability balance		5,504,000	12,263,000
Cash distributions		(1,937,000)	(6,759,000)
Expenses		1,058,000	0	$ 41,900,000
Ending liability balance	$ 5,504,000	4,625,000	5,504,000	12,263,000
Auxilium Restructuring \| Employee separation, retention and other benefit-related costs
Restructuring Reserve [Roll Forward]
Beginning liability balance		0	5,353,000
Cash distributions		0	(5,353,000)
Expenses		0		26,700,000
Ending liability balance	0	0	0	5,353,000
Auxilium Restructuring \| Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Beginning liability balance		5,504,000	6,910,000
Cash distributions		(1,937,000)	(1,406,000)
Expenses		1,058,000
Ending liability balance	5,504,000	4,625,000	5,504,000	6,910,000
US Generic Pharmaceuticals Restructuring 2015
Restructuring Reserve [Roll Forward]
Beginning liability balance		3,269,000	17,914,000
Cash distributions		(3,332,000)	(19,655,000)
Expenses		63,000	5,010,000	23,600,000
Ending liability balance	3,269,000	0	3,269,000	17,914,000
2016 US Generic Pharmaceuticals Restructuring
Restructuring Reserve [Roll Forward]
Beginning liability balance		9,939,000	0
Cash distributions		(10,672,000)	(7,044,000)
Expenses		984,000	16,983,000
Ending liability balance	9,939,000	251,000	9,939,000	0
2016 US Branded Pharmaceutical Restructuring
Restructuring Reserve [Roll Forward]
Beginning liability balance		21,768,000	0
Cash distributions		(21,768,000)	0
Expenses	61,500,000		21,768,000
Ending liability balance	21,768,000	0	21,768,000	0
2016 US Branded Pharmaceutical Restructuring \| Employee separation, retention and other benefit-related costs
Restructuring Reserve [Roll Forward]
Beginning liability balance		16,544,000	0
Cash distributions		(16,544,000)	0
Expenses	16,500,000		16,544,000
Ending liability balance	16,544,000	0	16,544,000	0
2016 US Branded Pharmaceutical Restructuring \| Contract Termination Charges
Restructuring Reserve [Roll Forward]
Beginning liability balance		5,224,000	0
Cash distributions		(5,224,000)	0
Expenses	5,200,000		5,224,000
Ending liability balance	5,224,000	0	5,224,000	$ 0
January 2017 Restructuring
Restructuring Reserve [Roll Forward]
Beginning liability balance		0
Cash distributions		(12,391,000)
Expenses		15,072,000
Ending liability balance	0	2,681,000	0
2017 US Generic Pharmaceuticals Restructuring
Restructuring Reserve [Roll Forward]
Beginning liability balance		0
Cash distributions		(18,692,000)
Expenses		43,277,000
Ending liability balance	0	24,585,000	0
2017 US Generic Pharmaceuticals Restructuring \| Employee separation, retention and other benefit-related costs
Restructuring Reserve [Roll Forward]
Beginning liability balance		0
Cash distributions		(6,578,000)
Expenses		29,553,000
Ending liability balance	0	22,975,000	0
2017 US Generic Pharmaceuticals Restructuring \| Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Beginning liability balance		0
Cash distributions		(12,114,000)
Expenses		13,724,000
Ending liability balance	$ 0	$ 1,610,000	$ 0

Acquisitions (Auxilium Pharmaceuticals, Inc.) (Narrative) (Details) - USD ($) $ in Thousands		3 Months Ended								12 Months Ended
	Jan. 29, 2015	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Acquisition-related and integration items		$ 26,400	$ 16,600	$ 4,200	$ 10,900	$ 7,400	$ 19,500	$ 48,200	$ 12,600	$ 58,086	$ 87,601	$ 105,250
Amortization of intangible assets										$ 773,766	876,451	561,302
Auxilium Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Aggregate consideration transferred	$ 2,600,000
Fair value of shares issued as part of acquisition	$ 1,520,000
Interest expense												1,100
Amortization of intangible assets												6,200
Auxilium Pharmaceuticals, Inc. \| Acquisition-Related And Integration Items
Business Acquisition [Line Items]
Acquisition-related and integration items											$ 0	$ 23,100
Common Stock \| Auxilium Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Ordinary shares issued (in shares)	18,609,835											18,609,835

Acquisitions (Schedule Of Revenue And Income And Net Loss Included In Consolidated Statements of Operations) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended									11 Months Ended	12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Revenue											$ 3,468,858	$ 4,010,274	$ 3,268,718
Net income (loss) attributable to Endo International plc	$ (368,417)	$ (96,670)	$ (1,396,518)	$ (173,828)	$ (3,337,856)	$ (218,919)	$ 343,578	$ (133,869)			$ (2,035,433)	$ (3,347,066)	$ (1,495,042)
Auxilium Pharmaceuticals, Inc.
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Revenue										$ 341,520
Net income (loss) attributable to Endo International plc										$ (469,986)
Basic and diluted net loss per share (in dollars per share)										$ (2.38)
Par Pharmaceutical Holdings, Inc.
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Revenue									$ 401,238
Net income (loss) attributable to Endo International plc									$ (4,348)
Basic and diluted net loss per share (in dollars per share)									$ (0.02)

Acquisitions (Schedule Of Pro Forma Consolidated Results) (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015 USD ($) $ / shares
Auxilium Pharmaceuticals, Inc.
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Revenue \| $	$ 3,292,293
Net loss attributable to Endo International plc \| $	$ (1,513,625)
Basic net income (loss) per share (in dollars per share) \| $ / shares	$ (7.68)
Diluted net income (loss) per share (in dollars per share) \| $ / shares	$ (7.68)
Par Pharmaceutical Holdings, Inc.
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Revenue \| $	$ 4,268,110
Net loss attributable to Endo International plc \| $	$ (1,594,130)
Basic net income (loss) per share (in dollars per share) \| $ / shares	$ (8.09)
Diluted net income (loss) per share (in dollars per share) \| $ / shares	$ (8.09)

Acquisitions (Par Pharmaceutical Holdings, Inc.) (Narrative) (Details) - USD ($) $ in Thousands			3 Months Ended								12 Months Ended
	Sep. 25, 2015	Jun. 10, 2015	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Acquisition-related costs			$ 26,400	$ 16,600	$ 4,200	$ 10,900	$ 7,400	$ 19,500	$ 48,200	$ 12,600	$ 58,086	$ 87,601	$ 105,250
Amortization of intangible assets											$ 773,766	$ 876,451	561,302
Par Pharmaceutical Holdings, Inc.
Business Acquisition [Line Items]
Aggregate consideration transferred	$ 8,140,000
Ordinary shares issued (in shares)	18,069,899	27,627,628
Equity consideration	$ 1,330,000
Acquisition-related costs													46,300
Increase (decrease) in interest expense													11,700
Amortization of intangible assets													$ 129,200

Acquisitions (Aspen Holdings) (Narrative) (Details) - Aspen Holdings $ in Millions	Oct. 01, 2015 USD ($) country
Business Acquisition [Line Items]
Number of countries the company operates in (more than 150) \| country	150
Payments to acquire business \| $	$ 135.6

Acquisitions (Voltaren Gel) (Narrative) (Details) - USD ($)	Jul. 01, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill		$ 4,450,082,000	$ 4,729,395,000	$ 7,299,354,000
Voltaren Gel
Business Acquisition [Line Items]
Aggregate consideration transferred	$ 162,700,000
Payments to acquire business	16,200,000
Contingent consideration	146,000,000
Net identifiable assets acquired	162,700,000
Goodwill	0
Finite-lived intangible assets acquired	$ 162,700,000
Estimated useful life	7 years

Segment Results - Schedule Of Reportable Segments Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($) segment	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments \| segment	4
Total net revenues to external customers	$ 3,468,858	$ 4,010,274	$ 3,268,718
Total segment adjusted income from continuing operations before income tax	1,608,175	1,717,622	1,517,996
U.S. Branded - Specialty & Established Pharmaceuticals
Segment Reporting Information [Line Items]
Total net revenues to external customers	957,525	1,166,294	1,284,607
Total segment adjusted income from continuing operations before income tax	485,515	553,806	694,440
U.S. Branded - Sterile Injectables
Segment Reporting Information [Line Items]
Total net revenues to external customers	750,471	576,399	114,719
Total segment adjusted income from continuing operations before income tax	563,103	426,170	76,627
U.S. Generic Pharmaceuticals
Segment Reporting Information [Line Items]
Total net revenues to external customers	1,530,530	1,988,214	1,557,697
Total segment adjusted income from continuing operations before income tax	501,249	653,309	665,140
International Pharmaceuticals
Segment Reporting Information [Line Items]
Total net revenues to external customers	230,332	279,367	311,695
Total segment adjusted income from continuing operations before income tax	$ 58,308	$ 84,337	$ 81,789

Segment Results - Schedule Of Reconciliations Of Consolidated Adjusted Income (Loss) Before Income Tax (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Total consolidated loss from continuing operations before income tax									$ (1,483,004)	$ (3,923,856)	$ (1,437,864)
Interest expense, net									488,228	452,679	373,214
Amortization of intangible assets									773,766	876,451	561,302
Acceleration of Auxilium employee equity awards at closing											37,600
Asset impairment charges	$ 130,400	$ 94,900	$ 725,000	$ 204,000	$ 3,518,100	$ 93,500	$ 40,000	$ 129,600	1,154,376	3,781,165	1,140,709
Acquisition-related costs	26,400	16,600	4,200	10,900	7,400	19,500	48,200	12,600	58,086	87,601	105,250
Costs associated with unused financing commitments									0	0	78,352
Other-than-temporary impairment of equity investment									0	0	18,869
Severance costs	84,500	80,700	24,600	22,700	37,100	9,800	22,200	38,500	53,000	57,900	60,200
Accelerated depreciation									123,700
Building costs											13,300
Provision for acquired remaining lease obligations											7,900
Transaction costs									8,100	63,800	170,900
Change in fair value of contingent consideration	$ 26,400	$ 15,400	$ 2,000	$ 6,200	$ (1,000)	$ 11,600	$ 23,900	$ (10,700)	49,949	23,823	(65,640)
Inventory Write-Offs
Segment Reporting Information [Line Items]
Restructuring expenses									13,700	24,500	41,200
Other Restructuring Costs
Segment Reporting Information [Line Items]
Restructuring expenses									22,000	25,100
Segment Reconciling Items
Segment Reporting Information [Line Items]
Interest expense, net									488,228	452,679	373,214
Corporate unallocated costs									165,298	189,043	171,242
Amortization of intangible assets									773,766	876,451	561,302
Inventory step-up and certain manufacturing costs that will be eliminated pursuant to integration plans									390	125,699	249,464
Upfront and milestone payments to partners									9,483	8,330	16,155
Separation benefits and other cost reduction initiatives									212,448	107,491	125,407
Impact of VOLTAREN® Gel generic competition									0	(7,750)	0
Acceleration of Auxilium employee equity awards at closing									0	0	37,603
Certain litigation-related and other contingencies, net									185,990	23,950	37,082
Asset impairment charges									1,154,376	3,781,165	1,140,709
Acquisition-related costs									58,086	87,601	105,250
Loss on extinguishment of debt									51,734	0	67,484
Costs associated with unused financing commitments									0	0	78,352
Other-than-temporary impairment of equity investment									0	0	18,869
Foreign currency impact related to the remeasurement of intercompany debt instruments									(1,403)	366	(25,121)
Other, net									(7,217)	(3,547)	(1,152)
Operating Segments
Segment Reporting Information [Line Items]
Total consolidated loss from continuing operations before income tax									$ 1,608,175	$ 1,717,622	$ 1,517,996

Segment Results - Additional Selected Financial Information For Reportable Segments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Total depreciation expense	$ 209,999	$ 106,858	$ 59,898
Operating Segments \| U.S. Branded - Specialty & Established Pharmaceuticals
Segment Reporting Information [Line Items]
Total depreciation expense	16,957	16,294	19,884
Operating Segments \| U.S. Branded - Sterile Injectables
Segment Reporting Information [Line Items]
Total depreciation expense	8,411	9,023	2,333
Operating Segments \| U.S. Generic Pharmaceuticals
Segment Reporting Information [Line Items]
Total depreciation expense	174,652	70,816	26,860
Operating Segments \| International Pharmaceuticals
Segment Reporting Information [Line Items]
Total depreciation expense	3,332	2,557	3,147
Corporate unallocated
Segment Reporting Information [Line Items]
Total depreciation expense	$ 6,647	$ 8,168	$ 7,674

Fair Value Measurements (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Restricted cash and cash equivalents	$ 324,400	$ 287,900
Restricted cash and cash equivalents classified as current assets	320,453	282,074
Goodwill impairment charges	$ 288,744	2,676,350
Minimum
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate range (percent)	10.00%
Maximum
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate range (percent)	22.00%
Vaginal Mesh Cases
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Settlement funds	$ 313,814	275,987
Money market funds \| Restricted cash and cash equivalents
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Settlement funds	$ 35,600	$ 26,200

Fair Value Measurements - Financial Liabilities Measured At Fair Value On Recurring Basis Using Significant Unobservable Inputs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Acquisition-related contingent consideration
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period	$ 262,113	$ 143,502
Acquisitions	0	146,866
Amounts settled	(122,559)	(55,896)
Measurement period adjustments	0	3,700
Changes in fair value recorded in earnings	49,949	23,823
Effect of currency translation	939	118
Fair Value Adjustments and Accretion		23,823
Payments and Other	(121,620)	(55,778)
End of period	190,442	262,113
Acquisition-related contingent consideration \| Qualitest
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period	0	1,137
Fair Value Adjustments and Accretion		(1,137)
Payments and Other		0
End of period		0
Acquisition-related contingent consideration \| Sumavel DosePro
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period	0	631
Fair Value Adjustments and Accretion		(631)
Payments and Other		0
End of period		0
Acquisition-related contingent consideration \| Auxilium acquisition
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period	21,097	26,435
Changes in fair value recorded in earnings	467
Fair Value Adjustments and Accretion		8,952
Payments and Other	(8,503)	(14,290)
End of period	13,061	21,097
Acquisition-related contingent consideration \| Lehigh Valley Technologies, Inc. acquisitions
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period	96,000	97,003
Changes in fair value recorded in earnings	40,016
Fair Value Adjustments and Accretion		30,676
Payments and Other	(73,015)	(31,679)
End of period	63,001	96,000
Acquisition-related contingent consideration \| VOLTAREN® Gel acquisition
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period	118,395	0
Changes in fair value recorded in earnings	18,586
Fair Value Adjustments and Accretion		(18,807)
Payments and Other	(38,857)	(8,853)
End of period	98,124	118,395
Acquisition-related contingent consideration \| Other
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period	26,621	18,296
Changes in fair value recorded in earnings	(9,120)
Fair Value Adjustments and Accretion		4,770
Payments and Other	(1,245)	(956)
End of period	16,256	26,621
Acquisition-related contingent consideration and other measurement period adjustments
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisitions	0	150,566
Acquisition-related contingent consideration and other measurement period adjustments \| Qualitest
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisitions		0
Acquisition-related contingent consideration and other measurement period adjustments \| Sumavel DosePro
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisitions		0
Acquisition-related contingent consideration and other measurement period adjustments \| Auxilium acquisition
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisitions	0	0
Acquisition-related contingent consideration and other measurement period adjustments \| Lehigh Valley Technologies, Inc. acquisitions
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisitions	0	0
Acquisition-related contingent consideration and other measurement period adjustments \| VOLTAREN® Gel acquisition
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisitions	0	146,055
Acquisition-related contingent consideration and other measurement period adjustments \| Other
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisitions	$ 0	$ 4,511

Fair Value Measurements - Fair Value Measurements (Schedule of Financial Assets Measured At Fair Value On A Nonrecurring Basis) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Assets:
Total expense for the year	$ (130,400)	$ (94,900)	$ (725,000)	$ (204,000)	$ (3,518,100)	$ (93,500)	$ (40,000)	$ (129,600)	$ (1,154,376)	$ (3,781,165)	$ (1,140,709)
U.S. Branded Pharmaceuticals
Assets:
Total expense for the year		$ (24,100)	$ (31,500)
U.S. Generic Pharmaceuticals
Assets:
Total expense for the year							$ (40,000)	$ (29,300)
U.S. Generic Pharmaceuticals \| 2017 US Generic Pharmaceuticals Restructuring
Assets:
Total expense for the year									(57,500)
Fair value, measurements, nonrecurring
Assets:
Total expense for the year									(865,633)	(3,802,493)
Fair value, measurements, nonrecurring \| Certain property, plant and equipment
Assets:
Total expense for the year									(65,676)
Fair value, measurements, nonrecurring \| Other
Assets:
Total expense for the year										(4,112)
Fair value, measurements, nonrecurring \| U.S. Branded Pharmaceuticals \| Intangible assets
Assets:
Total expense for the year									(76,674)	(110,430)
Fair value, measurements, nonrecurring \| U.S. Generic Pharmaceuticals \| Intangible assets
Assets:
Total expense for the year									(577,923)	(676,776)
Fair value, measurements, nonrecurring \| U.S. Generic Pharmaceuticals \| Certain property, plant and equipment
Assets:
Total expense for the year										(13,679)
Fair value, measurements, nonrecurring \| U.S. Generic Pharmaceuticals \| Goodwill
Assets:
Total expense for the year										(2,342,549)
Fair value, measurements, nonrecurring \| International Pharmaceuticals \| Intangible assets
Assets:
Total expense for the year									(145,360)	(301,698)
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Fair value, measurements, nonrecurring
Assets:
Certain property, plant and equipment	0								0
Other asset impairment charges					0					0
Total	0				0				0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Fair value, measurements, nonrecurring \| U.S. Branded Pharmaceuticals
Assets:
Certain segment intangible assets	0				0				0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Fair value, measurements, nonrecurring \| U.S. Generic Pharmaceuticals
Assets:
Certain property, plant and equipment					0					0
Certain segment intangible assets	0				0				0	0
Reporting unit goodwill					0					0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Fair value, measurements, nonrecurring \| International Pharmaceuticals
Assets:
Certain segment intangible assets	0				0				0	0
Significant Other Observable Inputs (Level 2) \| Fair value, measurements, nonrecurring
Assets:
Certain property, plant and equipment	0								0
Other asset impairment charges					0					0
Total	0				0				0	0
Significant Other Observable Inputs (Level 2) \| Fair value, measurements, nonrecurring \| U.S. Branded Pharmaceuticals
Assets:
Certain segment intangible assets	0				0				0	0
Significant Other Observable Inputs (Level 2) \| Fair value, measurements, nonrecurring \| U.S. Generic Pharmaceuticals
Assets:
Certain property, plant and equipment					0					0
Certain segment intangible assets	0				0				0	0
Reporting unit goodwill					0					0
Significant Other Observable Inputs (Level 2) \| Fair value, measurements, nonrecurring \| International Pharmaceuticals
Assets:
Certain segment intangible assets	0				0				0	0
Significant Unobservable Inputs (Level 3) \| Fair value, measurements, nonrecurring
Assets:
Certain property, plant and equipment	0								0
Other asset impairment charges					0					0
Total	423,258				4,753,685				423,258	4,753,685
Significant Unobservable Inputs (Level 3) \| Fair value, measurements, nonrecurring \| U.S. Branded Pharmaceuticals
Assets:
Certain segment intangible assets	34,326				4,621				34,326	4,621
Significant Unobservable Inputs (Level 3) \| Fair value, measurements, nonrecurring \| U.S. Generic Pharmaceuticals
Assets:
Certain property, plant and equipment					11,360					11,360
Certain segment intangible assets	367,160				872,474				367,160	872,474
Reporting unit goodwill					3,531,301					3,531,301
Significant Unobservable Inputs (Level 3) \| Fair value, measurements, nonrecurring \| International Pharmaceuticals
Assets:
Certain segment intangible assets	21,772				139,313				$ 21,772	139,313
Astora \| Fair value, measurements, nonrecurring \| Intangible assets
Assets:
Total expense for the year										(16,287)
Astora \| Fair value, measurements, nonrecurring \| Certain property, plant and equipment
Assets:
Total expense for the year										(5,041)
Astora \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Fair value, measurements, nonrecurring
Assets:
Certain property, plant and equipment					0					0
Certain segment intangible assets					0					0
Astora \| Significant Other Observable Inputs (Level 2) \| Fair value, measurements, nonrecurring
Assets:
Certain property, plant and equipment					0					0
Certain segment intangible assets					0					0
Astora \| Significant Unobservable Inputs (Level 3) \| Fair value, measurements, nonrecurring
Assets:
Certain property, plant and equipment					0					0
Certain segment intangible assets					0					0
Paladin Labs Inc. \| U.S. Branded Pharmaceuticals
Assets:
Total expense for the year	$ (500)
Paladin Labs Inc. \| International Pharmaceuticals
Assets:
Total expense for the year				$ (82,600)
Paladin Labs Inc. \| Fair value, measurements, nonrecurring \| Goodwill
Assets:
Total expense for the year										(272,578)
Paladin Labs Inc. \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Fair value, measurements, nonrecurring
Assets:
Reporting unit goodwill					0					0
Paladin Labs Inc. \| Significant Other Observable Inputs (Level 2) \| Fair value, measurements, nonrecurring
Assets:
Reporting unit goodwill					0					0
Paladin Labs Inc. \| Significant Unobservable Inputs (Level 3) \| Fair value, measurements, nonrecurring
Assets:
Reporting unit goodwill					170,572					170,572
Grupo Farmacéutico Somar \| Fair value, measurements, nonrecurring \| Goodwill
Assets:
Total expense for the year										(33,000)
Grupo Farmacéutico Somar \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Fair value, measurements, nonrecurring
Assets:
Reporting unit goodwill					0					0
Grupo Farmacéutico Somar \| Significant Other Observable Inputs (Level 2) \| Fair value, measurements, nonrecurring
Assets:
Reporting unit goodwill					0					0
Grupo Farmacéutico Somar \| Significant Unobservable Inputs (Level 3) \| Fair value, measurements, nonrecurring
Assets:
Reporting unit goodwill					24,044					24,044
Litha Joint Venture Investment \| Fair value, measurements, nonrecurring \| Goodwill
Assets:
Total expense for the year										(26,343)
Litha Joint Venture Investment \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Fair value, measurements, nonrecurring
Assets:
Reporting unit goodwill					0					0
Litha Joint Venture Investment \| Significant Other Observable Inputs (Level 2) \| Fair value, measurements, nonrecurring
Assets:
Reporting unit goodwill					0					0
Litha Joint Venture Investment \| Significant Unobservable Inputs (Level 3) \| Fair value, measurements, nonrecurring
Assets:
Reporting unit goodwill					$ 0					$ 0

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 124,685	$ 175,240
Work-in-process	109,897	100,494
Finished goods	156,855	279,937
Total	391,437	555,671
Long-term inventory	17,100	22,900
Inventories not yet available for sale	$ 5,900	$ 16,800

Property, Plant And Equipment - Schedule Of Property, Plant And Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cost:
Beginning Balance	$ 879,000
Additions	128,379
Disposals, transfers, impairments and other	(82,217)
Effect of currency translation	3,092
Ending Balance	928,254
Accumulated Depreciation:
Beginning Balance	(209,404)
Additions	(209,999)
Disposals, transfers and other	16,208
Effect of currency translation	(1,088)
Ending Balance	(404,283)
Net Book Amount:	523,971	$ 669,596
Land and Buildings
Cost:
Beginning Balance	322,537
Additions	19,871
Disposals, transfers, impairments and other	(12,333)
Effect of currency translation	1,391
Ending Balance	331,466
Accumulated Depreciation:
Beginning Balance	(50,770)
Additions	(93,633)
Disposals, transfers and other	(4,656)
Effect of currency translation	(343)
Ending Balance	(149,402)
Net Book Amount:	182,064	271,767
Machinery and Equipment
Cost:
Beginning Balance	227,833
Additions	49,088
Disposals, transfers, impairments and other	(9,939)
Effect of currency translation	836
Ending Balance	267,818
Accumulated Depreciation:
Beginning Balance	(64,319)
Additions	(76,986)
Disposals, transfers and other	6,964
Effect of currency translation	(400)
Ending Balance	(134,741)
Net Book Amount:	133,077	163,514
Leasehold Improve- ments
Cost:
Beginning Balance	50,359
Additions	11,067
Disposals, transfers, impairments and other	(1,271)
Effect of currency translation	309
Ending Balance	60,464
Accumulated Depreciation:
Beginning Balance	(21,263)
Additions	(6,607)
Disposals, transfers and other	1,088
Effect of currency translation	(85)
Ending Balance	(26,867)
Net Book Amount:	33,597	29,096
Computer Equipment and Software
Cost:
Beginning Balance	118,928
Additions	21,626
Disposals, transfers, impairments and other	(9,459)
Effect of currency translation	356
Ending Balance	131,451
Accumulated Depreciation:
Beginning Balance	(62,836)
Additions	(27,121)
Disposals, transfers and other	7,354
Effect of currency translation	(189)
Ending Balance	(82,792)
Net Book Amount:	48,659	56,092
Assets under Capital Lease
Cost:
Beginning Balance	9,155
Additions	0
Disposals, transfers, impairments and other	(4,259)
Effect of currency translation	0
Ending Balance	4,896
Accumulated Depreciation:
Beginning Balance	(5,773)
Additions	(2,645)
Disposals, transfers and other	4,257
Effect of currency translation	0
Ending Balance	(4,161)
Net Book Amount:	735	3,382
Furniture and Fixtures
Cost:
Beginning Balance	21,086
Additions	684
Disposals, transfers, impairments and other	(8,770)
Effect of currency translation	124
Ending Balance	13,124
Accumulated Depreciation:
Beginning Balance	(4,443)
Additions	(3,007)
Disposals, transfers and other	1,201
Effect of currency translation	(71)
Ending Balance	(6,320)
Net Book Amount:	6,804	16,643
Assets under Construc- tion
Cost:
Beginning Balance	129,102
Additions	26,043
Disposals, transfers, impairments and other	(36,186)
Effect of currency translation	76
Ending Balance	119,035
Accumulated Depreciation:
Beginning Balance	0
Additions	0
Disposals, transfers and other	0
Effect of currency translation	0
Ending Balance	0
Net Book Amount:	$ 119,035	$ 129,102

Property, Plant And Equipment (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total depreciation expense									$ 209,999	$ 106,858	$ 59,898
Asset impairment charges of long-lived assets									65,700	15,900	10,800
Asset impairment charges	$ 130,400	$ 94,900	$ 725,000	$ 204,000	$ 3,518,100	$ 93,500	$ 40,000	$ 129,600	1,154,376	3,781,165	$ 1,140,709
Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset impairment charges									47,200
AMS
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset impairment charges of long-lived assets										$ 5,000
Somar \| Disposal Group, Held-for-sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset impairment charges									$ 11,900

Goodwill And Other Intangibles - Schedule Of Changes In The Carrying Amount Of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended	12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Goodwill [Roll Forward]
Goodwill, beginning balance			$ 7,299,354	$ 4,729,395	$ 7,299,354
Measurement period adjustments					93,634
Effect of currency translation on gross balance				40,454	3,336
Effect of currency translation on accumulated impairment				(31,023)	9,421
Goodwill impairment charges				(288,744)	(2,676,350)
Goodwill, ending balance	$ 7,299,354			4,450,082	4,729,395	$ 7,299,354
U.S. Generic Pharmaceuticals
Goodwill [Roll Forward]
Goodwill, beginning balance			5,789,934	3,531,301	5,789,934
Measurement period adjustments					83,916
Effect of currency translation on gross balance				0	0
Effect of currency translation on accumulated impairment				0	0
Goodwill impairment charges				0	(2,342,549)	(181,000)
Goodwill, ending balance	5,789,934			3,531,301	3,531,301	5,789,934
U.S. Branded Pharmaceuticals
Goodwill [Roll Forward]
Goodwill, beginning balance			1,002,776	1,009,248	1,002,776
Measurement period adjustments					8,352
Effect of currency translation on gross balance				0	0
Effect of currency translation on accumulated impairment				0	0
Goodwill impairment charges	6,500	$ (680,000)	(5,500)	(180,430)	(1,880)
Goodwill, ending balance	1,002,776			828,818	1,009,248	1,002,776
International Pharmaceuticals
Goodwill [Roll Forward]
Goodwill, beginning balance			$ 506,644	188,846	506,644
Measurement period adjustments					1,366
Effect of currency translation on gross balance				40,454	3,336
Effect of currency translation on accumulated impairment				(31,023)	9,421
Goodwill impairment charges				(108,314)	(331,921)
Goodwill, ending balance	$ 506,644			$ 89,963	$ 188,846	$ 506,644

Goodwill And Other Intangibles - Accumulated Impairment (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Goodwill [Line Items]
Accumulated impairment losses	$ 3,661,904	$ 3,426,209
U.S. Generic Pharmaceuticals
Goodwill [Line Items]
Accumulated impairment losses	2,342,549	2,342,549
U.S. Branded Pharmaceuticals
Goodwill [Line Items]
Accumulated impairment losses	855,810	675,380
International Pharmaceuticals
Goodwill [Line Items]
Accumulated impairment losses	463,545	$ 408,280
Lithia and Somar \| Disposal Group, Held-for-sale, Not Discontinued Operations \| International Pharmaceuticals
Goodwill [Line Items]
Accumulated impairment losses	$ 84,100

Goodwill And Other Intangibles - Other Intangibles (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets	$ 790,311
Effect of currency translation	33,127
Amortization of intangible assets	773,766	$ 876,451	$ 561,302
Litha
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets	9,600
Lithia and BELBUCA
Finite-Lived Intangible Assets [Line Items]
Other intangibles, net	26,400
Lithia and Somar
Finite-Lived Intangible Assets [Line Items]
Effect of currency translation	$ 1,500

Goodwill And Other Intangibles - Schedule Of Other Intangible Assets (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Indefinite-lived intangibles:
Beginning Balance	$ 1,123,581
Acquisitions	0
Impairments	(334,490)
Other	(442,100)
Effect of Currency Translation	209
Ending Balance	347,200	$ 1,123,581
Finite-lived intangibles:
Beginning Balance	6,696,069
Acquisitions	0
Impairments	(455,821)
Other	378,409
Effect of Currency Translation	32,918
Ending Balance	6,651,575	6,696,069
Total other intangibles
Beginning balance	7,819,650
Acquisitions	0
Impairments	(790,311)
Other	(63,691)
Effect of Currency Translation	33,127
Ending balance	6,998,775	7,819,650
Accumulated amortization:
Beginning Balance	(1,960,353)
Amortization	(773,766)	(876,451)	$ (561,302)
Impairments	0
Other	63,691
Effect of Currency Translation	(10,663)
Ending Balance	(2,681,091)	(1,960,353)
Net other intangibles	4,317,684	5,859,297
Licenses
Finite-lived intangibles:
Beginning Balance	465,720
Acquisitions	0
Impairments	(8,178)
Other	(140)
Effect of Currency Translation	0
Ending Balance	457,402	465,720
Accumulated amortization:
Beginning Balance	(341,600)
Amortization	(28,761)
Impairments	0
Other	140
Effect of Currency Translation	0
Ending Balance	(370,221)	(341,600)
Tradenames
Finite-lived intangibles:
Beginning Balance	7,345
Acquisitions	0
Impairments	(808)
Other	(262)
Effect of Currency Translation	134
Ending Balance	6,409	7,345
Accumulated amortization:
Beginning Balance	(6,599)
Amortization	(42)
Impairments	0
Other	262
Effect of Currency Translation	(30)
Ending Balance	(6,409)	(6,599)
Developed technology
Finite-lived intangibles:
Beginning Balance	6,223,004
Acquisitions	0
Impairments	(446,835)
Other	378,811
Effect of Currency Translation	32,784
Ending Balance	6,187,764	6,223,004
Accumulated amortization:
Beginning Balance	(1,612,154)
Amortization	(744,963)
Impairments	0
Other	63,289
Effect of Currency Translation	(10,633)
Ending Balance	(2,304,461)	(1,612,154)
In-process research and development
Indefinite-lived intangibles:
Beginning Balance	1,123,581
Acquisitions	0
Impairments	(334,490)
Other	(442,100)
Effect of Currency Translation	209
Ending Balance	$ 347,200	$ 1,123,581
Weighted Average
Accumulated amortization:
Intangible life (years)	11 years
Weighted Average \| Licenses
Accumulated amortization:
Intangible life (years)	12 years
Weighted Average \| Developed technology
Accumulated amortization:
Intangible life (years)	11 years

Goodwill And Other Intangibles - Schedule Of Changes In Gross Carrying Amount Of Other Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended					12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Dec. 31, 2017
Finite-lived intangibles:
Beginning balance				$ 7,819,650		$ 7,819,650
Impairment of intangible assets						(790,311)
Ending balance	$ 6,998,775				$ 7,819,650	6,998,775
U.S. Generic Pharmaceuticals
Finite-lived intangibles:
Impairment of intangible assets	(125,300)	$ (54,200)	$ (268,200)	(72,700)	(507,200)
Other Intangible Assets
Finite-lived intangibles:
Beginning balance				$ 7,819,650		7,819,650
Transfer of intangible assets to Assets held for sale (NOTE 3)						(33,304)
Removal of certain fully amortized intangible assets						(30,387)
Effect of currency translation						33,127
Ending balance	$ 6,998,775				$ 7,819,650	6,998,775
Other Intangible Assets \| U.S. Branded Pharmaceuticals
Finite-lived intangibles:
Impairment of intangible assets						(76,674)
Other Intangible Assets \| U.S. Generic Pharmaceuticals
Finite-lived intangibles:
Impairment of intangible assets						(577,923)
Other Intangible Assets \| International Pharmaceuticals
Finite-lived intangibles:
Impairment of intangible assets						$ (135,714)

Goodwill And Other Intangibles - Schedule Of Estimated Amortization Of Intangibles (Details) $ in Thousands	Dec. 31, 2017 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2018	$ 598,603
2019	506,857
2020	469,339
2021	450,854
2022	$ 436,811

Goodwill And Other Intangibles - Impairments Narrative (Details) - USD ($) $ in Thousands				3 Months Ended										6 Months Ended	12 Months Ended
	Oct. 01, 2017	Oct. 01, 2016	Oct. 01, 2015	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Goodwill [Line Items]
Goodwill impairment charges (reduction)															$ 288,744	$ 2,676,350
Net goodwill impairment charge												$ 673,500
Impairment of intangible assets															790,311
Asset impairment charges				$ 130,400	$ 94,900	$ 725,000	$ 204,000	$ 3,518,100	$ 93,500	$ 40,000	$ 129,600				1,154,376	3,781,165	$ 1,140,709
Non-cash intangible asset impairment charge															455,821
2016 US Generic Pharmaceuticals Restructuring \| Asset Impairment Charges
Goodwill [Line Items]
Impairment of intangible assets																107,200
U.S. Generic Pharmaceuticals
Goodwill [Line Items]
Goodwill impairment charges (reduction)															0	2,342,549	181,000
Impairment of intangible assets				125,300	54,200	$ 268,200	72,700	507,200
Asset impairment charges										$ 40,000	29,300
U.S. Generic Pharmaceuticals \| 2017 US Generic Pharmaceuticals Restructuring
Goodwill [Line Items]
Asset impairment charges															57,500
U.S. Generic Pharmaceuticals \| 2016 US Generic Pharmaceuticals Restructuring \| Asset Impairment Charges
Goodwill [Line Items]
Asset impairment charges											$ 100,300
U.S. Branded Pharmaceuticals
Goodwill [Line Items]
Discount rate applied to estimated cash flows						9.50%
Goodwill impairment charges (reduction)												$ (6,500)	$ 680,000	$ 5,500	180,430	1,880
Asset impairment charges					$ 24,100	$ 31,500
U.S. Branded Pharmaceuticals \| Accounting Standards Update, 2017-04
Goodwill [Line Items]
Asset impairment charges						180,400
U.S. Branded Pharmaceuticals \| Opana
Goodwill [Line Items]
Asset impairment charges						20,600
U.S. Branded Pharmaceuticals \| Sumavel DosePro
Goodwill [Line Items]
Asset impairment charges								72,800
U.S. Branded Pharmaceuticals \| BELBUCA
Goodwill [Line Items]
Goodwill impairment charges (reduction)								1,900						37,600
U.S. Branded Pharmaceuticals \| Natesto, Testim, And Stendra Intangible Assets
Goodwill [Line Items]
Goodwill impairment charges (reduction)														152,000
U.S. Branded Pharmaceuticals \| Stendra
Goodwill [Line Items]
Goodwill impairment charges (reduction)														$ 9,500
International Pharmaceuticals
Goodwill [Line Items]
Goodwill impairment charges (reduction)															108,314	331,921
Non-cash intangible asset impairment charge								$ 285,500	$ 16,200								14,600
International Pharmaceuticals \| Serelaxin In-Process Research and Development Intangible Assets
Goodwill [Line Items]
Impairment of intangible assets							45,500
Somar \| Disposal Group, Held-for-sale, Not Discontinued Operations
Goodwill [Line Items]
Asset impairment charges															$ 11,900
Somar \| Disposal Group, Held-for-sale, Not Discontinued Operations \| International Pharmaceuticals
Goodwill [Line Items]
Goodwill impairment charges (reduction)						25,700
Impairment of intangible assets						$ 89,500
Minimum
Goodwill [Line Items]
Discount rate applied to estimated cash flows															10.00%
Minimum \| Fair Value, Inputs, Level 3 \| Goodwill and Indefinite-lived Intangible Assets
Goodwill [Line Items]
Discount rate applied to estimated cash flows	9.50%	8.50%	9.00%
Maximum
Goodwill [Line Items]
Discount rate applied to estimated cash flows															22.00%
Maximum \| Fair Value, Inputs, Level 3 \| Goodwill and Indefinite-lived Intangible Assets
Goodwill [Line Items]
Discount rate applied to estimated cash flows	12.50%	11.00%	16.00%
Paladin Labs Inc. \| U.S. Branded Pharmaceuticals
Goodwill [Line Items]
Asset impairment charges				$ 500
Paladin Labs Inc. \| International Pharmaceuticals
Goodwill [Line Items]
Discount rate applied to estimated cash flows															10.00%
Goodwill impairment charges (reduction)																272,600	$ 85,800
Asset impairment charges							$ 82,600
Grupo Farmacéutico Somar [Member] \| International Pharmaceuticals
Goodwill [Line Items]
Goodwill impairment charges (reduction)																33,000
Litha Joint Venture Investment \| International Pharmaceuticals
Goodwill [Line Items]
Goodwill impairment charges (reduction)																$ 26,300

License And Collaboration Agreements (BioSpecifics Technologies Corp) (Narrative) (Details)	1 Months Ended
	Jun. 30, 2004
Minimum
License And Collaboration Agreements [Line Items]
Royalty rate on net sales	5.00%
Maximum
License And Collaboration Agreements [Line Items]
Royalty rate on net sales	15.00%

Accounts Payable And Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accrued Liabilities [Abstract]
Trade accounts payable	$ 85,348	$ 126,712
Returns and allowances	291,034	332,455
Rebates	168,333	227,706
Chargebacks	14,604	33,092
Accrued interest	130,257	128,254
Accrued payroll and related benefits	113,908	115,224
Accrued royalties and other distribution partner payables	63,114	191,433
Acquisition-related contingent consideration—short-term	70,543	109,373
Other	159,684	189,835
Total	$ 1,096,825	$ 1,454,084

Debt (Components Of Total Indebtedness) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Principal Amount	$ 8,382,980	$ 8,398,930
Carrying Amount	8,276,237	8,272,503
Less current portion, net	34,205	131,125
Principal amount of total long-term debt, less current portion, net	8,348,775	8,267,805
Carrying amount of total long-term debt, less current portion, net	8,242,032	8,141,378
Fair value of long term debt	$ 7,500,000	$ 7,800,000
7.25% Senior Notes due 2022
Debt Instrument [Line Items]
Effective interest rate (as percent)	7.91%	7.91%
Principal Amount	$ 400,000	$ 400,000
Carrying Amount	$ 390,974	$ 389,150
Interest rate (as percent)	7.25%
5.75% Senior Notes due 2022
Debt Instrument [Line Items]
Effective interest rate (as percent)	6.04%	6.04%
Principal Amount	$ 700,000	$ 700,000
Carrying Amount	$ 692,855	$ 691,339
Interest rate (as percent)	5.75%
5.375% Senior Notes due 2023
Debt Instrument [Line Items]
Effective interest rate (as percent)	5.62%	5.62%
Principal Amount	$ 750,000	$ 750,000
Carrying Amount	$ 742,048	$ 740,733
Interest rate (as percent)	5.375%
6.00% Senior Notes due 2023
Debt Instrument [Line Items]
Effective interest rate (as percent)	6.28%	6.28%
Principal Amount	$ 1,635,000	$ 1,635,000
Carrying Amount	$ 1,613,446	$ 1,610,280
Interest rate (as percent)	6.00%
5.875% Senior Secured Notes due 2024
Debt Instrument [Line Items]
Effective interest rate (as percent)	6.14%	0.00%
Principal Amount	$ 300,000	$ 0
Carrying Amount	$ 295,513	$ 0
Interest rate (as percent)	5.875%
6.00% Senior Notes due 2025
Debt Instrument [Line Items]
Effective interest rate (as percent)	6.27%	6.27%
Principal Amount	$ 1,200,000	$ 1,200,000
Carrying Amount	$ 1,181,243	$ 1,179,203
Interest rate (as percent)	6.00%
Term Loan A Facility Due 2019
Debt Instrument [Line Items]
Effective interest rate (as percent)	0.00%	2.95%
Principal Amount	$ 0	$ 941,875
Carrying Amount	$ 0	$ 932,824
Term Loan B Facility Due 2022
Debt Instrument [Line Items]
Effective interest rate (as percent)	0.00%	4.06%
Principal Amount	$ 0	$ 2,772,000
Carrying Amount	$ 0	$ 2,728,919
Term Loan B Facility Due 2024
Debt Instrument [Line Items]
Effective interest rate (as percent)	5.46%	0.00%
Principal Amount	$ 3,397,925	$ 0
Carrying Amount	$ 3,360,103	$ 0
Other debt
Debt Instrument [Line Items]
Effective interest rate (as percent)	1.50%	1.50%
Principal Amount	$ 55	$ 55
Carrying Amount	$ 55	$ 55

Debt (Credit Facility) (Narrative) (Details) $ in Millions	Dec. 31, 2017 USD ($)
Revolving Credit Facility
Line of Credit Facility [Line Items]
Credit facility, remaining borrowing capacity	$ 996.8

Debt Debt (Senior Notes and Senior Secured Notes) (Details)	12 Months Ended
	Dec. 31, 2017
By or before December 31, 2017 \| Minimum
Debt Instrument, Redemption [Line Items]
Redemption price (as percent)	105.875%
By or before December 31, 2017 \| Maximum
Debt Instrument, Redemption [Line Items]
Redemption price (as percent)	106.00%
By or before December 31, 2017 \| Full Redemption
Debt Instrument, Redemption [Line Items]
Redemption price (as percent)	100.00%
By or before December 31, 2017 \| Partial Redemption
Debt Instrument, Redemption [Line Items]
Redemption price (as percent)	35.00%
After December 31, 2017 \| Minimum
Debt Instrument, Redemption [Line Items]
Redemption price (as percent)	100.00%
After December 31, 2017 \| Maximum
Debt Instrument, Redemption [Line Items]
Redemption price (as percent)	104.50%

Debt (April 2017 Refinancing) (Details)		3 Months Ended
Debt (April 2017 Refinancing) (Details)	Apr. 27, 2017 USD ($)	Jun. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Debt Instrument [Line Items]
Principal amount			$ 8,382,980,000	$ 8,398,930,000
Debt issuance costs	$ 56,700,000
Deferred debt issuance costs	$ 10,100,000	$ 51,700,000
2017 Credit Agreement \| Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument term	5 years
Principal amount	$ 1,000,000,000.0
Debt issuance costs	$ 10,500,000
Debt instrument maximum leverage ratio	2.5
Debt instrument secured leverage ratio	3.5
Debt instrument unsecured leverage ratio	6.5
2017 Credit Agreement \| Revolving Credit Facility \| London Interbank Offered Rate (LIBOR) \| Minimum
Debt Instrument [Line Items]
Basis spread on variable rate (as percent)	1.50%
2017 Credit Agreement \| Revolving Credit Facility \| London Interbank Offered Rate (LIBOR) \| Maximum
Debt Instrument [Line Items]
Basis spread on variable rate (as percent)	3.00%
2017 Credit Agreement \| Revolving Credit Facility \| Alternative Base Rate \| Minimum
Debt Instrument [Line Items]
Basis spread on variable rate (as percent)	0.50%
2017 Credit Agreement \| Revolving Credit Facility \| Alternative Base Rate \| Maximum
Debt Instrument [Line Items]
Basis spread on variable rate (as percent)	2.00%
2017 Credit Agreement \| Term Loan Facility
Debt Instrument [Line Items]
Debt instrument term	7 years
Principal amount	$ 3,415,000,000
Debt issuance costs	$ 41,300,000
2017 Credit Agreement \| Term Loan Facility \| London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Basis spread on variable rate (as percent)	4.25%
Basis spread floor (as percent)	0.75%
2017 Credit Agreement \| Term Loan Facility \| Alternative Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate (as percent)	3.75%
Basis spread floor (as percent)	1.75%
2017 Credit Agreement \| Senior Notes
Debt Instrument [Line Items]
Principal amount			$ 1,100,000,000.0
2017 Credit Agreement \| Senior Secured Notes
Debt Instrument [Line Items]
Debt issuance costs	$ 4,900,000
Senior Secured Notes Due 2024
Debt Instrument [Line Items]
Redemption price (as percent)	101.00%
Senior Secured Notes Due 2024 \| Prior to April 15, 2020
Debt Instrument [Line Items]
Redemption price, percentage of principal amount redeemed (as percent)	100.00%
Redemption price (as percent)	105.875%
Senior Secured Notes Due 2024 \| Maximum \| Prior to April 15, 2020
Debt Instrument [Line Items]
Redemption price, percentage of principal amount redeemed (as percent)	35.00%
Senior Secured Notes Due 2024 \| Senior Notes
Debt Instrument [Line Items]
Principal amount	$ 300,000,000
Interest rate (as percent)	5.875%
Letter of Credit
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 50,000,000
Swing line loans	75,000,000
Bridge Loan
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	50,000,000
Swing line loans	$ 75,000,000.0

Debt (Percentage Of Outstanding Principal Balance Of Non-Recourse Notes) (Details) - Senior Secured Notes Due 2024	Apr. 27, 2017
Debt Instrument [Line Items]
Redemption price (as percent)	101.00%
2020
Debt Instrument [Line Items]
Redemption price (as percent)	102.938%
2021
Debt Instrument [Line Items]
Redemption price (as percent)	101.469%
2022 and thereafter
Debt Instrument [Line Items]
Redemption price (as percent)	100.00%

Debt (Maturities On Long-Term Debt For Each Of The Next Five Years) (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
2018	$ 34,205,000
2019	34,150,000
2020	34,150,000
2021	34,150,000
2022	1,134,150,000
Principal amount	8,382,980,000	$ 8,398,930,000
Senior Notes \| 2017 Credit Agreement
Debt Instrument [Line Items]
Principal amount	1,100,000,000.0
Senior Notes \| Senior Notes Maturing Due 2022
Debt Instrument [Line Items]
Principal amount	$ 750,000,000.0

Commitments And Contingencies (Narrative) (Details) $ in Thousands	1 Months Ended					3 Months Ended		9 Months Ended	12 Months Ended			13 Months Ended
	Oct. 31, 2017 patent product	Aug. 31, 2017 USD ($) defendant	Oct. 31, 2015 motion	Aug. 31, 2015	Sep. 30, 2013 company	Dec. 31, 2017 USD ($) case	Jun. 30, 2017 USD ($) claim	Dec. 31, 2017 USD ($) product case	Dec. 31, 2017 USD ($) case	Dec. 31, 2016 USD ($)	Dec. 31, 2012 patent	Oct. 30, 2013	Feb. 20, 2018 claim
Loss Contingencies [Line Items]
Reserve for loss contingencies						$ 1,298,200		$ 1,298,200	$ 1,298,200
Increase in legal reserves						200,000
Current portion of legal settlement accrual						$ 1,087,793		$ 1,087,793	$ 1,087,793	$ 1,015,932
Number of cases alleging personal injury and/or wrongful death \| case						8		8	8
Vaginal Mesh Cases
Loss Contingencies [Line Items]
Product liability accrual increase							$ 775,500
Number of expected claims to be covered \| claim							22,000
Current portion of legal settlement accrual						$ 876,700		$ 876,700	$ 876,700
Payments to plaintiffs and qualified settlement funds									2,900,000
Settlement funds						$ 313,814		$ 313,814	$ 313,814	275,987
Testosterone Cases \| Subsequent Event
Loss Contingencies [Line Items]
Pending claims, number \| claim													1,300
Unapproved Drug Litigation
Loss Contingencies [Line Items]
Number of additional defendants \| company					50
Opioid-Related Matters
Loss Contingencies [Line Items]
Pending claims, number \| case						465		465	465
Number of cases filed by hospitals, health systems, unions, welfare funds or other third-party \| case						25		25	25
Pricing Matters Cases
Loss Contingencies [Line Items]
Number of products involved in claims \| product								18
Bier v. Endo International plc, et al. \| Current and Former Directors and Officers
Loss Contingencies [Line Items]
Number of additional defendants \| defendant		4
Opana
Loss Contingencies [Line Items]
Lawsuit filing period												45 days
Stay of approval period, hatch-waxman act												30 months
AMS \| Vaginal Mesh Cases
Loss Contingencies [Line Items]
Product liability accrual, period expense						$ 1,087,200		$ 1,087,200	$ 1,087,200
Loss contingency, claims settled, number \| case									71,000
Par Pharmaceutical, Inc. \| Pricing Matters Cases
Loss Contingencies [Line Items]
Number of products involved in claims \| product	6							6
Par Pharmaceutical, Inc. \| VASOSTRICT Related Matters
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon \| patent	5
Endo Pharmaceuticals Inc. \| Opana
Loss Contingencies [Line Items]
Settlement awarded		$ 25,000
Jubilant HollisterStier Laboratories LLC
Loss Contingencies [Line Items]
Long-term purchase commitment									$ 5,600	$ 6,300
Judicial Ruling \| Opana
Loss Contingencies [Line Items]
Number of patents found infringed upon \| patent											2
Period for generic product to be withdrawn			60 days	60 days
Number of post-trial motions \| motion			2

Commitments And Contingencies - Schedule of Loss Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Qualified Settlement Funds
Cash contributions to Qualified Settlement Funds	$ 668,306	$ 831,131	$ 743,132
Mesh Liability Accrual
Ending balance	1,298,200
Vaginal Mesh Cases
Qualified Settlement Funds
Beginning balance	275,987
Cash contributions to Qualified Settlement Funds	668,306
Cash distributions to settle disputes from Qualified Settlement Funds	(632,176)
Other	1,697
Ending balance	313,814	275,987
Vaginal Mesh Cases \| Mesh Product Liability Accrual
Mesh Liability Accrual
Beginning balance	963,117
Additional charges	775,474
Cash distributions to settle disputes from Qualified Settlement Funds	(632,176)
Cash distributions to settle disputes	(19,243)
Ending balance	$ 1,087,172	$ 963,117

Commitments And Contingencies - Summary Of Minimum Future Rental Payments Required Under Operating Leases and Capital Leases (Details) ft² in Thousands, $ in Thousands	Dec. 31, 2017 USD ($) ft²
Capital Leases
2018	$ 6,713
2019	6,633
2020	6,564
2021	6,681
2022	6,831
Thereafter	14,126
Total minimum lease payments	47,548
Less: Amount representing interest	4,168
Total present value of minimum payments	43,380
Less: Current portion of such obligations	6,713
Long-term capital lease obligations	$ 36,667
Area of real estate property \| ft²	90
Future minimum sublease rentals	$ 25,200
Operating Leases
2018	13,888
2019	14,120
2020	13,505
2021	11,758
2022	11,212
Thereafter	23,703
Total minimum lease payments	$ 88,186

Commitments And Contingencies - Leases (Narrative) (Details) $ in Millions		12 Months Ended
	Oct. 28, 2011 renewal_options	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Number of renewal options \| renewal_options	3
Additional period of renewal for lease agreement	60 months
Direct financing lease obligations		$ 38.4
Expenses incurred under operating leases		18.7	$ 22.2	$ 20.1
Accounts Payable
Direct financing lease obligations		4.6
Other Liabilities
Direct financing lease obligations		$ 33.8

Other Comprehensive Income (Loss) (Schedule Of Tax Effects Allocated To Each Component Of Other Comprehensive Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]
Before- Tax Amount	$ 143,317	$ 16,673	$ (235,519)
Tax Benefit (Expense)	296	14,136	(21,189)
OTHER COMPREHENSIVE INCOME (LOSS)	143,613	30,809	(256,708)
Net unrealized gain (loss) on securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Before Reclassification, Before Tax Amount	(811)	(1,588)	2,349
Before Reclassification, Tax Benefit (Expense)	296	674	(50)
Before Reclassification, Net-of-Tax Amount	(515)	(914)	2,299
Reclassification, Before Tax Amount	0	(6)	0
Reclassification, Tax Benefit (Expense)	0	0	0
Reclassification, Net-of-Tax Amount	0	(6)	0
Before- Tax Amount	(811)	(1,594)	2,349
Tax Benefit (Expense)	296	674	(50)
OTHER COMPREHENSIVE INCOME (LOSS)	(515)	(920)	2,299
Net unrealized gain (loss) on foreign currency
Accumulated Other Comprehensive Income (Loss) [Line Items]
Before Reclassification, Before Tax Amount	31,202	18,267	(263,425)
Before Reclassification, Tax Benefit (Expense)	0	13,462	(21,297)
Before Reclassification, Net-of-Tax Amount	31,202	31,729	(284,722)
Reclassification, Before Tax Amount	112,926	0	25,557
Reclassification, Tax Benefit (Expense)	0	0	158
Reclassification, Net-of-Tax Amount	112,926	0	25,715
Before- Tax Amount	144,128	18,267	(237,868)
Tax Benefit (Expense)	0	13,462	(21,139)
OTHER COMPREHENSIVE INCOME (LOSS)	$ 144,128	$ 31,729	$ (259,007)

Other Comprehensive Income (Loss) (Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Change in other comprehensive loss, net of tax	$ 484,880	$ 2,701,589	$ 5,967,976	$ 2,408,213
Net unrealized gains
Accumulated Other Comprehensive Income (Loss) [Line Items]
Change in other comprehensive loss, net of tax	380	895
Foreign currency translation loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Change in other comprehensive loss, net of tax	(210,201)	(354,329)
Accumulated other comprehensive loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Change in other comprehensive loss, net of tax	$ (209,821)	$ (353,434)	$ (384,205)	$ (124,088)

Shareholders' Equity (Narrative) (Details) - USD ($)				1 Months Ended	12 Months Ended
Shareholders' Equity (Narrative) (Details) - USD ($)	Sep. 25, 2015	Jun. 10, 2015	Jan. 29, 2015	Nov. 30, 2015	Dec. 31, 2017	Dec. 31, 2015	Dec. 31, 2016	Apr. 30, 2015	Feb. 11, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Euro deferred shares, shares issued					4,000,000		4,000,000		4,000,000
Euro deferred shares, par value (in dollars per share)					$ 0.01		$ 0.01		$ 0.01
Share price (in dollars per share)		$ 83.25
Unrecognized compensation cost					$ 58,200,000
2015 Share Buyback Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share repurchase program, authorized amount								$ 2,500,000,000.0
Share repurchases				$ 250,000,000
Share repurchases (in shares)				4,400,000
Over-Allotment Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ordinary shares issued (in shares)		3,603,603
Auxilium Pharmaceuticals, Inc.
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate consideration transferred			$ 2,600,000,000
Fair value of shares issued as part of acquisition			$ 1,520,000,000
Ordinary shares issued, value						$ 1,519,320,000
Auxilium Pharmaceuticals, Inc. \| Ordinary Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ordinary shares issued (in shares)			18,609,835			18,609,835
Ordinary shares issued, value						$ 2,000
Par Pharmaceutical Holdings, Inc.
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate consideration transferred	$ 8,140,000,000
Ordinary shares issued (in shares)	18,069,899	27,627,628
Ordinary shares issued, value						$ 1,325,248,000
Equity consideration	$ 1,330,000,000
Par Pharmaceutical Holdings, Inc. \| Ordinary Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ordinary shares issued (in shares)						18,069,899
Ordinary shares issued, value						$ 2,000
Par Pharmaceutical Holdings, Inc. \| Endo International
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ordinary shares issued, value		$ 2,300,000,000
Nonvested Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining requisite service period, non-vested stock options					2 years 6 months
Unrecognized compensation cost					$ 21,100,000
Performance Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Service period					3 years
Minimum \| Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period					3 years
Maximum \| Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period					4 years

Shareholders' Equity (Schedule of Buy-out of Noncontrolling Interests) (Details) - Litha Healthcare Group Limited $ in Thousands	12 Months Ended
	Dec. 31, 2015 USD ($)
Stockholders' Equity [Line Items]
Buy-out of noncontrolling interests, net of contributions	$ (39,608)
Accumulated Other Comprehensive (Loss) Income
Stockholders' Equity [Line Items]
Buy-out of noncontrolling interests, net of contributions	(3,904)
Noncontrolling Interests
Stockholders' Equity [Line Items]
Buy-out of noncontrolling interests, net of contributions	(32,732)
Additional Paid-in Capital
Stockholders' Equity [Line Items]
Buy-out of noncontrolling interests, net of contributions	$ (2,972)

Shared-based Compensation (Narrative) (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended			24 Months Ended
	Jun. 30, 2017	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2015	Jun. 30, 2015
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock-based compensation expense			$ 50,149,000	$ 59,769,000	$ 98,788,000
Acceleration of Auxilium employee equity awards at closing					37,600,000
Unrecognized compensation cost			58,200,000
Tax benefit from exercise of stock options			$ 0	$ 0	$ 11,700,000
Stock Options
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Target amount of share-based compensation awards, stock options (in shares)			5,288,675	2,578,105	794,757
Expiration period			10 years
Dividend yield			0.00%	0.00%	0.00%
Exercise price range, lower range limit (in dollars per share)			$ 7.55
Exercise price range, upper range limit (in dollars per share)			$ 89.68
Options exercised intrinsic value			$ 1,300,000	$ 27,200,000
Options grated, weighted average grant date fair value (in dollars per share)			$ 4.73	$ 11.46	$ 21.09
Stock Options \| Minimum
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Vesting period			3 years
Stock Options \| Maximum
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Vesting period			4 years
Nonvested Stock Options
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Unrecognized compensation cost			$ 21,100,000
Weighted average remaining requisite service period, non-vested stock options			2 years 6 months
Restricted Stock Units (RSUs) \| Minimum
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Vesting period			3 years
Restricted Stock Units (RSUs) \| Maximum
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Vesting period			4 years
Performance Stock Units
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Service period			3 years
PSU award percentage using free cash flow performance metric			50.00%
PSU award percentage using TSR metric			50.00%
Performance cycle			3 years	3 years		3 years
Performance Stock Units \| Minimum
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Award adjustment rate			0.00%	0.00%		0.00%
Performance Stock Units \| Maximum
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Award adjustment rate			200.00%	300.00%		300.00%
Restricted Stock Units (RSUs) and Performance Stock Units (PSUs)
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Target amount of share-based compensation awards (in shares)			4,168,477	1,582,429	927,214
Weighted average remaining requisite service period, non-vested restricted stock units			2 years 1 month 6 days
Nonvested Restricted Stock Units And Performance Stock Units
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Restricted and performance stock units, weighted average grant date fair value (in dollars per share)			$ 11.42	$ 43.52	$ 72.34	$ 72.34
Nonvested Restricted Stock
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Unrecognized compensation cost			$ 30,800,000	$ 6,300,000
AMS
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock-based compensation expense					$ 11,400,000
2015 Stock Incentive Plan
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Number of shares authorized							10,000,000.0
Number of shares available for grant			8,822,860
2010 Stock Incentive Plan
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Number of shares available for grant							5,000,000.0
Endo International PLC Amended and Restated 2015 Stock Incentive Plan [Member] \| Stock Incentive Plan
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Additional ordinary shares authorized for issuance (in shares)	10,000,000.0
Plan
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Target amount of share-based compensation awards, stock options (in shares)		1,000,000.0
Plan \| Performance Stock Units
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Target amount of share-based compensation awards (in shares)			300,000.0
Plan \| Nonvested Restricted Stock
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Target amount of share-based compensation awards (in shares)		100,000.0

Shared-based Compensation (Schedule Of Allocation Of Stock-Based Compensation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 50,149	$ 59,769	$ 98,788
Selling, general and administrative expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	38,292	54,176	79,928
Research and development expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	4,197	2,440	2,388
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	7,660	2,040	2,241
Discontinued Operations
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 0	$ 1,113	$ 14,231

Shared-based Compensation (Summary Of Activity Under Stock Incentive Plans) (Details) - Stock Options - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Number of Shares
Outstanding, beginning balance (in shares)	4,325,209	2,768,567	3,063,352
Granted (in shares)	5,288,675	2,578,105	794,757
Exercised (in shares)		(62,589)	(880,885)
Forfeited (in shares)	(623,987)	(858,556)	(201,397)
Expired (in shares)	(741,767)	(100,318)	(7,260)
Outstanding, ending balance (in shares)	8,248,130	4,325,209	2,768,567
Vested and expected to vest (in shares)	7,633,410
Exercisable (in shares)	1,826,250
Weighted Average Exercise Price
Outstanding, weighted average exercise price, beginning balance (in dollars per share)	$ 41.70	$ 51.56	$ 40.15
Granted, weighted average exercise price (in dollars per share)	10.42	35.45	77.27
Exercised, weighted average exercise price (in dollars per share)		31.19	30.93
Forfeited, weighted average exercise price (in dollars per share)	28.32	52.27	72.24
Expired, weighted average exercise price (in dollars per share)	40.29	60.71	45.20
Outstanding, weighted average exercise price, ending balance (in dollars per share)	22.79	$ 41.70	$ 51.56
Vested and expected to vest, end of period, weighted average exercise price (in dollars per share)	23.46
Exercisable, end of period, weighted average exercise price (in dollars per share)	$ 42.39
Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value
Outstanding, weighted average remaining contractual term	7 years 10 months 13 days
Vested and expected to vest, weighted average remaining contractual term	7 years 9 months 4 days
Exercisable, weighted average remaining contractual term	3 years 11 months 27 days
Outstanding, aggregate intrinsic value	$ 493,979
Vested and expected to vest, aggregate intrinsic value	435,456
Exercisable, aggregate intrinsic value	$ 0

Shared-based Compensation (Stock Option Assumption) (Details) - Stock Options	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	4 years	4 years	4 years
Risk-free interest rate	1.70%	1.10%	1.30%
Dividend yield	0.00%	0.00%	0.00%
Expected volatility	58.00%	43.00%	32.00%

Shared-based Compensation (Summary Of Restricted Stock Units and Performance Stock Units Activity) (Details) - Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Number of Shares
Outstanding, Beginning Balance	1,685,060	1,806,853	1,654,753
Granted	4,168,477	1,582,429	927,214
Forfeited	(552,981)	(975,994)	(251,351)
Vested	(575,883)	(728,228)	(523,763)
Outstanding, Ending Balance	4,724,673	1,685,060	1,806,853
Vested and expected to vest, end of period, Number of Shares	4,337,839
Aggregate Intrinsic Value
Outstanding, end of period	$ 36,616,216
Vested and expected to vest	$ 33,618,256

Other (Income) Expense, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Other Expense (Income) [Line Items]
Foreign currency (gain) loss, net	$ (2,801)	$ 2,991	$ (23,058)
Equity loss (earnings) from investments accounted for under the equity method, net	898	(1,190)	3,217
Other-than-temporary impairment of equity investment	0	0	18,869
Legal settlement	0	0	(12,500)
Costs associated with unused financing commitments	0	0	78,352
Other miscellaneous, net	(15,120)	(2,139)	(1,189)
Other (income) expense, net	(17,023)	$ (338)	63,691
Litha Joint Venture Investment
Other Expense (Income) [Line Items]
Gain on sale of business	$ 10,100
Equity Method Investments			$ 18,900

Income Taxes (Components Of Income Before Income Tax By Geography) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
United States	$ (1,866,222)	$ (4,309,211)	$ (626,740)
International	383,218	385,355	(811,124)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAX	$ (1,483,004)	$ (3,923,856)	$ (1,437,864)

Income Taxes (Narrative) (10K) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating Loss Carryforwards [Line Items]
Provisional tax benefit related to Tax Cuts And Jobs Act Of 2017	$ 36,200	$ 36,216	$ 0	$ 0
Worthless stock deduction			636,100	674,200
Valuation allowance	8,062,975	8,062,975	4,841,209
Increase (decrease) in valuation allowance		3,221,800	(4,414,200)
Undistributed earnings of foreign subsidiaries	169,800	169,800
Unrecognized income tax benefits	415,951	415,951	424,601	316,247	$ 105,330
Unrecognized tax benefits that would impact effective tax rate	289,900	289,900	435,400
Accrued interest and penalties	19,185	19,185		19,000
Interest and penalties		1,400	5,100	$ 1,600
Losses Within Jurisdictions, Primarily Luxembourg [Member]
Operating Loss Carryforwards [Line Items]
Increase (decrease) in valuation allowance		3,310,800
Jurisdictions Where Unable to Support Recognition of Deferred Tax Assets
Operating Loss Carryforwards [Line Items]
Increase (decrease) in valuation allowance			3,950,100
State Tax Benefits
Operating Loss Carryforwards [Line Items]
Increase (decrease) in valuation allowance		21,500	67,100
Remeasurement Of Certain Tax Assets [Member]
Operating Loss Carryforwards [Line Items]
Increase (decrease) in valuation allowance		$ 590,200
Deferred Tax Assets on US Generics
Operating Loss Carryforwards [Line Items]
Increase (decrease) in valuation allowance			$ 400,800
Minimum
Operating Loss Carryforwards [Line Items]
Statues Of Limitation		3 years
Maximum
Operating Loss Carryforwards [Line Items]
Statues Of Limitation		10 years
Accounting Standards Update 2016-16 \| New Accounting Pronouncement, Early Adoption, Effect \| Accounting Standards Update 2016-16
Operating Loss Carryforwards [Line Items]
Deferred tax assets, net	$ 479,700	$ 479,700

Income Taxes (Schedule of Income Tax) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Current, federal	$ (86,478)	$ 18,369	$ (308,909)
Current, state	(6,462)	9,501	(5,600)
Current, international	(1,224)	22,851	16,722
Total current income tax	(94,164)	50,721	(297,787)
Deferred, federal	(124,682)	(661,484)	(779,757)
Deferred, state	(3,225)	(239)	(70,221)
Deferred, international	(28,222)	(83,619)	(9,376)
Total deferred income tax	(156,129)	(745,342)	(859,354)
Excess tax benefits of stock compensation exercised	0	(5,463)	19,676
Valuation allowance	0	0	0
INCOME TAX	$ (250,293)	$ (700,084)	$ (1,137,465)

Income Taxes (Schedule Of Reconciliation Of Income Tax At Federal Statutory Income Tax Rate To Total Income Tax Provision) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Notional U.S. federal income tax provision at the statutory rate		$ (519,051)	$ (1,373,350)	$ (503,271)
State income tax, net of federal benefit		(11,473)	5,182	(45,823)
U.S. tax reform impact	$ (36,200)	(36,216)	0	0
Uncertain tax positions		58,120	(18,111)	30,974
Residual tax on non-U.S. net earnings		(1,350,811)	(301,666)	(359,831)
Effects of outside basis differences		0	(636,134)	(786,130)
Non-deductible goodwill impairment		60,808	926,881	248,403
Change in valuation allowance		1,648,836	762,604	278,339
Intra-entity transfers of assets		(53,509)	(92,859)	0
International Pharmaceuticals segment divestitures		(56,092)	0	0
Other		9,095	27,369	(126)
INCOME TAX		$ (250,293)	$ (700,084)	$ (1,137,465)

Income Taxes (Schedule Of Deferred Tax Assets And Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Accrued expenses and customer allowances	$ 299,142	$ 232,101
Compensation related to stock options	20,108	24,246
Deferred interest expense	46,230	57,440
Fixed assets and intangible assets	484,313	55,473
Loss on capital assets	49,585	9,904
Net operating loss carryforward	7,183,651	4,410,386
Uncertain tax positions	32,356	30,262
Research and development credit carryforward	4,838	4,244
Tax credit carryforwards	1,516	4,520
Uncertain tax positions	4,364	10,562
Total gross deferred income tax assets	8,126,103	4,839,138
Deferred tax liabilities:
Other	(2,042)	0
Outside basis difference	(92,635)	(182,409)
Total gross deferred income tax liabilities	(94,677)	(182,409)
Valuation allowance	(8,062,975)	(4,841,209)
Net deferred income tax liability	$ (31,549)	$ (184,480)

Income Taxes (Tax Credit Carryforwards) (Details) $ in Thousands	Dec. 31, 2017 USD ($)
Foreign \| Ireland
Tax Credit Carryforward [Line Items]
Operating loss carryforwards	$ 43,965
Foreign \| Luxembourg
Tax Credit Carryforward [Line Items]
Operating loss carryforwards	6,847,805
Domestic
Tax Credit Carryforward [Line Items]
Operating loss carryforwards	115,518
Domestic \| Capital Loss Carryforward
Tax Credit Carryforward [Line Items]
Operating loss carryforwards	27,114
State
Tax Credit Carryforward [Line Items]
Operating loss carryforwards	172,439
State \| Capital Loss Carryforward
Tax Credit Carryforward [Line Items]
Operating loss carryforwards	$ 20,920

Income Taxes (Valuation Allowances) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Valuation Allowance [Line Items]
Valuation allowance	$ 8,062,975	$ 4,841,209
Foreign \| Canada
Valuation Allowance [Line Items]
Valuation allowance	2,228
Foreign \| Ireland
Valuation Allowance [Line Items]
Valuation allowance	99,194
Foreign \| Luxembourg
Valuation Allowance [Line Items]
Valuation allowance	6,847,805
Domestic \| United States
Valuation Allowance [Line Items]
Valuation allowance	$ 1,110,172

Income Taxes (Schedule Of Reconciliation Of Change In Uncertain Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits, beginning balance	$ 424,601	$ 316,247	$ 105,330
Gross additions for current year positions	44,293	142,778	65,439
Gross reductions for prior period positions	(64,887)	(35,888)	(234)
Gross additions for prior period positions	22,765	2,111	3,460
Decrease due to lapse of statute of limitations	(13,151)	(3,085)	(75)
Additions related to acquisitions	0	2,350	150,152
Currency translation adjustment			(7,825)
Currency translation adjustment	2,330	88
Unrecognized tax benefits, ending balance	415,951	424,601	316,247
Accrued interest and penalties	19,185		$ 19,000
Total UTB balance including accrued interest and penalties	435,136	$ 443,600
Current portion	17,100
Non-current portion	$ 418,036

Savings And Investment Plan And Deferred Compensation Plans (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Savings And Investment Plan And Deferred Compensation [Line Items]
Contributions towards defined contribution savings and investment plans	$ 9.4	$ 11.5	$ 8.6
Endo 401(k) Plan
Savings And Investment Plan And Deferred Compensation [Line Items]
Maximum annual contributions per employee (percent)	4.00%
Endo 401(k) Plan, Matching Tier One
Savings And Investment Plan And Deferred Compensation [Line Items]
Employer matching contribution (percent)	100.00%
Percentage of employees gross pay	3.00%
Endo 401(k) Plan, Matching Tier Two
Savings And Investment Plan And Deferred Compensation [Line Items]
Employer matching contribution (percent)	50.00%
Percentage of employees gross pay	2.00%

Net Loss Per Share (Reconciliation Of The Numerator And Denominator Of Basic And Diluted Net Loss Per Share) (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Numerator:
Loss from continuing operations									$ (1,232,711)	$ (3,223,772)	$ (300,399)
Less: Net income (loss) from continuing operations attributable to noncontrolling interests									0	16	(283)
Loss from continuing operations attributable to Endo International plc ordinary shareholders	$ (271,581)	$ (99,687)	$ (696,020)	$ (165,423)	$ (3,333,325)	$ (191,496)	$ 389,812	$ (88,763)	(1,232,711)	(3,223,788)	(300,116)
Loss from discontinued operations attributable to Endo International plc ordinary shareholders, net of tax	(96,836)	3,017	(700,498)	(8,405)	(4,531)	(27,423)	(46,216)	(45,108)	(802,722)	(123,278)	(1,194,926)
NET LOSS ATTRIBUTABLE TO ENDO INTERNATIONAL PLC	$ (368,417)	$ (96,670)	$ (1,396,518)	$ (173,828)	$ (3,337,856)	$ (218,919)	$ 343,578	$ (133,869)	$ (2,035,433)	$ (3,347,066)	$ (1,495,042)
Denominator:
For basic per share data—weighted average shares (shares)	223,322	223,299	223,158	223,014	222,870	222,767	222,667	222,302	223,198	222,651	197,100
Dilutive effect of ordinary share equivalents (shares)									0	0	0
Dilutive effect of various convertible notes and warrants (shares)									0	0	0
For diluted per share data—weighted average shares (shares)	223,322	223,299	223,158	223,014	222,870	222,767	222,863	222,302	223,198	222,651	197,100

Quarterly Financial Data (Unaudited) (Schedule Of Quarterly Financial Data) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Total revenues	$ 768,640	$ 786,887	$ 875,731	$ 1,037,600	$ 1,241,513	$ 884,335	$ 920,887	$ 963,539
Gross profit	262,995	272,365	336,330	368,638	484,935	326,863	288,669	274,834
Loss from continuing operations	(271,581)	(99,687)	(696,020)	(165,423)	(3,333,325)	(191,496)	389,812	(88,763)	$ (1,232,711)	$ (3,223,788)	$ (300,116)
Discontinued operations, net of tax	(96,836)	3,017	(700,498)	(8,405)	(4,531)	(27,423)	(46,216)	(45,108)	(802,722)	(123,278)	(1,194,926)
Net loss attributable to Endo International plc	$ (368,417)	$ (96,670)	$ (1,396,518)	$ (173,828)	$ (3,337,856)	$ (218,919)	$ 343,578	$ (133,869)	$ (2,035,433)	$ (3,347,066)	$ (1,495,042)
Continuing operations, basic (in dollars per share)	$ (1.22)	$ (0.45)	$ (3.12)	$ (0.74)	$ (14.96)	$ (0.86)	$ 1.75	$ (0.40)	$ (5.52)	$ (14.48)	$ (1.52)
Discontinued operations, basic (in dollars per share)	(0.43)	0.02	(3.14)	(0.04)	(0.02)	(0.12)	(0.21)	(0.20)	(3.60)	(0.55)	(6.07)
Basic (in dollars per share)	(1.65)	(0.43)	(6.26)	(0.78)	(14.98)	(0.98)	1.54	(0.60)	(9.12)	(15.03)	(7.59)
Continuing operations, diluted (in dollars per share)	(1.22)	(0.45)	(3.12)	(0.74)	(14.96)	(0.86)	1.75	(0.40)	(5.52)	(14.48)	(1.52)
Discontinued operations, diluted (in dollars per share)	(0.43)	0.02	(3.14)	(0.04)	(0.02)	(0.12)	(0.21)	(0.20)	(3.60)	(0.55)	(6.07)
Diluted (in dollars per share)	$ (1.65)	$ (0.43)	$ (6.26)	$ (0.78)	$ (14.98)	$ (0.98)	$ 1.54	$ (0.60)	$ (9.12)	$ (15.03)	$ (7.59)
Weighted average shares—Basic (shares)	223,322	223,299	223,158	223,014	222,870	222,767	222,667	222,302	223,198	222,651	197,100
Weighted average shares—Diluted (shares)	223,322	223,299	223,158	223,014	222,870	222,767	222,863	222,302	223,198	222,651	197,100
Asset impairment charges	$ 130,400	$ 94,900	$ 725,000	$ 204,000	$ 3,518,100	$ 93,500	$ 40,000	$ 129,600	$ 1,154,376	$ 3,781,165	$ 1,140,709
Acquisition-related and integration items	26,400	16,600	4,200	10,900	7,400	19,500	48,200	12,600	58,086	87,601	105,250
Change in fair value of contingent consideration	26,400	15,400	2,000	6,200	(1,000)	11,600	23,900	(10,700)	49,949	23,823	(65,640)
Severance costs	84,500	80,700	24,600	22,700	37,100	9,800	22,200	38,500	53,000	57,900	60,200
Litigation-related and other contingencies, net	$ 200,000	(12,400)	(2,600)	$ 900	(4,800)	18,300	5,300	5,200	185,990	23,950	37,082
Loss on extinguishment of debt			$ 51,700						51,734	0	67,484
Inventory step-up					$ 13,900	$ 14,200	$ 29,100	$ 68,500	$ 390	$ 108,768	$ 232,461
Assets Impaired Second Quarter Of 2017
Asset impairment charges		$ 14,200

SCHEDULE II--Valuation and Qualifying Accounts (Details) - Valuation Allowance for Deferred Tax Assets - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	$ 4,841,209	$ 426,991	$ 40,646
Additions, Costs and Expenses	3,811,982	4,416,478	386,087
Deductions, Write-offs	0	(2,039)	(17,106)
Other	(590,216)	(221)	17,364
Balance at End of Period	$ 8,062,975	$ 4,841,209	$ 426,991

Fair Value Measurements - Financial Assets And Liabilities Measured At Fair Value On Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Assets:
Fair value of financial assets measured on recurring basis	$ 744,697	$ 128,477
Liabilities:
Fair value of financial liabilities measured on recurring basis	190,442	262,113
Acquisition-related contingent consideration—short-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	70,543	109,373
Acquisition-related contingent consideration—long-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	119,899	152,740
Money market funds
Assets:
Fair value of financial assets measured on recurring basis	439,831	26,210
Time deposits
Assets:
Fair value of financial assets measured on recurring basis	303,410	100,000
Equity securities
Assets:
Fair value of financial assets measured on recurring basis	1,456	2,267
Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets:
Fair value of financial assets measured on recurring basis	441,287	28,477
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Acquisition-related contingent consideration—short-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Acquisition-related contingent consideration—long-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Money market funds
Assets:
Fair value of financial assets measured on recurring basis	439,831	26,210
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Time deposits
Assets:
Fair value of financial assets measured on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Equity securities
Assets:
Fair value of financial assets measured on recurring basis	1,456	2,267
Significant Other Observable Inputs (Level 2)
Assets:
Fair value of financial assets measured on recurring basis	303,410	100,000
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Significant Other Observable Inputs (Level 2) \| Acquisition-related contingent consideration—short-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Significant Other Observable Inputs (Level 2) \| Acquisition-related contingent consideration—long-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Significant Other Observable Inputs (Level 2) \| Money market funds
Assets:
Fair value of financial assets measured on recurring basis	0	0
Significant Other Observable Inputs (Level 2) \| Time deposits
Assets:
Fair value of financial assets measured on recurring basis	303,410	100,000
Significant Other Observable Inputs (Level 2) \| Equity securities
Assets:
Fair value of financial assets measured on recurring basis	0	0
Significant Unobservable Inputs (Level 3)
Assets:
Fair value of financial assets measured on recurring basis	0	0
Liabilities:
Fair value of financial liabilities measured on recurring basis	190,442	262,113
Significant Unobservable Inputs (Level 3) \| Acquisition-related contingent consideration—short-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	70,543	109,373
Significant Unobservable Inputs (Level 3) \| Acquisition-related contingent consideration—long-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	119,899	152,740
Significant Unobservable Inputs (Level 3) \| Money market funds
Assets:
Fair value of financial assets measured on recurring basis	0	0
Significant Unobservable Inputs (Level 3) \| Time deposits
Assets:
Fair value of financial assets measured on recurring basis	0	0
Significant Unobservable Inputs (Level 3) \| Equity securities
Assets:
Fair value of financial assets measured on recurring basis	$ 0	$ 0